S8133710B2	NNP	O
-	:	O
Oligoadenylate	NN	O
synthetase	NN	O
(OAS)	)	O
-	:	O
Google	NN	O
Patents	NNS	O
Info	NNP	O
Links	NNP	O
Images	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
CROSS	NNP	O
REFERENCE	NNP	O
TO	NNP	O
RELATED	NNP	O
APPLICATIONS	NNP	O
This	DT	O
application	NN	O
is	VBZ	O
a	DT	O
divisional	JJ	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser.	.	O
No.	.	O
11/601,440,	,	O
filed	VBN	O
on	IN	O
Nov.	NNP	O
17,	,	O
2006,	,	O
now	RB	O
U.S.	NNP	O
Pat.	.	O
No.	.	O
7,732,177	CD	O
titled	VBN	O
“OLIGOADENYLATE	NN	O
SYNTHETASE	NNP	O
(OAS)”,	,	O
which	WDT	O
claims	VBZ	O
the	DT	O
benefit	NN	O
of	IN	O
U.S.	.	O
Provisional	JJ	O
Applications	NNP	O
Nos.	.	O
60/739,159,	,	O
filed	VBD	O
Nov.	NNP	O
23,	,	O
2005,	,	O
and	CC	O
60/752,668,	,	O
filed	VBN	O
Dec.	NNP	O
21,	,	O
2005,	,	O
all	DT	O
of	IN	O
which	WDT	O
are	VBP	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
their	PRP$	O
entirety.	.	O
This	DT	O
application	NN	O
claims	VBZ	O
the	DT	O
benefit	NN	O
of	IN	O
U.S.	.	O
Provisional	JJ	O
Applications	NNP	O
Nos.	.	O
60/739,159,	,	O
filed	VBD	O
Nov.	NNP	O
23,	,	O
2005,	,	O
and	CC	O
60/752,668,	,	O
filed	VBN	O
Dec.	NNP	O
21,	,	O
2005,	,	O
both	DT	O
of	IN	O
which	WDT	O
are	VBP	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
their	PRP$	O
entirety.	.	O
BACKGROUND	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
1.	.	O
Field	NN	O
of	IN	O
the	DT	O
Invention	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
relates	VBZ	O
to	TO	O
novel	VB	O
pharmaceutical	JJ	O
compositions	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
virus	NN	O
infections	NNS	O
and	CC	O
cancer	NN	O
in	IN	O
mammals.	.	O
2.	.	O
Description	NN	O
of	IN	O
the	DT	O
Related	NNP	O
Art	NNP	O
Oligoadenylate	NNP	O
synthetase	NN	O
(OAS)	)	O
proteins	NNS	O
are	VBP	O
interferon-induced	JJ	O
proteins	NNS	O
characterized	VBN	O
by	IN	O
their	PRP$	O
capacity	NN	O
to	TO	O
catalyze	VB	O
the	DT	O
synthesis	NN	O
of	IN	O
2-prime,	,	O
5-prime	JJ	O
oligomers	NNS	O
of	IN	O
adenosine	NN	O
(2-5As).	.	O
Hovanessian	JJ	O
et	NN	O
al.,	,	O
EMBO	NNP	O
6:1273-1280	CD	O
(1987)	)	O
found	VBD	O
that	IN	O
interferon-treated	JJ	O
human	JJ	O
cells	NNS	O
contain	VBP	O
several	JJ	O
OASs	NNP	O
corresponding	VBG	O
to	TO	O
proteins	NNS	O
of	IN	O
40	CD	O
(OAS1),	,	O
46	CD	O
(OAS1),	,	O
69	CD	O
(OAS2),	,	O
and	CC	O
100	CD	O
(OAS3)	)	O
kD.	.	O
Marie	NNP	B
et	CC	I
al.,	,	I
Biochem.	.	I
Biophys.	.	I
Res.	.	I
Commun.	.	I
160:580-587	CD	I
(1989)	)	I
generated	VBD	O
highly	RB	O
specific	JJ	O
polyclonal	JJ	O
antibodies	NNS	O
against	IN	O
p69,	,	O
the	DT	O
69-kD	JJ	O
OAS2.	.	O
By	IN	O
screening	VBG	O
an	DT	O
interferon-treated	JJ	O
human	NN	O
cell	NN	O
expression	NN	O
library	NN	O
with	IN	O
the	DT	O
anti-p69	JJ	O
antibodies,	,	O
Marie	NNP	B
and	CC	I
Hovanessian,	,	I
J.	NNP	I
Biol.	.	I
Chem.	.	I
267:9933-9939	CD	I
(1992)	)	I
isolated	VBD	O
a	DT	O
partial	JJ	O
OAS2	NNP	O
cDNA.	.	O
They	PRP	O
screened	VBD	O
additional	JJ	O
libraries	NNS	O
with	IN	O
the	DT	O
partial	JJ	O
cDNA	NN	O
and	CC	O
recovered	VBD	O
cDNAs	NNS	O
encoding	VBG	O
two	CD	O
OAS2	NNP	O
isoforms.	.	O
The	DT	O
smaller	JJR	O
isoform	NN	O
is	VBZ	O
encoded	VBN	O
by	IN	O
two	CD	O
mRNAs	NNS	O
that	WDT	O
differ	VBP	O
in	IN	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
3-prime	JJ	O
untranslated	JJ	O
region.	.	O
Northern	NNP	O
blot	NN	O
analysis	NN	O
revealed	VBD	O
that	IN	O
OAS2	NNP	O
is	VBZ	O
expressed	VBN	O
as	IN	O
four	CD	O
interferon-induced	JJ	O
mRNAs	NN	O
in	IN	O
human	JJ	O
cells.	.	O
The	DT	O
predicted	JJ	O
OAS2	NNP	O
proteins	NNS	O
have	VBP	O
a	DT	O
common	JJ	O
683-amino	JJ	O
acid	NN	O
sequence	NN	O
and	CC	O
different	JJ	O
3-prime	JJ	O
termini.	.	O
According	VBG	O
to	TO	O
SDS-PAGE	NN	O
of	IN	O
in	IN	O
vitro	JJ	O
transcription/translation	NN	O
products,	,	O
two	CD	O
isoforms	NNS	O
have	VBP	O
molecular	JJ	O
masses	NNS	O
of	IN	O
69	CD	O
and	CC	O
71	CD	O
kD.	.	O
Both	DT	O
isoforms	NNS	O
exhibited	VBD	O
OAS	NNP	O
activity	NN	O
in	IN	O
vitro.	.	O
Sequence	NN	O
analysis	NN	O
indicated	VBD	O
that	IN	O
OAS2	NNP	O
contains	VBZ	O
two	CD	O
OAS1-homologous	JJ	O
domains	NNS	O
separated	VBN	O
by	IN	O
a	DT	O
proline-rich	JJ	O
putative	JJ	O
linker	NN	O
region.	.	O
The	DT	O
N-	NNP	O
and	CC	O
C-terminal	JJ	O
domains	NNS	O
are	VBP	O
41%	NN	O
and	CC	O
53%	NN	O
identical	JJ	O
to	TO	O
OAS1,	,	O
respectively.	.	O
Likewise,	,	O
OAS3	NNP	O
contains	VBZ	O
three	CD	O
tandem	JJ	O
units	NNS	O
of	IN	O
the	DT	O
OAS1-homologous	JJ	O
domains.	.	O
By	IN	O
fluorescence	NN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
and	CC	O
by	IN	O
inclusion	NN	O
within	IN	O
mapped	JJ	O
clones,	,	O
Hovanian	JJ	B
et	NN	I
al.,	,	I
Genomics	NNP	I
52:267-277	CD	I
(1998)	)	I
determined	VBD	O
that	IN	O
the	DT	O
OAS1,	,	O
OAS2,	,	O
and	CC	O
OAS3	NNP	O
genes	NNS	O
are	VBP	O
clustered	VBN	O
with	IN	O
a	DT	O
130-kb	JJ	O
region	NN	O
on	IN	O
12q24.2.	.	O
2-5As	JJ	O
bind	NN	O
to	TO	O
and	CC	O
activate	VB	O
RNase	NNP	O
I,	,	O
which	WDT	O
degrades	VBZ	O
viral	JJ	O
and	CC	O
cellular	JJ	O
RNAs,	,	O
leading	VBG	O
to	TO	O
inhibition	NN	O
of	IN	O
cellular	JJ	O
protein	NN	O
synthesis	NN	O
and	CC	O
impairment	NN	O
of	IN	O
viral	JJ	O
replication.	.	O
A	DT	O
fourth	JJ	O
human	JJ	O
OAS	NNP	O
gene,	,	O
referred	VBD	O
to	TO	O
as	IN	O
OASL,	,	O
differs	NNS	O
from	IN	O
OAS1,	,	O
OAS2	NNP	O
and	CC	O
OAS3	NNP	O
in	IN	O
that	DT	O
OASL	NNP	O
lacks	VBZ	O
enzyme	JJ	O
activity.	.	O
The	DT	O
OASL	NNP	O
gene	NN	O
encodes	VBZ	O
a	DT	O
two-domain	JJ	O
protein	NN	O
composed	VBD	O
of	IN	O
an	DT	O
OAS	NNP	O
unit	NN	O
fused	VBD	O
to	TO	O
a	DT	O
164	CD	O
amino	NN	O
acid	JJ	O
C-terminal	JJ	O
domain	NN	O
that	WDT	O
is	VBZ	O
homologous	JJ	O
to	TO	O
a	DT	O
tandem	JJ	O
repeat	NN	O
of	IN	O
ubiquitin.	.	O
Eskildsen	NNP	B
et	RB	I
al.,	,	I
Nuc.	.	I
Acids	NNP	I
Res.	.	I
31:3166-3173,	,	I
2003;	:	I
Kakuta	NNP	B
et	FW	I
al.,	,	I
J.	NNP	I
Interferon	NNP	I
&	CC	I
Cytokine	NNP	I
Res.	.	I
22:981-993,	,	I
2002.)(	)	O
The	DT	O
present	JJ	O
invention	NN	O
fulfills	NNS	O
needs	VBZ	O
in	IN	O
the	DT	O
art	NN	O
by	IN	O
providing	VBG	O
engineering	NN	O
and	CC	O
modification	NN	O
of	IN	O
oligoadenylate	JJ	O
synthetase	NN	O
proteins	NNS	O
to	TO	O
improve	VB	O
their	PRP$	O
drug	NN	O
properties.	.	O
BRIEF	NNP	O
SUMMARY	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
relates	VBZ	O
to	TO	O
novel	VB	O
pharmaceutical	JJ	O
compositions	NNS	O
composed	VBN	O
of	IN	O
engineered	JJ	O
forms	NNS	O
of	IN	O
the	DT	O
oligoadenylate	NN	O
synthetases.	.	O
These	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
include	VBP	O
mutant	JJ	O
forms	NNS	O
designed	VBN	O
to	TO	O
have	VB	O
enhanced	VBN	O
cell	NN	O
permeability,	,	O
reduced	VBD	O
oxidative	JJ	O
potential,	,	O
enhanced	JJ	O
antiviral	JJ	O
activity,	,	O
enhanced	VBD	O
enzymatic	JJ	O
activity,	,	O
or	CC	O
absent	JJ	O
enzymatic	JJ	O
activity.	.	O
These	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
further	RBR	O
embody	NN	O
oligoadenylate	JJ	O
synthetases	NNS	O
chemically	RB	O
modified	VBN	O
with	IN	O
polyethylene	NN	O
glycol.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
relates	NNS	O
to	TO	O
any	DT	O
possible	JJ	O
combination	NN	O
of	IN	O
mutant	JJ	O
forms	NNS	O
or	CC	O
chemical	JJ	O
modifications	NNS	O
in	IN	O
a	DT	O
single	JJ	O
polypeptide.	.	O
The	DT	O
present	JJ	O
invention	NN	O
relates	VBZ	O
to	TO	O
mutant	VB	O
oligoadenylate	JJ	O
synthetase	NN	O
forms	NNS	O
that	WDT	O
have	VBP	O
no	DT	O
enzymatic	JJ	O
activity,	,	O
but	CC	O
that	IN	O
retain	VBP	O
their	PRP$	O
antiviral	JJ	O
activity,	,	O
described	VBN	O
as	IN	O
Class	NN	O
I	PRP	O
modifications	NNS	O
in	IN	O
FIG.	.	O
1.	.	O
These	DT	O
forms	NNS	O
have	VBP	O
one	CD	O
or	CC	O
two	CD	O
mutations	NNS	O
of	IN	O
aspartic	JJ	O
acid	NN	O
to	TO	O
alanine	VB	O
in	IN	O
the	DT	O
magnesium	NN	O
binding	VBG	O
site	NN	O
of	IN	O
the	DT	O
polypeptide,	,	O
rendering	VBG	O
the	DT	O
resulting	VBG	O
OAS	NNP	O
forms	NNS	O
enzymatically	RB	O
inactive	JJ	O
as	IN	O
shown	VBN	O
in	IN	O
FIG.	.	O
2.	.	O
These	DT	O
Class	NNP	O
I	PRP	O
enzymatically	RB	O
inactive	JJ	O
OAS	NNP	O
polypeptides	NNS	O
retain	VBP	O
antiviral	JJ	O
activity,	,	O
demonstrated	VBD	O
using	VBG	O
an	DT	O
encephalomyocarditis	NN	O
virus	NN	O
replication	NN	O
assay,	,	O
as	IN	O
shown	VBN	O
in	IN	O
FIG.	.	O
3.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
relates	VBZ	O
to	TO	O
mutant	VB	O
oligoadenylate	JJ	O
synthetase	NN	O
forms	NNS	O
that	WDT	O
have	VBP	O
reduced	VBN	O
oxidative	JJ	O
potential,	,	O
described	VBN	O
as	IN	O
Class	NNP	O
II	NNP	O
in	IN	O
FIG.	.	O
1.	.	O
These	DT	O
forms	NNS	O
have	VBP	O
one	CD	O
or	CC	O
more	JJR	O
cysteine	JJ	O
amino	NN	O
acid	NN	O
residues	NNS	O
deleted	VBD	O
or	CC	O
replaced	VBN	O
with	IN	O
an	DT	O
alternative	JJ	O
residue	NN	O
of	IN	O
the	DT	O
form:	:	O
alanine,	,	O
serine,	,	O
threonine,	,	O
methionine,	,	O
or	CC	O
glycine.	.	O
Deletion	NN	O
or	CC	O
modification	NN	O
of	IN	O
these	DT	O
residues	NNS	O
reduces	VBZ	O
the	DT	O
oxidative	JJ	O
potential	NN	O
of	IN	O
the	DT	O
resulting	JJ	O
polypeptide	JJ	O
drug	NN	O
product,	,	O
thereby	RB	O
improving	VBG	O
manufacturability	NN	O
and	CC	O
in	IN	O
vivo	JJ	O
serum	JJ	O
stability	NN	O
of	IN	O
the	DT	O
drug.	.	O
Manufacturability	NNP	O
is	VBZ	O
improved	VBN	O
by	IN	O
obviating	VBG	O
the	DT	O
need	NN	O
for	IN	O
a	DT	O
reducing	NN	O
environment	NN	O
during	IN	O
drug	NN	O
manufacture	NN	O
while	IN	O
reducing	VBG	O
the	DT	O
propensity	NN	O
of	IN	O
drug	NN	O
aggregation	NN	O
during	IN	O
manufacture,	,	O
transport,	,	O
and	CC	O
drug	NN	O
delivery.	.	O
Class	NN	O
II	NNP	O
modifications	NNS	O
also	RB	O
improve	VBP	O
stability	NN	O
of	IN	O
the	DT	O
drug	NN	O
in	IN	O
excipients	NNS	O
suitable	JJ	O
for	IN	O
use	NN	O
in	IN	O
man.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
relates	VBZ	O
to	TO	O
mutant	VB	O
oligoadenylate	JJ	O
synthetase	NN	O
forms	NNS	O
that	WDT	O
have	VBP	O
enhanced	VBN	O
cell	NN	O
permeability,	,	O
described	VBN	O
as	IN	O
Class	NNP	O
III	NNP	O
in	IN	O
FIG.	.	O
1.	.	O
Cell	NNP	O
permeability	NN	O
is	VBZ	O
enhanced	VBN	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
basic	JJ	O
amino	NN	O
acids,	,	O
histidine,	,	O
arginine,	,	O
and	CC	O
lysine,	,	O
to	TO	O
the	DT	O
amino	NN	O
terminus	NN	O
of	IN	O
the	DT	O
polypeptide.	.	O
Addition	NN	O
of	IN	O
basic	JJ	O
or	CC	O
positively-charged	JJ	O
amino	NN	O
acids	NNS	O
increases	VBZ	O
cell	NN	O
permeability	NN	O
through	IN	O
an	DT	O
absorptive	JJ	O
endocytic	JJ	O
process,	,	O
thereby	RB	O
increasing	VBG	O
the	DT	O
antiviral	JJ	O
activity	NN	O
of	IN	O
the	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
(compare	JJ	O
FIG.	.	O
3	LS	O
with	IN	O
FIG.	.	O
4).	.	O
Enhancement	NN	O
of	IN	O
absorptive	JJ	O
endocytosis	NN	O
of	IN	O
the	DT	O
polypeptide	JJ	O
drug	NN	O
through	IN	O
the	DT	O
addition	NN	O
of	IN	O
basic	JJ	O
amino	NN	O
acids	NNS	O
results	NNS	O
in	IN	O
the	DT	O
significant	JJ	O
accumulation	NN	O
of	IN	O
active	JJ	O
drug	NN	O
in	IN	O
intracellular,	,	O
detergent	NN	O
insoluble	JJ	O
stores	NNS	O
(FIG.	.	O
5)	)	O
thereby	RB	O
enhancing	VBG	O
in	IN	O
vivo	JJ	O
therapeutic	JJ	O
effect.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
relates	VBZ	O
to	TO	O
chemical	JJ	O
modifications	NNS	O
of	IN	O
the	DT	O
polypeptide	JJ	O
drug	NN	O
to	TO	O
contain	VB	O
a	DT	O
polyethylene	NN	O
glycol	NN	O
moiety,	,	O
described	VBN	O
as	IN	O
Class	NNP	O
IV	NNP	O
in	IN	O
FIG.	.	O
1.	.	O
Chemical	NNP	O
modification	NN	O
of	IN	O
cysteine	NN	O
residues	NNS	O
results	NNS	O
in	IN	O
retention	NN	O
of	IN	O
full	JJ	O
enzyme	NN	O
activity	NN	O
(as	IN	O
shown	VBN	O
in	IN	O
FIG.	.	O
6),	,	O
improved	VBN	O
in	IN	O
vitro	JJ	O
bulk	JJ	O
drug	NN	O
product	NN	O
stability,	,	O
enhanced	VBD	O
serum	JJ	O
elimination	NN	O
half	NN	O
life,	,	O
reduced	VBN	O
in	IN	O
vivo	JJ	O
drug	NN	O
immunogenicity,	,	O
and	CC	O
reduced	VBN	O
in	IN	O
vivo	NN	O
proteolytic	JJ	O
cleavage	NN	O
of	IN	O
the	DT	O
drug	NN	O
polypeptide.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
relates	VBZ	O
to	TO	O
additional	JJ	O
mutant	NN	O
oligoadenylate	NN	O
synthetase	NN	O
forms	NNS	O
having	VBG	O
significant	JJ	O
anti-viral	JJ	O
or	CC	O
anti-cancer	JJ	O
activity,	,	O
described	VBN	O
as	IN	O
Class	NNP	O
V	NNP	O
in	IN	O
FIG.	.	O
1.	.	O
Class	NN	O
V	NNP	O
polypeptides	NNS	O
are	VBP	O
additional	JJ	O
mutant	JJ	O
OAS	NNP	O
forms	NNS	O
resulting	VBG	O
from	IN	O
a	DT	O
mixture	NN	O
of	IN	O
developmental	NN	O
and	CC	O
optimizing	VBG	O
considerations	NNS	O
including	VBG	O
one	CD	O
or	CC	O
more	JJR	O
of:	:	O
manufacturing	NN	O
tests	NNS	O
in	IN	O
E.	NNP	O
coli,	,	O
recombinant	JJ	O
vector	NN	O
development,	,	O
and	CC	O
comparison	NN	O
with	IN	O
other	JJ	O
identified	JJ	O
forms	NNS	O
of	IN	O
OAS	NNP	O
proteins.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
relates	NNS	O
to	TO	O
any	DT	O
combination	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
mutations	NNS	O
or	CC	O
modifications	NNS	O
of	IN	O
FIG.	.	O
1	CD	O
within	IN	O
a	DT	O
single	JJ	O
polypeptide	NN	O
or	CC	O
pharmaceutical	JJ	O
composition.	.	O
The	DT	O
present	JJ	O
invention	NN	O
relates	VBZ	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
modified	JJ	O
polypeptides	NNS	O
of	IN	O
FIG.	.	O
1	CD	O
to	TO	O
treat	VB	O
or	CC	O
prevention	VB	O
virus	JJ	O
infection	NN	O
or	CC	O
cancer	NN	O
in	IN	O
a	DT	O
mammal.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
relates	VBZ	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG.	.	O
1	CD	O
or	CC	O
any	DT	O
combination	NN	O
of	IN	O
the	DT	O
modifications	NNS	O
of	IN	O
FIG.	.	O
1	CD	O
to	TO	O
enhance	VB	O
cellular	JJ	O
growth	NN	O
in	IN	O
a	DT	O
tissue,	,	O
such	JJ	O
as	IN	O
for	IN	O
example,	,	O
a	DT	O
lung	NN	O
or	CC	O
liver.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
relates	VBZ	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
any	DT	O
combination	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
mutations	NNS	O
or	CC	O
modifications	NNS	O
of	IN	O
FIG.	.	O
1	CD	O
within	IN	O
a	DT	O
single	JJ	O
polypeptide	NN	O
or	CC	O
pharmaceutical	JJ	O
composition	NN	O
for	IN	O
the	DT	O
prevention	NN	O
or	CC	O
treatment	NN	O
of	IN	O
virus	JJ	O
infection	NN	O
or	CC	O
cancer	NN	O
in	IN	O
a	DT	O
mammal	NN	O
or	CC	O
to	TO	O
promote	VB	O
cellular	JJ	O
or	CC	O
tissue	JJ	O
growth	NN	O
or	CC	O
proliferation	NN	O
in	IN	O
a	DT	O
mammal.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
the	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
a	DT	O
gene	NN	O
encoding	VBG	O
the	DT	O
modified	JJ	O
polypeptides	NNS	O
of	IN	O
FIG.	.	O
1.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment,	,	O
the	DT	O
gene	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
manufacture	VB	O
a	DT	O
drug	NN	O
product	NN	O
using	VBG	O
recombinant	JJ	O
DNA	NNP	O
technologies.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment,	,	O
expression	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
can	MD	O
be	VB	O
effected	VBN	O
in	IN	O
mammalian,	,	O
insect,	,	O
plant,	,	O
bacterial,	,	O
or	CC	O
fungal	JJ	O
cells.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
therapeutic	JJ	O
compound	NN	O
for	IN	O
preventing	VBG	O
or	CC	O
inhibiting	VBG	O
infection	NN	O
by	IN	O
a	DT	O
virus,	,	O
preferably	RB	O
a	DT	O
flavivirus,	,	O
most	RBS	O
preferably	RB	O
hepatitis	VBP	O
C	NNP	O
virus,	,	O
wherein	VBP	O
the	DT	O
therapeutic	JJ	O
compound	NN	O
is	VBZ	O
a	DT	O
polypeptide	NN	O
of	IN	O
FIG.	.	O
1.	.	O
In	IN	O
other	JJ	O
embodiments	NNS	O
the	DT	O
therapeutic	JJ	O
compound	NN	O
is	VBZ	O
a	DT	O
polynucleotide,	,	O
such	JJ	O
as	IN	O
DNA	NN	O
or	CC	O
RNA,	,	O
encoding	VBG	O
the	DT	O
polypeptide.	.	O
In	IN	O
other	JJ	O
embodiments	NNS	O
the	DT	O
therapeutic	JJ	O
compound	NN	O
is	VBZ	O
a	DT	O
combination	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG.	.	O
1,	,	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
mutations	NNS	O
or	CC	O
modifications	NNS	O
described	VBN	O
in	IN	O
FIG.	.	O
1	CD	O
within	IN	O
a	DT	O
single	JJ	O
polypeptide	NN	O
molecule.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
therapeutic	JJ	O
compound	NN	O
for	IN	O
preventing	VBG	O
or	CC	O
treating	VBG	O
cancer,	,	O
preferably	RB	O
prostate	JJ	O
cancer,	,	O
wherein	VBP	O
the	DT	O
therapeutic	JJ	O
compound	NN	O
is	VBZ	O
a	DT	O
polypeptide	NN	O
of	IN	O
FIG.	.	O
1.	.	O
In	IN	O
other	JJ	O
embodiments	NNS	O
the	DT	O
therapeutic	JJ	O
compound	NN	O
is	VBZ	O
a	DT	O
polynucleotide,	,	O
such	JJ	O
as	IN	O
DNA	NN	O
or	CC	O
RNA,	,	O
encoding	VBG	O
the	DT	O
polypeptide.	.	O
In	IN	O
further	JJ	O
embodiments,	,	O
compositions	NNS	O
are	VBP	O
provided	VBN	O
that	IN	O
comprise	NN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG.	.	O
1	CD	O
in	IN	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
carrier.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
prepare	VB	O
a	DT	O
medicament	NN	O
for	IN	O
preventing	VBG	O
or	CC	O
inhibiting	VBG	O
hepatitis	NN	O
C	NNP	O
or	CC	O
respiratory	JJ	O
syncytial	JJ	O
virus	NN	O
infection.	.	O
The	DT	O
invention	NN	O
still	RB	O
further	RB	O
relates	VBZ	O
to	TO	O
a	DT	O
method	NN	O
of	IN	O
preventing	VBG	O
or	CC	O
curing	VBG	O
infection	NN	O
by	IN	O
a	DT	O
flavivirus	NN	O
or	CC	O
any	DT	O
other	JJ	O
virus	NN	O
in	IN	O
a	DT	O
human	JJ	O
subject	NN	O
susceptible	NN	O
to	TO	O
the	DT	O
infection	NN	O
by	IN	O
administering	VBG	O
one	CD	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG.	.	O
1.	.	O
Other	JJ	O
embodiments	NNS	O
involve	VBP	O
the	DT	O
treatment	NN	O
of	IN	O
any	DT	O
mammal.	.	O
The	DT	O
invention	NN	O
embodies	NNS	O
also	RB	O
treatments	NNS	O
for	IN	O
infection	NN	O
with	IN	O
the	DT	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
(HIV).	.	O
The	DT	O
invention	NN	O
still	RB	O
further	RB	O
relates	VBZ	O
to	TO	O
a	DT	O
method	NN	O
of	IN	O
treating	VBG	O
cancer,	,	O
such	JJ	O
as	IN	O
prostate	JJ	O
cancer	NN	O
or	CC	O
breast	NN	O
cancer	NN	O
by	IN	O
administration	NN	O
of	IN	O
polypeptides	NNS	O
disclosed	VBN	O
herein.	.	O
The	DT	O
invention	NN	O
still	RB	O
further	RB	O
relates	VBZ	O
to	TO	O
a	DT	O
method	NN	O
of	IN	O
promoting	VBG	O
cellular	JJ	O
or	CC	O
tissue	NN	O
growth	NN	O
by	IN	O
administration	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
disclosed	VBD	O
herein	NN	O
or	CC	O
polynucleotides,	,	O
such	JJ	O
as	IN	O
DNA	NN	O
or	CC	O
RNA,	,	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention.	.	O
The	DT	O
invention	NN	O
still	RB	O
further	RB	O
relates	VBZ	O
to	TO	O
a	DT	O
method	NN	O
of	IN	O
reducing	VBG	O
inflammation	NN	O
by	IN	O
administration	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
disclosed	VBD	O
herein	NN	O
or	CC	O
polynucleotides,	,	O
such	JJ	O
as	IN	O
DNA	NN	O
or	CC	O
RNA,	,	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention.	.	O
The	DT	O
invention	NN	O
still	RB	O
further	RB	O
relates	VBZ	O
to	TO	O
a	DT	O
method	NN	O
of	IN	O
promoting	VBG	O
immune	JJ	O
suppression	NN	O
by	IN	O
administration	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
disclosed	VBD	O
herein	NN	O
or	CC	O
polynucleotides,	,	O
such	JJ	O
as	IN	O
DNA	NN	O
or	CC	O
RNA,	,	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention.	.	O
Also	RB	O
provided	VBN	O
is	VBZ	O
the	DT	O
use	NN	O
of	IN	O
any	DT	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG.	.	O
1	CD	O
as	IN	O
a	DT	O
component	NN	O
of	IN	O
a	DT	O
therapeutic	JJ	O
composition.	.	O
In	IN	O
a	DT	O
further	JJ	O
embodiment,	,	O
a	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG.	.	O
1	CD	O
can	MD	O
be	VB	O
administered	VBN	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
gene	NN	O
therapy.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
any	DT	O
method	NN	O
of	IN	O
preparing	VBG	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG.	.	O
1	CD	O
or	CC	O
the	DT	O
genes	NNS	O
encoding	VBG	O
said	VBD	O
polypeptides,	,	O
including	VBG	O
the	DT	O
use	NN	O
any	DT	O
recombinant	JJ	O
DNA	NN	O
methodologies.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
site	NN	O
directed	VBN	O
mutagenesis,	,	O
polymerase	NN	O
chain	NN	O
reaction,	,	O
or	CC	O
nucleic	JJ	O
acid	JJ	O
chemical	NN	O
synthesis	NN	O
to	TO	O
prepare	VB	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG.	.	O
1	CD	O
or	CC	O
their	PRP$	O
encoding	JJ	O
genes.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
methods	NNS	O
of	IN	O
chemically	RB	O
cross-linking	JJ	O
polyethylene	NN	O
glycol	NN	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention.	.	O
In	IN	O
one	CD	O
embodiment,	,	O
chemical	JJ	O
cross-linking	JJ	O
targets	NNS	O
the	DT	O
reactive	JJ	O
sulfhydryl	NN	O
species	NNS	O
of	IN	O
the	DT	O
cysteine	NN	O
residues.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment,	,	O
cross-linking	JJ	O
targets	NNS	O
a	DT	O
single	JJ	O
solvent-exposed	JJ	O
cysteine	NN	O
residue	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment,	,	O
chemical	JJ	O
cross-linking	NN	O
of	IN	O
polyethylene	NN	O
glycol	NN	O
is	VBZ	O
mediated	VBN	O
through	IN	O
the	DT	O
amino-terminal	JJ	O
primary	NN	O
or	CC	O
secondary	JJ	O
amines	NNS	O
of	IN	O
the	DT	O
polypeptide.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment,	,	O
chemical	JJ	O
cross-linking	NN	O
of	IN	O
polyethylene	NN	O
glycol	NN	O
is	VBZ	O
mediated	VBN	O
through	IN	O
any	DT	O
carboxyl	JJ	O
group	NN	O
of	IN	O
the	DT	O
polypeptide.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment,	,	O
cross-linking	NN	O
is	VBZ	O
achieved	VBN	O
by	IN	O
conjugation	NN	O
of	IN	O
polyethylene	NN	O
glycol	NN	O
to	TO	O
any	DT	O
lysine	NN	O
or	CC	O
arginine	NN	O
amino	NN	O
acid	VBP	O
residue	NN	O
of	IN	O
the	DT	O
polypeptide.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment,	,	O
multiple	JJ	O
sites	NNS	O
of	IN	O
polyethylene	NN	O
glycol	NN	O
conjugation	NN	O
can	MD	O
be	VB	O
achieved.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
forms	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG.	.	O
1	CD	O
that	WDT	O
are	VBP	O
derivatized	VBN	O
with	IN	O
polyethylene	NN	O
glycol	NN	O
for	IN	O
use	NN	O
in	IN	O
a	DT	O
therapeutic	JJ	O
product.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
forms	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG.	.	O
1	CD	O
that	WDT	O
are	VBP	O
derivatized	VBN	O
with	IN	O
polyethylene	NN	O
glycol	NN	O
for	IN	O
use	NN	O
in	IN	O
treating	VBG	O
virus	JJ	O
infection	NN	O
or	CC	O
cancer.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
forms	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG.	.	O
1	CD	O
that	WDT	O
are	VBP	O
derivatized	VBN	O
with	IN	O
polyethylene	NN	O
glycol	NN	O
for	IN	O
promoting	VBG	O
cellular	JJ	O
or	CC	O
tissue	NN	O
growth.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
administering	VBG	O
forms	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG.	.	O
1	CD	O
that	WDT	O
are	VBP	O
derivatized	VBN	O
with	IN	O
polyethylene	NN	O
glycol	NN	O
to	TO	O
a	DT	O
mammal.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
forms	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG.	.	O
1	CD	O
that	WDT	O
are	VBP	O
derivatized	VBN	O
with	IN	O
polyethylene	NN	O
glycol	NN	O
for	IN	O
use	NN	O
in	IN	O
treating	VBG	O
inflammation.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
forms	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG.	.	O
1	CD	O
that	WDT	O
are	VBP	O
derivatized	VBN	O
with	IN	O
polyethylene	NN	O
glycol	NN	O
for	IN	O
use	NN	O
in	IN	O
promoting	VBG	O
suppression	NN	O
of	IN	O
the	DT	O
immune	JJ	O
system	NN	O
of	IN	O
a	DT	O
mammal.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
methods	NNS	O
of	IN	O
chemically	RB	O
cross-linking	JJ	O
polyethylene	NN	O
glycol	NN	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention,	,	O
most	RBS	O
particularly	RB	O
those	DT	O
described	VBN	O
as	IN	O
Class	NNP	O
IV	NNP	O
in	IN	O
FIG.	.	O
1,	,	O
whereby	JJR	O
cross-linking	NN	O
is	VBZ	O
achieved	VBN	O
using	VBG	O
a	DT	O
maleimide,	,	O
ortho-pyridyldisulfide,	,	O
vinylsulfone,	,	O
or	CC	O
thiol	JJ	O
functional	JJ	O
group.	.	O
In	IN	O
a	DT	O
further	JJ	O
embodiment,	,	O
single	JJ	O
chain,	,	O
multiple	NN	O
chain,	,	O
multi-arm,	,	O
branched,	,	O
or	CC	O
forked	VBD	O
polyethylene	JJ	O
glycols	NNS	O
of	IN	O
any	DT	O
molecular	JJ	O
weight	NN	O
may	MD	O
be	VB	O
used.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment,	,	O
polyethylene	NN	O
glycols	NNS	O
may	MD	O
contain	VB	O
radioactive	JJ	O
or	CC	O
fluorescent	JJ	O
moieties.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
methods	NNS	O
of	IN	O
chemically	RB	O
cross-linking	JJ	O
polyethylene	NN	O
glycol	NN	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
using	VBG	O
succinimidyl	JJ	O
alpha-methylbutanoate,	,	O
succinimidyl	JJ	O
propionate,	,	O
N-hydroxysuccinimide,	,	O
ester,	,	O
aldehyde,	,	O
ortho-pyridylthioester,	,	O
or	CC	O
amine	JJ	O
functional	JJ	O
groups.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
increasing	VBG	O
the	DT	O
cell	NN	O
permeability	NN	O
of	IN	O
a	DT	O
drug	NN	O
by	IN	O
conjugation	NN	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention.	.	O
The	DT	O
invention	NN	O
further	RBR	O
provides	VBZ	O
for	IN	O
increasing	VBG	O
the	DT	O
cell	NN	O
permeability	NN	O
of	IN	O
a	DT	O
drug	NN	O
by	IN	O
conjugation	NN	O
to	TO	O
five	CD	O
or	CC	O
more	JJR	O
consecutive	JJ	O
amino	NN	O
acids	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
for	IN	O
delivering	VBG	O
a	DT	O
drug	NN	O
into	IN	O
a	DT	O
cell	NN	O
by	IN	O
conjugation	NN	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
or	CC	O
five	CD	O
or	CC	O
more	JJR	O
consecutive	JJ	O
amino	NN	O
acids	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention.	.	O
In	IN	O
a	DT	O
further	JJ	O
embodiment,	,	O
conjugation	NN	O
may	MD	O
be	VB	O
affected	VBN	O
using	VBG	O
chemical	JJ	O
methods	NNS	O
and	CC	O
may	MD	O
be	VB	O
through	IN	O
covalent	NN	O
or	CC	O
non-covalent	JJ	O
interaction.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment,	,	O
nucleic	JJ	O
acids	NNS	O
encoding	VBG	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
joined	VBN	O
with	IN	O
other	JJ	O
nucleic	JJ	O
acids	NNS	O
in	IN	O
order	NN	O
to	TO	O
make	VB	O
heterologous	JJ	O
polypeptides	NNS	O
with	IN	O
increased	VBN	O
cell	NN	O
permeability,	,	O
said	VBD	O
increased	VBN	O
permeability	NN	O
being	VBG	O
derived	VBN	O
from	IN	O
five	CD	O
or	CC	O
more	JJR	O
amino	JJ	O
acids	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention.	.	O
BRIEF	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
FIGURES	NNP	O
FIG.	.	O
1	CD	O
is	VBZ	O
a	DT	O
Table	JJ	O
describing	VBG	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
and	CC	O
their	PRP$	O
defining	JJ	O
mutations	NNS	O
or	CC	O
modifications	NNS	O
relative	VBP	O
to	TO	O
a	DT	O
reference	NN	O
amino	NN	O
acid	JJ	O
sequence.	.	O
FIG.	.	O
2	CD	O
is	VBZ	O
a	DT	O
comparison	NN	O
of	IN	O
oligoadenylate	JJ	O
synthetase	NN	O
activity	NN	O
of	IN	O
a	DT	O
Class	NNP	O
I-Class	NNP	O
III	NNP	O
combination	NN	O
mutant	NN	O
polypeptide	NN	O
(the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:4	NNP	O
(SEQ	NNP	O
ID	NNP	O
NO:4)	)	O
of	IN	O
FIG.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention)	)	O
versus	VBZ	O
a	DT	O
reference	NN	O
Class	NNP	O
III	NNP	O
polypeptide	NN	O
variant	NN	O
(the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:2	NNP	O
(SEQ	NNP	O
ID	NNP	O
NO:2)	)	O
of	IN	O
FIG.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention).	.	O
Lane	NNP	O
1:	:	O
50	CD	O
ng	NN	O
of	IN	O
the	DT	O
reference	NN	O
Class	NNP	O
III	NNP	O
variant.	.	O
Lane	NNP	O
2:	:	O
1	CD	O
g	NN	O
of	IN	O
a	DT	O
Class	NNP	O
I-Class	NNP	O
III	NNP	O
Variant.	.	O
Lane	NNP	O
3:	:	O
blank	JJ	O
reaction	NN	O
containing	VBG	O
no	DT	O
protein.	.	O
Oligoadenylate	NNP	O
synthetase	NN	O
activity	NN	O
is	VBZ	O
measured	VBN	O
according	VBG	O
to	TO	O
a	DT	O
standard	JJ	O
reaction	NN	O
involving	VBG	O
the	DT	O
incorporation	NN	O
of	IN	O
32P-labeled	JJ	O
adenosine	NN	O
triphosphate	NN	O
into	IN	O
2′-5′	JJ	O
oligoadenylate	NN	O
species	NNS	O
that	WDT	O
migrate	VBP	O
more	RBR	O
rapidly	RB	O
on	IN	O
polyethylenimine	NN	O
treated	VBN	O
thin	JJ	O
layer	NN	O
chromatography	NN	O
plates	VBZ	O
as	IN	O
described	VBN	O
in	IN	O
the	DT	O
specification.	.	O
FIG.	.	O
3	CD	O
demonstrates	VBZ	O
inhibition	NN	O
of	IN	O
EMCV-induced	NNP	O
cell	NN	O
death	NN	O
in	IN	O
Huh7	NNP	O
cells	NNS	O
by	IN	O
a	DT	O
Class	NNP	O
I-Class	NNP	O
III	NNP	O
combination	NN	O
mutant	NN	O
polypeptide	NN	O
(the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:4	NNP	O
of	IN	O
FIG.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention)	)	O
and	CC	O
a	DT	O
reference	NN	O
Class	NNP	O
III	NNP	O
modified	VBD	O
polypeptide	JJ	O
variant	NN	O
(the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:2	NNP	O
(SEQ	NNP	O
ID	NNP	O
NO:2)	)	O
of	IN	O
FIG.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention).	.	O
Huh7	NNP	O
cells	NNS	O
were	VBD	O
pretreated	VBN	O
for	IN	O
8	CD	O
hours	NNS	O
with	IN	O
increasing	VBG	O
concentrations	NNS	O
of	IN	O
a	DT	O
Class	NNP	O
I-Class	NNP	O
III	NNP	O
combination	NN	O
polypeptide,	,	O
a	DT	O
Class	NN	O
III	NNP	O
reference	NN	O
polypeptides,	,	O
or	CC	O
equivalent	JJ	O
amounts	NNS	O
of	IN	O
drug	NN	O
vehicle.	.	O
Cells	NNS	O
were	VBD	O
mock-infected	JJ	O
with	IN	O
medium	NN	O
or	CC	O
with	IN	O
50	CD	O
or	CC	O
250	CD	O
plaque	JJ	O
forming	VBG	O
units	NNS	O
(pfu)	)	O
of	IN	O
encephalomyocarditis	NN	O
virus	NN	O
for	IN	O
18	CD	O
hours.	.	O
Cell	NNP	O
viability	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
18	CD	O
hours	NNS	O
was	VBD	O
measured	VBN	O
by	IN	O
incubation	NN	O
of	IN	O
the	DT	O
cells	NNS	O
with	IN	O
a	DT	O
tetrazolium	NN	O
compound	NN	O
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,	,	O
inner	JJ	O
salt;	:	O
MTS)	)	O
followed	VBN	O
by	IN	O
the	DT	O
spectroscopic	JJ	O
measurement	NN	O
of	IN	O
absorbance	NN	O
at	IN	O
492	CD	O
nm	JJ	O
indicating	VBG	O
conversion	NN	O
of	IN	O
MTS	NNP	O
to	TO	O
formazan.	.	O
Higher	JJR	O
optical	JJ	O
densities	NNS	O
represent	VBP	O
a	DT	O
greater	JJR	O
proportion	NN	O
of	IN	O
live	JJ	O
cells	NNS	O
in	IN	O
the	DT	O
assay.	.	O
Both	DT	O
the	DT	O
Class	NNP	O
I-III	NNP	O
combination	NN	O
polypeptide	NN	O
and	CC	O
the	DT	O
Class	NNP	O
III	NNP	O
reference	NN	O
polypeptide	NN	O
inhibit	NN	O
virus-induced	JJ	O
cell	NN	O
death,	,	O
indicating	VBG	O
that	IN	O
the	DT	O
OAS	NNP	O
drugs	NNS	O
have	VBP	O
antiviral	JJ	O
activity	NN	O
independent	JJ	O
of	IN	O
enzymatic	JJ	O
activity.	.	O
FIG.	.	O
4	CD	O
shows	NNS	O
inhibition	NN	O
of	IN	O
EMCV-induced	NNP	O
cell	NN	O
death	NN	O
in	IN	O
Huh7	NNP	O
by	IN	O
a	DT	O
Class	NN	O
V	NNP	O
modified	VBD	O
polypeptide	NN	O
(the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:3	NNP	O
(SEQ	NNP	O
ID	NNP	O
NO:3)	)	O
of	IN	O
FIG.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention)	)	O
as	IN	O
described	VBN	O
in	IN	O
FIG.	.	O
1.	.	O
Huh7	NNP	O
cells	NNS	O
were	VBD	O
pretreated	VBN	O
for	IN	O
8	CD	O
hours	NNS	O
with	IN	O
increasing	VBG	O
concentrations	NNS	O
of	IN	O
the	DT	O
polypeptide	NN	O
or	CC	O
equivalent	JJ	O
amounts	NNS	O
of	IN	O
protein	NN	O
vehicle.	.	O
Cells	NNS	O
were	VBD	O
mock-infected	JJ	O
with	IN	O
medium	NN	O
or	CC	O
with	IN	O
250	CD	O
or	CC	O
500	CD	O
plaque	JJ	O
forming	VBG	O
units	NNS	O
(pfu)	)	O
of	IN	O
encephalomyocarditis	NN	O
virus	NN	O
for	IN	O
18	CD	O
hours.	.	O
Cell	NNP	O
viability	NN	O
was	VBD	O
measured	VBN	O
using	VBG	O
an	DT	O
MTS	NNP	O
assay	NN	O
by	IN	O
the	DT	O
change	NN	O
in	IN	O
absorbance	NN	O
at	IN	O
492	CD	O
nm	JJ	O
indicating	VBG	O
conversion	NN	O
of	IN	O
MTS	NNP	O
to	TO	O
formazan.	.	O
Class	NN	O
III	NNP	O
polypeptide	NN	O
drugs	NNS	O
have	VBP	O
increased	VBN	O
cell	NN	O
permeability	NN	O
and	CC	O
therefore	RB	O
increased	VBD	O
antiviral	JJ	O
activity	NN	O
(see	VB	O
FIG.	.	O
3)	)	O
compared	VBN	O
with,	,	O
for	IN	O
example,	,	O
the	DT	O
Class	NNP	O
V	NNP	O
polypeptide	NN	O
of	IN	O
the	DT	O
present	JJ	O
figure.	.	O
FIG.	.	O
5	CD	O
shows	NNS	O
increase	NN	O
in	IN	O
cell-associated	JJ	O
oligoadenylate	JJ	O
synthetase	NN	O
activity	NN	O
after	IN	O
treatment	NN	O
with	IN	O
a	DT	O
Class	NN	O
III	NNP	O
polypeptide	NN	O
variant	NN	O
(the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:2	NNP	O
(SEQ	NNP	O
ID	NNP	O
NO:2)	)	O
of	IN	O
FIG.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention).	.	O
Huh7	NNP	O
cells	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
6	CD	O
M	NNP	O
of	IN	O
the	DT	O
polypeptide	NN	O
for	IN	O
the	DT	O
indicated	JJ	O
period	NN	O
of	IN	O
time.	.	O
Cells	NNS	O
were	VBD	O
extensively	RB	O
trypsinized	VBN	O
to	TO	O
remove	VB	O
extracellular	JJ	O
protein	NN	O
and	CC	O
then	RB	O
lysed	VBD	O
with	IN	O
assay	JJ	O
buffer	NN	O
containing	VBG	O
0.1%	NN	O
NP40.	.	O
Detergent	NNP	O
soluble	JJ	O
and	CC	O
detergent	JJ	O
resistant	JJ	O
fractions	NNS	O
were	VBD	O
assayed	VBN	O
for	IN	O
oligoadenylate	JJ	O
synthetase	NN	O
activity	NN	O
as	IN	O
described	VBN	O
in	IN	O
the	DT	O
specification.	.	O
The	DT	O
fold-increase	NN	O
in	IN	O
cell-associated	JJ	O
oligoadenylate	JJ	O
synthetase	NN	O
activity	NN	O
is	VBZ	O
graphed	VBN	O
relative	JJ	O
to	TO	O
untreated	JJ	O
cells.	.	O
As	IN	O
demonstrated	VBN	O
in	IN	O
the	DT	O
figure,	,	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
the	DT	O
ability	NN	O
to	TO	O
penetrate	VB	O
cells	NNS	O
and	CC	O
enter	VB	O
both	DT	O
the	DT	O
cytoplasm	NN	O
and	CC	O
detergent	NN	O
resistant	JJ	O
membrane	NN	O
components.	.	O
This	DT	O
property	NN	O
of	IN	O
the	DT	O
drug	NN	O
is	VBZ	O
enhanced	VBN	O
in	IN	O
polypeptides	NNS	O
with	IN	O
Class	NNP	O
III	NNP	O
modifications	NNS	O
as	IN	O
described	VBN	O
in	IN	O
the	DT	O
figure.	.	O
FIG.	.	O
6A.	.	O
Coomassie	NNP	O
stained	VBD	O
12%	NN	O
polyacrylamide	JJ	O
gel	NN	O
of	IN	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
(the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:2	NNP	O
(SEQ	NNP	O
ID	NNP	O
NO:2)	)	O
of	IN	O
FIG.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention)	)	O
conjugated	VBD	O
to	TO	O
a	DT	O
20	CD	O
kilodalton,	,	O
single	JJ	O
chain,	,	O
maleimide	RB	O
conjugated	VBD	O
polyethylene	JJ	O
glycol	NN	O
(mPEG-MAL	JJ	O
20	CD	O
kDa).	.	O
Lane	NNP	O
1,	,	O
MW	NNP	O
standards;	:	O
lane	VBZ	O
2,	,	O
unmodified	JJ	O
polypeptide,	,	O
lanes	VBZ	O
3-7,	,	O
polypeptide	RB	O
reacted	VBD	O
with	IN	O
mPEG-MAL	JJ	O
20	CD	O
kDa	NN	O
at	IN	O
molar	JJ	O
ratios	NNS	O
of	IN	O
0.5:1,	,	O
1:1,	,	O
2:1,	,	O
5:1,	,	O
and	CC	O
10:1,	,	O
respectively.	.	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
well	RB	O
conjugated	VBN	O
through	IN	O
cysteine	NN	O
residues	NNS	O
to	TO	O
polyethylene	VB	O
glycols.	.	O
FIG.	.	O
6B.	.	O
Coomassie	NNP	O
stained	VBD	O
12%	NN	O
polyacrylamide	JJ	O
gel	NN	O
of	IN	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
(the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:2	NNP	O
(SEQ	NNP	O
ID	NNP	O
NO:2)	)	O
of	IN	O
FIG.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention)	)	O
conjugated	VBD	O
to	TO	O
a	DT	O
40	CD	O
kilodalton,	,	O
branched	VBD	O
chain,	,	O
maleimide	RB	O
conjugated	VBD	O
polyethylene	JJ	O
glycol	NN	O
(mPEG2-MAL	JJ	O
40	CD	O
kDa).	.	O
Lane	NNP	O
1,	,	O
MW	NNP	O
standards,	,	O
lane	NN	O
2,	,	O
unmodified	JJ	O
polypeptide,	,	O
lanes	VBZ	O
3-7,	,	O
polypeptide	RB	O
reacted	VBD	O
with	IN	O
mPEG2-MAL	JJ	O
40	CD	O
kDa	NN	O
at	IN	O
molar	JJ	O
ratios	NNS	O
of	IN	O
0.5:1,	,	O
1:1,	,	O
2:1,	,	O
5:1,	,	O
and	CC	O
10:1,	,	O
respectively.	.	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
well	RB	O
conjugated	VBN	O
to	TO	O
polyethylene	VB	O
glycols	NNS	O
through	IN	O
reactive	JJ	O
cysteines.	.	O
FIG.	.	O
6C.	.	O
Oligoadenylate	NNP	O
synthetase	NN	O
activity	NN	O
of	IN	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
(the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:2	NNP	O
(SEQ	NNP	O
ID	NNP	O
NO:2)	)	O
of	IN	O
FIG.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention)	)	O
conjugated	VBD	O
to	TO	O
mPEG2-MAL	JJ	O
20	CD	O
kDa	NN	O
or	CC	O
branched	VBN	O
mPEG2-MAL	JJ	O
40	CD	O
kDa.	.	O
Lane	NNP	O
1,	,	O
unmodified	JJ	O
polypeptide.	.	O
Lanes	NNS	O
2-6,	,	O
PEG2-MAL	JJ	O
20	CD	O
kDa-conjugated	JJ	O
polypeptides	NNS	O
reacted	VBD	O
at	IN	O
0.5:1,	,	O
1:1,	,	O
2:1,	,	O
5:1,	,	O
and	CC	O
10:1	CD	O
molar	JJ	O
ratios,	,	O
respectively.	.	O
Lanes	NNS	O
7-11,	,	O
mPEG-MAL	JJ	O
20	CD	O
kDa-conjugated	JJ	O
polypeptides	NNS	O
reacted	VBD	O
at	IN	O
0.5:1,	,	O
1:1,	,	O
2:1,	,	O
5:1,	,	O
and	CC	O
10:1	CD	O
molar	JJ	O
ratios,	,	O
respectively.	.	O
As	IN	O
can	MD	O
be	VB	O
seen	VBN	O
from	IN	O
the	DT	O
figure,	,	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
retain	VBP	O
full	JJ	O
enzymatic	JJ	O
activity	NN	O
when	WRB	O
conjugated	VBN	O
to	TO	O
polyethylene	VB	O
glycol	NN	O
at	IN	O
reactive	JJ	O
cysteines.	.	O
FIG.	.	O
7	CD	O
shows	VBZ	O
the	DT	O
polynucleotide	JJ	O
sequences	NNS	O
of	IN	O
SEQUENCE	NNP	O
2	CD	O
(SEQ	NNP	O
ID	NNP	O
NO:2);	:	O
SEQUENCE	$	O
3	CD	O
(SEQ	NNP	O
ID	NNP	O
NO:3);	:	O
and	CC	O
SEQUENCE	$	O
4	CD	O
(SEQ	NNP	O
ID	NNP	O
NO:4).	.	O
DETAILED	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Introduction	NNP	O
and	CC	O
Definitions	NNP	O
We	PRP	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
mutations	NNS	O
in	IN	O
the	DT	O
OAS	NNP	O
genes	NNS	O
confer	VBP	O
resistance	NN	O
to	TO	O
virus	VB	O
infection.	.	O
(U.S.	NNP	O
Patent	NNP	O
Application	NNP	O
Ser.	.	O
Nos.	.	O
60/513,888,	,	O
filed	VBN	O
Oct.	NNP	O
23,	,	O
2003;	:	O
60/542,373,	,	O
filed	VBD	O
Feb.	NNP	O
6,	,	O
2004;	:	O
60/554,758,	,	O
filed	VBN	O
Mar.	.	O
19,	,	O
2004;	:	O
60/560,524,	,	O
filed	VBN	O
Apr.	.	O
8,	,	O
2004;	:	O
60/578,323,	,	O
filed	VBN	O
Jun.	.	O
8,	,	O
2004;	:	O
60/605,243,	,	O
filed	VBN	O
Aug.	NNP	O
26,	,	O
2004;	:	O
10/972,135,	,	O
filed	VBN	O
Oct.	NNP	O
22,	,	O
2004;	:	O
60/677,680,	,	O
filed	VBD	O
May	NNP	O
4,	,	O
2005;	:	O
and	CC	O
60/710,704,	,	O
filed	VBN	O
Aug.	NNP	O
23,	,	O
2004,	,	O
all	DT	O
of	IN	O
which	WDT	O
are	VBP	O
incorporated	VBN	O
by	IN	O
reference	NN	O
herein.)	)	O
Several	JJ	O
novel	JJ	O
forms	NNS	O
of	IN	O
the	DT	O
OAS	NNP	O
1,	,	O
OAS2,	,	O
and	CC	O
OAS3	NNP	O
genes	NNS	O
have	VBP	O
been	VBN	O
cloned	VBN	O
by	IN	O
us,	,	O
and	CC	O
we	PRP	O
have	VBP	O
developed	VBN	O
pharmaceutical	JJ	O
compositions	NNS	O
derived	VBN	O
from	IN	O
these	DT	O
and	CC	O
other	JJ	O
novel	JJ	O
oligoadenylate	JJ	O
synthetase	NN	O
forms.	.	O
We	PRP	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
these	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
are	VBP	O
antiviral	JJ	O
in	IN	O
vitro	NN	O
and	CC	O
cause	NN	O
growth	NN	O
arrest	NN	O
in	IN	O
cancer	NN	O
cell	NN	O
lines.	.	O
We	PRP	O
have	VBP	O
further	RB	O
demonstrated	VBN	O
that	IN	O
these	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
promote	VBP	O
cellular	JJ	O
growth	NN	O
in	IN	O
certain	JJ	O
cell	NN	O
lines.	.	O
We	PRP	O
have	VBP	O
further	RB	O
demonstrated	VBN	O
that	IN	O
these	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
have	VBP	O
a	DT	O
mitogenic	JJ	O
effect.	.	O
We	PRP	O
have	VBP	O
further	RB	O
demonstrated	VBN	O
that	IN	O
these	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
have	VBP	O
the	DT	O
ability	NN	O
to	TO	O
enter	VB	O
a	DT	O
cell	NN	O
and	CC	O
remain	VBP	O
enzymatically	RB	O
active	JJ	O
in	IN	O
intracellular	JJ	O
stores	NNS	O
for	IN	O
several	JJ	O
days	NNS	O
or	CC	O
more.	.	O
We	PRP	O
have	VBP	O
further	RB	O
demonstrated	VBN	O
that	IN	O
the	DT	O
cell-penetrating	JJ	O
property	NN	O
of	IN	O
the	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
can	MD	O
be	VB	O
enhanced	VBN	O
through	IN	O
the	DT	O
addition	NN	O
of	IN	O
basic	JJ	O
amino	NN	O
acid	NN	O
residues	NNS	O
including	VBG	O
arginine,	,	O
lysine,	,	O
and	CC	O
histidine	NN	O
(described	VBN	O
as	IN	O
Class	NNP	O
III	NNP	O
in	IN	O
FIG.	.	O
1).	.	O
We	PRP	O
have	VBP	O
further	RB	O
demonstrated	VBN	O
that	IN	O
these	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
have	VBP	O
broad	JJ	O
antiviral	JJ	O
activity.	.	O
We	PRP	O
have	VBP	O
further	RB	O
demonstrated	VBN	O
that	IN	O
these	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
can	MD	O
be	VB	O
derivatized	VBN	O
with	IN	O
polyethylene	NN	O
glycol	NN	O
and	CC	O
retain	VB	O
their	PRP$	O
enzymatic	JJ	O
activity.	.	O
We	PRP	O
show	VBP	O
that	IN	O
the	DT	O
stability	NN	O
of	IN	O
the	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
is	VBZ	O
dependent	JJ	O
on	IN	O
the	DT	O
presence	NN	O
of	IN	O
reducing	VBG	O
agents	NNS	O
and	CC	O
we	PRP	O
propose	VBP	O
several	JJ	O
modifications	NNS	O
to	TO	O
provide	VB	O
more	JJR	O
oxidation	NN	O
resistant	JJ	O
forms	NNS	O
of	IN	O
the	DT	O
protein.	.	O
We	PRP	O
demonstrate	VBP	O
that	IN	O
bulk	NN	O
quantities	NNS	O
of	IN	O
the	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
can	MD	O
be	VB	O
manufactured	VBN	O
using	VBG	O
recombinant	JJ	O
DNA	NNP	O
technologies	NNS	O
by	IN	O
expression	NN	O
in	IN	O
Escherichia	NNP	O
coli.	.	O
We	PRP	O
further	VBP	O
demonstrate	VB	O
that	IN	O
these	DT	O
manufactured	VBD	O
pharmaceutical	JJ	O
compositions	NNS	O
can	MD	O
be	VB	O
administered	VBN	O
to	TO	O
mammals	NNS	O
and	CC	O
produce	VBP	O
no	DT	O
observable	JJ	O
toxic	NN	O
effects.	.	O
We	PRP	O
further	VBP	O
demonstrate	VB	O
that	IN	O
these	DT	O
manufactured	VBD	O
pharmaceutical	JJ	O
compositions	NNS	O
have	VBP	O
good	JJ	O
biodistribution	NN	O
and	CC	O
pharmacokinetic	JJ	O
properties	NNS	O
when	WRB	O
administered	VBN	O
to	TO	O
a	DT	O
mammal	JJ	O
by	IN	O
injection.	.	O
The	DT	O
present	JJ	O
invention	NN	O
describes	VBZ	O
mutant	JJ	O
or	CC	O
modified	JJ	O
oligoadenylate	JJ	O
synthetase	NN	O
polypeptides	NNS	O
that	WDT	O
efficiently	RB	O
enter	VBP	O
mammalian	JJ	O
cells	NNS	O
and	CC	O
enhance	VB	O
the	DT	O
performance	NN	O
of	IN	O
the	DT	O
OAS-RNAse	NNP	O
L	NNP	O
pathway.	.	O
These	DT	O
novel	JJ	O
polypeptide	NN	O
compositions	NNS	O
are	VBP	O
antiviral	JJ	O
in	IN	O
in	IN	O
vitro	NN	O
cell	NN	O
culture	NN	O
models.	.	O
They	PRP	O
also	RB	O
cause	VBP	O
certain	JJ	O
transformed	VBN	O
cell	NN	O
lines	NNS	O
to	TO	O
undergo	VB	O
growth	NN	O
arrest	NN	O
and	CC	O
promote	NN	O
cellular	JJ	O
growth	NN	O
in	IN	O
other	JJ	O
cell	NN	O
lines.	.	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
comprise	NN	O
five	CD	O
classes	NNS	O
of	IN	O
modified	JJ	O
oligoadenylate	JJ	O
synthetase	NN	O
proteins,	,	O
including:	:	O
Class	NN	O
I,	,	O
enzymatically	RB	O
inactive	JJ	O
antiviral	JJ	O
forms;	:	O
Class	NNP	O
II,	,	O
oxidation	NN	O
resistant	JJ	O
forms;	:	O
Class	NNP	O
III,	,	O
enhanced	VBD	O
cell	NN	O
permeable	JJ	O
forms;	:	O
Class	NNP	O
IV,	,	O
polyethylene	NN	O
glycol	NN	O
conjugated	VBD	O
forms;	:	O
and	CC	O
Class	NNP	O
V,	,	O
mixed	JJ	O
developmental	NN	O
and	CC	O
optimization	NN	O
forms.	.	O
The	DT	O
invention	NN	O
relates	VBZ	O
to	TO	O
the	DT	O
manufacture	NN	O
and	CC	O
use	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
virus	NN	O
infection,	,	O
inflammation,	,	O
and	CC	O
neoplastic	JJ	O
disease	NN	O
and	CC	O
to	TO	O
promote	VB	O
cellular	JJ	O
growth	NN	O
and	CC	O
regeneration	NN	O
in	IN	O
mammals.	.	O
In	IN	O
reference	NN	O
to	TO	O
the	DT	O
detailed	JJ	O
description,	,	O
the	DT	O
following	JJ	O
definitions	NNS	O
are	VBP	O
used:	:	O
A:	:	O
adenine;	:	O
C:	:	O
cytosine;	:	O
G:	:	O
guanine;	:	O
T:	:	O
thymine	NN	O
(in	IN	O
DNA);	:	O
and	CC	O
U:	:	O
uracil	NN	O
(in	IN	O
RNA)	)	O
Allele:	:	O
A	DT	O
variant	NN	O
of	IN	O
DNA	NNP	O
sequence	NN	O
of	IN	O
a	DT	O
specific	JJ	O
gene.	.	O
In	IN	O
diploid	JJ	O
cells	NNS	O
a	DT	O
maximum	NN	O
of	IN	O
two	CD	O
alleles	NNS	O
will	MD	O
be	VB	O
present,	,	O
each	DT	O
in	IN	O
the	DT	O
same	JJ	O
relative	JJ	O
position	NN	O
or	CC	O
locus	NN	O
on	IN	O
homologous	JJ	O
chromosomes	NNS	O
of	IN	O
the	DT	O
chromosome	NN	O
set.	.	O
When	WRB	O
alleles	NNS	O
at	IN	O
any	DT	O
one	CD	O
locus	NN	O
are	VBP	O
identical	JJ	O
the	DT	O
individual	NN	O
is	VBZ	O
said	VBD	O
to	TO	O
be	VB	O
homozygous	JJ	O
for	IN	O
that	DT	O
locus,	,	O
and	CC	O
when	WRB	O
they	PRP	O
differ	VBP	O
the	DT	O
individual	NN	O
is	VBZ	O
said	VBD	O
to	TO	O
be	VB	O
heterozygous	JJ	O
for	IN	O
that	DT	O
locus.	.	O
Since	IN	O
different	JJ	O
alleles	NNS	O
of	IN	O
any	DT	O
one	CD	O
gene	NN	O
may	MD	O
vary	VB	O
by	IN	O
only	RB	O
a	DT	O
single	JJ	O
base,	,	O
the	DT	O
possible	JJ	O
number	NN	O
of	IN	O
alleles	NNS	O
for	IN	O
any	DT	O
one	CD	O
gene	NN	O
is	VBZ	O
very	RB	O
large.	.	O
When	WRB	O
alleles	NNS	O
differ,	,	O
one	CD	O
is	VBZ	O
often	RB	O
dominant	JJ	O
to	TO	O
the	DT	O
other,	,	O
which	WDT	O
is	VBZ	O
said	VBD	O
to	TO	O
be	VB	O
recessive.	.	O
Dominance	NN	O
is	VBZ	O
a	DT	O
property	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
and	CC	O
does	VBZ	O
not	RB	O
imply	VB	O
inactivation	NN	O
of	IN	O
the	DT	O
recessive	JJ	O
allele	NN	O
by	IN	O
the	DT	O
dominant.	.	O
In	IN	O
numerous	JJ	O
examples	NNS	O
the	DT	O
normally	RB	O
functioning	JJ	O
(wild-type)	)	O
allele	NN	O
is	VBZ	O
dominant	JJ	O
to	TO	O
all	DT	O
mutant	JJ	O
alleles	NNS	O
of	IN	O
more	JJR	O
or	CC	O
less	RBR	O
defective	JJ	O
function.	.	O
In	IN	O
such	JJ	O
cases	NNS	O
the	DT	O
general	JJ	O
explanation	NN	O
is	VBZ	O
that	IN	O
one	CD	O
functional	JJ	O
allele	VBZ	O
out	IN	O
of	IN	O
two	CD	O
is	VBZ	O
sufficient	JJ	O
to	TO	O
produce	VB	O
enough	JJ	O
active	JJ	O
gene	NN	O
product	NN	O
to	TO	O
support	VB	O
normal	JJ	O
development	NN	O
of	IN	O
the	DT	O
organism	NN	O
(i.e.,	,	O
there	EX	O
is	VBZ	O
normally	RB	O
a	DT	O
two-fold	JJ	O
safety	NN	O
margin	NN	O
in	IN	O
quantity	NN	O
of	IN	O
gene	NN	O
product).	.	O
Haplotype:	:	O
One	CD	O
of	IN	O
many	JJ	O
possible	JJ	O
pluralities	NNS	O
of	IN	O
Alleles,	,	O
serially	RB	O
ordered	VBN	O
by	IN	O
chromosomal	JJ	O
localization	NN	O
and	CC	O
representing	VBG	O
that	DT	O
set	NN	O
of	IN	O
Alleles	NNP	O
carried	VBN	O
by	IN	O
one	CD	O
particular	JJ	O
homologous	JJ	O
chromosome	NN	O
of	IN	O
the	DT	O
chromosome	NN	O
set.	.	O
Nucleotide:	:	O
A	DT	O
monomeric	JJ	O
unit	NN	O
of	IN	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
consisting	NN	O
of	IN	O
a	DT	O
sugar	NN	O
moiety	NN	O
(pentose),	,	O
a	DT	O
phosphate,	,	O
and	CC	O
a	DT	O
nitrogenous	JJ	O
heterocyclic	JJ	O
base.	.	O
The	DT	O
base	NN	O
is	VBZ	O
linked	VBN	O
to	TO	O
the	DT	O
sugar	NN	O
moiety	NN	O
via	IN	O
the	DT	O
glycosidic	JJ	O
carbon	NN	O
(1′	CD	O
carbon	NN	O
of	IN	O
the	DT	O
pentose)	)	O
and	CC	O
that	DT	O
combination	NN	O
of	IN	O
base	NN	O
and	CC	O
sugar	NN	O
is	VBZ	O
a	DT	O
nucleoside.	.	O
When	WRB	O
the	DT	O
nucleoside	NN	O
contains	VBZ	O
a	DT	O
phosphate	NN	O
group	NN	O
bonded	VBD	O
to	TO	O
the	DT	O
3′	CD	O
or	CC	O
5′	CD	O
position	NN	O
of	IN	O
the	DT	O
pentose	NN	O
it	PRP	O
is	VBZ	O
referred	VBN	O
to	TO	O
as	IN	O
a	DT	O
nucleotide.	.	O
A	DT	O
sequence	NN	O
of	IN	O
operatively	RB	O
linked	VBN	O
nucleotides	NNS	O
is	VBZ	O
typically	RB	O
referred	VBN	O
to	TO	O
herein	VB	O
as	IN	O
a	DT	O
“base	NN	O
sequence”	NN	O
or	CC	O
“nucleotide	JJ	O
sequence”,	,	O
and	CC	O
their	PRP$	O
grammatical	JJ	O
equivalents,	,	O
and	CC	O
is	VBZ	O
represented	VBN	O
herein	NN	O
by	IN	O
a	DT	O
formula	NN	O
whose	WP$	O
left	VBD	O
to	TO	O
right	JJ	O
orientation	NN	O
is	VBZ	O
in	IN	O
the	DT	O
conventional	JJ	O
direction	NN	O
of	IN	O
5′-terminus	JJ	O
to	TO	O
3′-terminus.	.	O
Base	NNP	O
Pair	NNP	O
(bp):	:	O
A	DT	O
partnership	NN	O
of	IN	O
adenine	NN	O
(A)	)	O
with	IN	O
thymine	NN	O
(T),	,	O
or	CC	O
of	IN	O
cytosine	NN	O
(C)	)	O
with	IN	O
guanine	NN	O
(G)	)	O
in	IN	O
a	DT	O
double	JJ	O
stranded	JJ	O
DNA	NN	O
molecule.	.	O
In	IN	O
RNA,	,	O
uracil	NN	O
(U)	)	O
is	VBZ	O
substituted	VBN	O
for	IN	O
thymine.	.	O
When	WRB	O
referring	VBG	O
to	TO	O
RNA	NNP	O
herein,	,	O
the	DT	O
symbol	NN	O
T	NNP	O
may	MD	O
be	VB	O
used	VBN	O
interchangeably	RB	O
with	IN	O
U	NNP	O
to	TO	O
represent	VB	O
uracil	NN	O
at	IN	O
a	DT	O
particular	JJ	O
position	NN	O
in	IN	O
the	DT	O
RNA	NNP	O
molecule.	.	O
Nucleic	JJ	O
Acid:	:	O
A	DT	O
polymer	NN	O
of	IN	O
nucleotides,	,	O
either	CC	O
single	JJ	O
or	CC	O
double	JJ	O
stranded.	.	O
Polynucleotide:	:	O
A	DT	O
polymer	NN	O
of	IN	O
single	JJ	O
or	CC	O
double	JJ	O
stranded	JJ	O
nucleotides.	.	O
As	IN	O
used	VBN	O
herein	NN	O
“polynucleotide”	CD	O
and	CC	O
its	PRP$	O
grammatical	JJ	O
equivalents	NNS	O
will	MD	O
include	VB	O
the	DT	O
full	JJ	O
range	NN	O
of	IN	O
nucleic	JJ	O
acids.	.	O
A	DT	O
polynucleotide	NN	O
will	MD	O
typically	RB	O
refer	VB	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
comprised	VBN	O
of	IN	O
a	DT	O
linear	JJ	O
strand	NN	O
of	IN	O
two	CD	O
or	CC	O
more	JJR	O
deoxyribonucleotides	NNS	O
and/or	VBP	O
ribonucleotides.	.	O
The	DT	O
exact	JJ	O
size	NN	O
will	MD	O
depend	VB	O
on	IN	O
many	JJ	O
factors,	,	O
which	WDT	O
in	IN	O
turn	NN	O
depends	NNS	O
on	IN	O
the	DT	O
ultimate	JJ	O
conditions	NNS	O
of	IN	O
use,	,	O
as	IN	O
is	VBZ	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art.	.	O
The	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
primers,	,	O
probes,	,	O
RNA/DNA	NNP	O
segments,	,	O
oligonucleotides	NNS	O
or	CC	O
“oligos”	NN	O
(relatively	RB	O
short	JJ	O
polynucleotides),	,	O
genes,	,	O
vectors,	,	O
plasmids,	,	O
and	CC	O
the	DT	O
like.	.	O
Gene:	:	O
A	DT	O
nucleic	JJ	O
acid	NN	O
whose	WP$	O
nucleotide	JJ	O
sequence	NN	O
codes	NNS	O
for	IN	O
an	DT	O
RNA	NNP	O
or	CC	O
polypeptide.	.	O
A	DT	O
gene	NN	O
can	MD	O
be	VB	O
either	CC	O
RNA	NNP	O
or	CC	O
DNA.	.	O
Duplex	NNP	O
DNA:	:	O
A	DT	O
double-stranded	JJ	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
comprising	VBG	O
two	CD	O
strands	NNS	O
of	IN	O
substantially	RB	O
complementary	JJ	O
polynucleotides	NNS	O
held	VBD	O
together	RB	O
by	IN	O
one	CD	O
or	CC	O
more	JJR	O
hydrogen	JJ	O
bonds	NNS	O
between	IN	O
each	DT	O
of	IN	O
the	DT	O
complementary	JJ	O
bases	NNS	O
present	VBP	O
in	IN	O
a	DT	O
base	JJ	O
pair	NN	O
of	IN	O
the	DT	O
duplex.	.	O
Because	IN	O
the	DT	O
nucleotides	NNS	O
that	WDT	O
form	VBP	O
a	DT	O
base	NN	O
pair	NN	O
can	MD	O
be	VB	O
either	CC	O
a	DT	O
ribonucleotide	JJ	O
base	NN	O
or	CC	O
a	DT	O
deoxyribonucleotide	JJ	O
base,	,	O
the	DT	O
phrase	NN	O
“duplex	NNP	O
DNA”	NNP	O
refers	NNS	O
to	TO	O
either	VB	O
a	DT	O
DNA-DNA	JJ	O
duplex	JJ	O
comprising	VBG	O
two	CD	O
DNA	NNP	O
strands	NNS	O
(ds	VB	O
DNA),	,	O
or	CC	O
an	DT	O
RNA-DNA	JJ	O
duplex	NN	O
comprising	VBG	O
one	CD	O
DNA	NN	O
and	CC	O
one	CD	O
RNA	NNP	O
strand.	.	O
Complementary	JJ	O
Bases	NNP	O
Nucleotides	NNP	O
that	IN	O
normally	RB	O
pair	VB	O
up	RP	O
when	WRB	O
DNA	NN	O
or	CC	O
RNA	NNP	O
adopts	VBZ	O
a	DT	O
double	JJ	O
stranded	JJ	O
configuration.	.	O
Complementary	NNP	O
Nucleotide	NNP	O
Sequence:	:	O
A	DT	O
sequence	NN	O
of	IN	O
nucleotides	NNS	O
in	IN	O
a	DT	O
single-stranded	JJ	O
molecule	NN	O
of	IN	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
that	WDT	O
is	VBZ	O
sufficiently	RB	O
complementary	JJ	O
to	TO	O
that	DT	O
on	IN	O
another	DT	O
single	JJ	O
strand	NN	O
to	TO	O
specifically	RB	O
hybridize	VB	O
to	TO	O
it	PRP	O
with	IN	O
consequent	JJ	O
hydrogen	NN	O
bonding.	.	O
Conserved:	:	O
A	DT	O
nucleotide	JJ	O
sequence	NN	O
is	VBZ	O
conserved	VBN	O
with	IN	O
respect	NN	O
to	TO	O
a	DT	O
preselected	VBN	O
(reference)	)	O
sequence	NN	O
if	IN	O
it	PRP	O
non-randomly	RB	O
hybridizes	VBZ	O
to	TO	O
an	DT	O
exact	JJ	O
complement	NN	O
of	IN	O
the	DT	O
preselected	JJ	O
sequence.	.	O
Hybridization:	:	O
The	DT	O
pairing	NN	O
of	IN	O
substantially	RB	O
complementary	JJ	O
nucleotide	NN	O
sequences	NNS	O
(strands	NNS	O
of	IN	O
nucleic	JJ	O
acid)	)	O
to	TO	O
form	VB	O
a	DT	O
duplex	NN	O
or	CC	O
heteroduplex	NN	O
by	IN	O
the	DT	O
establishment	NN	O
of	IN	O
hydrogen	NN	O
bonds	NNS	O
between	IN	O
complementary	JJ	O
base	NN	O
pairs.	.	O
It	PRP	O
is	VBZ	O
a	DT	O
specific,	,	O
i.e.	.	O
non-random,	,	O
interaction	NN	O
between	IN	O
two	CD	O
complementary	JJ	O
polynucleotides	NNS	O
that	WDT	O
can	MD	O
be	VB	O
competitively	RB	O
inhibited.	.	O
Nucleotide	NNP	O
Analog:	:	O
A	DT	O
purine	NN	O
or	CC	O
pyrimidine	VB	O
nucleotide	IN	O
that	DT	O
differs	NNS	O
structurally	RB	O
from	IN	O
A,	,	O
T,	,	O
G,	,	O
C,	,	O
or	CC	O
U,	,	O
but	CC	O
is	VBZ	O
sufficiently	RB	O
similar	JJ	O
to	TO	O
substitute	VB	O
for	IN	O
the	DT	O
normal	JJ	O
nucleotide	NN	O
in	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule.	.	O
DNA	NN	O
Homolog:	:	O
A	DT	O
nucleic	JJ	O
acid	NN	O
having	VBG	O
a	DT	O
preselected	VBN	O
conserved	JJ	O
nucleotide	JJ	O
sequence	NN	O
and	CC	O
a	DT	O
sequence	NN	O
coding	NN	O
for	IN	O
a	DT	O
receptor	NN	O
capable	JJ	O
of	IN	O
binding	VBG	O
a	DT	O
preselected	JJ	O
ligand.	.	O
Upstream:	:	O
In	IN	O
the	DT	O
direction	NN	O
opposite	NN	O
to	TO	O
the	DT	O
direction	NN	O
of	IN	O
DNA	NNP	O
transcription,	,	O
and	CC	O
therefore	RB	O
going	VBG	O
from	IN	O
5′	CD	O
to	TO	O
3′	CD	O
on	IN	O
the	DT	O
non-coding	JJ	O
strand,	,	O
or	CC	O
3′	CD	O
to	TO	O
5′	CD	O
on	IN	O
the	DT	O
mRNA.	.	O
Downstream:	:	O
Further	RB	O
along	IN	O
a	DT	O
DNA	NN	O
sequence	NN	O
in	IN	O
the	DT	O
direction	NN	O
of	IN	O
sequence	NN	O
transcription	NN	O
or	CC	O
read	VB	O
out,	,	O
that	WDT	O
is	VBZ	O
traveling	VBG	O
in	IN	O
a	DT	O
3′-	JJ	O
to	TO	O
5′-direction	JJ	O
along	IN	O
the	DT	O
non-coding	JJ	O
strand	NN	O
of	IN	O
the	DT	O
DNA	NN	O
or	CC	O
5′-	JJ	O
to	TO	O
3′-direction	JJ	O
along	IN	O
the	DT	O
RNA	NNP	O
transcript.	.	O
Stop	NNP	O
Codon:	:	O
Any	NN	O
of	IN	O
three	CD	O
codons	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
code	VB	O
for	IN	O
an	DT	O
amino	NN	O
acid,	,	O
but	CC	O
instead	RB	O
cause	VB	O
termination	NN	O
of	IN	O
protein	JJ	O
synthesis.	.	O
They	PRP	O
are	VBP	O
UAG,	,	O
UAA	NNP	O
and	CC	O
UGA	NNP	O
and	CC	O
are	VBP	O
also	RB	O
referred	VBN	O
to	TO	O
as	IN	O
a	DT	O
nonsense	NN	O
or	CC	O
termination	NN	O
codon.	.	O
Reading	VBG	O
Frame:	:	O
Particular	JJ	O
sequence	NN	O
of	IN	O
contiguous	JJ	O
nucleotide	JJ	O
triplets	NNS	O
(codons)	)	O
employed	VBN	O
in	IN	O
translation.	.	O
The	DT	O
reading	NN	O
frame	NN	O
depends	VBZ	O
on	IN	O
the	DT	O
location	NN	O
of	IN	O
the	DT	O
translation	NN	O
initiation	NN	O
codon.	.	O
Intron:	:	O
Also	RB	O
referred	VBD	O
to	TO	O
as	IN	O
an	DT	O
intervening	NN	O
sequence,	,	O
a	DT	O
noncoding	JJ	O
sequence	NN	O
of	IN	O
DNA	NN	O
that	WDT	O
is	VBZ	O
initially	RB	O
copied	VBN	O
into	IN	O
RNA	NNP	O
but	CC	O
is	VBZ	O
cut	VBN	O
out	IN	O
of	IN	O
the	DT	O
final	JJ	O
RNA	NNP	O
transcript.	.	O
Protein	NNP	O
or	CC	O
polypeptide:	:	O
The	DT	O
term	NN	O
“protein”	NN	O
or	CC	O
“polypeptide”	JJ	O
refers	NNS	O
to	TO	O
a	DT	O
polymer	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
and	CC	O
does	VBZ	O
not	RB	O
refer	VB	O
to	TO	O
a	DT	O
specific	JJ	O
length	NN	O
of	IN	O
the	DT	O
product.	.	O
Peptides,	,	O
oligopeptides,	,	O
polypeptides,	,	O
proteins,	,	O
and	CC	O
polyproteins,	,	O
as	RB	O
well	RB	O
as	IN	O
fragments	NNS	O
of	IN	O
these,	,	O
are	VBP	O
included	VBN	O
within	IN	O
this	DT	O
definition.	.	O
The	DT	O
term	NN	O
may	MD	O
include	VB	O
post	NN	O
expression	NN	O
modifications	NNS	O
of	IN	O
the	DT	O
protein,	,	O
for	IN	O
example,	,	O
glycosylations,	,	O
acetylations,	,	O
phosphorylations	NNS	O
and	CC	O
the	DT	O
like.	.	O
Included	VBN	O
within	IN	O
the	DT	O
definition	NN	O
are,	,	O
for	IN	O
example,	,	O
proteins	VBZ	O
containing	VBG	O
one	CD	O
or	CC	O
more	JJR	O
analogs	NNS	O
of	IN	O
an	DT	O
amino	NN	O
acid	NN	O
(including,	,	O
for	IN	O
example,	,	O
unnatural	JJ	O
amino	NN	O
acids,	,	O
etc.),	,	O
proteins	VBZ	O
with	IN	O
substituted	JJ	O
linkages,	,	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
modifications	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art,	,	O
both	DT	O
naturally	RB	O
occurring	VBG	O
and	CC	O
non-naturally	RB	O
occurring.	.	O
Unless	IN	O
otherwise	RB	O
indicated,	,	O
the	DT	O
position	NN	O
numbering	NN	O
of	IN	O
amino	NN	O
acid	NN	O
residues	NNS	O
recited	VBN	O
herein	NN	O
is	VBZ	O
relative	JJ	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
SEQUENCE:1	NNP	O
(SEQ	NNP	O
ID	NNP	O
NO:1)	)	O
of	IN	O
FIG.	.	O
1.	.	O
A	DT	O
“variant”	NN	O
is	VBZ	O
a	DT	O
polypeptide	JJ	O
comprising	VBG	O
a	DT	O
sequence	NN	O
which	WDT	O
differs	NNS	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
amino	JJ	O
acid	JJ	O
position(s)	)	O
from	IN	O
that	DT	O
of	IN	O
a	DT	O
parent	NN	O
polypeptide	NN	O
sequence.	.	O
The	DT	O
term	NN	O
“parent	NN	O
polypeptide”	NN	O
is	VBZ	O
intended	VBN	O
to	TO	O
indicate	VB	O
the	DT	O
polypeptide	NN	O
sequence	NN	O
to	TO	O
be	VB	O
modified	VBN	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention.	.	O
A	DT	O
“fragment”	NN	O
or	CC	O
“subsequence”	NN	O
is	VBZ	O
any	DT	O
portion	NN	O
of	IN	O
an	DT	O
entire	JJ	O
sequence,	,	O
up	RB	O
to	TO	O
but	CC	O
not	RB	O
including	VBG	O
the	DT	O
entire	JJ	O
sequence.	.	O
Thus,	,	O
a	DT	O
fragment	NN	O
or	CC	O
subsequence	NN	O
refers	NNS	O
to	TO	O
a	DT	O
sequence	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
or	CC	O
nucleic	JJ	O
acids	NNS	O
that	WDT	O
comprises	VBZ	O
a	DT	O
part	NN	O
of	IN	O
a	DT	O
longer	JJR	O
sequence	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
(e.g.,	,	O
polypeptide)	)	O
or	CC	O
nucleic	JJ	O
acids	NNS	O
(e.g.,	,	O
polynucleotide).	.	O
A	DT	O
polypeptide,	,	O
nucleic	JJ	O
acid,	,	O
or	CC	O
other	JJ	O
component	NN	O
is	VBZ	O
“isolated”	JJ	O
when	WRB	O
it	PRP	O
is	VBZ	O
partially	RB	O
or	CC	O
completely	RB	O
separated	VBN	O
from	IN	O
components	NNS	O
with	IN	O
which	WDT	O
it	PRP	O
is	VBZ	O
normally	RB	O
associated	VBN	O
(other	JJ	O
peptides,	,	O
polypeptides,	,	O
proteins	NNS	O
(including	VBG	O
complexes,	,	O
e.g.,	,	O
polymerases	NNS	O
and	CC	O
ribosomes	NNS	O
which	WDT	O
may	MD	O
accompany	VB	O
a	DT	O
native	JJ	O
sequence),	,	O
nucleic	JJ	O
acids,	,	O
cells,	,	O
synthetic	JJ	O
reagents,	,	O
cellular	JJ	O
contaminants,	,	O
cellular	JJ	O
components,	,	O
etc.),	,	O
e.g.,	,	O
such	JJ	O
as	IN	O
from	IN	O
other	JJ	O
components	NNS	O
with	IN	O
which	WDT	O
it	PRP	O
is	VBZ	O
normally	RB	O
associated	VBN	O
in	IN	O
the	DT	O
cell	NN	O
from	IN	O
which	WDT	O
it	PRP	O
was	VBD	O
originally	RB	O
derived.	.	O
A	DT	O
polypeptide,	,	O
nucleic	JJ	O
acid,	,	O
or	CC	O
other	JJ	O
component	NN	O
is	VBZ	O
isolated	VBN	O
when	WRB	O
it	PRP	O
is	VBZ	O
partially	RB	O
or	CC	O
completely	RB	O
recovered	VBD	O
or	CC	O
separated	VBN	O
from	IN	O
other	JJ	O
components	NNS	O
of	IN	O
its	PRP$	O
natural	JJ	O
environment	NN	O
such	JJ	O
that	IN	O
it	PRP	O
is	VBZ	O
the	DT	O
predominant	JJ	O
species	NNS	O
present	VBP	O
in	IN	O
a	DT	O
composition,	,	O
mixture,	,	O
or	CC	O
collection	NN	O
of	IN	O
components	NNS	O
(i.e.	.	O
on	IN	O
a	DT	O
molar	JJ	O
basis	NN	O
it	PRP	O
is	VBZ	O
more	RBR	O
abundant	JJ	O
than	IN	O
any	DT	O
other	JJ	O
individual	JJ	O
species	NNS	O
in	IN	O
the	DT	O
composition).	.	O
In	IN	O
some	DT	O
instances,	,	O
the	DT	O
preparation	NN	O
consists	VBZ	O
of	IN	O
more	JJR	O
than	IN	O
about	RB	O
60%,	,	O
70%	NN	O
or	CC	O
75%,	,	O
typically	RB	O
more	JJR	O
than	IN	O
about	RB	O
80%,	,	O
or	CC	O
preferably	RB	O
more	JJR	O
than	IN	O
about	RB	O
90%	NN	O
of	IN	O
the	DT	O
isolated	JJ	O
species.	.	O
A	DT	O
“substantially	RB	O
pure”	NN	O
or	CC	O
“isolated”	VB	O
nucleic	JJ	O
acid	NN	O
(e.g.,	,	O
RNA	NNP	O
or	CC	O
DNA),	,	O
polypeptide,	,	O
protein,	,	O
or	CC	O
composition	NN	O
also	RB	O
means	VBZ	O
where	WRB	O
the	DT	O
object	NN	O
species	NNS	O
(e.g.,	,	O
nucleic	JJ	O
acid	NN	O
or	CC	O
polypeptide)	)	O
comprises	VBZ	O
at	IN	O
least	JJS	O
about	IN	O
50,	,	O
60,	,	O
or	CC	O
70	CD	O
percent	NN	O
by	IN	O
weight	NN	O
(on	IN	O
a	DT	O
molar	JJ	O
basis)	)	O
of	IN	O
all	DT	O
macromolecular	JJ	O
species	NNS	O
present.	.	O
A	DT	O
substantially	RB	O
pure	NN	O
or	CC	O
isolated	JJ	O
composition	NN	O
can	MD	O
also	RB	O
comprise	VB	O
at	IN	O
least	JJS	O
about	IN	O
80,	,	O
90,	,	O
or	CC	O
95	CD	O
percent	NN	O
by	IN	O
weight	NN	O
of	IN	O
all	DT	O
macromolecular	JJ	O
species	NNS	O
present	VBP	O
in	IN	O
the	DT	O
composition.	.	O
An	DT	O
isolated	JJ	O
object	NN	O
species	NNS	O
can	MD	O
also	RB	O
be	VB	O
purified	VBN	O
to	TO	O
essential	JJ	O
homogeneity	NN	O
(contaminant	JJ	O
species	NNS	O
cannot	RB	O
be	VB	O
detected	VBN	O
in	IN	O
the	DT	O
composition	NN	O
by	IN	O
conventional	JJ	O
detection	NN	O
methods)	)	O
wherein	VBP	O
the	DT	O
composition	NN	O
consists	VBZ	O
essentially	RB	O
of	IN	O
derivatives	NNS	O
of	IN	O
a	DT	O
single	JJ	O
macromolecular	NN	O
species.	.	O
The	DT	O
term	NN	O
“purified”	NNP	O
generally	RB	O
denotes	VBZ	O
that	IN	O
a	DT	O
nucleic	JJ	O
acid,	,	O
polypeptide,	,	O
or	CC	O
protein	NN	O
gives	VBZ	O
rise	NN	O
to	TO	O
essentially	RB	O
one	CD	O
band	NN	O
in	IN	O
an	DT	O
electrophoretic	JJ	O
gel.	.	O
It	PRP	O
typically	RB	O
means	VBZ	O
that	IN	O
the	DT	O
nucleic	JJ	O
acid,	,	O
polypeptide,	,	O
or	CC	O
protein	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
about	IN	O
50%	NN	O
pure,	,	O
60%	NN	O
pure,	,	O
70%	NN	O
pure,	,	O
75%	NN	O
pure,	,	O
more	JJR	O
preferably	RB	O
at	IN	O
least	JJS	O
about	IN	O
85%	NN	O
pure,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
at	IN	O
least	JJS	O
about	IN	O
99%	NN	O
pure.	.	O
The	DT	O
term	NN	O
“isolated	VBD	O
nucleic	JJ	O
acid”	NN	O
may	MD	O
refer	VB	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	NN	O
(e.g.,	,	O
DNA	NNP	O
or	CC	O
RNA)	)	O
that	WDT	O
is	VBZ	O
not	RB	O
immediately	RB	O
contiguous	JJ	O
with	IN	O
both	DT	O
of	IN	O
the	DT	O
coding	NN	O
sequences	NNS	O
with	IN	O
which	WDT	O
it	PRP	O
is	VBZ	O
immediately	RB	O
contiguous	JJ	O
(i.e.,	,	O
one	CD	O
at	IN	O
the	DT	O
5′	CD	O
and	CC	O
one	CD	O
at	IN	O
the	DT	O
3′	CD	O
end)	)	O
in	IN	O
the	DT	O
naturally	RB	O
occurring	VBG	O
genome	NN	O
of	IN	O
the	DT	O
organism	NN	O
from	IN	O
which	WDT	O
the	DT	O
nucleic	NN	O
acid	NN	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
derived.	.	O
Thus,	,	O
this	DT	O
term	NN	O
includes,	,	O
e.g.,	,	O
a	DT	O
cDNA	NN	O
or	CC	O
a	DT	O
genomic	JJ	O
DNA	NNP	O
fragment	NN	O
produced	VBN	O
by	IN	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
(PCR)	)	O
or	CC	O
restriction	NN	O
endonuclease	NN	O
treatment,	,	O
whether	IN	O
such	JJ	O
cDNA	NN	O
or	CC	O
genomic	JJ	O
DNA	NNP	O
fragment	NN	O
is	VBZ	O
incorporated	VBN	O
into	IN	O
a	DT	O
vector,	,	O
integrated	VBN	O
into	IN	O
the	DT	O
genome	NN	O
of	IN	O
the	DT	O
same	JJ	O
or	CC	O
a	DT	O
different	JJ	O
species	NNS	O
than	IN	O
the	DT	O
organism,	,	O
including,	,	O
e.g.,	,	O
a	DT	O
virus,	,	O
from	IN	O
which	WDT	O
it	PRP	O
was	VBD	O
originally	RB	O
derived,	,	O
linked	VBN	O
to	TO	O
an	DT	O
additional	JJ	O
coding	NN	O
sequence	NN	O
to	TO	O
form	VB	O
a	DT	O
hybrid	JJ	O
gene	NN	O
encoding	VBG	O
a	DT	O
chimeric	JJ	O
polypeptide,	,	O
or	CC	O
independent	JJ	O
of	IN	O
any	DT	O
other	JJ	O
DNA	NN	O
sequences.	.	O
The	DT	O
DNA	NN	O
may	MD	O
be	VB	O
double-stranded	JJ	O
or	CC	O
single-stranded,	,	O
sense	NN	O
or	CC	O
antisense.	.	O
A	DT	O
“recombinant	JJ	O
polynucleotide”	NN	O
or	CC	O
a	DT	O
“recombinant	JJ	O
polypeptide”	NN	O
is	VBZ	O
a	DT	O
non-naturally	RB	O
occurring	VBG	O
polynucleotide	NN	O
or	CC	O
polypeptide	NN	O
which	WDT	O
may	MD	O
include	VB	O
nucleic	JJ	O
acid	NN	O
or	CC	O
amino	NN	O
acid	NN	O
sequences,	,	O
respectively,	,	O
from	IN	O
more	JJR	O
than	IN	O
one	CD	O
source	NN	O
nucleic	JJ	O
acid	NN	O
or	CC	O
polypeptide,	,	O
which	WDT	O
source	NN	O
nucleic	NN	O
acid	NN	O
or	CC	O
polypeptide	NN	O
can	MD	O
be	VB	O
a	DT	O
naturally	RB	O
occurring	VBG	O
nucleic	JJ	O
acid	NN	O
or	CC	O
polypeptide,	,	O
or	CC	O
can	MD	O
itself	PRP	O
have	VB	O
been	VBN	O
subjected	VBN	O
to	TO	O
mutagenesis	NN	O
or	CC	O
other	JJ	O
type	NN	O
of	IN	O
modification.	.	O
A	DT	O
nucleic	JJ	O
acid	NN	O
or	CC	O
polypeptide	NN	O
may	MD	O
be	VB	O
deemed	VBN	O
“recombinant”	JJ	O
when	WRB	O
it	PRP	O
is	VBZ	O
synthetic	JJ	O
or	CC	O
artificial	JJ	O
or	CC	O
engineered,	,	O
or	CC	O
derived	VBN	O
from	IN	O
a	DT	O
synthetic	JJ	O
or	CC	O
artificial	JJ	O
or	CC	O
engineered	JJ	O
polypeptide	NN	O
or	CC	O
nucleic	JJ	O
acid.	.	O
A	DT	O
recombinant	JJ	O
nucleic	JJ	O
acid	NN	O
(e.g.,	,	O
DNA	NNP	O
or	CC	O
RNA)	)	O
can	MD	O
be	VB	O
made	VBN	O
by	IN	O
the	DT	O
combination	NN	O
(e.g.,	,	O
artificial	JJ	O
combination)	)	O
of	IN	O
at	IN	O
least	JJS	O
two	CD	O
segments	NNS	O
of	IN	O
sequence	NN	O
that	WDT	O
are	VBP	O
not	RB	O
typically	RB	O
included	VBN	O
together,	,	O
not	RB	O
typically	RB	O
associated	VBN	O
with	IN	O
one	CD	O
another,	,	O
or	CC	O
are	VBP	O
otherwise	RB	O
typically	RB	O
separated	VBN	O
from	IN	O
one	CD	O
another.	.	O
A	DT	O
recombinant	JJ	O
nucleic	JJ	O
acid	NN	O
can	MD	O
comprise	VB	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
formed	VBN	O
by	IN	O
the	DT	O
joining	NN	O
together	RB	O
or	CC	O
combination	NN	O
of	IN	O
nucleic	JJ	O
acid	JJ	O
segments	NNS	O
from	IN	O
different	JJ	O
sources	NNS	O
and/or	VBP	O
artificially	RB	O
synthesized.	.	O
A	DT	O
“recombinant	JJ	O
polypeptide”	NN	O
often	RB	O
refers	VBZ	O
to	TO	O
a	DT	O
polypeptide	NN	O
that	WDT	O
results	NNS	O
from	IN	O
a	DT	O
cloned	VBN	O
or	CC	O
recombinant	JJ	O
nucleic	JJ	O
acid.	.	O
The	DT	O
source	NN	O
polynucleotides	NNS	O
or	CC	O
polypeptides	NNS	O
from	IN	O
which	WDT	O
the	DT	O
different	JJ	O
nucleic	JJ	O
acid	NN	O
or	CC	O
amino	NN	O
acid	JJ	O
sequences	NNS	O
are	VBP	O
derived	VBN	O
are	VBP	O
sometimes	RB	O
homologous	JJ	O
(i.e.,	,	O
have,	,	O
or	CC	O
encode	VB	O
a	DT	O
polypeptide	NN	O
that	WDT	O
encodes,	,	O
the	DT	O
same	JJ	O
or	CC	O
a	DT	O
similar	JJ	O
structure	NN	O
and/or	NN	O
function),	,	O
and	CC	O
are	VBP	O
often	RB	O
from	IN	O
different	JJ	O
isolates,	,	O
serotypes,	,	O
strains,	,	O
species,	,	O
of	IN	O
organism	NN	O
or	CC	O
from	IN	O
different	JJ	O
disease	NN	O
states,	,	O
for	IN	O
example.	.	O
The	DT	O
term	NN	O
“recombinant”	NN	O
when	WRB	O
used	VBN	O
with	IN	O
reference,	,	O
e.g.,	,	O
to	TO	O
a	DT	O
cell,	,	O
polynucleotide,	,	O
vector,	,	O
protein,	,	O
or	CC	O
polypeptide	VB	O
typically	RB	O
indicates	VBZ	O
that	IN	O
the	DT	O
cell,	,	O
polynucleotide,	,	O
or	CC	O
vector	NN	O
has	VBZ	O
been	VBN	O
modified	VBN	O
by	IN	O
the	DT	O
introduction	NN	O
of	IN	O
a	DT	O
heterologous	JJ	O
(or	CC	O
foreign)	)	O
nucleic	JJ	O
acid	NN	O
or	CC	O
the	DT	O
alteration	NN	O
of	IN	O
a	DT	O
native	JJ	O
nucleic	NN	O
acid,	,	O
or	CC	O
that	IN	O
the	DT	O
protein	NN	O
or	CC	O
polypeptide	NN	O
has	VBZ	O
been	VBN	O
modified	VBN	O
by	IN	O
the	DT	O
introduction	NN	O
of	IN	O
a	DT	O
heterologous	JJ	O
amino	NN	O
acid,	,	O
or	CC	O
that	IN	O
the	DT	O
cell	NN	O
is	VBZ	O
derived	VBN	O
from	IN	O
a	DT	O
cell	NN	O
so	RB	O
modified.	.	O
Recombinant	JJ	O
cells	NNS	O
express	JJ	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
that	WDT	O
are	VBP	O
not	RB	O
found	VBN	O
in	IN	O
the	DT	O
native	JJ	O
(non-recombinant)	)	O
form	NN	O
of	IN	O
the	DT	O
cell	NN	O
or	CC	O
express	JJ	O
native	JJ	O
nucleic	NN	O
acid	NN	O
sequences	NNS	O
that	WDT	O
would	MD	O
otherwise	RB	O
be	VB	O
abnormally	RB	O
expressed,	,	O
under-expressed,	,	O
or	CC	O
not	RB	O
expressed	VBN	O
at	IN	O
all.	.	O
The	DT	O
term	NN	O
“recombinant”	NN	O
when	WRB	O
used	VBN	O
with	IN	O
reference	NN	O
to	TO	O
a	DT	O
cell	NN	O
indicates	VBZ	O
that	IN	O
the	DT	O
cell	NN	O
replicates	VBZ	O
a	DT	O
heterologous	JJ	O
nucleic	NN	O
acid,	,	O
or	CC	O
expresses	VBZ	O
a	DT	O
polypeptide	NN	O
encoded	VBN	O
by	IN	O
a	DT	O
heterologous	JJ	O
nucleic	JJ	O
acid.	.	O
Recombinant	JJ	O
cells	NNS	O
can	MD	O
contain	VB	O
coding	JJ	O
sequences	NNS	O
that	WDT	O
are	VBP	O
not	RB	O
found	VBN	O
within	IN	O
the	DT	O
native	JJ	O
(non-recombinant)	)	O
form	NN	O
of	IN	O
the	DT	O
cell.	.	O
Recombinant	JJ	O
cells	NNS	O
can	MD	O
also	RB	O
contain	VB	O
coding	VBG	O
sequences	NNS	O
found	VBN	O
in	IN	O
the	DT	O
native	JJ	O
form	NN	O
of	IN	O
the	DT	O
cell	NN	O
wherein	VBZ	O
the	DT	O
coding	NN	O
sequences	NNS	O
are	VBP	O
modified	VBN	O
and	CC	O
re-introduced	JJ	O
into	IN	O
the	DT	O
cell	NN	O
by	IN	O
artificial	JJ	O
means.	.	O
The	DT	O
term	NN	O
also	RB	O
encompasses	VBZ	O
cells	NNS	O
that	WDT	O
contain	VBP	O
a	DT	O
nucleic	JJ	O
acid	NN	O
endogenous	JJ	O
to	TO	O
the	DT	O
cell	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
modified	VBN	O
without	IN	O
removing	VBG	O
the	DT	O
nucleic	JJ	O
acid	NN	O
from	IN	O
the	DT	O
cell;	:	O
such	JJ	O
modifications	NNS	O
include	VBP	O
those	DT	O
obtained	VBN	O
by	IN	O
gene	NN	O
replacement,	,	O
site-specific	JJ	O
mutation,	,	O
recombination,	,	O
and	CC	O
related	JJ	O
techniques.	.	O
The	DT	O
term	NN	O
“recombinantly	RB	O
produced”	VBZ	O
refers	NNS	O
to	TO	O
an	DT	O
artificial	JJ	O
combination	NN	O
usually	RB	O
accomplished	VBN	O
by	IN	O
either	DT	O
chemical	JJ	O
synthesis	NN	O
means,	,	O
recursive	JJ	O
sequence	NN	O
recombination	NN	O
of	IN	O
nucleic	JJ	O
acid	JJ	O
segments	NNS	O
or	CC	O
other	JJ	O
diversity	NN	O
generation	NN	O
methods	NNS	O
(such	JJ	O
as,	,	O
e.g.,	,	O
shuffling)	)	O
of	IN	O
nucleotides,	,	O
or	CC	O
manipulation	NN	O
of	IN	O
isolated	JJ	O
segments	NNS	O
of	IN	O
nucleic	JJ	O
acids,	,	O
e.g.,	,	O
by	IN	O
genetic	JJ	O
engineering	NN	O
techniques	NNS	O
known	VBN	O
to	TO	O
those	DT	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art.	.	O
“Recombinantly	RB	O
expressed”	VBZ	O
typically	RB	O
refers	NNS	O
to	TO	O
techniques	NNS	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
a	DT	O
recombinant	JJ	O
nucleic	JJ	O
acid	NN	O
in	IN	O
vitro	NN	O
and	CC	O
transfer	NN	O
of	IN	O
the	DT	O
recombinant	JJ	O
nucleic	JJ	O
acid	NN	O
into	IN	O
cells	NNS	O
in	IN	O
vivo,	,	O
in	IN	O
vitro,	,	O
or	CC	O
ex	VB	O
vivo	NN	O
where	WRB	O
it	PRP	O
may	MD	O
be	VB	O
expressed	VBN	O
or	CC	O
propagated.	.	O
An	DT	O
“immunogen”	JJ	O
refers	NNS	O
to	TO	O
a	DT	O
substance	NN	O
capable	JJ	O
of	IN	O
provoking	VBG	O
an	DT	O
immune	JJ	O
response,	,	O
and	CC	O
includes,	,	O
e.g.,	,	O
antigens,	,	O
autoantigens	NNS	O
that	IN	O
play	VBP	O
a	DT	O
role	NN	O
in	IN	O
induction	NN	O
of	IN	O
autoimmune	NN	O
diseases,	,	O
and	CC	O
tumor-associated	JJ	O
antigens	NNS	O
expressed	VBN	O
on	IN	O
cancer	NN	O
cells.	.	O
An	DT	O
immune	JJ	O
response	NN	O
generally	RB	O
refers	VBZ	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
a	DT	O
cellular	JJ	O
or	CC	O
antibody-mediated	JJ	O
response	NN	O
to	TO	O
an	DT	O
agent,	,	O
such	JJ	O
as	IN	O
an	DT	O
antigen	NN	O
or	CC	O
fragment	JJ	O
thereof	NN	O
or	CC	O
nucleic	JJ	O
acid	JJ	O
encoding	VBG	O
such	JJ	O
agent.	.	O
In	IN	O
some	DT	O
instances,	,	O
such	PDT	O
a	DT	O
response	NN	O
comprises	VBZ	O
a	DT	O
production	NN	O
of	IN	O
at	IN	O
least	JJS	O
one	CD	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
CTLs,	,	O
B	NNP	O
cells,	,	O
or	CC	O
various	JJ	O
classes	NNS	O
of	IN	O
T	NNP	O
cells	NNS	O
that	WDT	O
are	VBP	O
directed	VBN	O
specifically	RB	O
to	TO	O
antigen-presenting	JJ	O
cells	NNS	O
expressing	VBG	O
the	DT	O
antigen	NN	O
of	IN	O
interest.	.	O
An	DT	O
“antigen”	JJ	O
refers	NNS	O
to	TO	O
a	DT	O
substance	NN	O
that	WDT	O
is	VBZ	O
capable	JJ	O
of	IN	O
eliciting	VBG	O
the	DT	O
formation	NN	O
of	IN	O
antibodies	NNS	O
in	IN	O
a	DT	O
host	NN	O
or	CC	O
generating	VBG	O
a	DT	O
specific	JJ	O
population	NN	O
of	IN	O
lymphocytes	NNS	O
reactive	VBP	O
with	IN	O
that	DT	O
substance.	.	O
Antigens	NNS	O
are	VBP	O
typically	RB	O
macromolecules	NNS	O
(e.g.,	,	O
proteins	NNS	O
and	CC	O
polysaccharides)	)	O
that	WDT	O
are	VBP	O
foreign	JJ	O
to	TO	O
the	DT	O
host.	.	O
An	DT	O
“adjuvant”	JJ	O
refers	NNS	O
to	TO	O
a	DT	O
substance	NN	O
that	WDT	O
enhances	VBZ	O
an	DT	O
antigen's	POS	O
immune-stimulating	JJ	O
properties	NNS	O
or	CC	O
the	DT	O
pharmacological	JJ	O
effect(s)	)	O
of	IN	O
a	DT	O
drug.	.	O
An	DT	O
adjuvant	NN	O
may	MD	O
non-specifically	RB	O
enhance	VB	O
the	DT	O
immune	JJ	O
response	NN	O
to	TO	O
an	DT	O
antigen.	.	O
“Freund's	POS	O
Complete	NNP	O
Adjuvant,”	NNP	O
for	IN	O
example,	,	O
is	VBZ	O
an	DT	O
emulsion	NN	O
of	IN	O
oil	NN	O
and	CC	O
water	NN	O
containing	VBG	O
an	DT	O
immunogen,	,	O
an	DT	O
emulsifying	NN	O
agent	NN	O
and	CC	O
mycobacteria.	.	O
Another	DT	O
example,	,	O
“Freund's	POS	O
incomplete	JJ	O
adjuvant,”	EX	O
is	VBZ	O
the	DT	O
same,	,	O
but	CC	O
without	IN	O
mycobacteria.	.	O
A	DT	O
“vector”	NN	O
is	VBZ	O
a	DT	O
component	NN	O
or	CC	O
composition	NN	O
for	IN	O
facilitating	VBG	O
cell	NN	O
transduction	NN	O
or	CC	O
transfection	NN	O
by	IN	O
a	DT	O
selected	VBN	O
nucleic	NN	O
acid,	,	O
or	CC	O
expression	NN	O
of	IN	O
the	DT	O
nucleic	JJ	O
acid	NN	O
in	IN	O
the	DT	O
cell.	.	O
Vectors	NNS	O
include,	,	O
e.g.,	,	O
plasmids,	,	O
cosmids,	,	O
viruses,	,	O
YACs,	,	O
bacteria,	,	O
poly-lysine,	,	O
etc.	.	O
An	DT	O
“expression	NN	O
vector”	NN	O
is	VBZ	O
a	DT	O
nucleic	JJ	O
acid	JJ	O
construct	NN	O
or	CC	O
sequence,	,	O
generated	VBN	O
recombinantly	RB	O
or	CC	O
synthetically,	,	O
with	IN	O
a	DT	O
series	NN	O
of	IN	O
specific	JJ	O
nucleic	JJ	O
acid	NN	O
elements	NNS	O
that	WDT	O
permit	VBP	O
transcription	NN	O
of	IN	O
a	DT	O
particular	JJ	O
nucleic	NN	O
acid	NN	O
in	IN	O
a	DT	O
host	NN	O
cell.	.	O
The	DT	O
expression	NN	O
vector	NN	O
can	MD	O
be	VB	O
part	NN	O
of	IN	O
a	DT	O
plasmid,	,	O
virus,	,	O
or	CC	O
nucleic	JJ	O
acid	JJ	O
fragment.	.	O
The	DT	O
expression	NN	O
vector	NN	O
typically	RB	O
includes	VBZ	O
a	DT	O
nucleic	JJ	O
acid	NN	O
to	TO	O
be	VB	O
transcribed	VBN	O
operably	RB	O
linked	VBN	O
to	TO	O
a	DT	O
promoter.	.	O
The	DT	O
nucleic	JJ	O
acid	NN	O
to	TO	O
be	VB	O
transcribed	VBN	O
is	VBZ	O
typically	RB	O
under	IN	O
the	DT	O
direction	NN	O
or	CC	O
control	NN	O
of	IN	O
the	DT	O
promoter.	.	O
The	DT	O
term	NN	O
“subject”	NNP	O
as	IN	O
used	VBN	O
herein	NN	O
includes,	,	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to,	,	O
an	DT	O
organism;	:	O
a	DT	O
mammal,	,	O
including,	,	O
e.g.,	,	O
a	DT	O
human,	,	O
non-human	JJ	O
primate	NN	O
(e.g.,	,	O
baboon,	,	O
orangutan,	,	O
monkey),	,	O
mouse,	,	O
pig,	,	O
cow,	,	O
goat,	,	O
cat,	,	O
rabbit,	,	O
rat,	,	O
guinea	NN	O
pig,	,	O
hamster,	,	O
horse,	,	O
monkey,	,	O
sheep,	,	O
or	CC	O
other	JJ	O
non-human	JJ	O
mammal;	:	O
a	DT	O
non-mammal,	,	O
including,	,	O
e.g.,	,	O
a	DT	O
non-mammalian	JJ	O
vertebrate,	,	O
such	JJ	O
as	IN	O
a	DT	O
bird	NN	O
(e.g.,	,	O
a	DT	O
chicken	NN	O
or	CC	O
duck)	)	O
or	CC	O
a	DT	O
fish,	,	O
and	CC	O
a	DT	O
non-mammalian	JJ	O
invertebrate.	.	O
The	DT	O
term	NN	O
“pharmaceutical	JJ	O
composition”	NN	O
means	VBZ	O
a	DT	O
composition	NN	O
suitable	NN	O
for	IN	O
pharmaceutical	JJ	O
use	NN	O
in	IN	O
a	DT	O
subject,	,	O
including	VBG	O
an	DT	O
animal	NN	O
or	CC	O
human.	.	O
A	DT	O
pharmaceutical	JJ	O
composition	NN	O
generally	RB	O
comprises	VBZ	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
an	DT	O
active	JJ	O
agent	NN	O
and	CC	O
a	DT	O
carrier,	,	O
including,	,	O
e.g.,	,	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
carrier.	.	O
The	DT	O
term	NN	O
“effective	JJ	O
amount”	NN	O
means	VBZ	O
a	DT	O
dosage	NN	O
or	CC	O
amount	NN	O
sufficient	JJ	O
to	TO	O
produce	VB	O
a	DT	O
desired	JJ	O
result.	.	O
The	DT	O
desired	JJ	O
result	NN	O
may	MD	O
comprise	VB	O
an	DT	O
objective	NN	O
or	CC	O
subjective	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
recipient	NN	O
of	IN	O
the	DT	O
dosage	NN	O
or	CC	O
amount.	.	O
A	DT	O
“prophylactic	JJ	O
treatment”	NN	O
is	VBZ	O
a	DT	O
treatment	NN	O
administered	VBN	O
to	TO	O
a	DT	O
subject	NN	O
who	WP	O
does	VBZ	O
not	RB	O
display	VB	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
a	DT	O
disease,	,	O
pathology,	,	O
or	CC	O
medical	JJ	O
disorder,	,	O
or	CC	O
displays	VBZ	O
only	RB	O
early	JJ	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
a	DT	O
disease,	,	O
pathology,	,	O
or	CC	O
disorder,	,	O
such	JJ	O
that	IN	O
treatment	NN	O
is	VBZ	O
administered	VBN	O
for	IN	O
the	DT	O
purpose	NN	O
of	IN	O
diminishing,	,	O
preventing,	,	O
or	CC	O
decreasing	VBG	O
the	DT	O
risk	NN	O
of	IN	O
developing	VBG	O
the	DT	O
disease,	,	O
pathology,	,	O
or	CC	O
medical	JJ	O
disorder.	.	O
A	DT	O
prophylactic	JJ	O
treatment	NN	O
functions	NNS	O
as	IN	O
a	DT	O
preventative	JJ	O
treatment	NN	O
against	IN	O
a	DT	O
disease	NN	O
or	CC	O
disorder.	.	O
A	DT	O
“prophylactic	JJ	O
activity”	NN	O
is	VBZ	O
an	DT	O
activity	NN	O
of	IN	O
an	DT	O
agent,	,	O
such	JJ	O
as	IN	O
a	DT	O
nucleic	JJ	O
acid,	,	O
vector,	,	O
gene,	,	O
polypeptide,	,	O
protein,	,	O
substance,	,	O
or	CC	O
composition	NN	O
thereof	NN	O
that,	,	O
when	WRB	O
administered	VBN	O
to	TO	O
a	DT	O
subject	NN	O
who	WP	O
does	VBZ	O
not	RB	O
display	VB	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
pathology,	,	O
disease	NN	O
or	CC	O
disorder,	,	O
or	CC	O
who	WP	O
displays	VBZ	O
only	RB	O
early	JJ	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
pathology,	,	O
disease,	,	O
or	CC	O
disorder,	,	O
diminishes,	,	O
prevents,	,	O
or	CC	O
decreases	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
the	DT	O
subject	JJ	O
developing	VBG	O
a	DT	O
pathology,	,	O
disease,	,	O
or	CC	O
disorder.	.	O
A	DT	O
“prophylactically	RB	O
useful”	JJ	O
agent	NN	O
or	CC	O
compound	NN	O
(e.g.,	,	O
nucleic	JJ	O
acid	NN	O
or	CC	O
polypeptide)	)	O
refers	NNS	O
to	TO	O
an	DT	O
agent	NN	O
or	CC	O
compound	NN	O
that	WDT	O
is	VBZ	O
useful	JJ	O
in	IN	O
diminishing,	,	O
preventing,	,	O
treating,	,	O
or	CC	O
decreasing	VBG	O
development	NN	O
of	IN	O
pathology,	,	O
disease	NN	O
or	CC	O
disorder.	.	O
A	DT	O
“therapeutic	JJ	O
treatment”	NN	O
is	VBZ	O
a	DT	O
treatment	NN	O
administered	VBN	O
to	TO	O
a	DT	O
subject	NN	O
who	WP	O
displays	VBZ	O
symptoms	NNS	O
or	CC	O
signs	NNS	O
of	IN	O
pathology,	,	O
disease,	,	O
or	CC	O
disorder,	,	O
in	IN	O
which	WDT	O
treatment	NN	O
is	VBZ	O
administered	VBN	O
to	TO	O
the	DT	O
subject	NN	O
for	IN	O
the	DT	O
purpose	NN	O
of	IN	O
diminishing	VBG	O
or	CC	O
eliminating	VBG	O
those	DT	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
pathology,	,	O
disease,	,	O
or	CC	O
disorder.	.	O
A	DT	O
“therapeutic	JJ	O
activity”	NN	O
is	VBZ	O
an	DT	O
activity	NN	O
of	IN	O
an	DT	O
agent,	,	O
such	JJ	O
as	IN	O
a	DT	O
nucleic	JJ	O
acid,	,	O
vector,	,	O
gene,	,	O
polypeptide,	,	O
protein,	,	O
substance,	,	O
or	CC	O
composition	NN	O
thereof,	,	O
that	WDT	O
eliminates	VBZ	O
or	CC	O
diminishes	VBZ	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
pathology,	,	O
disease	NN	O
or	CC	O
disorder,	,	O
when	WRB	O
administered	VBN	O
to	TO	O
a	DT	O
subject	JJ	O
suffering	VBG	O
from	IN	O
such	JJ	O
signs	NNS	O
or	CC	O
symptoms.	.	O
A	DT	O
“therapeutically	RB	O
useful”	JJ	O
agent	NN	O
or	CC	O
compound	NN	O
(e.g.,	,	O
nucleic	JJ	O
acid	NN	O
or	CC	O
polypeptide)	)	O
indicates	VBZ	O
that	IN	O
an	DT	O
agent	NN	O
or	CC	O
compound	NN	O
is	VBZ	O
useful	JJ	O
in	IN	O
diminishing,	,	O
treating,	,	O
or	CC	O
eliminating	VBG	O
such	JJ	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
a	DT	O
pathology,	,	O
disease	NN	O
or	CC	O
disorder.	.	O
Modes	NNS	O
of	IN	O
Practicing	VBG	O
the	DT	O
Invention	NNP	O
2′,5′-oligoadenylate	JJ	O
synthetases	NNS	O
(OAS)	)	O
are	VBP	O
a	DT	O
family	NN	O
of	IN	O
IFN-inducible,	,	O
RNA	NNP	O
dependent	NN	O
effector	NN	O
enzymes	VBZ	O
that	IN	O
synthesize	VB	O
short	JJ	O
2′	CD	O
to	TO	O
5′	CD	O
linked	VBN	O
oligoadenylate	NN	O
(2-5A)	)	O
molecules	NNS	O
from	IN	O
ATP.	.	O
2-5A	JJ	O
molecules	NNS	O
bind	IN	O
to	TO	O
and	CC	O
activate	VB	O
the	DT	O
RNAseL	NNP	O
enzyme,	,	O
which	WDT	O
once	RB	O
activated,	,	O
degrades	VBZ	O
viral	JJ	O
and	CC	O
cellular	JJ	O
RNAs	NNP	O
and	CC	O
blocks	NNS	O
cellular	JJ	O
protein	NN	O
synthesis.	.	O
OAS	NNP	O
enzymes	VBZ	O
constitute	VBP	O
an	DT	O
important	JJ	O
part	NN	O
of	IN	O
the	DT	O
nonspecific	JJ	O
immune	NN	O
defense	NN	O
against	IN	O
viral	JJ	O
infections	NNS	O
and	CC	O
have	VBP	O
been	VBN	O
used	VBN	O
as	IN	O
a	DT	O
cellular	JJ	O
marker	NN	O
for	IN	O
viral	JJ	O
infection.	.	O
In	IN	O
addition	NN	O
to	TO	O
the	DT	O
role	NN	O
in	IN	O
hepatitis	NN	O
C	NNP	O
infection	NN	O
discussed	VBD	O
herein,	,	O
OAS	NNP	O
activity	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
other	JJ	O
disease	NN	O
states,	,	O
particularly	RB	O
those	DT	O
in	IN	O
which	WDT	O
a	DT	O
viral	JJ	O
infection	NN	O
plays	VBZ	O
a	DT	O
role.	.	O
While	IN	O
specific	JJ	O
pathogenic	JJ	O
mechanisms	NNS	O
are	VBP	O
subjects	NNS	O
of	IN	O
current	JJ	O
analysis,	,	O
viral	JJ	O
infections	NNS	O
are	VBP	O
believed	VBN	O
to	TO	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
diseases	NNS	O
such	JJ	O
as	IN	O
diabetes.	.	O
Lymphocytic	JJ	O
OAS	NNP	O
activity	NN	O
is	VBZ	O
significantly	RB	O
elevated	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
1	CD	O
diabetes,	,	O
suggesting	VBG	O
that	IN	O
OAS	NNP	O
may	MD	O
be	VB	O
an	DT	O
important	JJ	O
link	NN	O
between	IN	O
viral	JJ	O
infections	NNS	O
and	CC	O
disease	NN	O
development.	.	O
In	IN	O
a	DT	O
study	NN	O
involving	VBG	O
diabetic	JJ	O
twins	NNS	O
from	IN	O
monozygotic	JJ	O
twin	NN	O
pairs,	,	O
Bonnevie-Nielsen	NNP	O
et	FW	O
al.	.	O
Clin	NNP	B
Immunol.	.	I
2000	CD	I
July;	:	I
96(1):11-8)	)	I
(showed	VBD	O
that	IN	O
OAS	NNP	O
is	VBZ	O
persistently	RB	O
activated	VBN	O
in	IN	O
both	DT	O
recent-onset	JJ	O
and	CC	O
long-standing	JJ	O
type	NN	O
1	CD	O
diabetes.	.	O
Continuously	RB	O
elevated	JJ	O
OAS	NNP	O
activity	NN	O
in	IN	O
type	NN	O
1	CD	O
diabetes	NN	O
is	VBZ	O
clearly	RB	O
different	JJ	O
from	IN	O
a	DT	O
normal	JJ	O
antiviral	JJ	O
response	NN	O
and	CC	O
might	MD	O
indicate	VB	O
a	DT	O
chronic	JJ	O
stimulation	NN	O
of	IN	O
the	DT	O
enzyme,	,	O
a	DT	O
failure	NN	O
of	IN	O
down	JJ	O
regulatory	JJ	O
mechanisms,	,	O
or	CC	O
an	DT	O
aberrant	JJ	O
response	NN	O
to	TO	O
endogenous	JJ	O
or	CC	O
exogenous	JJ	O
viruses	NNS	O
or	CC	O
their	PRP$	O
products.	.	O
A	DT	O
more	RBR	O
direct	JJ	O
link	NN	O
between	IN	O
a	DT	O
viral	JJ	O
infection	NN	O
and	CC	O
the	DT	O
development	NN	O
of	IN	O
diabetes	NNS	O
is	VBZ	O
exemplified	VBN	O
by	IN	O
a	DT	O
number	NN	O
of	IN	O
studies	NNS	O
showing	VBG	O
that	IN	O
between	IN	O
13	CD	O
and	CC	O
33%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
have	VBP	O
diabetes	NNS	O
mellitus	NNS	O
(type	JJ	O
2	CD	O
diabetes),	,	O
a	DT	O
level	NN	O
that	WDT	O
is	VBZ	O
significantly	RB	O
increased	VBN	O
compared	VBN	O
with	IN	O
that	DT	O
in	IN	O
matched	VBN	O
healthy	JJ	O
controls	NNS	O
or	CC	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
Knobler	NNP	B
et	RB	I
al.	.	I
Am	NNP	I
J	NNP	I
Gastroenterol.	.	I
2003	CD	I
December;	:	I
98(12):2751-6).(	.	O
While	IN	O
OAS	NNP	O
has	VBZ	O
not	RB	O
to	TO	O
date	NN	O
been	VBN	O
reported	VBN	O
to	TO	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
diabetes	NNS	O
mellitus	VBP	O
following	VBG	O
hepatitis	NN	O
C	NNP	O
infection,	,	O
it	PRP	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
marker	NN	O
for	IN	O
the	DT	O
antiviral	JJ	O
response	NN	O
system.	.	O
Furthermore,	,	O
the	DT	O
results	NNS	O
reported	VBD	O
according	VBG	O
to	TO	O
the	DT	O
present	JJ	O
invention	NN	O
illustrate	NN	O
that	IN	O
if	IN	O
hepatitis	NN	O
C	NNP	O
infection	NN	O
is	VBZ	O
causally	RB	O
related	VBN	O
to	TO	O
diabetes	NNS	O
mellitus,	,	O
inhibition	NN	O
or	CC	O
abolition	NN	O
of	IN	O
hepatitis	NN	O
C	NNP	O
infection	NN	O
using	VBG	O
the	DT	O
compositions	NNS	O
and	CC	O
methods	NNS	O
disclosed	VBN	O
herein	NN	O
may	MD	O
be	VB	O
advantageous	JJ	O
in	IN	O
preventing	VBG	O
or	CC	O
alleviating	VBG	O
development	NN	O
of	IN	O
diabetes	NNS	O
mellitus.	.	O
A	DT	O
further	JJ	O
published	VBN	O
study	NN	O
has	VBZ	O
shown	VBN	O
that	IN	O
OAS	NNP	O
plays	VBZ	O
an	DT	O
essential	JJ	O
role	NN	O
in	IN	O
wound	NN	O
healing	NN	O
and	CC	O
its	PRP$	O
pathological	JJ	O
disorders,	,	O
particularly	RB	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
venous	JJ	O
ulcers	NNS	O
and	CC	O
diabetes-associated	JJ	O
poorly-healing	JJ	O
wounds	NNS	O
(WO	NNP	O
02/090552).	.	O
In	IN	O
the	DT	O
case	NN	O
of	IN	O
poor	JJ	O
wound	NN	O
healing,	,	O
OAS	NNP	O
mRNA	NN	O
levels	NNS	O
in	IN	O
the	DT	O
affected	JJ	O
tissues	NNS	O
were	VBD	O
reduced,	,	O
rather	RB	O
than	IN	O
elevated	VBN	O
as	IN	O
in	IN	O
lymphocytes	NNS	O
derived	VBN	O
from	IN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
type	JJ	O
1	CD	O
diabetes.	.	O
These	DT	O
findings	NNS	O
point	NN	O
to	TO	O
OAS	NNP	O
as	IN	O
an	DT	O
etiologically	RB	O
important	JJ	O
marker	NN	O
of	IN	O
immune	JJ	O
reactions	NNS	O
in	IN	O
diabetes	NNS	O
and	CC	O
diabetes-related	JJ	O
wound	NN	O
healing.	.	O
OAS	NNP	O
may	MD	O
also	RB	O
play	VB	O
an	DT	O
intermediary	JJ	O
role	NN	O
in	IN	O
cell	NN	O
processes	NNS	O
involved	VBN	O
in	IN	O
prostate	NN	O
cancer.	.	O
A	DT	O
primary	JJ	O
biochemical	JJ	O
function	NN	O
of	IN	O
OAS	NNP	O
is	VBZ	O
to	TO	O
promote	VB	O
the	DT	O
activity	NN	O
of	IN	O
RNaseL,	,	O
a	DT	O
uniquely-regulated	JJ	O
endoribonuclease	NN	O
that	WDT	O
is	VBZ	O
enzymatically	RB	O
stimulated	VBN	O
by	IN	O
2-5A	JJ	O
molecules.	.	O
RNaseL	NNP	O
has	VBZ	O
a	DT	O
well-established	JJ	O
role	NN	O
in	IN	O
mediating	VBG	O
the	DT	O
antiviral	JJ	O
effects	NNS	O
of	IN	O
IFN,	,	O
and	CC	O
is	VBZ	O
a	DT	O
strong	JJ	O
candidate	NN	O
for	IN	O
the	DT	O
hereditary	JJ	O
prostate	NN	O
cancer	NN	O
1	CD	O
allele	NN	O
(HPC1).	.	O
Mutations	NNS	O
in	IN	O
RNaseL	NNP	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
predispose	VB	O
men	NNS	O
to	TO	O
an	DT	O
increased	VBN	O
incidence	NN	O
of	IN	O
prostate	NN	O
cancer,	,	O
which	WDT	O
in	IN	O
some	DT	O
cases	NNS	O
reflect	VBP	O
more	RBR	O
aggressive	JJ	O
disease	NN	O
and/or	NN	O
decreased	VBD	O
age	NN	O
of	IN	O
onset	NN	O
compared	VBN	O
with	IN	O
non	JJ	O
RNase	NNP	O
L-linked	JJ	O
cases.	.	O
Xiang	NNP	B
et	CC	I
al.	.	I
(Cancer	NNP	I
Res.	.	I
2003	CD	I
Oct.	NNP	I
15;	:	I
63(20):6795-801)	)	I
demonstrated	VBD	O
that	IN	O
biostable	JJ	O
phosphorothiolate	JJ	O
analogs	NNS	O
of	IN	O
2-5A	JJ	O
induced	JJ	O
RNaseL	NNP	O
activity	NN	O
and	CC	O
caused	VBD	O
apoptosis	NN	O
in	IN	O
cultures	NNS	O
of	IN	O
late-stage	JJ	O
metastatic	JJ	O
human	JJ	O
prostate	NN	O
cancer	NN	O
cell	NN	O
lines.	.	O
Their	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
elevation	NN	O
of	IN	O
OAS	NNP	O
activity	NN	O
with	IN	O
a	DT	O
concurrent	JJ	O
increase	NN	O
in	IN	O
2-5A	JJ	O
levels	NNS	O
may	MD	O
facilitate	VB	O
the	DT	O
destruction	NN	O
of	IN	O
cancer	NN	O
cells	NNS	O
through	IN	O
a	DT	O
potent	JJ	O
apoptotic	JJ	O
pathway.	.	O
Thus,	,	O
use	NN	O
of	IN	O
compositions	NNS	O
and	CC	O
methods	NNS	O
disclosed	VBN	O
herein	NN	O
may	MD	O
find	VB	O
utility	NN	O
in	IN	O
the	DT	O
detection,	,	O
treatment	NN	O
and/or	JJ	O
prevention	NN	O
of	IN	O
prostate	NN	O
cancer.	.	O
OAS	NNP	O
may	MD	O
further	RB	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
normal	JJ	O
cell	NN	O
growth	NN	O
regulation,	,	O
either	CC	O
through	IN	O
its	PRP$	O
regulation	NN	O
of	IN	O
RNaseL	NNP	O
or	CC	O
through	RB	O
another	DT	O
as	IN	O
yet	RB	O
undiscovered	JJ	O
pathway.	.	O
There	EX	O
is	VBZ	O
considerable	JJ	O
evidence	NN	O
to	TO	O
support	VB	O
the	DT	O
importance	NN	O
of	IN	O
OAS	NNP	O
in	IN	O
negatively	RB	O
regulating	VBG	O
cell	NN	O
growth.	.	O
Rysiecki	NNP	B
et	CC	I
al.	.	I
(J.	NNP	I
Interferon	NNP	I
Res.	.	I
1989	CD	I
December;	:	I
9(6):649-57)	)	I
demonstrated	VBD	O
that	IN	O
stable	JJ	O
transfection	NN	O
of	IN	O
human	JJ	O
OAS	NNP	O
into	IN	O
a	DT	O
glioblastoma	NN	O
cell	NN	O
line	NN	O
results	NNS	O
in	IN	O
reduced	JJ	O
cellular	JJ	O
proliferation.	.	O
OAS	NNP	O
levels	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
measurable	JJ	O
in	IN	O
several	JJ	O
studies	NNS	O
comparing	VBG	O
quiescent	JJ	O
versus	NN	O
proliferating	VBG	O
cell	NN	O
lines	NNS	O
(e.g.	.	O
Hassel	NNP	B
and	CC	I
Ts'O,	,	I
Mol	NNP	I
Carcinog.	.	I
1992;	:	I
5(1):41-51	NN	I
and	CC	O
Kimchi	NNP	B
et	FW	I
al.,	,	I
Eur	NNP	I
J	NNP	I
Biochem.	.	I
1981;	:	I
114(1):5-10)	)	I
and	CC	O
in	IN	O
each	DT	O
case	NN	O
the	DT	O
OAS	NNP	O
levels	NNS	O
were	VBD	O
greatest	JJS	O
in	IN	O
quiescent	NN	O
cells.	.	O
Other	JJ	O
studies	NNS	O
have	VBP	O
shown	VBN	O
a	DT	O
correlation	NN	O
between	IN	O
OAS	NNP	O
level	NN	O
and	CC	O
cell	NN	O
cycle	NN	O
phase,	,	O
with	IN	O
OAS	NNP	O
levels	NNS	O
rising	VBG	O
sharply	RB	O
during	IN	O
late	JJ	O
S	NNP	O
phase	NN	O
and	CC	O
then	RB	O
dropping	VBG	O
abruptly	RB	O
in	IN	O
G2	NNP	O
Wells	NNP	B
and	CC	I
Mallucci,	,	I
Exp	NNP	I
Cell	NNP	I
Res.	.	I
1985	CD	I
JulY;	:	I
159(1):27-36).(	.	O
Several	JJ	O
studies	NNS	O
have	VBP	O
shown	VBN	O
a	DT	O
correlation	NN	O
between	IN	O
the	DT	O
induction	NN	O
of	IN	O
OAS	NNP	O
and	CC	O
the	DT	O
onset	NN	O
of	IN	O
antiproliferative	JJ	O
effects	NNS	O
following	VBG	O
stimulation	NN	O
with	IN	O
various	JJ	O
forms	NNS	O
of	IN	O
interferon	NN	O
(see	VB	O
Player	NNP	B
and	CC	I
Torrence,	,	I
Pharmacol	NNP	I
Ther.	.	I
1998	CD	I
May;	:	I
78(2):55-113).Induction	.	O
of	NN	O
OAS	IN	O
has	NNP	O
also	VBZ	O
been	RB	O
shown	VBN	O
during	VBN	O
cell	IN	O
differentiation	NN	O
(e.g.,	NN	O
Salzberg	,	B
et	NNP	I
al.,	CC	I
J	,	I
Cell	NNP	I
Sci.	NNP	I
1996	.	I
June;	CD	I
109(Pt	:	I
6):1517-26	NNP	I
and	NN	O
Schwartz	CC	B
and	NNP	I
Nilson,	CC	I
Mol	,	I
Cell	NNP	I
Biol.	NNP	I
1989	.	I
September;	CD	I
9(9):3897-903).Other	:	O
reports	.	O
of	JJ	O
induction	NNS	O
of	IN	O
OAS	NN	O
by	IN	O
platelet	NNP	O
derived	IN	O
growth	NN	O
factor	VBN	O
(PDGF)	NN	O
Zullo	NN	B
et	)	I
al.	NNP	I
Cell.	RB	I
1985	.	I
December;	.	I
43(3	CD	I
Pt	:	I
2):793-800)	CD	I
(and	NNP	O
under	)	O
conditions	CC	O
of	IN	O
heat-shock	NNS	O
induced	IN	O
growth	NN	O
Chousterman	JJ	B
et	NN	I
al.,	NNP	I
J	VBZ	I
Biol	,	I
Chem.	NNP	I
1987	NNP	I
Apr.	.	I
5;	CD	I
262(10):4806-11)	.	I
(lead	:	O
to	)	O
the	NN	O
hypothesis	TO	O
that	DT	O
induction	NN	O
of	IN	O
OAS	NN	O
is	IN	O
a	NNP	O
normal	VBZ	O
cell	DT	O
growth	JJ	O
control	NN	O
mechanism.	NN	O
Thus,	NN	O
use	.	O
of	,	O
compositions	NN	O
and	IN	O
methods	NNS	O
disclosed	CC	O
herein	NNS	O
may	VBN	O
find	NN	O
broad	MD	O
utility	VB	O
in	JJ	O
the	NN	O
detection,	IN	O
treatment	DT	O
and/or	,	O
prevention	NN	O
of	JJ	O
cancer	NN	O
or	IN	O
in	NN	O
the	CC	O
promotion	IN	O
of	DT	O
cellular	NN	O
or	IN	O
tissue	JJ	O
growth	CC	O
or	JJ	O
tissue	NN	O
regeneration.	CC	O
Therapeutic	NN	O
Agents	.	O
for	JJ	O
Restoring	NNS	O
and/or	IN	O
Enhancing	VBG	O
OAS	JJ	O
Function	NNP	O
As	NNP	O
described	NNP	O
previously	IN	O
the	VBN	O
polypeptides	RB	O
of	DT	O
the	NNS	O
present	IN	O
invention	DT	O
may	JJ	O
be	NN	O
advantageous	MD	O
in	VB	O
the	JJ	O
treatment	IN	O
of	DT	O
virus	NN	O
infection	IN	O
or	JJ	O
other	NN	O
indications	CC	O
including	JJ	O
but	NNS	O
not	VBG	O
limited	CC	O
to	RB	O
cancer,	JJ	O
diabetes	TO	O
mellitus,	,	O
inflammation,	VBZ	O
tissue	,	O
regeneration,	,	O
and	NN	O
wound	,	O
healing.	CC	O
The	IN	O
discussion	.	O
below	DT	O
pertains	NN	O
to	IN	O
administration	NNS	O
of	TO	O
any	NN	O
of	IN	O
the	DT	O
foregoing	IN	O
proteins	DT	O
or	NN	O
polypeptides.	VBZ	O
The	CC	O
polypeptides	.	O
of	DT	O
the	NNS	O
present	IN	O
invention	DT	O
may	JJ	O
be	NN	O
a	MD	O
naturally	VB	O
purified	DT	O
product,	RB	O
or	JJ	O
a	,	O
product	CC	O
of	DT	O
chemical	NN	O
synthetic	IN	O
procedures,	JJ	O
or	JJ	O
produced	,	O
by	CC	O
recombinant	VBN	O
techniques	IN	O
from	JJ	O
a	NNS	O
prokaryotic	IN	O
or	DT	O
eukaryotic	JJ	O
host	CC	O
(for	JJ	O
example,	NN	O
by	IN	O
bacterial,	,	O
yeast,	IN	O
higher	,	O
plant,	,	O
insect	JJR	O
and	,	O
mammalian	NN	O
cells	CC	O
in	JJ	O
culture)	NNS	O
of	IN	O
a	)	O
polynucleotide	IN	O
sequence	DT	O
of	JJ	O
the	NN	O
present	IN	O
invention.	DT	O
Depending	JJ	O
upon	.	O
the	VBG	O
host	IN	O
employed	DT	O
in	NN	O
a	VBN	O
recombinant	IN	O
production	DT	O
procedure,	JJ	O
the	NN	O
polypeptides	,	O
of	DT	O
the	NNS	O
present	IN	O
invention	DT	O
may	JJ	O
be	NN	O
glycosylated	MD	O
with	VB	O
mammalian	VBN	O
or	IN	O
other	JJ	O
eukaryotic	CC	O
carbohydrates	JJ	O
or	JJ	O
may	NNS	O
be	CC	O
non-glycosylated.	MD	O
Polypeptides	VB	O
of	.	O
the	NNS	O
invention	IN	O
may	DT	O
also	NN	O
include	MD	O
an	RB	O
initial	VB	O
methionine	DT	O
amino	JJ	O
acid	NN	O
residue	NN	O
(at	NN	O
position	NN	O
minus	IN	O
1).	NN	O
The	FW	O
polypeptides	.	O
of	DT	O
the	NNS	O
present	IN	O
invention	DT	O
also	JJ	O
include	NN	O
the	RB	O
protein	VBP	O
sequences	DT	O
defined	NN	O
in	NNS	O
FIG.	VBN	O
1	IN	O
and	.	O
derivatives	CD	O
thereof	CC	O
including	NNS	O
analogs	VBP	O
and	VBG	O
fragments	NNS	O
that	CC	O
function	NNS	O
similarly	WDT	O
to	VBP	O
the	RB	O
FIG.	TO	O
1	DT	O
forms.	.	O
Thus,	CD	O
for	.	O
example,	,	O
one	IN	O
or	,	O
more	CD	O
of	CC	O
the	JJR	O
amino	IN	O
acid	DT	O
residues	NN	O
of	NN	O
the	NNS	O
polypeptide	IN	O
may	DT	O
be	NN	O
replaced	MD	O
by	VB	O
conserved	VBN	O
amino	IN	O
acid	JJ	O
residues,	NN	O
as	NN	O
long	,	O
as	RB	O
the	RB	O
function	IN	O
of	DT	O
the	NN	O
polypeptides	IN	O
is	DT	O
maintained.	NNS	O
The	VBZ	O
polypeptides	.	O
may	DT	O
be	NNS	O
employed	MD	O
in	VB	O
accordance	VBN	O
with	IN	O
the	NN	O
present	IN	O
invention	DT	O
by	JJ	O
expression	NN	O
of	IN	O
such	NN	O
polypeptides	IN	O
in	JJ	O
vivo,	NNS	O
which	IN	O
is	,	O
often	WDT	O
referred	VBZ	O
to	RB	O
as	VBN	O
gene	TO	O
therapy.	IN	O
Thus,	NN	O
for	.	O
example,	,	O
cells	IN	O
may	,	O
be	NNS	O
transduced	MD	O
with	VB	O
a	VBN	O
polynucleotide	IN	O
(DNA	DT	O
or	NN	O
RNA)	NNP	O
encoding	CC	O
the	)	O
polypeptides	VBG	O
ex	DT	O
vivo,	NNS	O
with	VBP	O
those	,	O
transduced	IN	O
cells	DT	O
then	JJ	O
being	NNS	O
provided	RB	O
to	VBG	O
a	VBN	O
patient	TO	O
to	DT	O
be	NN	O
treated	TO	O
with	VB	O
the	VBN	O
polypeptide.	IN	O
Such	DT	O
methods	.	O
are	JJ	O
well	NNS	O
known	VBP	O
in	RB	O
the	VBN	O
art.	IN	O
For	DT	O
example,	.	O
cells	IN	O
may	,	O
be	NNS	O
transduced	MD	O
by	VB	O
procedures	VBN	O
known	IN	O
in	NNS	O
the	VBN	O
art	IN	O
by	DT	O
use	NN	O
of	IN	O
a	NN	O
retroviral	IN	O
particle	DT	O
containing	JJ	O
RNA	NN	O
encoding	VBG	O
a	NNP	O
polypeptide	VBG	O
of	DT	O
the	NN	O
present	IN	O
invention.	DT	O
Similarly,	JJ	O
transduction	.	O
of	,	O
cells	NN	O
may	IN	O
be	NNS	O
accomplished	MD	O
in	VB	O
vivo	VBN	O
for	IN	O
expression	NN	O
of	IN	O
the	NN	O
polypeptide	IN	O
in	DT	O
vivo,	NN	O
for	IN	O
example,	,	O
by	IN	O
procedures	,	O
known	IN	O
in	NNS	O
the	VBN	O
art.	IN	O
As	DT	O
known	.	O
in	IN	O
the	VBN	O
art,	IN	O
a	DT	O
producer	,	O
cell	DT	O
for	NN	O
producing	NN	O
a	IN	O
retroviral	VBG	O
particle	DT	O
containing	JJ	O
RNA	NN	O
encoding	VBG	O
the	NNP	O
polypeptides	VBG	O
of	DT	O
the	NNS	O
present	IN	O
invention	DT	O
may	JJ	O
be	NN	O
administered	MD	O
to	VB	O
a	VBN	O
patient	TO	O
for	DT	O
transduction	NN	O
in	IN	O
vivo	NN	O
and	IN	O
expression	NN	O
of	CC	O
the	NN	O
polypeptides	IN	O
in	DT	O
vivo.	NNS	O
These	IN	O
and	.	O
other	DT	O
methods	CC	O
for	JJ	O
administering	NNS	O
the	IN	O
polypeptides	VBG	O
of	DT	O
the	NNS	O
present	IN	O
invention	DT	O
by	JJ	O
such	NN	O
methods	IN	O
should	JJ	O
be	NNS	O
apparent	MD	O
to	VB	O
those	JJ	O
skilled	TO	O
in	DT	O
the	VBN	O
art	IN	O
from	DT	O
the	NN	O
teachings	IN	O
of	DT	O
the	NNS	O
present	IN	O
invention.	DT	O
For	JJ	O
example,	.	O
the	IN	O
expression	,	O
vehicle	DT	O
for	NN	O
transducing	NN	O
cells	IN	O
may	VBG	O
be	NNS	O
other	MD	O
than	VB	O
a	JJ	O
retrovirus,	IN	O
for	DT	O
example,	,	O
an	IN	O
adenovirus	,	O
which	DT	O
may	NN	O
be	WDT	O
used	MD	O
to	VB	O
transduce	VBN	O
cells	TO	O
in	VB	O
vivo	NNS	O
after	IN	O
combination	NN	O
with	IN	O
a	NN	O
suitable	IN	O
delivery	DT	O
vehicle.	JJ	O
Furthermore,	NN	O
the	.	O
polypeptides	,	O
of	DT	O
the	NNS	O
present	IN	O
invention	DT	O
are	JJ	O
able,	NN	O
as	VBP	O
part	,	O
of	IN	O
their	NN	O
native	IN	O
function,	PRP$	O
to	JJ	O
transduce	,	O
across	TO	O
a	VB	O
cell	IN	O
membrane	DT	O
and	NN	O
mediate	NN	O
their	CC	O
antiviral	VB	O
effects	PRP$	O
in	JJ	O
the	NNS	O
absence	IN	O
of	DT	O
a	NN	O
delivery	IN	O
vector	DT	O
or	NN	O
expression	NN	O
vehicle.	CC	O
The	NN	O
mechanism	.	O
of	DT	O
polypeptide	NN	O
transduction	IN	O
is	JJ	O
likely	NN	O
absorptive	VBZ	O
endocytosis	JJ	O
or	JJ	O
lipid	NN	O
raft-mediated	CC	O
macropinocytosis,	JJ	O
with	JJ	O
significant	,	O
amounts	IN	O
of	JJ	O
the	NNS	O
active	IN	O
polypeptide	DT	O
being	JJ	O
present	NN	O
in	VBG	O
the	JJ	O
cytoplasm	IN	O
and	DT	O
in	NN	O
detergent	CC	O
insoluble	IN	O
membrane	NN	O
fractions	JJ	O
of	NN	O
treated	NNS	O
cells	IN	O
as	JJ	O
demonstrated	NNS	O
in	IN	O
FIG.	VBN	O
5.	IN	O
The	.	O
essentially	.	O
basic	DT	O
and	RB	O
positively	JJ	O
charged	CC	O
character	RB	O
of	VBN	O
the	NN	O
proteins	IN	O
likely	DT	O
mediates	NNS	O
this	JJ	O
unusual	VBZ	O
characteristic,	DT	O
making	JJ	O
the	,	O
polypeptides	VBG	O
themselves	DT	O
effective	NNS	O
pharmaceutical	PRP	O
compositions	JJ	O
without	JJ	O
the	NNS	O
need	IN	O
for	DT	O
carriers	NN	O
to	IN	O
increase	NNS	O
cell	TO	O
permeability.	VB	O
The	NN	O
cell	.	O
transduction	DT	O
properties	NN	O
of	NN	O
basic,	NNS	O
positively	IN	O
charged	,	O
proteins	RB	O
has	VBN	O
been	NNS	O
previously	VBZ	O
described	VBN	O
and	RB	O
is	VBN	O
well	CC	O
known	VBZ	O
to	RB	O
those	VBN	O
skilled	TO	O
in	DT	O
the	VBN	O
art	IN	O
Ryser	DT	B
and	NN	I
Hancock,	NNP	I
Science.	CC	I
1965	,	I
Oct.	.	I
22;	CD	I
150(695):501-3).(	NNP	O
It	:	O
is	.	O
clear	PRP	O
from	VBZ	O
FIG.	JJ	O
2	IN	O
and	.	O
FIG.	CD	O
3	CC	O
of	.	O
the	CD	O
present	IN	O
invention	DT	O
that	JJ	O
the	NN	O
polypeptides	IN	O
of	DT	O
the	NNS	O
invention	IN	O
can	DT	O
affect	NN	O
an	MD	O
antiviral	VB	O
function	DT	O
in	JJ	O
cell	NN	O
culture	IN	O
that	NN	O
can	NN	O
only	WDT	O
be	MD	O
mediated	RB	O
by	VB	O
transduction	VBN	O
of	IN	O
the	NN	O
polypeptides	IN	O
into	DT	O
the	NNS	O
cell.	IN	O
Class	DT	O
III	.	O
modifications	NN	O
to	NNP	O
the	NNS	O
reference	TO	O
polypeptide	DT	O
increase	NN	O
their	IN	O
basic	VB	O
charge	PRP$	O
and	JJ	O
therefore	NN	O
their	CC	O
cell	VB	O
permeability	PRP$	O
(compare	NN	O
FIG.	NN	O
3	JJ	O
with	.	O
FIG.	LS	O
4).	IN	O
In	.	O
the	.	O
case	IN	O
where	DT	O
the	NN	O
polypeptides	WRB	O
are	DT	O
prepared	NNS	O
as	VBP	O
a	VBN	O
liquid	IN	O
formulation	DT	O
and	JJ	O
administered	NN	O
by	CC	O
injection,	VBN	O
preferably	IN	O
the	,	O
solution	RB	O
is	DT	O
an	NN	O
isotonic	VBZ	O
salt	DT	O
solution	JJ	O
containing	NN	O
140	NN	O
millimolar	VBG	O
sodium	CD	O
chloride	JJ	O
and	NN	O
10	NN	O
millimolar	CC	O
calcium	CD	O
at	JJ	O
pH	NN	O
7.4.	IN	O
The	JJ	O
injection	.	O
may	DT	O
be	NN	O
administered,	MD	O
for	VB	O
example,	,	O
in	IN	O
a	,	O
therapeutically	IN	O
effective	DT	O
amount,	RB	O
preferably	JJ	O
in	,	O
a	RB	O
dose	IN	O
of	DT	O
about	NN	O
1	IN	O
μg/kg	IN	O
body	CD	O
weight	NNS	O
to	NN	O
about	VBD	O
5	TO	O
mg/kg	IN	O
body	CD	O
weight	NNS	O
daily,	NN	O
taking	VBD	O
into	,	O
account	VBG	O
the	IN	O
routes	NN	O
of	DT	O
administration,	NNS	O
health	IN	O
of	,	O
the	NN	O
patient,	IN	O
etc.	DT	O
The	,	O
polypeptide(s)	.	O
of	DT	O
the	)	O
present	IN	O
invention	DT	O
may	JJ	O
be	NN	O
employed	MD	O
in	VB	O
combination	VBN	O
with	IN	O
a	NN	O
suitable	IN	O
pharmaceutical	DT	O
carrier.	JJ	O
Such	JJ	O
compositions	.	O
comprise	JJ	O
a	NNS	O
therapeutically	VBP	O
effective	DT	O
amount	RB	O
of	JJ	O
the	NN	O
protein,	IN	O
and	DT	O
a	,	O
pharmaceutically	CC	O
acceptable	DT	O
carrier	RB	O
or	JJ	O
excipient.	NN	O
Such	CC	O
a	.	O
carrier	JJ	O
includes	DT	O
but	NN	O
is	VBZ	O
not	CC	O
limited	VBZ	O
to	RB	O
saline,	VBN	O
buffered	TO	O
saline,	,	O
dextrose,	VBN	O
water,	,	O
glycerol,	,	O
ethanol,	,	O
and	,	O
combinations	,	O
thereof.	CC	O
The	NNS	O
formulation	.	O
should	DT	O
suit	NN	O
the	MD	O
mode	VB	O
of	DT	O
administration.	NN	O
The	IN	O
polypeptide(s)	.	O
of	DT	O
the	)	O
present	IN	O
invention	DT	O
can	JJ	O
also	NN	O
be	MD	O
modified	RB	O
by	VB	O
chemically	VBN	O
linking	IN	O
the	RB	O
polypeptide	VBG	O
to	DT	O
one	NN	O
or	TO	O
more	CD	O
moieties	CC	O
or	JJR	O
conjugates	NNS	O
to	CC	O
enhance	NNS	O
the	TO	O
activity,	VB	O
cellular	DT	O
distribution,	,	O
or	JJ	O
cellular	,	O
uptake	CC	O
of	JJ	O
the	NN	O
polypeptide(s).	IN	O
Such	DT	O
moieties	.	O
or	JJ	O
conjugates	NNS	O
include	CC	O
lipids	NNS	O
such	VBP	O
as	NNS	O
cholesterol,	JJ	O
cholic	IN	O
acid,	,	O
thioether,	JJ	O
aliphatic	,	O
chains,	,	O
phospholipids	JJ	O
and	,	O
their	NNS	O
derivatives,	CC	O
polyamines,	PRP$	O
polyethylene	,	O
glycol	,	O
(PEG),	NN	O
palmityl	NN	O
moieties,	,	O
and	JJ	O
others	,	O
as	CC	O
disclosed	NNS	O
in,	IN	O
for	VBN	O
example,	,	O
U.S.	IN	O
Pat.	,	O
Nos.	NNP	O
5,514,758,	.	O
5,565,552,	.	O
5,567,810,	,	O
5,574,142,	,	O
5,585,481,	,	O
5,587,371,	,	O
5,597,696	,	O
and	,	O
5,958,773.	CD	O
The	CC	O
polypeptide(s)	.	O
of	DT	O
the	)	O
present	IN	O
invention	DT	O
may	JJ	O
also	NN	O
be	MD	O
modified	RB	O
to	VB	O
target	VBN	O
specific	TO	O
cell	VB	O
types	JJ	O
for	NN	O
a	NNS	O
particular	IN	O
disease	DT	O
indication,	JJ	O
including	NN	O
but	,	O
not	VBG	O
limited	CC	O
to	RB	O
liver	JJ	O
cells	TO	O
in	VB	O
the	NNS	O
case	IN	O
of	DT	O
hepatitis	NN	O
C	IN	O
infection.	NN	O
As	NNP	O
can	.	O
be	IN	O
appreciated	MD	O
by	VB	O
those	VBN	O
skilled	IN	O
in	DT	O
the	VBN	O
art,	IN	O
suitable	DT	O
methods	,	O
have	JJ	O
been	NNS	O
described	VBP	O
that	VBN	O
achieve	VBN	O
the	IN	O
described	VBP	O
targeting	DT	O
goals	NN	O
and	VBG	O
include,	NNS	O
without	CC	O
limitation,	,	O
liposomal	IN	O
targeting,	,	O
receptor-mediated	JJ	O
endocytosis,	,	O
and	JJ	O
antibody-antigen	,	O
binding.	CC	O
In	JJ	O
one	.	O
embodiment,	IN	O
the	CD	O
asiaglycoprotein	,	O
receptor	DT	O
may	NNS	O
be	NN	O
used	MD	O
to	VB	O
target	VBN	O
liver	TO	O
cells	VB	O
by	RB	O
the	NNS	O
addition	IN	O
of	DT	O
a	NN	O
galactose	IN	O
moiety	DT	O
to	JJ	O
the	NN	O
polypeptide(s).	TO	O
In	DT	O
another	.	O
embodiment,	IN	O
mannose	DT	O
moieties	,	O
may	JJ	O
be	NNS	O
conjugated	MD	O
to	VB	O
the	VBN	O
polypeptide(s)	TO	O
in	DT	O
order	)	O
to	IN	O
target	NN	O
the	TO	O
mannose	VB	O
receptor	DT	O
found	JJ	O
on	NN	O
macrophages	VBD	O
and	IN	O
liver	NNS	O
cells.	CC	O
As	NN	O
one	.	O
skilled	IN	O
in	CD	O
the	VBD	O
art	IN	O
will	DT	O
recognize,	NN	O
multiple	MD	O
delivery	,	O
and	JJ	O
targeting	NN	O
methods	CC	O
may	VBG	O
be	NNS	O
combined.	MD	O
For	VB	O
example,	.	O
the	IN	O
polypeptide(s)	,	O
of	DT	O
the	)	O
present	IN	O
invention	DT	O
may	JJ	O
be	NN	O
targeted	MD	O
to	VB	O
liver	VBN	O
cells	TO	O
by	VB	O
encapsulation	NNS	O
within	IN	O
liposomes,	NN	O
such	IN	O
liposomes	,	O
being	JJ	O
conjugated	NNS	O
to	VBG	O
galactose	VBN	O
for	TO	O
targeting	VB	O
to	IN	O
the	VBG	O
asialoglycoprotein	TO	O
receptor.	DT	O
The	NN	O
invention	.	O
also	DT	O
provides	NN	O
a	RB	O
pharmaceutical	VBZ	O
pack	DT	O
or	JJ	O
kit	NN	O
comprising	CC	O
one	VB	O
or	VBG	O
more	CD	O
containers	CC	O
filled	JJR	O
with	NNS	O
one	VBD	O
or	IN	O
more	CD	O
of	CC	O
the	JJR	O
ingredients	IN	O
of	DT	O
the	NNS	O
pharmaceutical	IN	O
compositions	DT	O
of	JJ	O
the	NNS	O
invention.	IN	O
Associated	DT	O
with	.	O
such	VBN	O
container(s)	IN	O
can	JJ	O
be	)	O
a	MD	O
notice	VB	O
in	DT	O
the	NN	O
form	IN	O
prescribed	DT	O
by	NN	O
a	VBN	O
governmental	IN	O
agency	DT	O
regulating	JJ	O
the	NN	O
manufacture,	VBG	O
use	DT	O
or	,	O
sale	NN	O
of	CC	O
pharmaceuticals	NN	O
or	IN	O
biological	NNS	O
products,	CC	O
which	JJ	O
notice	,	O
reflects	WDT	O
approval	VBZ	O
by	VBZ	O
the	NN	O
agency	IN	O
of	DT	O
manufacture,	NN	O
use	IN	O
or	,	O
sale	NN	O
for	CC	O
human	NN	O
administration.	IN	O
In	JJ	O
addition,	.	O
the	IN	O
polypeptide	,	O
of	DT	O
the	NN	O
present	IN	O
invention	DT	O
may	JJ	O
be	NN	O
employed	MD	O
in	VB	O
conjunction	VBN	O
with	IN	O
other	NN	O
therapeutic	IN	O
compounds.	JJ	O
When	JJ	O
the	.	O
polypeptide(s)	WRB	O
of	DT	O
the	)	O
present	IN	O
invention	DT	O
are	JJ	O
used	NN	O
as	VBP	O
a	VBN	O
pharmaceutical,	IN	O
they	DT	O
can	,	O
be	PRP	O
given	MD	O
to	VB	O
mammals,	VBN	O
in	TO	O
a	,	O
suitable	IN	O
vehicle.	DT	O
When	JJ	O
the	.	O
polypeptides	WRB	O
of	DT	O
the	NNS	O
present	IN	O
invention	DT	O
are	JJ	O
used	NN	O
as	VBP	O
a	VBN	O
pharmaceutical	IN	O
as	DT	O
described	JJ	O
above,	IN	O
they	VBN	O
are	,	O
given,	PRP	O
for	VBP	O
example,	,	O
in	IN	O
therapeutically	,	O
effective	IN	O
doses	RB	O
of	JJ	O
about	NNS	O
10	IN	O
μg/kg	IN	O
body	CD	O
weight	NNS	O
to	NN	O
about	VBD	O
10	TO	O
mg/kg	IN	O
body	CD	O
weight	NNS	O
daily,	NN	O
taking	VBD	O
into	,	O
account	VBG	O
the	IN	O
routes	NN	O
of	DT	O
administration,	NNS	O
health	IN	O
of	,	O
the	NN	O
patient,	IN	O
etc.	DT	O
The	,	O
amount	.	O
given	DT	O
is	NN	O
preferably	VBN	O
adequate	VBZ	O
to	RB	O
achieve	JJ	O
prevention	TO	O
or	VB	O
inhibition	NN	O
of	CC	O
infection	NN	O
by	IN	O
a	NN	O
virus,	IN	O
preferably	DT	O
a	,	O
flavivirus,	RB	O
most	DT	O
preferably	,	O
RSV	RBS	O
and	RB	O
HCV,	NNP	O
prevention	CC	O
or	,	O
treatment	NN	O
of	CC	O
cancer,	NN	O
inflammation,	IN	O
diabetes,	,	O
or	,	O
other	,	O
diseases.	CC	O
The	JJ	O
proteins,	.	O
their	DT	O
fragments	,	O
or	PRP$	O
other	NNS	O
derivatives,	CC	O
or	JJ	O
analogs	,	O
thereof,	CC	O
or	NNS	O
cells	,	O
expressing	CC	O
them	NNS	O
can	VBG	O
be	PRP	O
used	MD	O
as	VB	O
an	VBN	O
immunogen	IN	O
to	DT	O
produce	NN	O
antibodies	TO	O
thereto.	VB	O
These	NNS	O
antibodies	.	O
can	DT	O
be,	NNS	O
for	MD	O
example,	,	O
polyclonal,	IN	O
monoclonal,	,	O
chimeric,	,	O
single	,	O
chain,	,	O
Fab	JJ	O
fragments,	,	O
or	NNP	O
the	,	O
product	CC	O
of	DT	O
an	NN	O
Fab	IN	O
expression	DT	O
library.	NNP	O
Various	NN	O
procedures	.	O
known	JJ	O
in	NNS	O
the	VBN	O
art	IN	O
may	DT	O
be	NN	O
used	MD	O
for	VB	O
the	VBN	O
production	IN	O
of	DT	O
polyclonal	NN	O
antibodies.	IN	O
Antibodies	JJ	O
generated	.	O
against	NNS	O
the	VBN	O
polypeptide(s)	IN	O
of	DT	O
the	)	O
present	IN	O
invention	DT	O
can	JJ	O
be	NN	O
obtained	MD	O
by	VB	O
direct	VBN	O
injection	IN	O
of	JJ	O
the	NN	O
polypeptide	IN	O
into	DT	O
an	NN	O
animal	IN	O
or	DT	O
by	NN	O
administering	CC	O
the	IN	O
polypeptide	VBG	O
to	DT	O
an	NN	O
animal,	TO	O
preferably	DT	O
a	,	O
nonhuman.	RB	O
The	DT	O
antibody	.	O
so	DT	O
obtained	NN	O
will	RB	O
then	VBN	O
bind	MD	O
the	RB	O
polypeptide	VB	O
itself.	DT	O
In	NN	O
this	.	O
manner,	IN	O
even	DT	O
a	,	O
sequence	RB	O
encoding	DT	O
only	NN	O
a	VBG	O
fragment	RB	O
of	DT	O
the	NN	O
polypeptide	IN	O
can	DT	O
be	NN	O
used	MD	O
to	VB	O
generate	VBN	O
antibodies	TO	O
binding	VB	O
the	NNS	O
whole	VBG	O
native	DT	O
polypeptide.	JJ	O
Moreover,	JJ	O
a	.	O
panel	,	O
of	DT	O
such	NN	O
antibodies	IN	O
specific	JJ	O
to	NNS	O
a	VBP	O
large	TO	O
number	DT	O
of	JJ	O
polypeptides	NN	O
can	IN	O
be	NNS	O
used.	MD	O
For	VB	O
preparation	.	O
of	IN	O
monoclonal	NN	O
antibodies,	IN	O
any	JJ	O
technique	,	O
which	DT	O
provides	NN	O
antibodies	WDT	O
produced	VBZ	O
by	NNS	O
continuous	VBN	O
cell	IN	O
line	JJ	O
cultures	NN	O
can	NN	O
be	NNS	O
used.	MD	O
Examples	VB	O
include	.	O
the	NNS	O
hybridoma	VBP	O
technique	DT	O
Kohler	NN	B
and	NN	I
Milstein,	NNP	I
1975,	CC	I
Nature,	,	I
256:495-597),(	,	O
the	,	O
trioma	,	O
technique,	DT	O
the	NN	O
human	,	O
B-cell	DT	O
hybridoma	JJ	O
technique	NNP	O
Kozbor,	NN	B
et	NN	I
al.,	,	I
1983,	FW	I
Immunology	,	I
Today	,	I
4:72),(	NNP	O
and	NNP	O
the	,	O
EBV-hybridoma	CC	O
technique	DT	O
to	NNP	O
produce	NN	O
human	TO	O
monoclonal	VB	O
antibodies	JJ	O
Coe,	JJ	B
et	NNS	I
al.,	,	I
1985,	FW	I
Monoclonal	,	I
Antibodies	,	I
and	NNP	I
Cancer	NNPS	I
Therapy,	CC	I
Alan	NNP	I
R.	,	I
Liss,	NNP	I
Inc.	NNP	I
pp.	,	I
77-96).(	NNP	O
Techniques	.	O
described	.	O
for	NNS	O
the	VBN	O
production	IN	O
of	DT	O
single	NN	O
chain	IN	O
antibodies	JJ	O
(U.S.	NN	O
Pat.	NNS	O
No.	NNP	O
4,946,778)	.	O
can	.	O
be	)	O
adapted	MD	O
to	VB	O
produce	VBN	O
single	TO	O
chain	VB	O
antibodies	JJ	O
to	NN	O
immunogenic	NNS	O
polypeptide	TO	O
products	VB	O
of	JJ	O
this	NNS	O
invention.	IN	O
The	DT	O
antibodies	.	O
can	DT	O
be	NNS	O
used	MD	O
in	VB	O
methods	VBN	O
relating	IN	O
to	NNS	O
the	VBG	O
localization	TO	O
and	DT	O
activity	NN	O
of	CC	O
the	NN	O
protein	IN	O
sequences	DT	O
of	NN	O
the	NNS	O
invention,	IN	O
e.g.,	DT	O
for	,	O
imaging	,	O
these	IN	O
proteins,	VBG	O
measuring	DT	O
levels	,	O
thereof	VBG	O
in	NNS	O
appropriate	VBN	O
physiological	IN	O
samples,	JJ	O
and	JJ	O
the	,	O
like.	CC	O
The	DT	O
invention	.	O
provides	DT	O
for	NN	O
polypeptides	VBZ	O
that	IN	O
differ	NNS	O
from	WDT	O
the	VBP	O
polypeptides	IN	O
of	DT	O
FIG.	NNS	O
1	IN	O
by	.	O
1	CD	O
to	IN	O
34	CD	O
amino	TO	O
acids,	CD	O
such	NN	O
differences	,	O
may	JJ	O
include	NNS	O
substitutions,	MD	O
insertions,	VB	O
deletions,	,	O
the	,	O
incorporation	,	O
of	DT	O
modified	NN	O
amino	IN	O
acids	VBN	O
or	NN	O
amino	NNS	O
acid	CC	O
derivatives,	NN	O
and	JJ	O
the	,	O
addition	CC	O
or	DT	O
deletion	NN	O
of	CC	O
amino	NN	O
acids	IN	O
from	JJ	O
the	NNS	O
C-terminus	IN	O
or	DT	O
N-terminus	NNP	O
of	CC	O
the	NNP	O
polypeptides.	IN	O
The	DT	O
invention	.	O
provides	DT	O
for	NN	O
therapeutic	VBZ	O
and	IN	O
prophylactic	JJ	O
uses	CC	O
of	JJ	O
these	NNS	O
polypeptides	IN	O
including	DT	O
but	NNS	O
not	VBG	O
limited	CC	O
to	RB	O
the	JJ	O
treatment	TO	O
of	DT	O
virus	NN	O
infection,	IN	O
neoplasm,	NN	O
cancer,	,	O
diabetes,	,	O
and	,	O
to	,	O
promote	CC	O
cell	TO	O
growth	VB	O
and	NN	O
differentiation	NN	O
and	CC	O
tissue	NN	O
regeneration.	CC	O
The	NN	O
invention	.	O
provides	DT	O
for	NN	O
polynucleotides	VBZ	O
encoding	IN	O
the	NNS	O
polypeptides	VBG	O
of	DT	O
the	NNS	O
invention	IN	O
and	DT	O
uses	NN	O
thereof	CC	O
including	VBZ	O
but	JJ	O
not	VBG	O
limited	CC	O
to	RB	O
uses	JJ	O
in	TO	O
manufacturing	NNS	O
the	IN	O
polypeptides,	VBG	O
as	DT	O
gene	,	O
therapies,	IN	O
as	NN	O
diagnostic	,	O
tools,	IN	O
etc.	JJ	O
The	,	O
invention	.	O
provides	DT	O
for	NN	O
the	VBZ	O
following	IN	O
classes	DT	O
of	JJ	O
polypeptide:	NNS	O
Class	IN	O
I	:	O
Polypeptide	NN	O
Modifications	PRP	O
The	VBP	O
Class	PDT	O
I	DT	O
modifications	NN	O
of	PRP	O
the	NNS	O
present	IN	O
invention	DT	O
represent	JJ	O
enzymatically	NN	O
inactive	NN	O
oligoadenylate	RB	O
synthetase	JJ	O
forms	NN	O
created	NN	O
by	NNS	O
mutation	VBN	O
of	IN	O
the	NN	O
magnesium	IN	O
binding	DT	O
site	NN	O
of	VBG	O
the	NN	O
native	IN	O
protein.	DT	O
These	JJ	O
enzymatically	.	O
inactive	DT	O
polypeptides	RB	O
retain	JJ	O
antiviral	NNS	O
activity	VBP	O
and	JJ	O
constitute	NN	O
novel	CC	O
therapeutic	NN	O
compositions	JJ	O
under	JJ	O
the	NNS	O
present	IN	O
invention.	DT	O
An	JJ	O
example	.	O
of	DT	O
the	NN	O
in	IN	O
vitro	DT	O
antiviral	IN	O
activity	JJ	O
of	JJ	O
a	NN	O
Class	IN	O
I	DT	O
modified	NN	O
polypeptide	PRP	O
is	VBD	O
demonstrated	NN	O
in	VBZ	O
FIG.	VBN	O
3.	IN	O
The	.	O
polypeptides	.	O
of	DT	O
the	NNS	O
invention	IN	O
include	DT	O
all	NN	O
enzymatically	VBP	O
inactive	DT	O
forms	RB	O
of	JJ	O
the	NNS	O
oligoadenylate	IN	O
synthetases,	DT	O
such	NN	O
forms	,	O
being	JJ	O
those	NNS	O
that	VBG	O
do	DT	O
not	WDT	O
synthesize	VBP	O
2-prime-5-prime	RB	O
oligaodenylates,	VB	O
and	JJ	O
uses	,	O
thereof.	CC	O
Class	VBZ	O
II	.	O
Polypeptide	NNP	O
Modifications	NNP	O
The	NNP	O
Class	NNP	O
II	DT	O
modifications	NNP	O
of	NNP	O
the	NNS	O
present	IN	O
invention	DT	O
represent	JJ	O
mutant	NN	O
oligoadenylate	NN	O
synthetase	JJ	O
forms	NN	O
that	NN	O
have	NNS	O
increased	WDT	O
in	VBP	O
vitro	VBN	O
and	IN	O
in	NN	O
vivo	CC	O
stability	IN	O
by	JJ	O
virtue	NN	O
of	IN	O
the	NN	O
removal	IN	O
of	DT	O
one	NN	O
or	IN	O
more	CD	O
highly-reactive,	CC	O
sulfhydryl-containing	JJR	O
cysteine	,	O
residues.	JJ	O
Removal	NN	O
of	.	O
one	NN	O
or	IN	O
more	CD	O
sulfhydryl	CC	O
groups	JJR	O
prevents	JJ	O
protein	NNS	O
aggregation	NNS	O
during	JJ	O
purification	NN	O
and	IN	O
handling	NN	O
and	CC	O
obviates	NN	O
the	CC	O
need	VBZ	O
for	DT	O
supplementary	NN	O
reducing	IN	O
agent	JJ	O
during	VBG	O
bulk	NN	O
drug	IN	O
product	JJ	O
manufacturing.	NN	O
Removal	NN	O
or	.	O
replacement	NN	O
of	CC	O
cysteine	NN	O
residues	IN	O
increases	NN	O
drug	NNS	O
stability	VBZ	O
in	NN	O
excipients	NN	O
suitable	IN	O
for	NNS	O
in-human	JJ	O
use.	IN	O
Cysteines	JJ	O
that	.	O
can	NNS	O
be	WDT	O
removed	MD	O
or	VB	O
modified	VBN	O
while	CC	O
preserving	VBN	O
the	IN	O
prophylactic	VBG	O
or	DT	O
therapeutic	JJ	O
activity	CC	O
of	JJ	O
the	NN	O
polypeptide	IN	O
include	DT	O
the	NN	O
cysteines	VBP	O
at	DT	O
positions	NNS	O
25,	IN	O
38,	NNS	O
and	,	O
54	,	O
of	CC	O
the	CD	O
reference	IN	O
oligoadenylate	DT	O
synthetase	NN	O
polypeptide	JJ	O
sequence	NN	O
of	JJ	O
FIG.	NN	O
1.	IN	O
The	.	O
cysteine	.	O
at	DT	O
position	NN	O
25	IN	O
is	NN	O
surface	CD	O
exposed	VBZ	O
and	NN	O
modified	VBN	O
by	CC	O
iodoacetamide	VBN	O
in	IN	O
the	NN	O
porcine	IN	O
form.	DT	O
This	JJ	O
cysteine	.	O
is	DT	O
neither	NN	O
strongly	VBZ	O
conserved	RB	O
nor	RB	O
does	VBN	O
it	CC	O
have	VBZ	O
a	PRP	O
strong	VB	O
interaction	DT	O
with	JJ	O
any	NN	O
other	IN	O
functional	DT	O
group	JJ	O
of	JJ	O
the	NN	O
protein.	IN	O
The	DT	O
cysteine	.	O
at	DT	O
position	NN	O
38	IN	O
with	NN	O
reference	CD	O
to	IN	O
FIG.	NN	O
1	TO	O
is	.	O
also	CD	O
solvent	VBZ	O
exposed	RB	O
and	JJ	O
modified	VBN	O
by	CC	O
iodoacetamide	VBN	O
in	IN	O
the	NN	O
porcine	IN	O
structure.	DT	O
This	NN	O
cysteine	.	O
forms	DT	O
a	NN	O
weak	VBZ	O
hydrogen	DT	O
bond	JJ	O
to	NN	O
the	NN	O
valine	TO	O
58	DT	O
backbone	NN	O
and	CD	O
is	NN	O
poorly	CC	O
conserved.	VBZ	O
Cysteine	RB	O
54	.	O
hydrogen	NNP	O
bonds	CD	O
to	NN	O
the	NNS	O
valine	TO	O
53	DT	O
backbone,	NN	O
but	CD	O
is	,	O
not	CC	O
conserved	VBZ	O
and	RB	O
appears	VBN	O
to	CC	O
have	VBZ	O
no	TO	O
important	VB	O
interaction	DT	O
elsewhere	JJ	O
on	NN	O
the	RB	O
structure.	IN	O
Because	DT	O
of	.	O
their	IN	O
solvent	IN	O
exposure,	PRP$	O
weak	NN	O
interaction	,	O
with	JJ	O
other	NN	O
parts	IN	O
of	JJ	O
the	NNS	O
protein	IN	O
structure,	DT	O
and	NN	O
poor	,	O
conservation,	CC	O
each	JJ	O
of	,	O
these	DT	O
three	IN	O
amino	DT	O
acids	CD	O
can	NN	O
be	NNS	O
deleted	MD	O
or	VB	O
modified	VBN	O
to	CC	O
increase	VBN	O
oxidation	TO	O
resistance	VB	O
and	NN	O
protein	NN	O
stability	CC	O
in	NN	O
vitro	NN	O
and	IN	O
in	NN	O
vivo	CC	O
while	IN	O
preserving	NN	O
prophylactic	IN	O
or	VBG	O
therapeutic	JJ	O
activity.	CC	O
The	JJ	O
remaining	.	O
seven	DT	O
cysteine	VBG	O
residues	CD	O
can	JJ	O
be	NNS	O
modified	MD	O
with	VB	O
varying	VBN	O
degrees	IN	O
of	VBG	O
reduction	NNS	O
in	IN	O
prophylactic	NN	O
or	IN	O
therapeutic	JJ	O
activity.	CC	O
Cysteine	JJ	O
45	.	O
is	NNP	O
in	CD	O
a	VBZ	O
hydrophobic	IN	O
pocket	DT	O
and	JJ	O
conserved	NN	O
in	CC	O
the	VBN	O
active	IN	O
(C-terminal)	DT	O
domains	JJ	O
of	)	O
OAS2	NNS	O
and	IN	O
3.	NNP	O
Cysteine	CC	O
109	.	O
is	NNP	O
in	CD	O
a	VBZ	O
hydrophobic	IN	O
pocket.	DT	O
Cysteine	JJ	O
177	.	O
is	NNP	O
buried	CD	O
and	VBZ	O
possibly	VBN	O
hydrogen	CC	O
bonds	RB	O
to	VB	O
the	NNS	O
polypeptide	TO	O
backbone.	DT	O
Cysteine	NN	O
189	.	O
is	NNP	O
buried,	CD	O
hydrogen	VBZ	O
bonds	,	O
to	NN	O
glutamine	NNS	O
91	TO	O
and	VB	O
phenylalanine	CD	O
153,	CC	O
and	VB	O
is	,	O
highly	CC	O
conserved.	VBZ	O
Cysteine	RB	O
219	.	O
is	NNP	O
located	CD	O
in	VBZ	O
a	VBN	O
hydrophobic	IN	O
neighborhood	DT	O
and	JJ	O
possibly	NN	O
hydrogen	CC	O
bonds	RB	O
with	VB	O
tryptophan	NNS	O
215.	IN	O
Further,	JJ	O
this	.	O
amino	,	O
acid	DT	O
is	NN	O
relatively	NN	O
well	VBZ	O
conserved	RB	O
in	RB	O
OAS1,	VBN	O
2,	IN	O
and	,	O
3.	,	O
Cysteine	CC	O
269	.	O
is	NNP	O
surface	CD	O
exposed,	VBZ	O
but	NN	O
hydrogen	,	O
bonds	CC	O
to	NN	O
the	NNS	O
backbone	TO	O
of	DT	O
the	NN	O
conserved	IN	O
leucine	DT	O
291	JJ	O
and	NN	O
is	CD	O
itself	CC	O
highly	VBZ	O
conserved.	PRP	O
Finally,	RB	O
cysteine	.	O
331	,	O
is	NN	O
buried	CD	O
within	VBZ	O
the	VBN	O
structure	IN	O
and	DT	O
hydrogen	NN	O
bonds	CC	O
with	NN	O
the	NNS	O
backbone	IN	O
of	DT	O
leucine	NN	O
4.	IN	O
For	JJ	O
these	.	O
reasons,	IN	O
the	DT	O
foregoing	,	O
seven	DT	O
cysteine	VBG	O
residues	CD	O
respond	JJ	O
more	NNS	O
poorly	VBP	O
to	JJR	O
modification.	RB	O
The	TO	O
polypeptides	.	O
of	DT	O
the	NNS	O
invention	IN	O
include	DT	O
all	NN	O
oligoadenylate	VBP	O
synthetase	DT	O
polypeptides	JJ	O
that	NN	O
are	NNS	O
modified	WDT	O
to	VBP	O
reduce	VBN	O
oxidative	TO	O
potential,	VB	O
including	JJ	O
but	,	O
not	VBG	O
limited	CC	O
to	RB	O
the	JJ	O
polypeptides	TO	O
of	DT	O
FIG.	NNS	O
1.	IN	O
Class	.	O
III	.	O
Polypeptide	NN	O
Modifications	NNP	O
The	NNP	O
Class	NNP	O
III	DT	O
modifications	NNP	O
of	NNP	O
the	NNS	O
present	IN	O
invention	DT	O
result	JJ	O
in	NN	O
polypeptides	NN	O
having	IN	O
increased	NNS	O
cell	VBG	O
permeability	VBN	O
by	NN	O
virtue	NN	O
of	IN	O
the	NN	O
addition	IN	O
of	DT	O
basic	NN	O
residues	IN	O
at	JJ	O
the	NNS	O
amino-terminus	IN	O
of	DT	O
the	NN	O
proteins.	IN	O
Histidine,	DT	O
arginine,	.	O
and	,	O
lysine	,	O
residues	CC	O
all	NN	O
increase	NNS	O
the	DT	O
cell	VBP	O
permeability	DT	O
of	NN	O
the	NN	O
native	IN	O
protein.	DT	O
As	JJ	O
one	.	O
skilled	IN	O
in	CD	O
the	VBD	O
art	IN	O
will	DT	O
recognize,	NN	O
any	MD	O
length	,	O
of	DT	O
homopolymeric	NN	O
basic	IN	O
residues	JJ	O
can	JJ	O
increase	NNS	O
polypeptide	MD	O
cell	VB	O
permeability	RB	O
(U.S.	JJ	O
Pat.	NN	O
No.	NNP	O
4,847,240).	.	O
Modification	.	O
of	.	O
the	NN	O
amino	IN	O
terminus	DT	O
of	NN	O
the	NN	O
protein	IN	O
preserves	DT	O
full	NN	O
enzymatic	VBZ	O
activity	JJ	O
while	JJ	O
increasing	NN	O
cell	IN	O
permeability.	VBG	O
In	NN	O
some	.	O
cases,	IN	O
the	DT	O
cell	,	O
permeability	DT	O
of	NN	O
the	NN	O
polypeptide	IN	O
can	DT	O
be	NN	O
increased	MD	O
more	VB	O
than	VBN	O
ten-fold	JJR	O
by	IN	O
addition	JJ	O
of	IN	O
a	NN	O
Class	IN	O
III	DT	O
modification.	NNP	O
Nevertheless,	NNP	O
all	.	O
of	,	O
the	DT	O
oligoadenylate	IN	O
synthetases	DT	O
of	JJ	O
the	NNS	O
invention	IN	O
have	DT	O
some	NN	O
cell	VBP	O
penetrating	DT	O
ability,	NN	O
even	VBG	O
in	,	O
the	RB	O
absence	IN	O
of	DT	O
a	NN	O
Class	IN	O
III	DT	O
modification.	NNP	O
It	NNP	O
is	.	O
therefore	PRP	O
the	VBZ	O
intention	RB	O
of	DT	O
the	NN	O
present	IN	O
invention	DT	O
to	JJ	O
include	NN	O
uses	TO	O
of	VB	O
the	NNS	O
polypeptides	IN	O
of	DT	O
the	NNS	O
invention,	IN	O
including	DT	O
the	,	O
parent	VBG	O
polypeptide	DT	O
of	NN	O
SEQUENCE:1	NN	O
(SEQ	IN	O
ID	NNP	O
NO:1),	NNP	O
FIG.	NNP	O
1,	,	O
and	.	O
any	,	O
fragments	CC	O
or	DT	O
subsequences	NNS	O
thereof,	CC	O
to	NNS	O
mediate	,	O
an	TO	O
increase	VB	O
in	DT	O
cell	NN	O
permeability	IN	O
of	JJ	O
any	NN	O
other	IN	O
molecule.	DT	O
Said	JJ	O
increase	.	O
in	JJ	O
cell	NN	O
permeability	IN	O
can	NN	O
be	NN	O
affected	MD	O
by	VB	O
any	VBN	O
covalent	IN	O
or	DT	O
non-covalent	NN	O
attachment	CC	O
between	JJ	O
the	NN	O
polypeptides	IN	O
of	DT	O
the	NNS	O
invention	IN	O
and	DT	O
the	NN	O
molecule	CC	O
in	DT	O
need	NN	O
of	IN	O
increased	NN	O
cell	IN	O
permeability.	VBN	O
Class	NN	O
IV	.	O
Polypeptide	NN	O
Modifications	NNP	O
The	NNP	O
Class	NNP	O
IV	DT	O
modifications	NNP	O
of	NNP	O
the	NNS	O
present	IN	O
invention	DT	O
result	JJ	O
in	NN	O
polypeptides	NN	O
having	IN	O
increased	NNS	O
serum	VBG	O
stability,	VBN	O
reduced	JJ	O
immunogenicity,	,	O
reduced	VBN	O
susceptibility	,	O
to	VBN	O
nucleases	NN	O
in	TO	O
vivo,	NNS	O
and	IN	O
increased	,	O
cell	CC	O
permeability	VBD	O
by	NN	O
virtue	NN	O
of	IN	O
their	NN	O
modification	IN	O
with	PRP$	O
polyethylene	NN	O
glycol.	IN	O
As	JJ	O
one	.	O
skilled	IN	O
in	CD	O
the	VBD	O
art	IN	O
will	DT	O
recognize,	NN	O
numerous	MD	O
methods	,	O
of	JJ	O
derivatization	NNS	O
of	IN	O
proteins	NN	O
with	IN	O
polyethylene	NNS	O
glycol	IN	O
are	NN	O
known.	NNS	O
Preferred	VBP	O
embodiments	.	O
include	JJ	O
the	NNS	O
derivatization	VBP	O
of	DT	O
one	NN	O
or	IN	O
more	CD	O
reactive	CC	O
cysteine	JJR	O
residues	JJ	O
using	NN	O
a	NNS	O
maleimide	VBG	O
coupling	DT	O
reagent	NN	O
to	VBG	O
a	NN	O
single	TO	O
or	DT	O
branched-chain	JJ	O
polyethylene	CC	O
glycol	JJ	O
of	NN	O
40	NN	O
kilodaltons	IN	O
or	CD	O
less	NNS	O
in	CC	O
molecular	JJR	O
weight.	IN	O
Such	JJ	O
polyethylene	.	O
coupled	JJ	O
polypeptides	NN	O
retain	VBD	O
full	NNS	O
enzymatic	VBP	O
activity	JJ	O
as	JJ	O
demonstrated	NN	O
in	IN	O
FIG.	VBN	O
6.	IN	O
Pegylation	.	O
of	.	O
the	NN	O
polypeptides	IN	O
of	DT	O
the	NNS	O
present	IN	O
invention	DT	O
at	JJ	O
one	NN	O
or	IN	O
more	CD	O
solvent	CC	O
exposed	JJR	O
cysteines,	JJ	O
including	VBN	O
but	,	O
not	VBG	O
limited	CC	O
to	RB	O
the	JJ	O
cysteines	TO	O
at	DT	O
position	NNS	O
25,	IN	O
38,	NN	O
and	,	O
54,	,	O
is	CC	O
also	,	O
envisioned.	VBZ	O
Further,	RB	O
modification	.	O
or	,	O
mutation	NN	O
of	CC	O
the	NN	O
protein	IN	O
to	DT	O
remove	NN	O
one	TO	O
or	VB	O
more	CD	O
solvent	CC	O
exposed	JJR	O
cysteines	JJ	O
(a	VBN	O
Class	NNS	O
II	DT	O
modification)	NN	O
in	NNP	O
order	)	O
to	IN	O
facilitate	NN	O
the	TO	O
preferential	VB	O
polyethylene	DT	O
glycol	JJ	O
derivatization	NN	O
of	JJ	O
any	NN	O
other	IN	O
cysteine	DT	O
(a	JJ	O
Class	NN	O
IV	DT	O
modification)	NN	O
is	NNP	O
also	)	O
envisioned	VBZ	O
by	RB	O
the	VBN	O
present	IN	O
invention.	DT	O
The	JJ	O
polypeptides	.	O
of	DT	O
the	NNS	O
invention	IN	O
include	DT	O
all	NN	O
oligoadenylate	VBP	O
synthetase	DT	O
polypeptides	JJ	O
that	NN	O
are	NNS	O
conjugated	WDT	O
to	VBP	O
a	VBN	O
non-polypeptide	TO	O
moiety,	DT	O
such	JJ	O
moieties	,	O
include	JJ	O
but	NNS	O
are	VBP	O
not	CC	O
limited	VBP	O
to	RB	O
polymer	VBN	O
molecules,	TO	O
sugar	VB	O
moieties,	,	O
lipophilic	NN	O
compounds,	,	O
or	JJ	O
organic	,	O
derivatizing	CC	O
agents.	JJ	O
Class	NN	O
V	.	O
Polypeptide	NN	O
Modifications	NNP	O
The	NNP	O
Class	NNP	O
V	DT	O
modifications	NNP	O
of	NNP	O
the	NNS	O
present	IN	O
invention	DT	O
represent	JJ	O
additional	NN	O
polypeptide	VBP	O
forms	JJ	O
that	NN	O
also	NNS	O
possess	WDT	O
desirable	RB	O
pharmaceutical	VBP	O
properties.	JJ	O
These	JJ	O
modifications	.	O
are	DT	O
derived	NNS	O
in	VBP	O
order	VBN	O
to	IN	O
achieve	NN	O
one	TO	O
or	VB	O
more	CD	O
of	CC	O
the	JJR	O
following:	IN	O
simplify	DT	O
recombinant	:	O
vector	VB	O
construction;	JJ	O
optimize	NN	O
the	:	O
ribosomal	VB	O
binding	DT	O
site;	JJ	O
improve	NN	O
manufacturability	:	O
in	VB	O
E.	NN	O
coli;	IN	O
and	NNP	O
increase	:	O
amino	CC	O
acid	VB	O
similarity	NN	O
with	JJ	O
other	NN	O
identified	IN	O
OAS	JJ	O
polypeptides,	JJ	O
while	NNP	O
maintaining	,	O
desirable	IN	O
pharmaceutical	VBG	O
properties	JJ	O
such	JJ	O
as	NNS	O
anti-viral	JJ	O
or	IN	O
anti-cancer	JJ	O
activity.	CC	O
Pharmaceutical	JJ	O
Compositions	.	O
The	JJ	O
invention	NNP	O
provides	DT	O
pharmaceutical	NN	O
compositions	VBZ	O
of	JJ	O
the	NNS	O
polypeptides	IN	O
as	DT	O
active	NNS	O
ingredients	IN	O
for	JJ	O
a	NNS	O
therapeutic	IN	O
application.	DT	O
These	JJ	O
compositions	.	O
can	DT	O
also	NNS	O
be	MD	O
used	RB	O
in	VB	O
the	VBN	O
method	IN	O
of	DT	O
the	NN	O
present	IN	O
invention.	DT	O
In	JJ	O
general	.	O
the	IN	O
pharmaceutical	JJ	O
composition	DT	O
for	JJ	O
inhibiting	NN	O
virus	IN	O
infection,	VBG	O
cancer,	JJ	O
neoplasm,	,	O
inflammation,	,	O
or	,	O
other	,	O
disease	CC	O
in	JJ	O
a	NN	O
mammal	IN	O
or	DT	O
subject	NN	O
includes	CC	O
an	JJ	O
effective	VBZ	O
amount	DT	O
of	JJ	O
at	NN	O
least	IN	O
one	IN	O
polypeptide	JJS	O
as	CD	O
described	NN	O
above	IN	O
needed	VBN	O
for	IN	O
the	VBN	O
practice	IN	O
of	DT	O
the	NN	O
invention,	IN	O
or	DT	O
a	,	O
fragment	CC	O
thereof	DT	O
shown	JJ	O
to	NN	O
have	VBN	O
the	TO	O
same	VB	O
effect,	DT	O
and	JJ	O
a	,	O
pharmaceutically	CC	O
physiologically	DT	O
acceptable	RB	O
carrier	RB	O
or	JJ	O
diluent.	NN	O
According	CC	O
to	.	O
the	VBG	O
present	TO	O
invention,	DT	O
a	JJ	O
pharmaceutical	,	O
composition	DT	O
can	JJ	O
be	NN	O
composed	MD	O
of	VB	O
two	VBN	O
or	IN	O
more	CD	O
of	CC	O
the	JJR	O
polypeptides	IN	O
of	DT	O
FIG.	NNS	O
1	IN	O
in	.	O
combination.	CD	O
The	IN	O
pharmaceutical	.	O
composition	DT	O
may	JJ	O
further	NN	O
be	MD	O
composed	RB	O
of	VB	O
a	VBN	O
single	IN	O
polypeptide	DT	O
that	JJ	O
contains	NN	O
one	WDT	O
or	VBZ	O
more	CD	O
of	CC	O
the	JJR	O
modifications	IN	O
of	DT	O
FIG.	NNS	O
1	IN	O
within	.	O
a	CD	O
contiguous	IN	O
molecule.	DT	O
The	JJ	O
compositions	.	O
can	DT	O
be	NNS	O
administered	MD	O
orally,	VB	O
subcutaneously,	VBN	O
or	,	O
parenterally	,	O
including	CC	O
intravenous,	RB	O
intraarterial,	VBG	O
intramuscular,	,	O
intraperitoneally,	,	O
and	,	O
intranasal	,	O
administration,	CC	O
as	JJ	O
well	,	O
as	RB	O
intrathecal	RB	O
and	IN	O
infusion	JJ	O
techniques	CC	O
as	NN	O
required.	NNS	O
The	IN	O
pharmaceutically	.	O
acceptable	DT	O
carriers,	RB	O
diluents,	JJ	O
adjuvants	,	O
and	,	O
vehicles	NNS	O
as	CC	O
well	NNS	O
as	RB	O
implant	RB	O
carriers	IN	O
generally	JJ	O
refer	NNS	O
to	RB	O
inert,	VBP	O
non-toxic	TO	O
solid	,	O
or	JJ	O
liquid	JJ	O
fillers,	CC	O
diluents	JJ	O
or	,	O
encapsulating	NNS	O
material	CC	O
not	VBG	O
reacting	NN	O
with	RB	O
the	VBG	O
active	IN	O
ingredients	DT	O
of	JJ	O
the	NNS	O
invention.	IN	O
Cationic	DT	O
lipids	.	O
may	JJ	O
also	NNS	O
be	MD	O
included	RB	O
in	VB	O
the	VBN	O
composition	IN	O
to	DT	O
facilitate	NN	O
polypeptide	TO	O
uptake.	VB	O
Implants	JJ	O
of	.	O
the	NNS	O
compounds	IN	O
are	DT	O
also	NNS	O
useful.	VBP	O
In	RB	O
general,	.	O
the	IN	O
pharmaceutical	,	O
compositions	DT	O
are	JJ	O
sterile.	NNS	O
The	VBP	O
present	.	O
invention	DT	O
relates	JJ	O
to	NN	O
compositions	VBZ	O
of	TO	O
the	NNS	O
polypeptides	IN	O
to	DT	O
which	NNS	O
a	TO	O
detectable	WDT	O
label	DT	O
is	JJ	O
attached,	NN	O
such	VBZ	O
as	,	O
a	JJ	O
fluorescent,	IN	O
chemiluminescent	DT	O
or	,	O
radioactive	NN	O
molecule.	CC	O
Another	JJ	O
example	.	O
is	DT	O
a	NN	O
pharmaceutical	VBZ	O
composition	DT	O
which	JJ	O
may	NN	O
be	WDT	O
formulated	MD	O
by	VB	O
known	VBN	O
techniques	IN	O
using	VBN	O
known	NNS	O
materials,	VBG	O
see,	JJ	O
Remington's	,	B
Pharmaceutical	,	I
Sciences,	POS	I
18th	NNP	I
Ed.	,	I
(1990,	CD	I
Mack	.	I
Publishing	,	I
Co.,	NNP	I
Easton,	NNP	I
Pa.	,	I
18042)	,	I
pp.	NNP	I
1435-1712,	)	I
which	.	O
are	,	O
herein	WDT	O
incorporated	VBP	O
by	RB	O
reference.	VBN	O
Generally,	IN	O
the	.	O
formulation	,	O
will	DT	O
depend	NN	O
on	MD	O
a	VB	O
variety	IN	O
of	DT	O
factors	NN	O
such	IN	O
as	NNS	O
administration,	JJ	O
stability,	IN	O
production	,	O
concerns	,	O
and	NN	O
other	NNS	O
factors.	CC	O
The	JJ	O
polypeptides	.	O
of	DT	O
FIG.	NNS	O
1	IN	O
may	.	O
be	CD	O
administered	MD	O
by	VB	O
injection	VBN	O
or	IN	O
by	NN	O
pulmonary	CC	O
administration	IN	O
via	JJ	O
inhalation.	NN	O
Enteric	IN	O
dosage	.	O
forms	JJ	O
may	NN	O
also	NNS	O
be	MD	O
available,	RB	O
and	VB	O
therefore	,	O
oral	CC	O
administration	RB	O
may	JJ	O
be	NN	O
effective.	MD	O
The	VB	O
polypeptides	.	O
of	DT	O
the	NNS	O
invention	IN	O
may	DT	O
be	NN	O
inserted	MD	O
into	VB	O
liposomes	VBN	O
or	IN	O
other	NNS	O
microcarriers	CC	O
for	JJ	O
delivery,	NNS	O
and	IN	O
may	,	O
be	CC	O
formulated	MD	O
in	VB	O
gels	VBN	O
or	IN	O
other	NNS	O
compositions	CC	O
for	JJ	O
sustained	NNS	O
release.	IN	O
Although	JJ	O
preferred	.	O
compositions	IN	O
will	VBN	O
vary	NNS	O
depending	MD	O
on	VB	O
the	VBG	O
use	IN	O
to	DT	O
which	NN	O
the	TO	O
composition	WDT	O
will	DT	O
be	NN	O
put,	MD	O
generally,	VB	O
for	,	O
the	,	O
polypeptides	IN	O
of	DT	O
the	NNS	O
present	IN	O
invention,	DT	O
preferred	JJ	O
pharmaceutical	,	O
compositions	JJ	O
are	JJ	O
those	NNS	O
prepared	VBP	O
for	DT	O
subcutaneous	JJ	O
injection	IN	O
or	JJ	O
for	NN	O
pulmonary	CC	O
administration	IN	O
via	JJ	O
inhalation,	NN	O
although	IN	O
the	,	O
particular	IN	O
formulations	DT	O
for	JJ	O
each	NNS	O
type	IN	O
of	DT	O
administration	NN	O
will	IN	O
depend	NN	O
on	MD	O
the	VB	O
characteristics	IN	O
of	DT	O
the	NNS	O
specific	IN	O
polypeptide.	DT	O
Therapeutic	JJ	O
formulations	.	O
of	JJ	O
the	NNS	O
polypeptides	IN	O
or	DT	O
polypeptide	NNS	O
conjugates	CC	O
of	VB	O
the	NNS	O
invention	IN	O
are	DT	O
typically	NN	O
administered	VBP	O
in	RB	O
a	VBN	O
composition	IN	O
that	DT	O
includes	NN	O
one	WDT	O
or	VBZ	O
more	CD	O
pharmaceutically	CC	O
acceptable	JJR	O
carriers	RB	O
or	JJ	O
excipients.	NNS	O
Such	CC	O
pharmaceutical	.	O
compositions	JJ	O
may	JJ	O
be	NNS	O
prepared	MD	O
in	VB	O
a	VBN	O
manner	IN	O
known	DT	O
per	NN	O
se	VBN	O
in	IN	O
the	NN	O
art	IN	O
to	DT	O
result	NN	O
in	TO	O
a	VB	O
polypeptide	IN	O
pharmaceutical	DT	O
that	JJ	O
is	JJ	O
sufficiently	WDT	O
storage-stable	VBZ	O
and	RB	O
is	JJ	O
suitable	CC	O
for	VBZ	O
administration	JJ	O
to	IN	O
humans	NN	O
or	TO	O
animals.	NNS	O
The	CC	O
polypeptides	.	O
or	DT	O
polypeptide	NNS	O
conjugates	CC	O
of	VB	O
the	NNS	O
invention	IN	O
can	DT	O
be	NN	O
used	MD	O
“as	VB	O
is”	VBN	O
and/or	NNP	O
in	JJ	O
a	NN	O
salt	IN	O
form	DT	O
thereof.	JJ	O
Suitable	NN	O
salts	.	O
include,	JJ	O
but	NNS	O
are	,	O
not	CC	O
limited	VBP	O
to,	RB	O
salts	VBN	O
with	,	O
alkali	NNS	O
metals	IN	O
or	JJ	O
alkaline	NNS	O
earth	CC	O
metals,	VB	O
such	JJ	O
as	,	O
sodium,	JJ	O
potassium,	IN	O
calcium	,	O
and	,	O
magnesium,	NN	O
as	CC	O
well	,	O
as	RB	O
e.g.	RB	O
zinc	IN	O
salts.	.	O
These	NN	O
salts	.	O
or	DT	O
complexes	NNS	O
may	CC	O
by	NNS	O
present	MD	O
as	IN	O
a	NN	O
crystalline	IN	O
and/or	DT	O
amorphous	NN	O
structure.	RB	O
“Pharmaceutically	JJ	O
acceptable”	.	O
means	RB	O
a	JJ	O
carrier	VBZ	O
or	DT	O
excipient	NN	O
that	CC	O
at	NN	O
the	WDT	O
dosages	IN	O
and	DT	O
concentrations	NNS	O
employed	CC	O
does	NNS	O
not	VBD	O
cause	VBZ	O
any	RB	O
untoward	VB	O
effects	DT	O
in	JJ	O
the	NNS	O
patients	IN	O
to	DT	O
whom	NNS	O
it	TO	O
is	WP	O
administered.	PRP	O
Such	VBZ	O
pharmaceutically	.	O
acceptable	JJ	O
carriers	RB	O
and	JJ	O
excipients	NNS	O
are	CC	O
well	NNS	O
known	VBP	O
in	RB	O
the	VBN	O
art	IN	O
(see	DT	O
Remington's	NN	B
Pharmaceutical	VB	I
Sciences,	POS	I
18th	NNP	I
edition,	,	I
A.	CD	I
R.	,	I
Gennaro,	NNP	I
Ed.,	NNP	I
Mack	,	I
Publishing	,	I
Company	NNP	I
(1990);	NNP	I
Pharmaceutical	NNP	B
Formulation	:	I
Development	JJ	I
of	NNP	I
Peptides	NNP	I
and	IN	I
Proteins,	NNP	I
S.	CC	I
Frokjaer	,	I
and	NNP	I
L.	NNP	I
Hovgaard,	CC	I
Eds.,	NNP	I
Taylor	,	I
&	,	I
Francis	NNP	I
(2000);	CC	I
and	NNP	O
Handbook	:	B
of	CC	I
Pharmaceutical	NNP	I
Excipients,	IN	I
3rd	NNP	I
edition,	,	I
A.	CD	I
Kibbe,	,	I
Ed.,	NNP	I
Pharmaceutical	,	I
Press	,	I
(2000)).The	NNP	O
composition	NNP	O
of	.	O
the	DT	O
invention	NN	O
may	IN	O
be	DT	O
administered	NN	O
alone	MD	O
or	VB	O
in	VBN	O
conjunction	RB	O
with	CC	O
other	IN	O
therapeutic	NN	O
agents.	IN	O
Ribavirin	JJ	O
and	JJ	O
interferon	.	O
alpha,	NNP	O
for	CC	O
example,	NN	O
have	,	O
been	IN	O
shown	,	O
to	VBP	O
be	VBN	O
an	VBN	O
effective	TO	O
treatment	VB	O
for	DT	O
HCV	JJ	O
infection	NN	O
when	IN	O
used	NNP	O
in	NN	O
combination.	WRB	O
Their	VBN	O
efficacy	IN	O
in	.	O
combination	PRP$	O
exceeds	NN	O
the	IN	O
efficacy	NN	O
of	VBZ	O
either	DT	O
drug	NN	O
product	IN	O
when	CC	O
used	NN	O
alone.	NN	O
The	WRB	O
compositions	VBN	O
of	.	O
the	DT	O
invention	NNS	O
may	IN	O
be	DT	O
administered	NN	O
alone	MD	O
or	VB	O
in	VBN	O
combination	RB	O
with	CC	O
interferon,	IN	O
ribavirin	NN	O
and/or	IN	O
a	,	O
variety	VB	O
of	IN	O
small	DT	O
molecules	NN	O
that	IN	O
are	JJ	O
being	NNS	O
developed	WDT	O
against	VBP	O
both	VBG	O
viral	VBN	O
targets	IN	O
(viral	DT	O
proteases,	JJ	O
viral	NNS	O
polymerase,	JJ	O
assembly	,	O
of	JJ	O
viral	,	O
replication	NN	O
complexes)	IN	O
and	JJ	O
host	NN	O
targets	)	O
(host	CC	O
proteases	$	O
required	NNS	O
for	NN	O
viral	NNS	O
processing,	VBN	O
host	IN	O
kinases	JJ	O
required	,	O
for	NN	O
phosphorylation	NNS	O
of	VBN	O
viral	IN	O
targets	NN	O
such	IN	O
as	JJ	O
NS5A	NNS	O
and	JJ	O
inhibitors	IN	O
of	NNP	O
host	CC	O
factors	NNS	O
required	IN	O
to	NN	O
efficiently	NNS	O
utilize	VBD	O
the	TO	O
viral	RB	O
IRES).	VB	O
Cytokines	DT	O
may	JJ	O
be	.	O
co-administered,	NNS	O
such	MD	O
as	VB	O
for	,	O
example	JJ	O
IL-2,	IN	O
IL-12,	IN	O
IL-23,	NN	O
IL-27,	,	O
or	,	O
IFN-gamma.	,	O
These	,	O
agents	CC	O
may	.	O
be	DT	O
incorporated	NNS	O
as	MD	O
part	VB	O
of	VBN	O
the	IN	O
same	NN	O
pharmaceutical	IN	O
composition	DT	O
or	JJ	O
may	JJ	O
be	NN	O
administered	CC	O
separately	MD	O
from	VB	O
the	VBN	O
polypeptides	RB	O
or	IN	O
conjugates	DT	O
of	NNS	O
the	CC	O
invention,	NNS	O
either	IN	O
concurrently	DT	O
or	,	O
in	CC	O
accordance	RB	O
with	CC	O
another	IN	O
treatment	NN	O
schedule.	IN	O
In	DT	O
addition,	NN	O
the	.	O
polypeptides,	IN	O
polypeptide	,	O
conjugates	DT	O
or	,	O
compositions	VB	O
of	NNS	O
the	CC	O
invention	NNS	O
may	IN	O
be	DT	O
used	NN	O
as	MD	O
an	VB	O
adjuvant	VBN	O
to	IN	O
other	DT	O
therapies.	NN	O
A	TO	O
“patient”	JJ	O
for	.	O
the	DT	O
purposes	NN	O
of	IN	O
the	DT	O
present	NNS	O
invention	IN	O
includes	DT	O
both	JJ	O
humans	NN	O
and	VBZ	O
other	CC	O
mammals.	NNS	O
Thus	CC	O
the	JJ	O
methods	.	O
are	RB	O
applicable	DT	O
to	NNS	O
both	VBP	O
human	JJ	O
therapy	TO	O
and	DT	O
veterinary	JJ	O
applications.	NN	O
The	CC	O
pharmaceutical	JJ	O
composition	.	O
comprising	DT	O
the	JJ	O
polypeptide	NN	O
or	VBG	O
conjugate	DT	O
of	NN	O
the	CC	O
invention	NN	O
may	IN	O
be	DT	O
formulated	NN	O
in	MD	O
a	VB	O
variety	VBN	O
of	IN	O
forms,	DT	O
e.g.,	NN	O
as	IN	O
a	,	O
liquid,	,	O
gel,	IN	O
lyophilized,	DT	O
or	,	O
as	,	O
a	,	O
compressed	CC	O
solid.	IN	O
The	DT	O
preferred	JJ	O
form	.	O
will	DT	O
depend	JJ	O
upon	NN	O
the	MD	O
particular	VB	O
indication	IN	O
being	DT	O
treated	JJ	O
and	NN	O
will	VBG	O
be	VBN	O
apparent	CC	O
to	MD	O
one	VB	O
skilled	JJ	O
in	TO	O
the	CD	O
art.	VBN	O
The	IN	O
administration	DT	O
of	.	O
the	DT	O
formulations	NN	O
of	IN	O
the	DT	O
present	NNS	O
invention	IN	O
can	DT	O
be	JJ	O
performed	NN	O
in	MD	O
a	VB	O
variety	VBN	O
of	IN	O
ways,	DT	O
including,	NN	O
but	IN	O
not	,	O
limited	,	O
to,	CC	O
orally,	RB	O
subcutaneously,	JJ	O
intravenously,	,	O
intracerebrally,	,	O
intranasally,	,	O
transdermally,	,	O
intraperitoneally,	,	O
intramuscularly,	,	O
intrapulmonary,	,	O
intrathecally,	,	O
vaginally,	,	O
rectally,	,	O
intraocularly,	,	O
or	,	O
in	,	O
any	,	O
other	CC	O
acceptable	IN	O
manner.	DT	O
The	JJ	O
formulations	JJ	O
can	.	O
be	DT	O
administered	NNS	O
continuously	MD	O
by	VB	O
infusion,	VBN	O
although	RB	O
bolus	IN	O
injection	,	O
is	IN	O
acceptable,	JJ	O
using	NN	O
techniques	VBZ	O
well	,	O
known	VBG	O
in	NNS	O
the	RB	O
art,	VBN	O
such	IN	O
as	DT	O
pumps	,	O
(e.g.,	JJ	O
subcutaneous	IN	O
osmotic	NNS	O
pumps)	,	O
or	JJ	O
implantation.	JJ	O
In	)	O
some	CC	O
instances	.	O
the	IN	O
formulations	DT	O
may	NNS	O
be	DT	O
directly	NNS	O
applied	MD	O
as	VB	O
a	RB	O
solution	VBN	O
or	IN	O
spray.	DT	O
An	NN	O
example	CC	O
of	.	O
a	DT	O
pharmaceutical	NN	O
composition	IN	O
is	DT	O
a	JJ	O
solution	NN	O
designed	VBZ	O
for	DT	O
parenteral	NN	O
administration.	VBN	O
Although	IN	O
in	JJ	O
many	.	O
cases	IN	O
pharmaceutical	IN	O
solution	JJ	O
formulations	NNS	O
are	JJ	O
provided	NN	O
in	NNS	O
liquid	VBP	O
form,	VBN	O
appropriate	IN	O
for	JJ	O
immediate	,	O
use,	NN	O
such	IN	O
parenteral	JJ	O
formulations	,	O
may	JJ	O
also	JJ	O
be	NNS	O
provided	MD	O
in	RB	O
frozen	VB	O
or	VBN	O
in	IN	O
lyophilized	JJ	O
form.	CC	O
In	IN	O
the	JJ	O
former	.	O
case,	IN	O
the	DT	O
composition	JJ	O
must	,	O
be	DT	O
thawed	NN	O
prior	MD	O
to	VB	O
use.	VBN	O
The	RB	O
latter	TO	O
form	.	O
is	DT	O
often	JJ	O
used	NN	O
to	VBZ	O
enhance	RB	O
the	VBN	O
stability	TO	O
of	VB	O
the	DT	O
active	NN	O
compound	IN	O
contained	DT	O
in	JJ	O
the	NN	O
composition	VBN	O
under	IN	O
a	DT	O
wider	NN	O
variety	IN	O
of	DT	O
storage	JJR	O
conditions,	NN	O
as	IN	O
it	NN	O
is	,	O
recognized	IN	O
by	PRP	O
those	VBZ	O
skilled	VBN	O
in	IN	O
the	DT	O
art	VBN	O
that	IN	O
lyophilized	DT	O
preparations	NN	O
are	WDT	O
generally	VBD	O
more	NNS	O
stable	VBP	O
than	RB	O
their	RBR	O
liquid	JJ	O
counterparts.	IN	O
Such	PRP$	O
lyophilized	JJ	O
preparations	.	O
are	JJ	O
reconstituted	JJ	O
prior	NNS	O
to	VBP	O
use	VBN	O
by	RB	O
the	TO	O
addition	VB	O
of	IN	O
one	DT	O
or	NN	O
more	IN	O
suitable	CD	O
pharmaceutically	CC	O
acceptable	JJR	O
diluents	JJ	O
such	RB	O
as	JJ	O
sterile	NNS	O
water	JJ	O
for	IN	O
injection	JJ	O
or	NN	O
sterile	IN	O
physiological	NN	O
saline	CC	O
solution.	JJ	O
Parenterals	JJ	O
may	NN	O
be	.	O
prepared	NNS	O
for	MD	O
storage	VB	O
as	VBN	O
lyophilized	IN	O
formulations	NN	O
or	IN	O
aqueous	JJ	O
solutions	NNS	O
by	CC	O
mixing,	JJ	O
as	NNS	O
appropriate,	IN	O
the	,	O
polypeptide	IN	O
having	,	O
the	DT	O
desired	NN	O
degree	VBG	O
of	DT	O
purity	JJ	O
with	NN	O
one	IN	O
or	NN	O
more	IN	O
pharmaceutically	CD	O
acceptable	CC	O
carriers,	JJR	O
excipients	RB	O
or	JJ	O
stabilizers	,	O
typically	NNS	O
employed	CC	O
in	NNS	O
the	RB	O
art	VBN	O
(all	IN	O
of	DT	O
which	NN	O
are	DT	O
termed	IN	O
“excipients”),	WDT	O
for	VBP	O
example	VBN	O
buffering	,	O
agents,	IN	O
stabilizing	NN	O
agents,	NN	O
preservatives,	,	O
isotonifiers,	VBG	O
non-ionic	,	O
detergents,	,	O
antioxidants	,	O
and/or	JJ	O
other	,	O
miscellaneous	NNS	O
additives.	VBP	O
Buffering	JJ	O
agents	JJ	O
help	.	O
to	VBG	O
maintain	NNS	O
the	VB	O
pH	TO	O
in	VB	O
the	DT	O
range	NN	O
which	IN	O
approximates	DT	O
physiological	NN	O
conditions.	WDT	O
They	VBZ	O
are	JJ	O
typically	.	O
present	PRP	O
at	VBP	O
a	RB	O
concentration	JJ	O
ranging	IN	O
from	DT	O
about	NN	O
2	VBG	O
mM	IN	O
to	IN	O
about	CD	O
50	NNS	O
mM.	TO	O
Suitable	IN	O
buffering	CD	O
agents	.	O
for	JJ	O
use	NN	O
with	NNS	O
the	IN	O
present	NN	O
invention	IN	O
include	DT	O
both	JJ	O
organic	NN	O
and	VBP	O
inorganic	DT	O
acids	JJ	O
and	CC	O
salts	JJ	O
thereof	NNS	O
such	CC	O
as	NNS	O
citrate	VBP	O
buffers	JJ	O
(e.g.,	IN	O
monosodium	NN	O
citrate-disodium	NNS	O
citrate	,	O
mixture,	NN	O
citric	NN	O
acid-trisodium	NN	O
citrate	,	O
mixture,	JJ	O
citric	JJ	O
acid-monosodium	NN	O
citrate	,	O
mixture,	JJ	O
etc.),	JJ	O
succinate	NN	O
buffers	,	O
(e.g.,	,	O
succinic	JJ	O
acid-monosodium	NNS	O
succinate	,	O
mixture,	JJ	O
succinic	NN	O
acid-sodium	NN	O
hydroxide	,	O
mixture,	JJ	O
succinic	NN	O
acid-disodium	NN	O
succinate	,	O
mixture,	JJ	O
etc.),	NN	O
tartrate	NN	O
buffers	,	O
(e.g.,	,	O
tartaric	JJ	O
acid-sodium	NNS	O
tartrate	,	O
mixture,	JJ	O
tartaric	JJ	O
acid-potassium	NN	O
tartrate	,	O
mixture,	JJ	O
tartaric	JJ	O
acid-sodium	NN	O
hydroxide	,	O
mixture,	JJ	O
etc.),	JJ	O
fumarate	NN	O
buffers	,	O
(e.g.,	,	O
fumaric	JJ	O
acid-monosodium	NNS	O
fumarate	,	O
mixture,	JJ	O
fumaric	JJ	O
acid-disodium	NN	O
fumarate	,	O
mixture,	JJ	O
monosodium	JJ	O
fumarate-disodium	NN	O
fumarate	,	O
mixture,	NN	O
etc.),	JJ	O
gluconate	NN	O
buffers	,	O
(e.g.,	,	O
gluconic	JJ	O
acid-sodium	NNS	O
glyconate	,	O
mixture,	JJ	O
gluconic	NN	O
acid-sodium	NN	O
hydroxide	,	O
mixture,	JJ	O
gluconic	NN	O
acid-potassium	NN	O
glyuconate	,	O
mixture,	JJ	O
etc.),	NN	O
oxalate	NN	O
buffer	,	O
(e.g.,	,	O
oxalic	JJ	O
acid-sodium	NN	O
oxalate	,	O
mixture,	JJ	O
oxalic	JJ	O
acid-sodium	NN	O
hydroxide	,	O
mixture,	JJ	O
oxalic	JJ	O
acid-potassium	NN	O
oxalate	,	O
mixture,	JJ	O
etc.),	JJ	O
lactate	NN	O
buffers	,	O
(e.g.,	,	O
lactic	JJ	O
acid-sodium	NNS	O
lactate	,	O
mixture,	JJ	O
lactic	NN	O
acid-sodium	NN	O
hydroxide	,	O
mixture,	JJ	O
lactic	NN	O
acid-potassium	NN	O
lactate	,	O
mixture,	JJ	O
etc.)	NN	O
and	NN	O
acetate	,	O
buffers	)	O
(e.g.,	CC	O
acetic	NN	O
acid-sodium	NNS	O
acetate	,	O
mixture,	JJ	O
acetic	NN	O
acid-sodium	NN	O
hydroxide	,	O
mixture,	JJ	O
etc.).	NN	O
Additional	NN	O
possibilities	,	O
are	.	O
phosphate	JJ	O
buffers,	NNS	O
histidine	VBP	O
buffers	JJ	O
and	,	O
trimethylamine	NN	O
salts	NNS	O
such	CC	O
as	NN	O
Tris.	NNS	O
Preservatives	JJ	O
are	IN	O
added	.	O
to	NNS	O
retard	VBP	O
microbial	VBN	O
growth,	TO	O
and	VB	O
are	JJ	O
typically	,	O
added	CC	O
in	VBP	O
amounts	RB	O
of	VBN	O
about	IN	O
0.2%-1%	NNS	O
(w/v).	IN	O
Suitable	RB	O
preservatives	NN	O
for	.	O
use	JJ	O
with	NNS	O
the	IN	O
present	NN	O
invention	IN	O
include	DT	O
phenol,	JJ	O
benzyl	NN	O
alcohol,	VBP	O
meta-cresol,	,	O
methyl	NN	O
paraben,	,	O
propyl	,	O
paraben,	NN	O
octadecyldimethylbenzyl	,	O
ammonium	NN	O
chloride,	,	O
benzalkonium	JJ	O
halides	NN	O
(e.g.,	,	O
benzalkonium	NN	O
chloride,	NNS	O
bromide	,	O
or	NN	O
iodide),	,	O
hexamethonium	NN	O
chloride,	CC	O
alkyl	,	O
parabens	JJ	O
such	,	O
as	JJ	O
methyl	NNS	O
or	JJ	O
propyl	IN	O
paraben,	NN	O
catechol,	CC	O
resorcinol,	NN	O
cyclohexanol	,	O
and	,	O
3-pentanol.	,	O
Isotonicifiers	NN	O
are	CC	O
added	.	O
to	NNS	O
ensure	VBP	O
isotonicity	VBN	O
of	TO	O
liquid	VB	O
compositions	NN	O
and	IN	O
include	JJ	O
polyhydric	NNS	O
sugar	CC	O
alcohols,	VBP	O
preferably	JJ	O
trihydric	NN	O
or	,	O
higher	RB	O
sugar	JJ	O
alcohols,	CC	O
such	JJR	O
as	NN	O
glycerin,	,	O
erythritol,	JJ	O
arabitol,	IN	O
xylitol,	,	O
sorbitol	,	O
and	,	O
mannitol.	,	O
Polyhydric	NN	O
alcohols	CC	O
can	.	O
be	JJ	O
present	NNS	O
in	MD	O
an	VB	O
amount	JJ	O
between	IN	O
0.1%	DT	O
and	NN	O
25%	IN	O
by	NN	O
weight,	CC	O
typically	NN	O
1%	IN	O
to	,	O
5%,	RB	O
taking	NN	O
into	TO	O
account	,	O
the	VBG	O
relative	IN	O
amounts	NN	O
of	DT	O
the	JJ	O
other	NNS	O
ingredients.	IN	O
Stabilizers	DT	O
refer	JJ	O
to	.	O
a	NNS	O
broad	VBP	O
category	TO	O
of	DT	O
excipients	JJ	O
which	NN	O
can	IN	O
range	NNS	O
in	WDT	O
function	MD	O
from	VB	O
a	IN	O
bulking	NN	O
agent	IN	O
to	DT	O
an	NN	O
additive	NN	O
which	TO	O
solubilizes	DT	O
the	JJ	O
therapeutic	WDT	O
agent	VBZ	O
or	DT	O
helps	JJ	O
to	NN	O
prevent	CC	O
denaturation	VBZ	O
or	TO	O
adherence	VB	O
to	NN	O
the	CC	O
container	NN	O
wall.	TO	O
Typical	DT	O
stabilizers	NN	O
can	.	O
be	JJ	O
polyhydric	NNS	O
sugar	MD	O
alcohols	VB	O
(enumerated	JJ	O
above);	NN	O
amino	NNS	O
acids	VBN	O
such	:	O
as	JJ	O
arginine,	NNS	O
lysine,	JJ	O
glycine,	IN	O
glutamine,	,	O
asparagine,	,	O
histidine,	,	O
alanine,	,	O
ornithine,	,	O
L-leucine,	,	O
2-phenylalanine,	,	O
glutamic	,	O
acid,	,	O
threonine,	,	O
etc.,	JJ	O
organic	,	O
sugars	,	O
or	,	O
sugar	JJ	O
alcohols,	NNS	O
such	CC	O
as	NN	O
lactose,	,	O
trehalose,	JJ	O
stachyose,	IN	O
mannitol,	,	O
sorbitol,	,	O
xylitol,	,	O
ribitol,	,	O
myoinisitol,	,	O
galactitol,	,	O
glycerol	,	O
and	,	O
the	,	O
like,	NN	O
including	CC	O
cyclitols	DT	O
such	,	O
as	VBG	O
inositol;	NNS	O
polyethylene	JJ	O
glycol;	IN	O
amino	:	O
acid	CC	O
polymers;	:	O
sulfur-containing	CC	O
reducing	JJ	O
agents,	:	O
such	JJ	O
as	NN	O
urea,	,	O
glutathione,	JJ	O
thioctic	IN	O
acid,	,	O
sodium	,	O
thioglycolate,	JJ	O
thioglycerol,	,	O
alpha-monothioglycerol	NN	O
and	,	O
sodium	,	O
thiosulfate;	NN	O
low	CC	O
molecular	NN	O
weight	:	O
polypeptides	JJ	O
(i.e.,	JJ	O
<10	NN	O
residues);	NNS	O
proteins	,	O
such	CD	O
as	:	O
human	NNS	O
serum	JJ	O
albumin,	IN	O
bovine	JJ	O
serum	NN	O
albumin,	,	O
gelatin	NN	O
or	NN	O
immunoglobulins;	,	O
hydrophilic	NN	O
polymers	CC	O
such	:	O
as	JJ	O
polyvinylpyrrolidone;	NNS	O
monosaccharides	JJ	O
such	IN	O
as	:	O
xylose,	NNS	O
mannose,	JJ	O
fructose	IN	O
and	,	O
glucose;	,	O
disaccharides	JJ	O
such	CC	O
as	:	O
lactose,	NNS	O
maltose	JJ	O
and	IN	O
sucrose;	,	O
trisaccharides	JJ	O
such	CC	O
as	:	O
raffinose,	NNS	O
and	JJ	O
polysaccharides	IN	O
such	,	O
as	CC	O
dextran.	NNS	O
Stabilizers	JJ	O
are	IN	O
typically	.	O
present	NNS	O
in	VBP	O
the	RB	O
range	JJ	O
of	IN	O
from	DT	O
0.1	NN	O
to	IN	O
10,000	IN	O
parts	CD	O
by	TO	O
weight	CD	O
based	NNS	O
on	IN	O
the	NN	O
active	VBN	O
protein	IN	O
weight.	DT	O
Non-ionic	JJ	O
surfactants	NN	O
or	.	O
detergents	JJ	O
(also	NNS	O
known	CC	O
as	NNS	O
“wetting	RB	O
agents”)	VBN	O
may	IN	O
be	VBG	O
present	)	O
to	MD	O
help	VB	O
solubilize	JJ	O
the	TO	O
therapeutic	VB	O
agent	VB	O
as	DT	O
well	JJ	O
as	NN	O
to	RB	O
protect	RB	O
the	IN	O
therapeutic	TO	O
polypeptide	VB	O
against	DT	O
agitation-induced	JJ	O
aggregation,	NN	O
which	IN	O
also	JJ	O
permits	,	O
the	WDT	O
formulation	RB	O
to	VBZ	O
be	DT	O
exposed	NN	O
to	TO	O
shear	VB	O
surface	VBN	O
stress	TO	O
without	VB	O
causing	NN	O
denaturation	NN	O
of	IN	O
the	VBG	O
polypeptide.	NN	O
Suitable	IN	O
non-ionic	DT	O
surfactants	.	O
include	JJ	O
polysorbates	JJ	O
(20,	NNS	O
80,	VBP	O
etc.),	NNS	O
polyoxamers	,	O
(184,	,	O
188	,	O
etc.),	NNS	O
Pluronic®	,	O
polyols,	CD	O
polyoxyethylene	,	O
sorbitan	NNP	O
monoethers	,	O
(Tween®-20,	JJ	O
Tween®-80,	NN	O
etc.).	NNS	O
Additional	,	O
miscellaneous	,	O
excipients	.	O
include	NNP	O
bulking	JJ	O
agents	NNS	O
or	VBP	O
fillers	VBG	O
(e.g.,	NNS	O
starch),	CC	O
chelating	NNS	O
agents	,	O
(e.g.,	,	O
EDTA),	VBG	O
antioxidants	NNS	O
(e.g.,	,	O
ascorbic	,	O
acid,	NNS	O
methionine,	,	O
vitamin	JJ	O
E)	,	O
and	,	O
cosolvents.	FW	O
The	)	O
active	CC	O
ingredient	.	O
may	DT	O
also	JJ	O
be	NN	O
entrapped	MD	O
in	RB	O
microcapsules	VB	O
prepared,	VBN	O
for	IN	O
example,	NNS	O
by	,	O
coascervation	IN	O
techniques	,	O
or	IN	O
by	NN	O
interfacial	NNS	O
polymerization,	CC	O
for	IN	O
example	JJ	O
hydroxymethylcellulose,	,	O
gelatin	IN	O
or	NN	O
poly-(methylmethacylate)	,	O
microcapsules,	NN	O
in	CC	O
colloidal	)	O
drug	,	O
delivery	IN	O
systems	JJ	O
(for	NN	O
example	NN	O
liposomes,	NNS	O
albumin	IN	O
microspheres,	NN	O
microemulsions,	,	O
nano-particles	NN	O
and	,	O
nanocapsules)	,	O
or	NNS	O
in	CC	O
macroemulsions.	)	O
Such	CC	O
techniques	IN	O
are	.	O
disclosed	JJ	O
in	NNS	O
Remington's	VBP	O
Pharmaceutical	VBN	O
Sciences,	IN	O
supra.	POS	O
In	NNP	O
one	,	O
aspect	.	O
of	IN	O
the	CD	O
invention	NN	O
the	IN	O
composition	DT	O
is	NN	O
a	DT	O
liquid	NN	O
composition,	VBZ	O
such	DT	O
as	JJ	O
an	,	O
aqueous	JJ	O
composition,	IN	O
and	DT	O
comprises	JJ	O
a	,	O
sulfoalkyl	CC	O
ether	VBZ	O
cyclodextrin	DT	O
derivative.	NN	O
Parenteral	RB	O
formulations	JJ	O
to	.	O
be	JJ	O
used	NNS	O
for	TO	O
in	VB	O
vivo	VBN	O
administration	IN	O
must	IN	O
be	JJ	O
sterile.	NN	O
This	MD	O
is	VB	O
readily	.	O
accomplished,	DT	O
for	VBZ	O
example,	RB	O
by	,	O
filtration	IN	O
through	,	O
sterile	IN	O
filtration	NN	O
membranes.	IN	O
Suitable	JJ	O
examples	NN	O
of	.	O
sustained-release	JJ	O
preparations	NNS	O
include	IN	O
semi-permeable	JJ	O
matrices	NNS	O
of	VBP	O
solid	JJ	O
hydrophobic	NNS	O
polymers	IN	O
containing	JJ	O
the	NN	O
polypeptide	NNS	O
or	VBG	O
conjugate,	DT	O
the	NN	O
matrices	CC	O
having	,	O
a	DT	O
suitable	NNS	O
form	VBG	O
such	DT	O
as	JJ	O
a	NN	O
film	JJ	O
or	IN	O
microcapsules.	DT	O
Examples	NN	O
of	CC	O
sustained-release	.	O
matrices	NNS	O
include	IN	O
polyesters,	JJ	O
hydrogels	NNS	O
(for	VBP	O
example,	,	O
poly(2-hydroxyethyl-methacrylate)	NNS	O
or	IN	O
poly(vinylalcohol)),	,	O
polylactides,	)	O
copolymers	CC	O
of	,	O
L-glutamic	,	O
acid	NNS	O
and	IN	O
ethyl-L-glutamate,	NNP	O
non-degradable	NN	O
ethylene-vinyl	CC	O
acetate,	,	O
degradable	JJ	O
lactic	JJ	O
acid-glycolic	,	O
acid	JJ	O
copolymers	JJ	O
such	JJ	O
as	NN	O
the	NNS	O
ProLease®	JJ	O
technology	IN	O
or	DT	O
Lupron	NNP	O
Depot®	NN	O
(injectable	CC	O
microspheres	NNP	O
composed	NNP	O
of	JJ	O
lactic	NNS	O
acid-glycolic	VBN	O
acid	IN	O
copolymer	JJ	O
and	JJ	O
leuprolide	NN	O
acetate),	NN	O
and	CC	O
poly-D-(−)-3-hydroxybutyric	JJ	O
acid.	,	O
While	CC	O
polymers	JJ	O
such	.	O
as	IN	O
ethylene-vinyl	NNS	O
acetate	JJ	O
and	IN	O
lactic	JJ	O
acid-glycolic	NN	O
acid	CC	O
enable	JJ	O
release	JJ	O
of	NN	O
molecules	JJ	O
for	NN	O
long	IN	O
periods	NNS	O
such	IN	O
as	RB	O
up	NNS	O
to	JJ	O
or	IN	O
over	IN	O
100	TO	O
days,	CC	O
certain	IN	O
hydrogels	CD	O
release	,	O
proteins	JJ	O
for	NNS	O
shorter	VBP	O
time	NNS	O
periods.	IN	O
When	JJR	O
encapsulated	NN	O
polypeptides	.	O
remain	WRB	O
in	VBN	O
the	NNS	O
body	VBP	O
for	IN	O
a	DT	O
long	NN	O
time,	IN	O
they	DT	O
may	JJ	O
denature	,	O
or	PRP	O
aggregate	MD	O
as	VB	O
a	CC	O
result	VB	O
of	IN	O
exposure	DT	O
to	NN	O
moisture	IN	O
at	NN	O
37°	TO	O
C.,	VB	O
resulting	IN	O
in	CD	O
a	,	O
loss	VBG	O
of	IN	O
biological	DT	O
activity	NN	O
and	IN	O
possible	JJ	O
changes	NN	O
in	CC	O
immunogenicity.	JJ	O
Rational	NNS	O
strategies	IN	O
can	.	O
be	JJ	O
devised	NNS	O
for	MD	O
stabilization	VB	O
depending	VBN	O
on	IN	O
the	NN	O
mechanism	VBG	O
involved.	IN	O
For	DT	O
example,	NN	O
if	.	O
the	IN	O
aggregation	,	O
mechanism	IN	O
is	DT	O
discovered	NN	O
to	NN	O
be	VBZ	O
intermolecular	VBN	O
S—S	TO	O
bond	VB	O
formation	JJ	O
through	NNP	O
thio-disulfide	NN	O
interchange,	NN	O
stabilization	IN	O
may	JJ	O
be	,	O
achieved	NN	O
by	MD	O
modifying	VB	O
sulfhydryl	VBN	O
residues,	IN	O
lyophilizing	VBG	O
from	NN	O
acidic	,	O
solutions,	VBG	O
controlling	IN	O
moisture	JJ	O
content,	,	O
using	VBG	O
appropriate	NN	O
additives,	,	O
and	VBG	O
developing	JJ	O
specific	,	O
polymer	CC	O
matrix	VBG	O
compositions.	JJ	O
Oral	NN	O
administration	NN	O
of	.	O
the	JJ	O
peptides	NN	O
and	IN	O
peptide	DT	O
conjugates	NNS	O
is	CC	O
an	NN	O
intended	NNS	O
practice	VBZ	O
of	DT	O
the	JJ	O
invention.	NN	O
For	IN	O
oral	DT	O
administration,	.	O
the	IN	O
pharmaceutical	JJ	O
composition	,	O
may	DT	O
be	JJ	O
in	NN	O
solid	MD	O
or	VB	O
liquid	IN	O
form,	JJ	O
e.g.,	CC	O
in	JJ	O
the	,	O
form	,	O
of	IN	O
a	DT	O
capsule,	NN	O
tablet,	IN	O
suspension,	DT	O
emulsion	,	O
or	,	O
solution.	,	O
The	NN	O
pharmaceutical	CC	O
composition	.	O
is	DT	O
preferably	JJ	O
made	NN	O
in	VBZ	O
the	RB	O
form	VBN	O
of	IN	O
a	DT	O
dosage	NN	O
unit	IN	O
containing	DT	O
a	NN	O
given	NN	O
amount	VBG	O
of	DT	O
the	VBN	O
active	NN	O
ingredient.	IN	O
A	DT	O
suitable	JJ	O
daily	.	O
dose	DT	O
for	JJ	O
a	JJ	O
human	NN	O
or	IN	O
other	DT	O
mammal	JJ	O
may	CC	O
vary	JJ	O
widely	NN	O
depending	MD	O
on	VB	O
the	RB	O
condition	VBG	O
of	IN	O
the	DT	O
patient	NN	O
and	IN	O
other	DT	O
factors,	NN	O
but	CC	O
can	JJ	O
be	,	O
determined	CC	O
by	MD	O
persons	VB	O
skilled	VBN	O
in	IN	O
the	NNS	O
art	VBN	O
using	IN	O
routine	DT	O
methods.	NN	O
Solid	VBG	O
dosage	JJ	O
forms	.	O
for	JJ	O
oral	NN	O
administration	NNS	O
may	IN	O
include	JJ	O
capsules,	NN	O
tablets,	MD	O
suppositories,	VB	O
powders	,	O
and	,	O
granules.	,	O
In	NNS	O
such	CC	O
solid	.	O
dosage	IN	O
forms,	JJ	O
the	JJ	O
active	NN	O
compound	,	O
may	DT	O
be	JJ	O
admixed	NN	O
with	MD	O
at	VB	O
least	VBN	O
one	IN	O
inert	IN	O
diluent	JJS	O
such	CD	O
as	JJ	O
sucrose,	NN	O
lactose,	JJ	O
or	IN	O
starch.	,	O
Such	,	O
dosage	CC	O
forms	.	O
may	JJ	O
also	NN	O
comprise,	NNS	O
as	MD	O
is	RB	O
normal	,	O
practice,	IN	O
additional	VBZ	O
substances,	JJ	O
e.g.,	,	O
lubricating	JJ	O
agents	,	O
such	,	O
as	VBG	O
magnesium	NNS	O
stearate.	JJ	O
In	IN	O
the	NN	O
case	.	O
of	IN	O
capsules,	DT	O
tablets	NN	O
and	IN	O
pills,	,	O
the	NNS	O
dosage	CC	O
forms	,	O
may	DT	O
also	NN	O
comprise	NNS	O
buffering	MD	O
agents.	RB	O
Tablets	VB	O
and	VBG	O
pills	.	O
can	NNS	O
additionally	CC	O
be	NNS	O
prepared	MD	O
with	RB	O
enteric	VB	O
coatings.	VBN	O
The	IN	O
polypeptides	JJ	O
or	.	O
conjugates	DT	O
may	NNS	O
be	CC	O
admixed	NNS	O
with	MD	O
adjuvants	VB	O
such	VBN	O
as	IN	O
lactose,	NNS	O
sucrose,	JJ	O
starch	IN	O
powder,	,	O
cellulose	,	O
esters	JJ	O
of	,	O
alkanoic	JJ	O
acids,	NNS	O
stearic	IN	O
acid,	JJ	O
talc,	,	O
magnesium	JJ	O
stearate,	,	O
magnesium	,	O
oxide,	NN	O
sodium	,	O
and	NN	O
calcium	,	O
salts	NN	O
of	CC	O
phosphoric	NN	O
and	NNS	O
sulphuric	IN	O
acids,	NN	O
acacia,	CC	O
gelatin,	JJ	O
sodium	,	O
alginate,	,	O
polyvinyl-pyrrolidine,	,	O
and/or	NN	O
polyvinyl	,	O
alcohol,	,	O
and	JJ	O
tableted	NN	O
or	,	O
encapsulated	CC	O
for	VBD	O
conventional	CC	O
administration.	VBN	O
Alternatively,	IN	O
they	JJ	O
may	.	O
be	,	O
dissolved	PRP	O
in	MD	O
saline,	VB	O
water,	VBN	O
polyethylene	IN	O
glycol,	,	O
propylene	,	O
glycol,	NN	O
ethanol,	,	O
oils	NN	O
(such	,	O
as	,	O
corn	NNS	O
oil,	JJ	O
peanut	IN	O
oil,	NN	O
cottonseed	,	O
oil	NN	O
or	,	O
sesame	VB	O
oil),	NN	O
tragacanth	CC	O
gum,	VB	O
and/or	,	O
various	JJ	O
buffers.	,	O
Other	RB	O
adjuvants	JJ	O
and	.	O
modes	JJ	O
of	NNS	O
administration	CC	O
are	NNS	O
well	IN	O
known	NN	O
in	VBP	O
the	RB	O
pharmaceutical	VBN	O
art.	IN	O
The	DT	O
carrier	JJ	O
or	.	O
diluent	DT	O
may	NN	O
include	CC	O
time	NN	O
delay	MD	O
material,	VB	O
such	NN	O
as	JJ	O
glyceryl	,	O
monostearate	JJ	O
or	IN	O
glyceryl	JJ	O
distearate	NN	O
alone	CC	O
or	JJ	O
with	NN	O
a	RB	O
wax,	CC	O
or	IN	O
other	DT	O
materials	,	O
well	CC	O
known	JJ	O
in	NNS	O
the	RB	O
art.	VBN	O
The	IN	O
pharmaceutical	DT	O
compositions	.	O
may	DT	O
be	JJ	O
subjected	NNS	O
to	MD	O
conventional	VB	O
pharmaceutical	VBN	O
operations	TO	O
such	JJ	O
as	JJ	O
sterilization	NNS	O
and/or	JJ	O
may	IN	O
contain	NN	O
conventional	NN	O
adjuvants	MD	O
such	VB	O
as	JJ	O
preservatives,	NNS	O
stabilizers,	JJ	O
wetting	IN	O
agents,	,	O
emulsifiers,	,	O
buffers,	VBG	O
fillers,	,	O
etc.,	,	O
e.g.,	,	O
as	,	O
disclosed	,	O
elsewhere	,	O
herein.	IN	O
Liquid	VBN	O
dosage	RB	O
forms	.	O
for	NNP	O
oral	NN	O
administration	NNS	O
may	IN	O
include	JJ	O
pharmaceutically	NN	O
acceptable	MD	O
emulsions,	VB	O
solutions,	RB	O
suspensions,	JJ	O
syrups	,	O
and	,	O
elixirs	,	O
containing	NNS	O
inert	CC	O
diluents	NNS	O
commonly	VBG	O
used	JJ	O
in	NNS	O
the	RB	O
art,	VBN	O
such	IN	O
as	DT	O
water.	,	O
Such	JJ	O
compositions	IN	O
may	.	O
also	JJ	O
comprise	NNS	O
adjuvants	MD	O
such	RB	O
as	VB	O
wetting	NNS	O
agents,	JJ	O
sweeteners,	IN	O
flavoring	VBG	O
agents	,	O
and	,	O
perfuming	VBG	O
agents.	NNS	O
Formulations	CC	O
suitable	VBG	O
for	.	O
pulmonary	NNS	O
administration	JJ	O
are	IN	O
intended	JJ	O
as	NN	O
part	VBP	O
of	VBN	O
the	IN	O
invention.	NN	O
Formulations	IN	O
suitable	DT	O
for	.	O
use	NNS	O
with	JJ	O
a	IN	O
nebulizer,	NN	O
either	IN	O
jet	DT	O
or	,	O
ultrasonic,	CC	O
will	NN	O
typically	CC	O
comprise	,	O
the	MD	O
polypeptide	RB	O
or	VB	O
conjugate	DT	O
dissolved	NN	O
in	CC	O
water	NN	O
at	VBN	O
a	IN	O
concentration	NN	O
of,	IN	O
e.g.,	DT	O
about	NN	O
0.01	,	O
to	,	O
25	RB	O
mg	CD	O
of	TO	O
conjugate	CD	O
per	NN	O
mL	IN	O
of	NN	O
solution,	IN	O
preferably	NN	O
about	IN	O
0.1	,	O
to	RB	O
10	IN	O
mg/mL.	CD	O
The	TO	O
formulation	CD	O
may	.	O
also	DT	O
include	NN	O
a	MD	O
buffer	RB	O
and	VB	O
a	DT	O
simple	NN	O
sugar	CC	O
(e.g.,	DT	O
for	JJ	O
protein	NN	O
stabilization	,	O
and	IN	O
regulation	JJ	O
of	NN	O
osmotic	CC	O
pressure),	NN	O
and/or	IN	O
human	JJ	O
serum	,	O
albumin	JJ	O
ranging	JJ	O
in	NN	O
concentration	NN	O
from	VBG	O
0.1	IN	O
to	NN	O
10	IN	O
mg/ml.	CD	O
Examples	TO	O
of	CD	O
buffers	.	O
that	NNS	O
may	IN	O
be	NNS	O
used	WDT	O
are	MD	O
sodium	VB	O
acetate,	VBN	O
citrate	VBP	O
and	JJ	O
glycine.	,	O
Preferably,	NN	O
the	CC	O
buffer	.	O
will	,	O
have	DT	O
a	NN	O
composition	MD	O
and	VB	O
molarity	DT	O
suitable	NN	O
to	CC	O
adjust	NN	O
the	JJ	O
solution	TO	O
to	VB	O
a	DT	O
pH	NN	O
in	TO	O
the	DT	O
range	NN	O
of	IN	O
3	DT	O
to	NN	O
9.	IN	O
Generally,	CD	O
buffer	TO	O
molarities	.	O
of	,	O
from	JJR	O
1	NNS	O
mM	IN	O
to	IN	O
50	CD	O
mM	NNS	O
are	TO	O
suitable	CD	O
for	NNS	O
this	VBP	O
purpose.	JJ	O
Examples	IN	O
of	DT	O
sugars	.	O
which	NNS	O
can	IN	O
be	NNS	O
utilized	WDT	O
are	MD	O
lactose,	VB	O
maltose,	VBN	O
mannitol,	VBP	O
sorbitol,	,	O
trehalose,	,	O
and	,	O
xylose,	,	O
usually	,	O
in	CC	O
amounts	,	O
ranging	RB	O
from	IN	O
1%	NNS	O
to	VBG	O
10%	IN	O
by	NN	O
weight	TO	O
of	NN	O
the	IN	O
formulation.	NN	O
The	IN	O
nebulizer	DT	O
formulation	.	O
may	DT	O
also	JJ	O
contain	NN	O
a	MD	O
surfactant	RB	O
to	VB	O
reduce	DT	O
or	NN	O
prevent	TO	O
surface	VB	O
induced	CC	O
aggregation	VB	O
of	NN	O
the	JJ	O
protein	NN	O
caused	IN	O
by	DT	O
atomization	NN	O
of	VBN	O
the	IN	O
solution	NN	O
in	IN	O
forming	DT	O
the	NN	O
aerosol.	IN	O
Various	VBG	O
conventional	DT	O
surfactants	.	O
can	JJ	O
be	JJ	O
employed,	NNS	O
such	MD	O
as	VB	O
polyoxyethylene	,	O
fatty	JJ	O
acid	IN	O
esters	NN	O
and	JJ	O
alcohols,	NN	O
and	NNS	O
polyoxyethylene	CC	O
sorbitan	,	O
fatty	CC	O
acid	JJ	O
esters.	NN	O
Amounts	JJ	O
will	NN	O
generally	.	O
range	NNS	O
between	MD	O
0.001%	RB	O
and	VB	O
4%	IN	O
by	NN	O
weight	CC	O
of	NN	O
the	IN	O
formulation.	NN	O
An	IN	O
especially	DT	O
preferred	.	O
surfactant	DT	O
for	RB	O
purposes	JJ	O
of	NN	O
this	IN	O
invention	NNS	O
is	IN	O
polyoxyethylene	DT	O
sorbitan	NN	O
monooleate.	VBZ	O
Specific	JJ	O
formulations	JJ	O
and	.	O
methods	JJ	O
of	NNS	O
generating	CC	O
suitable	NNS	O
dispersions	IN	O
of	VBG	O
liquid	JJ	O
particles	NNS	O
of	IN	O
the	JJ	O
invention	NNS	O
are	IN	O
described	DT	O
in	NN	O
WO	VBP	O
94/20069,	VBN	O
U.S.	IN	O
Pat.	NNP	O
No.	,	O
5,915,378,	NNP	O
U.S.	.	O
Pat.	.	O
No.	,	O
5,960,792,	NNP	O
U.S.	.	O
Pat.	.	O
No.	,	O
5,957,124,	NNP	O
U.S.	.	O
Pat.	.	O
No.	,	O
5,934,272,	NNP	O
U.S.	.	O
Pat.	.	O
No.	,	O
5,915,378,	NNP	O
U.S.	.	O
Pat.	.	O
No.	,	O
5,855,564,	NNP	O
U.S.	.	O
Pat.	.	O
No.	,	O
5,826,570	NNP	O
and	.	O
U.S.	.	O
Pat.	CD	O
No.	CC	O
5,522,385	NNP	O
which	.	O
are	.	O
hereby	CD	O
incorporated	WDT	O
by	VBP	O
reference.	RB	O
Formulations	VBN	O
for	IN	O
use	.	O
with	NNS	O
a	IN	O
metered	NN	O
dose	IN	O
inhaler	DT	O
device	VBN	O
will	NN	O
generally	NN	O
comprise	NN	O
a	MD	O
finely	RB	O
divided	VB	O
powder.	DT	O
This	RB	O
powder	VBN	O
may	.	O
be	DT	O
produced	NN	O
by	MD	O
lyophilizing	VB	O
and	VBN	O
then	IN	O
milling	VBG	O
a	CC	O
liquid	RB	O
conjugate	VBG	O
formulation	DT	O
and	JJ	O
may	NN	O
also	NN	O
contain	CC	O
a	MD	O
stabilizer	RB	O
such	VB	O
as	DT	O
human	NN	O
serum	JJ	O
albumin	IN	O
(HSA).	JJ	O
Typically,	NN	O
more	NN	O
than	.	O
0.5%	,	O
(w/w)	JJR	O
HSA	IN	O
is	NN	O
added.	)	O
Additionally,	NNP	O
one	VBZ	O
or	.	O
more	,	O
sugars	CD	O
or	CC	O
sugar	JJR	O
alcohols	NNS	O
may	CC	O
be	NN	O
added	NNS	O
to	MD	O
the	VB	O
preparation	VBN	O
if	TO	O
necessary.	DT	O
Examples	NN	O
include	IN	O
lactose	.	O
maltose,	NNS	O
mannitol,	VBP	O
sorbitol,	JJ	O
sorbitose,	,	O
trehalose,	,	O
xylitol,	,	O
and	,	O
xylose.	,	O
The	,	O
amount	CC	O
added	.	O
to	DT	O
the	NN	O
formulation	VBD	O
can	TO	O
range	DT	O
from	NN	O
about	MD	O
0.01	VB	O
to	IN	O
200%	RB	O
(w/w),	CD	O
preferably	TO	O
from	NN	O
approximately	,	O
1	RB	O
to	IN	O
50%,	RB	O
of	CD	O
the	TO	O
conjugate	,	O
present.	IN	O
Such	DT	O
formulations	NN	O
are	.	O
then	JJ	O
lyophilized	NNS	O
and	VBP	O
milled	RB	O
to	VBN	O
the	CC	O
desired	VBN	O
particle	TO	O
size.	DT	O
The	VBN	O
properly	NN	O
sized	.	O
particles	DT	O
are	JJ	O
then	VBN	O
suspended	NNS	O
in	VBP	O
a	RB	O
propellant	VBN	O
with	IN	O
the	DT	O
aid	NN	O
of	IN	O
a	DT	O
surfactant.	NN	O
The	IN	O
propellant	DT	O
may	.	O
be	DT	O
any	NN	O
conventional	MD	O
material	VB	O
employed	DT	O
for	JJ	O
this	NN	O
purpose,	VBN	O
such	IN	O
as	DT	O
a	,	O
chlorofluorocarbon,	JJ	O
a	IN	O
hydrochlorofluorocarbon,	DT	O
a	,	O
hydrofluorocarbon,	DT	O
or	,	O
a	DT	O
hydrocarbon,	,	O
including	CC	O
trichlorofluoromethane,	DT	O
dichlorodifluoromethane,	,	O
dichlorotetrafluoroethanol,	VBG	O
and	,	O
1,1,1,2-tetrafluoroethane,	,	O
or	,	O
combinations	CC	O
thereof.	,	O
Suitable	CC	O
surfactants	NNS	O
include	.	O
sorbitan	JJ	O
trioleate	NNS	O
and	VBP	O
soya	JJ	O
lecithin.	NN	O
Oleic	CC	O
acid	NN	O
may	.	O
also	NNP	O
be	NN	O
useful	MD	O
as	RB	O
a	VB	O
surfactant.	JJ	O
This	IN	O
mixture	DT	O
is	.	O
then	DT	O
loaded	NN	O
into	VBZ	O
the	RB	O
delivery	VBN	O
device.	IN	O
An	DT	O
example	NN	O
of	.	O
a	DT	O
commercially	NN	O
available	IN	O
metered	DT	O
dose	RB	O
inhaler	JJ	O
suitable	VBN	O
for	JJ	O
use	NN	O
in	NN	O
the	IN	O
present	NN	O
invention	IN	O
is	DT	O
the	JJ	O
Ventolin	NN	O
metered	VBZ	O
dose	DT	O
inhaler,	NNP	O
manufactured	VBD	O
by	JJ	O
Glaxo	,	O
Inc.,	VBN	O
Research	IN	O
Triangle	NNP	O
Park,	,	O
N.C.,	NNP	O
USA.	NNP	O
Formulations	,	O
for	,	O
powder	.	O
inhalers	NNS	O
will	IN	O
comprise	NN	O
a	NNS	O
finely	MD	O
divided	VB	O
dry	DT	O
powder	RB	O
containing	VBN	O
polypeptides	JJ	O
or	NN	O
polypeptide	VBG	O
conjugates	NNS	O
and	CC	O
may	VB	O
also	NNS	O
include	CC	O
a	MD	O
bulking	RB	O
agent,	VB	O
such	DT	O
as	JJ	O
lactose,	,	O
sorbitol,	JJ	O
sucrose,	IN	O
or	,	O
mannitol	,	O
in	,	O
amounts	CC	O
which	NN	O
facilitate	IN	O
dispersal	NNS	O
of	WDT	O
the	VBP	O
powder	NN	O
from	IN	O
the	DT	O
device,	NN	O
e.g.,	IN	O
50%	DT	O
to	,	O
90%	,	O
by	NN	O
weight	TO	O
of	NN	O
the	IN	O
formulation.	NN	O
The	IN	O
particles	DT	O
of	.	O
the	DT	O
powder	NNS	O
shall	IN	O
have	DT	O
aerodynamic	NN	O
properties	MD	O
in	VB	O
the	JJ	O
lung	NNS	O
corresponding	IN	O
to	DT	O
particles	NN	O
with	VBG	O
a	TO	O
density	NNS	O
of	IN	O
about	DT	O
1	NN	O
g/cm2	IN	O
having	IN	O
a	CD	O
median	NNS	O
diameter	VBG	O
less	DT	O
than	JJ	O
10	NN	O
micrometers,	JJR	O
preferably	IN	O
between	CD	O
0.5	,	O
and	RB	O
5	IN	O
micrometers,	CD	O
most	CC	O
preferably	CD	O
of	,	O
between	JJS	O
1.5	RB	O
and	IN	O
3.5	IN	O
micrometers.	CD	O
An	CC	O
example	CD	O
of	.	O
a	DT	O
powder	NN	O
inhaler	IN	O
suitable	DT	O
for	NN	O
use	NN	O
in	NN	O
accordance	IN	O
with	NN	O
the	IN	O
teachings	NN	O
herein	IN	O
is	DT	O
the	NNS	O
Spinhaler	NN	O
powder	VBZ	O
inhaler,	DT	O
manufactured	NNP	O
by	NN	O
Fisons	,	O
Corp.,	VBN	O
Bedford,	IN	O
Mass.,	NNP	O
USA.	,	O
The	,	O
powders	,	O
for	.	O
these	DT	O
devices	NNS	O
may	IN	O
be	DT	O
generated	NNS	O
and/or	MD	O
delivered	VB	O
by	VBN	O
methods	RB	O
disclosed	VBN	O
in	IN	O
U.S.	NNS	O
Pat.	VBN	O
No.	IN	O
5,997,848,	NNP	O
U.S.	.	O
Pat.	.	O
No.	,	O
5,993,783,	NNP	O
U.S.	.	O
Pat.	.	O
No.	,	O
5,985,248,	NNP	O
U.S.	.	O
Pat.	.	O
No.	,	O
5,976,574,	NNP	O
U.S.	.	O
Pat.	.	O
No.	,	O
5,922,354,	NNP	O
U.S.	.	O
Pat.	.	O
No.	,	O
5,785,049	NNP	O
and	.	O
U.S.	.	O
Pat.	CD	O
No.	CC	O
5,654,007.	NNP	O
Mechanical	.	O
devices	.	O
designed	.	O
for	JJ	O
pulmonary	NNS	O
delivery	VBN	O
of	IN	O
therapeutic	JJ	O
products,	NN	O
include	IN	O
but	JJ	O
are	,	O
not	VBP	O
limited	CC	O
to	VBP	O
nebulizers,	RB	O
metered	VBN	O
dose	TO	O
inhalers,	,	O
and	VBD	O
powder	JJ	O
inhalers,	,	O
all	CC	O
of	NN	O
which	,	O
are	DT	O
familiar	IN	O
to	WDT	O
those	VBP	O
of	JJ	O
skill	TO	O
in	DT	O
the	IN	O
art.	NN	O
Specific	IN	O
examples	DT	O
of	.	O
commercially	JJ	O
available	NNS	O
devices	IN	O
suitable	RB	O
for	JJ	O
the	NNS	O
practice	JJ	O
of	IN	O
this	DT	O
invention	NN	O
are	IN	O
the	DT	O
Ultravent	NN	O
nebulizer,	VBP	O
manufactured	DT	O
by	NNP	O
Mallinckrodt,	,	O
Inc.,	VBN	O
St.	IN	O
Louis,	,	O
Mo.,	,	O
USA;	NNP	O
the	,	O
Acorn	,	O
II	:	O
nebulizer,	DT	O
manufactured	NNP	O
by	NNP	O
Marquest	,	O
Medical	VBN	O
Products,	IN	O
Englewood,	NNP	O
Colo.,	NNP	O
USA;	,	O
the	,	O
Ventolin	,	O
metered	:	O
dose	DT	O
inhaler,	NNP	O
manufactured	VBD	O
by	JJ	O
Glaxo	,	O
Inc.,	VBN	O
Research	IN	O
Triangle	NNP	O
Park,	,	O
N.C.,	NNP	O
USA;	NNP	O
the	,	O
Spinhaler	,	O
powder	:	O
inhaler,	DT	O
manufactured	NNP	O
by	NN	O
Fisons	,	O
Corp.,	VBN	O
Bedford,	IN	O
Mass.,	NNP	O
USA	,	O
the	,	O
“standing	,	O
cloud”	NNP	O
device	DT	O
of	VBG	O
Nektar	JJ	O
Therapeutics,	NN	O
Inc.,	IN	O
San	NNP	O
Carlos,	,	O
Calif.,	,	O
USA;	NNP	O
the	,	O
AIR	,	O
inhaler	:	O
manufactured	DT	O
by	NNP	O
Alkermes,	NN	O
Cambridge,	VBN	O
Mass.,	IN	O
USA;	,	O
and	,	O
the	,	O
AERx	:	O
pulmonary	CC	O
drug	DT	O
delivery	NNP	O
system	JJ	O
manufactured	NN	O
by	NN	O
Aradigm	NN	O
Corporation,	VBN	O
Hayward,	IN	O
Calif.,	NNP	O
USA.	,	O
The	,	O
present	,	O
invention	.	O
also	DT	O
provides	JJ	O
kits	NN	O
including	RB	O
the	VBZ	O
polypeptides,	NNS	O
conjugates,	VBG	O
polynucleotides,	DT	O
expression	,	O
vectors,	,	O
cells,	,	O
methods,	NN	O
compositions,	,	O
and	,	O
systems,	,	O
and	,	O
apparatuses	CC	O
of	,	O
the	CC	O
invention.	NNS	O
Kits	IN	O
of	DT	O
the	.	O
invention	NNS	O
optionally	IN	O
comprise	DT	O
at	NN	O
least	RB	O
one	VB	O
of	IN	O
the	JJS	O
following	CD	O
of	IN	O
the	DT	O
invention:	NN	O
(1)	IN	O
an	DT	O
apparatus,	:	O
system,	)	O
system	DT	O
component,	,	O
or	,	O
apparatus	NN	O
component	,	O
as	CC	O
described	RB	O
herein;	JJ	O
(2)	IN	O
at	JJ	O
least	:	O
one	)	O
kit	IN	O
component	JJS	O
comprising	CD	O
a	NN	O
polypeptide	NN	O
or	VBG	O
conjugate	DT	O
or	NN	O
polynucleotide	CC	O
of	NN	O
the	CC	O
invention;	NN	O
a	IN	O
plasmid	DT	O
expression	:	O
vector	DT	O
encoding	JJ	O
a	NN	O
polypeptide	NN	O
of	VBG	O
the	DT	O
invention;	NN	O
a	IN	O
cell	DT	O
expressing	:	O
a	DT	O
polypeptide	NN	O
of	VBG	O
the	DT	O
invention;	NN	O
or	IN	O
a	DT	O
composition	:	O
comprising	CC	O
at	DT	O
least	NN	O
one	VBG	O
of	IN	O
any	JJS	O
such	CD	O
component;	IN	O
(3)	DT	O
instructions	JJ	O
for	:	O
practicing	)	O
any	NNS	O
method	IN	O
described	VBG	O
herein,	DT	O
including	NN	O
a	VBD	O
therapeutic	,	O
or	VBG	O
prophylactic	DT	O
method,	JJ	O
instructions	CC	O
for	JJ	O
using	,	O
any	NNS	O
component	IN	O
identified	VBG	O
in	DT	O
(2)	NN	O
or	VBN	O
any	IN	O
composition	)	O
of	CC	O
any	DT	O
such	NN	O
component;	IN	O
and/or	DT	O
instructions	JJ	O
for	:	O
operating	CC	O
any	NNS	O
apparatus,	IN	O
system	VBG	O
or	DT	O
component	,	O
described	NN	O
herein;	CC	O
(4)	NN	O
a	VBN	O
container	:	O
for	)	O
holding	DT	O
said	NN	O
at	IN	O
least	VBG	O
one	VBD	O
such	IN	O
component	JJS	O
or	CD	O
composition,	JJ	O
and	NN	O
(5)	CC	O
packaging	,	O
materials.	CC	O
In	)	O
a	NN	O
further	.	O
aspect,	IN	O
the	DT	O
present	JJ	O
invention	,	O
provides	DT	O
for	JJ	O
the	NN	O
use	VBZ	O
of	IN	O
any	DT	O
apparatus,	NN	O
component,	IN	O
composition,	DT	O
or	,	O
kit	,	O
described	,	O
above	CC	O
and	VB	O
herein,	VBN	O
for	IN	O
the	CC	O
practice	,	O
of	IN	O
any	DT	O
method	NN	O
or	IN	O
assay	DT	O
described	NN	O
herein,	CC	O
and/or	VB	O
for	VBN	O
the	,	O
use	NN	O
of	IN	O
any	DT	O
apparatus,	NN	O
component,	IN	O
composition,	DT	O
or	,	O
kit	,	O
to	,	O
practice	CC	O
any	VB	O
assay	TO	O
or	NN	O
method	DT	O
described	NN	O
herein.	CC	O
Chemical	NN	O
Modifications,	VBN	O
Conjugates,	.	O
and	NNP	O
Fusions	,	O
Any	,	O
polypeptide	CC	O
of	NNP	O
the	NNP	O
invention	NN	O
may	IN	O
be	DT	O
present	NN	O
as	MD	O
part	VB	O
of	JJ	O
a	IN	O
larger	NN	O
polypeptide	IN	O
sequence,	DT	O
e.g.	JJR	O
a	JJ	O
fusion	,	O
protein,	.	O
such	DT	O
as	NN	O
occurs	,	O
upon	JJ	O
the	IN	O
addition	NNS	O
of	IN	O
one	DT	O
or	NN	O
more	IN	O
domains	CD	O
or	CC	O
subsequences	JJR	O
for	NNS	O
stabilization	CC	O
or	NNS	O
detection	IN	O
or	NN	O
purification	CC	O
of	NN	O
the	CC	O
polypeptide.	NN	O
A	IN	O
polypeptide	DT	O
purification	.	O
subsequence	DT	O
may	JJ	O
include,	NN	O
e.g.,	NN	O
an	MD	O
epitope	,	O
tag,	,	O
a	DT	O
FLAG	NN	O
tag,	,	O
a	DT	O
polyhistidine	NNP	O
sequence,	,	O
a	DT	O
GST	NN	O
fusion,	,	O
or	DT	O
any	NNP	O
other	,	O
detection/purification	CC	O
subsequence	DT	O
or	JJ	O
“tag”	NN	O
known	NN	O
in	CC	O
the	VB	O
art.	VBN	O
These	IN	O
additional	DT	O
domains	.	O
or	DT	O
subsequences	JJ	O
either	NNS	O
have	CC	O
little	NNS	O
or	CC	O
no	VBP	O
effect	JJ	O
on	CC	O
the	DT	O
activity	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention,	NN	O
or	IN	O
can	DT	O
be	,	O
removed	CC	O
by	MD	O
post	VB	O
synthesis	VBN	O
processing	IN	O
steps	NN	O
such	NN	O
as	VBG	O
by	NNS	O
treatment	JJ	O
with	IN	O
a	IN	O
protease,	NN	O
inclusion	IN	O
of	DT	O
an	,	O
intein,	NN	O
or	IN	O
the	DT	O
like.	,	O
The	CC	O
invention	DT	O
includes	.	O
fusion	DT	O
proteins	NN	O
comprising	VBZ	O
a	NN	O
polypeptide	NNS	O
of	VBG	O
the	DT	O
invention,	NN	O
e.g.,	IN	O
as	DT	O
described	,	O
herein,	,	O
fused	IN	O
to	VBN	O
an	,	O
Ig	VBD	O
molecule,	TO	O
e.g.,	DT	O
a	NNP	O
human	,	O
IgG	,	O
Fc	DT	O
(“fragment	JJ	O
crystallizable,”	NNP	O
or	NNP	O
fragment	JJ	O
complement	''	O
binding)	CC	O
hinge,	JJ	O
CH2	NN	O
domain	)	O
and	,	O
CH3	NNP	O
domain,	NN	O
and	CC	O
nucleotide	NNP	O
sequences	,	O
encoding	CC	O
such	RB	O
fusion	NNS	O
protein.	VBG	O
Fc	JJ	O
is	NN	O
the	.	O
portion	NNP	O
of	VBZ	O
the	DT	O
antibody	NN	O
responsible	IN	O
for	DT	O
binding	NN	O
to	JJ	O
antibody	IN	O
receptors	VBG	O
on	TO	O
cells	NN	O
and	NNS	O
the	IN	O
C1q	NNS	O
component	CC	O
of	DT	O
complement.	NNP	O
These	NN	O
fusion	IN	O
proteins	.	O
and	DT	O
their	NN	O
encoding	NNS	O
nucleic	CC	O
acids	PRP$	O
are	NN	O
useful	JJ	O
as	NNS	O
prophylactic	VBP	O
and/or	JJ	O
therapeutic	IN	O
drugs	JJ	O
or	NN	O
as	JJ	O
diagnostic	NNS	O
tools	CC	O
(see	IN	O
also,	JJ	O
e.g.,	NNS	O
Challita-Eid,	VB	B
P.	,	I
et	,	I
al.	,	I
(1998)	NNP	I
J.	CC	I
Immunol.	.	I
160:3419-3426;	)	I
Sturmhoefel,	NNP	B
K.	.	I
et	:	I
al.	,	I
(1999)	NNP	I
Cancer	CC	I
Res	.	I
59:4964-4972).The	)	O
invention	NNP	O
also	NNP	O
includes	.	O
fusion	DT	O
proteins	NN	O
comprising	RB	O
a	VBZ	O
polypeptide	NN	O
of	NNS	O
the	VBG	O
invention,	DT	O
fused	NN	O
to	IN	O
an	DT	O
albumin	,	O
molecule,	VBN	O
such	TO	O
as	DT	O
human	NN	O
serum	,	O
albumin	JJ	O
(HSA),	IN	O
as	JJ	O
described,	NN	O
for	NN	O
example,	,	O
in	IN	O
U.S.	,	O
Pat.	IN	O
No.	,	O
5,876,969,	IN	O
and	NNP	O
nucleotide	.	O
sequences	.	O
encoding	,	O
the	CC	O
fusion	RB	O
protein.	NNS	O
The	VBG	O
Ig	DT	O
and	NN	O
albumin	.	O
fusion	DT	O
proteins	NNP	O
may	CC	O
exhibit	JJ	O
increased	NN	O
polypeptide	NNS	O
serum	MD	O
half-life	VB	O
and/or	JJ	O
functional	NN	O
in	VBD	O
vivo	JJ	O
half-life,	JJ	O
reduced	NN	O
polypeptide	IN	O
antigenicity,	JJ	O
increased	,	O
polypeptide	VBD	O
storage	JJ	O
stability,	,	O
or	VBD	O
increasing	JJ	O
bioavailability,	NN	O
e.g.	,	O
increased	CC	O
AUCsc,	VBG	O
and	,	O
are	.	O
thus	VBN	O
may	,	O
be	CC	O
useful	VBP	O
as	RB	O
prophylactic	MD	O
and/or	VB	O
therapeutic	JJ	O
drugs.	IN	O
All	JJ	O
of	NN	O
the	JJ	O
polypeptides	.	O
of	DT	O
the	IN	O
invention	DT	O
have	NNS	O
an	IN	O
inherent	DT	O
ability	NN	O
to	VBP	O
transduce	DT	O
across	JJ	O
cellular	NN	O
membranes	TO	O
and	VB	O
affect	IN	O
therapeutic	JJ	O
functions	NNS	O
within	CC	O
cells.	JJ	O
The	JJ	O
invention	NNS	O
therefore	IN	O
provides	.	O
for	DT	O
the	NN	O
use	RB	O
of	VBZ	O
the	IN	O
polypeptides	DT	O
of	NN	O
the	IN	O
invention	DT	O
to	NNS	O
enhance	IN	O
the	DT	O
cell	NN	O
permeability	TO	O
or	VB	O
transducibility	DT	O
of	NN	O
any	NN	O
other	CC	O
molecule.	NN	O
The	IN	O
invention	DT	O
further	JJ	O
provides	.	O
for	DT	O
the	NN	O
use	RBR	O
of	VBZ	O
any	IN	O
fragment	DT	O
or	NN	O
subfragment	IN	O
of	DT	O
the	NN	O
polypeptides	CC	O
of	NN	O
the	IN	O
invention	DT	O
to	NNS	O
enhance	IN	O
the	DT	O
cell	NN	O
permeability	TO	O
of	VB	O
any	DT	O
other	NN	O
molecule,	NN	O
such	IN	O
fragments	DT	O
or	JJ	O
subfragments	,	O
being	JJ	O
of	NNS	O
about	CC	O
5	NNS	O
amino	VBG	O
acids	IN	O
in	IN	O
length,	CD	O
of	JJ	O
about	NNS	O
10	IN	O
amino	,	O
acids	IN	O
in	IN	O
length,	CD	O
such	JJ	O
as	NNS	O
15	IN	O
amino	,	O
acids	JJ	O
in	IN	O
length,	CD	O
e.g.	NN	O
about	NNS	O
20	IN	O
amino	,	O
acids	.	O
in	IN	O
length,	CD	O
of	JJ	O
about	NNS	O
25	IN	O
amino	,	O
acids	IN	O
in	IN	O
length,	CD	O
of	JJ	O
about	NNS	O
30	IN	O
amino	,	O
acids	IN	O
in	IN	O
length,	CD	O
such	JJ	O
as	NNS	O
35	IN	O
amino	,	O
acids	JJ	O
in	IN	O
length,	CD	O
of	NN	O
about	NNS	O
35-50	IN	O
amino	,	O
acids	IN	O
in	IN	O
length,	JJ	O
of	NN	O
about	NNS	O
50-100	IN	O
amino	,	O
acids	IN	O
in	IN	O
length,	JJ	O
such	NN	O
as	NNS	O
75	IN	O
amino	,	O
acids	JJ	O
in	IN	O
length,	CD	O
e.g.	NN	O
100-125	NNS	O
amino	IN	O
acids	,	O
in	.	O
length.	JJ	O
Any	NN	O
polypeptide	NNS	O
of	IN	O
the	.	O
invention	DT	O
may	NN	O
also	IN	O
comprise	DT	O
one	NN	O
or	MD	O
more	RB	O
modified	VB	O
amino	CD	O
acid.	CC	O
The	JJR	O
modified	JJ	O
amino	NN	O
acid	.	O
may	DT	O
be,	VBN	O
e.g.,	NN	O
a	NN	O
glycosylated	MD	O
amino	,	O
acid,	,	O
a	DT	O
PEGylated	JJ	O
amino	NN	O
acid,	,	O
a	DT	O
farnesylated	NNP	O
amino	NN	O
acid,	,	O
an	DT	O
acetylated	JJ	O
amino	NN	O
acid,	,	O
a	DT	O
biotinylated	JJ	O
amino	NN	O
acid,	,	O
an	DT	O
amino	VBN	O
acid	NN	O
conjugated	,	O
to	DT	O
a	NN	O
lipid	NN	O
moiety,	VBD	O
or	TO	O
an	DT	O
amino	JJ	O
acid	,	O
conjugated	CC	O
to	DT	O
an	JJ	O
organic	NN	O
derivatizing	VBD	O
agent.	TO	O
The	DT	O
presence	JJ	O
of	NN	O
modified	.	O
amino	DT	O
acids	NN	O
may	IN	O
be	VBN	O
advantageous	NN	O
in,	NNS	O
for	MD	O
example,	VB	O
(a)	JJ	O
increasing	,	O
polypeptide	IN	O
serum	,	O
half-life	)	O
and/or	VBG	O
functional	JJ	O
in	NN	O
vivo	JJ	O
half-life,	JJ	O
(b)	NN	O
reducing	IN	O
polypeptide	JJ	O
antigenicity,	,	O
(c)	)	O
increasing	VBG	O
polypeptide	JJ	O
storage	,	O
stability,	)	O
or	VBG	O
(d)	JJ	O
increasing	NN	O
bioavailability,	,	O
e.g.	CC	O
increasing	)	O
the	VBG	O
AUCsc.	,	O
Amino	.	O
acid(s)	VBG	O
are	DT	O
modified,	.	O
for	NNP	O
example,	)	O
co-translationally	VBP	O
or	,	O
post-translationally	IN	O
during	,	O
recombinant	RB	O
production	CC	O
(e.g.,	RB	O
N-linked	IN	O
glycosylation	JJ	O
at	NN	O
N-X-S/T	,	O
motifs	JJ	O
during	NN	O
expression	IN	O
in	NNP	O
mammalian	NNS	O
cells)	IN	O
or	NN	O
modified	IN	O
by	JJ	O
synthetic	)	O
means.	CC	O
Pegylated	VBN	O
polypeptides	IN	O
of	JJ	O
the	.	O
invention	NNP	O
include	NNS	O
but	IN	O
are	DT	O
not	NN	O
limited	VBP	O
to	CC	O
the	VBP	O
polypeptide	RB	O
modifications	VBN	O
described	TO	O
as	DT	O
Class	NN	O
IV	NNS	O
in	VBD	O
FIG.	IN	O
1	NNP	O
and	NNP	O
as	IN	O
implemented	.	O
in	CD	O
FIG.	CC	O
6.	RB	O
In	VBN	O
another	IN	O
aspect,	.	O
the	.	O
invention	IN	O
relates	DT	O
to	,	O
a	DT	O
conjugate	NN	O
comprising	VBZ	O
a	TO	O
polypeptide	DT	O
of	NN	O
the	VBG	O
invention	DT	O
and	NN	O
at	IN	O
least	DT	O
one	NN	O
non-polypeptide	CC	O
moiety	IN	O
attached	JJS	O
to	CD	O
the	JJ	O
polypeptide,	NN	O
such	VBN	O
as	TO	O
e.g.	DT	O
those	,	O
modified	JJ	O
polypeptides	IN	O
described	.	O
as	DT	O
Class	VBN	O
IV	NNS	O
in	VBD	O
FIG.	IN	O
1	NNP	O
and	NNP	O
as	IN	O
implemented	.	O
in	CD	O
FIG.	CC	O
6.	RB	O
The	VBN	O
invention	IN	O
provides	.	O
for	.	O
polypeptides	DT	O
that	NN	O
differ	VBZ	O
from	IN	O
the	NNS	O
polypeptides	WDT	O
of	VBP	O
FIG.	IN	O
1	DT	O
by	NNS	O
1	IN	O
to	.	O
34	CD	O
amino	IN	O
acid	CD	O
substitutions	TO	O
or	CD	O
insertions	NN	O
where	JJ	O
such	NNS	O
substitutions	CC	O
or	NNS	O
insertions	WRB	O
introduce	JJ	O
one	NNS	O
or	CC	O
more	NNS	O
attachment	VBP	O
groups	CD	O
for	CC	O
the	JJR	O
non-polypeptide	JJ	O
moiety	NNS	O
(e.g.,	IN	O
by	DT	O
substitution	JJ	O
of	NN	O
an	,	O
amino	IN	O
acid	NN	O
residue	IN	O
for	DT	O
a	NN	O
different	NN	O
residue	NN	O
which	IN	O
comprises	DT	O
an	JJ	O
attachment	NN	O
group	WDT	O
for	VBZ	O
the	DT	O
non-polypeptide	NN	O
moiety,	NN	O
or	IN	O
by	DT	O
insertion	JJ	O
of	,	O
an	CC	O
additional	IN	O
amino	NN	O
acid	IN	O
residue	DT	O
which	JJ	O
comprises	NN	O
an	NN	O
attachment	NN	O
group	WDT	O
for	VBZ	O
the	DT	O
non-polypeptide	NN	O
moiety).	NN	O
The	IN	O
term	DT	O
“conjugate”	JJ	O
(or	.	O
interchangeably	DT	O
“polypeptide	NN	O
conjugate”	NNP	O
or	CC	O
“conjugated	RB	O
polypeptide”)	JJ	O
is	NN	O
intended	CC	O
to	VBN	O
indicate	)	O
a	VBZ	O
heterogeneous	VBN	O
(in	TO	O
the	VB	O
sense	DT	O
of	JJ	O
composite)	IN	O
molecule	DT	O
formed	NN	O
by	IN	O
the	)	O
covalent	NN	O
attachment	VBN	O
of	IN	O
one	DT	O
or	JJ	O
more	NN	O
polypeptides	IN	O
of	CD	O
the	CC	O
invention	JJR	O
to	NNS	O
one	IN	O
or	DT	O
more	NN	O
non-polypeptide	TO	O
moieties.	CD	O
The	CC	O
term	JJR	O
“covalent	JJ	O
attachment”	.	O
means	DT	O
that	NN	O
the	NNP	O
polypeptide	NN	O
and	VBZ	O
the	IN	O
non-polypeptide	DT	O
moiety	NN	O
are	CC	O
either	DT	O
directly	JJ	O
covalently	NN	O
joined	VBP	O
to	DT	O
one	RB	O
another,	RB	O
or	VBN	O
else	TO	O
are	CD	O
indirectly	,	O
covalently	CC	O
joined	RB	O
to	VBP	O
one	RB	O
another	RB	O
through	VBN	O
an	TO	O
intervening	CD	O
moiety	DT	O
or	IN	O
moieties,	DT	O
such	JJ	O
as	NN	O
a	CC	O
bridge,	,	O
spacer,	JJ	O
or	IN	O
linkage	DT	O
moiety	,	O
or	,	O
moieties.	CC	O
Preferably,	VB	O
a	NN	O
conjugated	CC	O
polypeptide	.	O
is	,	O
soluble	DT	O
at	JJ	O
relevant	NN	O
concentrations	VBZ	O
and	JJ	O
conditions,	IN	O
i.e.	JJ	O
soluble	NNS	O
in	CC	O
physiological	,	O
fluids	.	O
such	JJ	O
as	IN	O
blood.	JJ	O
Examples	NNS	O
of	JJ	O
conjugated	IN	O
polypeptides	.	O
of	NNS	O
the	IN	O
invention	JJ	O
include	NNS	O
glycosylated	IN	O
and/or	DT	O
PEGylated	NN	O
polypeptides.	VBP	O
The	VBN	O
term	RB	O
“non-conjugated	NNP	O
polypeptide”	.	O
may	DT	O
be	NN	O
used	JJ	O
to	NN	O
refer	MD	O
to	VB	O
the	VBN	O
polypeptide	TO	O
part	VB	O
of	TO	O
the	DT	O
conjugated	JJ	O
polypeptide.	NN	O
The	IN	O
term	DT	O
“non-polypeptide	JJ	O
moiety”	.	O
is	DT	O
intended	NN	O
to	JJ	O
mean	NN	O
a	VBZ	O
molecule	VBN	O
that	TO	O
is	VB	O
capable	DT	O
of	NN	O
conjugating	WDT	O
to	VBZ	O
an	JJ	O
attachment	IN	O
group	VBG	O
of	TO	O
the	DT	O
polypeptide.	JJ	O
Preferred	NN	O
examples	IN	O
of	DT	O
non-polypeptide	.	O
moieties	NNP	O
include	NNS	O
polymer	IN	O
molecules,	JJ	O
sugar	NNS	O
moieties,	VBP	O
lipophilic	JJ	O
compounds,	,	O
or	NN	O
organic	,	O
derivatizing	JJ	O
agents,	,	O
in	CC	O
particular	JJ	O
polymer	NN	O
molecules	,	O
or	IN	O
sugar	JJ	O
moieties.	NN	O
It	NNS	O
will	CC	O
be	NN	O
understood	.	O
that	PRP	O
the	MD	O
non-polypeptide	VB	O
moiety	JJ	O
is	IN	O
linked	DT	O
to	JJ	O
the	NN	O
polypeptide	VBZ	O
through	VBN	O
an	TO	O
attachment	DT	O
group	NN	O
of	IN	O
the	DT	O
polypeptide.	JJ	O
Except	NN	O
where	IN	O
the	DT	O
number	.	O
of	IN	O
non-polypeptide	WRB	O
moieties,	DT	O
such	NN	O
as	IN	O
polymer	JJ	O
molecule(s),	,	O
attached	JJ	O
to	IN	O
the	NN	O
polypeptide	,	O
is	VBN	O
expressly	TO	O
indicated,	DT	O
every	NN	O
reference	VBZ	O
to	RB	O
“a	,	O
non-polypeptide	DT	O
moiety”	NN	O
attached	TO	O
to	VB	O
the	JJ	O
polypeptide	NN	O
or	VBN	O
otherwise	TO	O
used	DT	O
in	NN	O
the	CC	O
present	RB	O
invention	VBN	O
shall	IN	O
be	DT	O
a	JJ	O
reference	NN	O
to	MD	O
one	VB	O
or	DT	O
more	NN	O
non-polypeptide	TO	O
moieties	CD	O
attached	CC	O
to	JJR	O
the	JJ	O
polypeptide.	NNS	O
The	VBN	O
term	TO	O
“polymer	DT	O
molecule”	.	O
is	DT	O
defined	NN	O
as	NNP	O
a	NN	O
molecule	VBZ	O
formed	VBN	O
by	IN	O
covalent	DT	O
linkage	NN	O
of	VBN	O
two	IN	O
or	JJ	O
more	NN	O
monomers,	IN	O
wherein	CD	O
none	CC	O
of	JJR	O
the	,	O
monomers	VBP	O
is	NN	O
an	IN	O
amino	DT	O
acid	NNS	O
residue.	VBZ	O
The	DT	O
term	JJ	O
“polymer”	NN	O
may	.	O
be	DT	O
used	NN	O
interchangeably	NN	O
with	MD	O
the	VB	O
term	VBN	O
“polymer	RB	O
molecule”.	IN	O
The	DT	O
term	NN	O
“sugar	NNP	O
moiety”	.	O
is	DT	O
intended	NN	O
to	NNP	O
indicate	NN	O
a	VBZ	O
carbohydrate	VBN	O
molecule	TO	O
attached	VB	O
by	DT	O
in	NN	O
vivo	NN	O
or	VBN	O
in	IN	O
vitro	IN	O
glycosylation,	NN	O
such	CC	O
as	IN	O
N-	JJ	O
or	,	O
O-glycosylation.	JJ	O
An	IN	O
“N-glycosylation	NNP	O
site”	CC	O
has	.	O
the	DT	O
sequence	NN	O
N-X-S/T/C,	NN	O
wherein	VBZ	O
X	DT	O
is	NN	O
any	,	O
amino	NN	O
acid	NNP	O
residue	VBZ	O
except	DT	O
proline,	JJ	O
N	NN	O
is	JJ	O
asparagine	IN	O
and	,	O
S/T/C	NNP	O
is	VBZ	O
either	JJ	O
serine,	CC	O
threonine	NNP	O
or	VBZ	O
cysteine,	DT	O
preferably	,	O
serine	NN	O
or	CC	O
threonine,	,	O
and	RB	O
most	NN	O
preferably	CC	O
threonine.	,	O
An	CC	O
“O-glycosylation	JJS	O
site”	RB	O
comprises	.	O
the	DT	O
OH-group	JJ	O
of	NN	O
a	VBZ	O
serine	DT	O
or	NNP	O
threonine	IN	O
residue.	DT	O
The	NN	O
term	CC	O
“attachment	NN	O
group”	.	O
is	DT	O
intended	NN	O
to	NN	O
indicate	NN	O
an	VBZ	O
amino	VBN	O
acid	TO	O
residue	VB	O
group	DT	O
capable	NN	O
of	NN	O
coupling	JJ	O
to	NN	O
the	JJ	O
relevant	IN	O
non-polypeptide	VBG	O
moiety	TO	O
such	DT	O
as	JJ	O
a	JJ	O
polymer	NN	O
molecule	JJ	O
or	IN	O
a	DT	O
sugar	NN	O
moiety.	NN	O
For	CC	O
in	DT	O
vivo	JJ	O
N-glycosylation,	.	O
the	IN	O
term	IN	O
“attachment	JJ	O
group”	,	O
is	DT	O
used	NN	O
in	NN	O
an	NN	O
unconventional	VBZ	O
way	VBN	O
to	IN	O
indicate	DT	O
the	JJ	O
amino	NN	O
acid	TO	O
residues	VB	O
constituting	DT	O
an	NN	O
N-glycosylation	NN	O
site	NNS	O
(with	VBG	O
the	DT	O
sequence	JJ	O
N-X-S/T/C,	NN	O
wherein	IN	O
X	DT	O
is	NN	O
any	,	O
amino	NN	O
acid	NNP	O
residue	VBZ	O
except	DT	O
proline,	JJ	O
N	NN	O
is	JJ	O
asparagine	IN	O
and	,	O
S/T/C	NNP	O
is	VBZ	O
either	JJ	O
serine,	CC	O
threonine	NNP	O
or	VBZ	O
cysteine,	DT	O
preferably	,	O
serine	NN	O
or	CC	O
threonine,	,	O
and	RB	O
most	NN	O
preferably	CC	O
threonine).	,	O
Although	CC	O
the	JJS	O
asparagine	RB	O
residue	.	O
of	IN	O
the	DT	O
N-glycosylation	JJ	O
site	NN	O
is	IN	O
the	DT	O
one	NNP	O
to	NN	O
which	VBZ	O
the	DT	O
sugar	NN	O
moiety	TO	O
is	WDT	O
attached	DT	O
during	NN	O
glycosylation,	NN	O
such	VBZ	O
attachment	VBN	O
cannot	IN	O
be	,	O
achieved	JJ	O
unless	NN	O
the	RB	O
other	VB	O
amino	VBN	O
acid	IN	O
residues	DT	O
of	JJ	O
the	NN	O
N-glycosylation	IN	O
site	NNS	O
is	IN	O
present.	DT	O
Accordingly,	NNP	O
when	NN	O
the	VBZ	O
non-polypeptide	.	O
moiety	,	O
is	WRB	O
a	DT	O
sugar	JJ	O
moiety	NN	O
and	VBZ	O
the	DT	O
conjugation	NN	O
is	NN	O
to	CC	O
be	DT	O
achieved	NN	O
by	VBZ	O
N-glycosylation,	TO	O
the	VB	O
term	VBN	O
“amino	IN	O
acid	,	O
residue	DT	O
comprising	NN	O
an	NNP	O
attachment	NN	O
group	NN	O
for	VBG	O
the	DT	O
non-polypeptide	NN	O
moiety”	NN	O
as	IN	O
used	DT	O
in	JJ	O
connection	NN	O
with	IN	O
alterations	VBN	O
of	IN	O
the	NN	O
amino	IN	O
acid	NNS	O
sequence	IN	O
of	DT	O
the	NN	O
polypeptide	JJ	O
of	NN	O
the	IN	O
invention	DT	O
is	NN	O
to	IN	O
be	DT	O
understood	NN	O
as	VBZ	O
one,	TO	O
two	VB	O
or	JJ	O
all	IN	O
of	,	O
the	CD	O
amino	CC	O
acid	DT	O
residues	IN	O
constituting	DT	O
an	NN	O
N-glycosylation	NN	O
site	NNS	O
is/are	VBG	O
to	DT	O
be	JJ	O
altered	NN	O
in	NN	O
such	TO	O
a	VB	O
manner	VBN	O
that	IN	O
either	JJ	O
a	DT	O
functional	NN	O
N-glycosylation	IN	O
site	CC	O
is	DT	O
introduced	JJ	O
into	NNP	O
the	NN	O
amino	VBZ	O
acid	VBN	O
sequence,	IN	O
removed	DT	O
from	NN	O
said	NN	O
sequence,	,	O
or	VBN	O
a	IN	O
functional	VBD	O
N-glycosylation	,	O
site	CC	O
is	DT	O
retained	JJ	O
in	NNP	O
the	NN	O
amino	VBZ	O
acid	VBN	O
sequence	IN	O
(e.g.	DT	O
by	NN	O
substituting	NN	O
a	NN	O
serine	.	O
residue,	IN	O
which	VBG	O
already	DT	O
constitutes	NN	O
part	,	O
of	WDT	O
an	RB	O
N-glycosylation	VBZ	O
site,	NN	O
with	IN	O
a	DT	O
threonine	NNP	O
residue	,	O
and	IN	O
vice	DT	O
versa).	NN	O
The	NN	O
term	CC	O
“introduce”	NN	O
(i.e.,	.	O
an	DT	O
“introduced”	NN	O
amino	NNP	O
acid	,	O
residue,	DT	O
“introduction”	NN	O
of	NN	O
an	NN	O
amino	,	O
acid	NNP	O
residue)	IN	O
is	DT	O
primarily	NN	O
intended	NN	O
to	)	O
mean	VBZ	O
substitution	RB	O
of	VBN	O
an	TO	O
existing	VB	O
amino	NN	O
acid	IN	O
residue	DT	O
for	VBG	O
another	NN	O
amino	NN	O
acid	NN	O
residue,	IN	O
but	DT	O
may	NN	O
also	NN	O
mean	,	O
insertion	CC	O
of	MD	O
an	RB	O
additional	VB	O
amino	NN	O
acid	IN	O
residue.	DT	O
The	JJ	O
term	NN	O
“remove”	NN	O
(i.e.,	.	O
a	DT	O
“removed”	NN	O
amino	NNP	O
acid	,	O
residue,	DT	O
“removal”	NNP	O
of	NN	O
an	NN	O
amino	,	O
acid	NNP	O
residue)	IN	O
is	DT	O
primarily	NN	O
intended	NN	O
to	)	O
mean	VBZ	O
substitution	RB	O
of	VBN	O
the	TO	O
amino	VB	O
acid	NN	O
residue	IN	O
to	DT	O
be	NN	O
removed	NN	O
for	NN	O
another	TO	O
amino	VB	O
acid	VBN	O
residue,	IN	O
but	DT	O
may	NN	O
also	NN	O
mean	,	O
deletion	CC	O
(without	MD	O
substitution)	RB	O
of	VB	O
the	NN	O
amino	IN	O
acid	)	O
residue	IN	O
to	DT	O
be	NN	O
removed.	NN	O
The	NN	O
term	TO	O
“amino	VB	O
acid	.	O
residue	DT	O
comprising	NN	O
an	NNP	O
attachment	NN	O
group	NN	O
for	VBG	O
the	DT	O
non-polypeptide	NN	O
moiety”	NN	O
is	IN	O
intended	DT	O
to	JJ	O
indicate	NN	O
that	VBZ	O
the	VBN	O
amino	TO	O
acid	VB	O
residue	IN	O
is	DT	O
one	NN	O
to	NN	O
which	NN	O
the	VBZ	O
non-polypeptide	CD	O
moiety	TO	O
binds	WDT	O
(in	DT	O
the	JJ	O
case	NN	O
of	NNS	O
an	IN	O
introduced	DT	O
amino	NN	O
acid	IN	O
residue)	DT	O
or	JJ	O
would	NN	O
have	NNS	O
bound	)	O
(in	CC	O
the	MD	O
case	VB	O
of	VBN	O
a	IN	O
removed	DT	O
amino	NN	O
acid	IN	O
residue).	DT	O
The	VBN	O
term	NN	O
“functional	NN	O
in	.	O
vivo	DT	O
half-life”	NN	O
is	NNP	O
used	IN	O
in	JJ	O
its	NN	O
normal	VBZ	O
meaning,	VBN	O
i.e.	IN	O
the	PRP$	O
time	JJ	O
at	,	O
which	.	O
50%	DT	O
of	NN	O
the	IN	O
biological	WDT	O
activity	NN	O
of	IN	O
the	DT	O
polypeptide	JJ	O
is	NN	O
still	IN	O
present	DT	O
in	NN	O
the	VBZ	O
body/target	RB	O
organ,	JJ	O
or	IN	O
the	DT	O
time	NN	O
at	,	O
which	CC	O
the	DT	O
activity	NN	O
of	IN	O
the	WDT	O
polypeptide	DT	O
is	NN	O
50%	IN	O
of	DT	O
the	NN	O
initial	VBZ	O
value.	NN	O
The	IN	O
functional	DT	O
in	JJ	O
vivo	.	O
half-life	DT	O
may	JJ	O
be	IN	O
determined	JJ	O
in	NN	O
an	MD	O
experimental	VB	O
animal,	VBN	O
such	IN	O
as	DT	O
rat,	JJ	O
mouse,	,	O
rabbit,	JJ	O
dog	IN	O
or	,	O
monkey.	,	O
Preferably,	,	O
the	NN	O
functional	CC	O
in	.	O
vivo	,	O
half-life	DT	O
is	NN	O
determined	IN	O
in	JJ	O
a	NN	O
non-human	VBZ	O
primate,	VBN	O
such	IN	O
as	DT	O
a	JJ	O
monkey.	,	O
Furthermore,	JJ	O
the	IN	O
functional	DT	O
in	.	O
vivo	,	O
half-life	DT	O
may	NN	O
be	IN	O
determined	JJ	O
for	NN	O
a	MD	O
sample	VB	O
that	VBN	O
has	IN	O
been	DT	O
administered	NN	O
intravenously	WDT	O
or	VBZ	O
subcutaneously.	VBN	O
As	VBN	O
an	RB	O
alternative	CC	O
to	.	O
determining	IN	O
functional	DT	O
in	NN	O
vivo	TO	O
half-life,	VBG	O
“serum	JJ	O
half-life”	IN	O
may	JJ	O
be	,	O
determined,	JJ	O
i.e.	NN	O
the	MD	O
time	VB	O
at	,	O
which	.	O
50%	DT	O
of	NN	O
the	IN	O
polypeptide	WDT	O
circulates	NN	O
in	IN	O
the	DT	O
plasma	NN	O
or	VBZ	O
bloodstream	IN	O
prior	DT	O
to	NN	O
being	CC	O
cleared.	NN	O
Determination	RB	O
of	TO	O
serum	VBG	O
half-life	.	O
is	NN	O
often	IN	O
more	JJ	O
simple	NN	O
than	VBZ	O
determining	RB	O
the	RBR	O
functional	JJ	O
in	IN	O
vivo	VBG	O
half-life	DT	O
and	JJ	O
the	IN	O
magnitude	JJ	O
of	NN	O
serum	CC	O
half-life	DT	O
is	NN	O
usually	IN	O
a	JJ	O
good	NN	O
indication	VBZ	O
of	RB	O
the	DT	O
magnitude	JJ	O
of	NN	O
functional	IN	O
in	DT	O
vivo	NN	O
half-life.	IN	O
Alternatively	JJ	O
terms	IN	O
to	JJ	O
serum	.	O
half-life	RB	O
include	NNS	O
“plasma	TO	O
half-life”,	VB	O
“circulating	JJ	O
half-life”,	NN	O
“serum	NNP	O
clearance”,	,	O
“plasma	VBG	O
clearance”	,	O
and	NNP	O
“clearance	,	O
half-life”.	NNP	O
The	NN	O
term	CC	O
“serum”	NN	O
is	.	O
used	DT	O
in	NN	O
its	NNP	O
normal	VBZ	O
meaning,	VBN	O
i.e.	IN	O
as	PRP$	O
blood	JJ	O
plasma	,	O
without	.	O
fibrinogen	IN	O
and	NN	O
other	NN	O
clotting	IN	O
factors.	NN	O
The	CC	O
term	JJ	O
“increased”	VBG	O
as	.	O
used	DT	O
about	NN	O
the	NNP	O
functional	IN	O
in	VBN	O
vivo	IN	O
half-life	DT	O
or	NN	O
serum	IN	O
half-life	JJ	O
is	NN	O
used	CC	O
to	JJ	O
indicate	NN	O
that	VBZ	O
the	VBN	O
relevant	TO	O
half-life	VB	O
of	IN	O
the	DT	O
conjugate	JJ	O
of	NN	O
the	IN	O
invention	DT	O
is	NN	O
statistically	IN	O
significantly	DT	O
increased	NN	O
relative	VBZ	O
to	RB	O
that	RB	O
of	VBN	O
a	NN	O
reference	TO	O
molecule	DT	O
or	IN	O
the	DT	O
corresponding	NN	O
non-conjugated	NN	O
polypeptide.	CC	O
Thus,	DT	O
interesting	JJ	O
conjugates	JJ	O
of	.	O
the	,	O
invention	VBG	O
include	NNS	O
those	IN	O
which	DT	O
have	NN	O
an	VBP	O
increased	DT	O
functional	WDT	O
in	VBP	O
vivo	DT	O
half-life	VBN	O
or	NN	O
an	IN	O
increased	JJ	O
serum	NN	O
half-life	CC	O
as	DT	O
compared	VBN	O
to	NN	O
a	NN	O
reference	IN	O
molecule	VBN	O
mentioned	TO	O
above.	DT	O
The	NN	O
term	NN	O
“AUCsc”	VBN	O
or	.	O
“Area	DT	O
Under	NN	O
the	NN	O
Curve	CC	O
when	NN	O
administered	IN	O
subcutaneously”	DT	O
is	NNP	O
used	WRB	O
in	VBN	O
its	NN	O
normal	VBZ	O
meaning,	VBN	O
i.e.,	IN	O
as	PRP$	O
the	JJ	O
area	,	O
under	,	O
the	IN	O
drug	DT	O
concentration	NN	O
vs.	IN	O
time	DT	O
curve,	NN	O
where	NN	O
the	FW	O
conjugated	NN	O
molecule	,	O
has	WRB	O
been	DT	O
administered	VBN	O
subcutaneously	NN	O
to	VBZ	O
an	VBN	O
experimental	VBN	O
animal.	RB	O
Once	TO	O
the	DT	O
experimental	JJ	O
drug	.	O
concentration	RB	O
time	DT	O
points	JJ	O
have	NN	O
been	NN	O
determined,	NN	O
the	NNS	O
AUCsc	VBP	O
may	VBN	O
conveniently	,	O
be	DT	O
calculated	NNP	O
by	MD	O
a	RB	O
computer	VB	O
program,	VBN	O
such	IN	O
as	DT	O
GraphPad	NN	O
Prism	,	O
3.01	JJ	O
The	IN	O
term	NNP	O
“increased”	NNP	O
as	CD	O
used	DT	O
about	NN	O
the	NNP	O
AUGsc	IN	O
is	VBN	O
used	IN	O
to	DT	O
indicate	NNP	O
that	VBZ	O
the	VBN	O
Area	TO	O
Under	VB	O
the	IN	O
Curve	DT	O
for	NNP	O
a	IN	O
conjugate	DT	O
of	NNP	O
the	IN	O
invention,	DT	O
when	NN	O
administered	IN	O
subcutaneously,	DT	O
is	,	O
statistically	WRB	O
significantly	VBN	O
increased	,	O
relative	VBZ	O
to	RB	O
that	RB	O
of	VBN	O
a	NN	O
reference	TO	O
molecule	DT	O
or	IN	O
the	DT	O
corresponding	NN	O
non-conjugated	NN	O
polypeptide,	CC	O
when	DT	O
determined	JJ	O
under	JJ	O
comparable	,	O
conditions.	WRB	O
The	VBN	O
term	IN	O
“Tmax,sc”	JJ	O
is	.	O
used	DT	O
about	NN	O
the	NN	O
time	VBZ	O
point	VBN	O
in	IN	O
the	DT	O
drug	NN	O
concentration	NN	O
vs.	IN	O
time	DT	O
curve	NN	O
where	NN	O
the	FW	O
highest	NN	O
drug	NN	O
concentration	WRB	O
in	DT	O
serum	JJS	O
is	NN	O
observed.	NN	O
By	IN	O
removing	NN	O
and/or	VBZ	O
introducing	.	O
amino	IN	O
acid	VBG	O
residues	JJ	O
comprising	VBG	O
an	NN	O
attachment	NN	O
group	NNS	O
for	VBG	O
the	DT	O
non-polypeptide	NN	O
moiety	NN	O
it	IN	O
is	DT	O
possible	JJ	O
to	NN	O
specifically	PRP	O
adapt	VBZ	O
the	JJ	O
polypeptide	TO	O
so	RB	O
as	VB	O
to	DT	O
make	NN	O
the	RB	O
molecule	IN	O
more	TO	O
susceptible	VB	O
to	DT	O
conjugation	NN	O
to	RBR	O
the	JJ	O
non-polypeptide	TO	O
moiety	NN	O
of	TO	O
choice,	DT	O
to	JJ	O
optimize	NN	O
the	IN	O
conjugation	,	O
pattern	TO	O
(e.g.	VB	O
to	DT	O
ensure	NN	O
an	NN	O
optimal	.	O
distribution	TO	O
of	VB	O
non-polypeptide	DT	O
moieties	JJ	O
on	NN	O
the	IN	O
surface	JJ	O
of	NNS	O
the	IN	O
oliagoadenylate	DT	O
synthetase	NN	O
molecule	IN	O
and	DT	O
thereby,	JJ	O
e.g.,	NN	O
effectively	NN	O
shield	CC	O
epitopes	,	O
and	,	O
other	RB	O
surface	VBN	O
parts	NNS	O
of	CC	O
the	JJ	O
polypeptide	NN	O
without	NNS	O
significantly	IN	O
impairing	DT	O
the	NN	O
function	IN	O
thereof).	RB	O
For	VBG	O
instance,	DT	O
by	NN	O
introduction	.	O
of	IN	O
attachment	,	O
groups,	IN	O
the	NN	O
oligoadenylate	IN	O
synthetase	NN	O
polypeptide	,	O
is	DT	O
altered	JJ	O
in	NN	O
the	NN	O
content	VBZ	O
of	VBN	O
the	IN	O
specific	DT	O
amino	NN	O
acid	IN	O
residues	DT	O
to	JJ	O
which	NN	O
the	NN	O
relevant	NNS	O
non-polypeptide	TO	O
moiety	WDT	O
binds,	DT	O
whereby	JJ	O
a	JJ	O
more	NN	O
efficient,	,	O
specific	WRB	O
and/or	DT	O
extensive	RBR	O
conjugation	,	O
is	JJ	O
achieved.	VBP	O
By	JJ	O
removal	NN	O
of	VBZ	O
one	.	O
or	IN	O
more	NN	O
attachment	IN	O
groups	CD	O
it	CC	O
is	JJR	O
possible	JJ	O
to	NNS	O
avoid	PRP	O
conjugation	VBZ	O
to	JJ	O
the	TO	O
non-polypeptide	VB	O
moiety	NN	O
in	TO	O
parts	DT	O
of	JJ	O
the	NN	O
polypeptide	IN	O
in	NNS	O
which	IN	O
such	DT	O
conjugation	NN	O
is	IN	O
disadvantageous,	WDT	O
e.g.,	JJ	O
to	NN	O
an	VBZ	O
amino	,	O
acid	,	O
residue	TO	O
located	DT	O
at	NN	O
or	NN	O
near	JJ	O
a	VBN	O
functional	IN	O
site	CC	O
of	IN	O
the	DT	O
polypeptide	JJ	O
(since	NN	O
conjugation	IN	O
at	DT	O
such	NN	O
a	IN	O
site	NN	O
may	IN	O
result	PDT	O
in	DT	O
inactivation	NN	O
or	MD	O
reduced	VB	O
therapeutic	IN	O
or	NN	O
prophylactic	CC	O
activity	VBN	O
of	JJ	O
the	CC	O
resulting	JJ	O
conjugate).	NN	O
Further,	IN	O
it	DT	O
may	VBG	O
be	.	O
advantageous	,	O
to	PRP	O
remove	MD	O
an	VB	O
attachment	JJ	O
group	TO	O
located	VB	O
close	DT	O
to	NN	O
another	NN	O
attachment	VBD	O
group.	RB	O
It	TO	O
will	DT	O
be	NN	O
understood	.	O
that	PRP	O
the	MD	O
amino	VB	O
acid	JJ	O
residue	IN	O
comprising	DT	O
an	NN	O
attachment	NN	O
group	JJ	O
for	VBG	O
a	DT	O
non-polypeptide	NN	O
moiety,	NN	O
whether	IN	O
it	DT	O
be	JJ	O
removed	,	O
or	IN	O
introduced,	PRP	O
is	VB	O
selected	VBN	O
on	CC	O
the	,	O
basis	VBZ	O
of	VBN	O
the	IN	O
nature	DT	O
of	NN	O
the	IN	O
non-polypeptide	DT	O
moiety	NN	O
and,	IN	O
in	DT	O
some	JJ	O
instances,	NN	O
on	,	O
the	IN	O
basis	DT	O
of	,	O
the	IN	O
conjugation	DT	O
method	NN	O
to	IN	O
be	DT	O
used.	NN	O
For	NN	O
instance,	TO	O
when	VB	O
the	.	O
non-polypeptide	IN	O
moiety	,	O
is	WRB	O
a	DT	O
polymer	JJ	O
molecule,	NN	O
such	VBZ	O
as	DT	O
a	NN	O
polyethylene	,	O
glycol	JJ	O
or	IN	O
polyalkylene	DT	O
oxide	NN	O
derived	NN	O
molecule,	CC	O
amino	NN	O
acid	RB	O
residues	VBD	O
capable	,	O
of	JJ	O
functioning	NN	O
as	NNS	O
an	JJ	O
attachment	IN	O
group	VBG	O
may	IN	O
be	DT	O
selected	JJ	O
from	NN	O
the	MD	O
group	VB	O
consisting	VBN	O
of	IN	O
cysteine,	DT	O
lysine	NN	O
(and/or	VBG	O
the	IN	O
N-terminal	,	O
amino	NN	O
group	IN	O
of	DT	O
the	NNP	O
polypeptide),	NN	O
aspartic	NN	O
acid,	IN	O
glutamic	DT	O
acid,	,	O
histidine	JJ	O
and	,	O
arginine.	JJ	O
When	,	O
the	NN	O
non-polypeptide	CC	O
moiety	.	O
is	WRB	O
a	DT	O
sugar	JJ	O
moiety,	NN	O
the	VBZ	O
attachment	DT	O
group	NN	O
is	,	O
an	DT	O
in	NN	O
vivo	NN	O
or	VBZ	O
in	DT	O
vitro	IN	O
N-	NN	O
or	CC	O
O-glycosylation	IN	O
site,	JJ	O
preferably	JJ	O
an	CC	O
N-glycosylation	JJ	O
site.	,	O
In	RB	O
case	DT	O
of	JJ	O
removal	.	O
of	IN	O
an	NN	O
attachment	IN	O
group,	NN	O
the	IN	O
relevant	DT	O
amino	NN	O
acid	,	O
residue	DT	O
comprising	JJ	O
such	NN	O
group	NN	O
and	JJ	O
occupying	VBG	O
a	JJ	O
position	NN	O
as	CC	O
defined	VBG	O
above	DT	O
may	NN	O
be	IN	O
substituted	VBN	O
with	IN	O
a	MD	O
different	VB	O
amino	VBN	O
acid	IN	O
residue	DT	O
that	JJ	O
does	NN	O
not	NN	O
comprise	NN	O
an	WDT	O
attachment	VBZ	O
group	RB	O
for	VB	O
the	DT	O
non-polypeptide	NN	O
moiety	NN	O
in	IN	O
question,	DT	O
or	JJ	O
may	NN	O
be	IN	O
deleted.	,	O
Removal	CC	O
of	MD	O
an	VB	O
N-glycosylation	.	O
group,	NN	O
may	IN	O
also	DT	O
be	NNP	O
accomplished	,	O
by	MD	O
insertion	RB	O
or	VB	O
removal	VBN	O
of	IN	O
an	NN	O
amino	CC	O
acid	NN	O
reside	IN	O
within	DT	O
the	NN	O
motif	NN	O
N-X-S/T/C.	NN	O
In	IN	O
case	DT	O
of	JJ	O
introduction	.	O
of	IN	O
an	NN	O
attachment	IN	O
group,	NN	O
an	IN	O
amino	DT	O
acid	NN	O
residue	,	O
comprising	DT	O
such	NN	O
group	NN	O
is	JJ	O
introduced	VBG	O
into	JJ	O
the	NN	O
position,	VBZ	O
such	VBN	O
as	IN	O
by	DT	O
substitution	,	O
of	JJ	O
the	IN	O
amino	IN	O
acid	NN	O
residue	IN	O
occupying	DT	O
such	NN	O
position.	NN	O
The	JJ	O
exact	VBG	O
number	JJ	O
of	.	O
attachment	DT	O
groups	JJ	O
available	NN	O
for	IN	O
conjugation	JJ	O
is	NNS	O
dependent	JJ	O
on	IN	O
the	NN	O
effect	VBZ	O
desired	JJ	O
to	IN	O
be	DT	O
achieved	NN	O
by	VBD	O
conjugation.	TO	O
The	VB	O
effect	VBN	O
to	IN	O
be	.	O
obtained	DT	O
is,	NN	O
e.g.,	TO	O
dependent	VB	O
on	VBN	O
the	,	O
nature	,	O
and	NN	O
degree	IN	O
of	DT	O
conjugation	NN	O
(e.g.	CC	O
the	NN	O
identity	IN	O
of	NN	O
the	.	O
non-polypeptide	DT	O
moiety,	NN	O
the	IN	O
number	DT	O
of	JJ	O
non-polypeptide	,	O
moieties	DT	O
desirable	NN	O
or	IN	O
possible	JJ	O
to	NNS	O
conjugate	JJ	O
to	CC	O
the	JJ	O
polypeptide,	TO	O
where	VB	O
they	TO	O
should	DT	O
be	,	O
conjugated	WRB	O
or	PRP	O
where	MD	O
conjugation	VB	O
should	VBN	O
be	CC	O
avoided,	WRB	O
etc.).	NN	O
For	MD	O
instance,	VB	O
if	,	O
reduced	.	O
immunogenicity	IN	O
is	,	O
desired,	IN	O
the	VBN	O
number	NN	O
(and	VBZ	O
location	,	O
of)	DT	O
attachment	NN	O
groups	CC	O
should	NN	O
be	)	O
sufficient	NN	O
to	NNS	O
shield	MD	O
most	VB	O
or	JJ	O
all	TO	O
epitopes.	VB	O
This	JJS	O
is	CC	O
normally	DT	O
obtained	.	O
when	DT	O
a	VBZ	O
greater	RB	O
proportion	VBN	O
of	WRB	O
the	DT	O
polypeptide	JJR	O
is	NN	O
shielded.	IN	O
Effective	DT	O
shielding	NN	O
of	VBZ	O
epitopes	.	O
is	JJ	O
normally	NN	O
achieved	IN	O
when	NNS	O
the	VBZ	O
total	RB	O
number	VBN	O
of	WRB	O
attachment	DT	O
groups	JJ	O
available	NN	O
for	IN	O
conjugation	JJ	O
is	NNS	O
in	JJ	O
the	IN	O
range	NN	O
of	VBZ	O
1-6	IN	O
attachment	DT	O
groups,	NN	O
e.g.,	IN	O
1-5,	JJ	O
such	NN	O
as	,	O
in	,	O
the	,	O
range	JJ	O
of	IN	O
1-3,	IN	O
such	DT	O
as	NN	O
1,	IN	O
2,	,	O
or	JJ	O
3	IN	O
attachment	,	O
groups.	,	O
Functional	CC	O
in	CD	O
vivo	JJ	O
half-life	.	O
is	NNP	O
i.a.	IN	O
dependent	JJ	O
on	NN	O
the	VBZ	O
molecular	.	O
weight	NN	O
of	IN	O
the	DT	O
conjugate,	JJ	O
and	NN	O
the	IN	O
number	DT	O
of	,	O
attachment	CC	O
groups	DT	O
needed	NN	O
for	IN	O
providing	JJ	O
increased	NNS	O
half-life	VBN	O
thus	IN	O
depends	VBG	O
on	JJ	O
the	JJ	O
molecular	RB	O
weight	VBZ	O
of	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
in	IN	O
question.	DT	O
Some	JJ	O
such	NN	O
conjugates	IN	O
comprise	.	O
1-6,	DT	O
e.g.,	JJ	O
1-5,	NNS	O
such	VBP	O
as	,	O
1-3,	,	O
e.g.	,	O
1,	JJ	O
2,	IN	O
or	,	O
3	.	O
non-polypeptide	,	O
moieties	,	O
each	CC	O
having	CD	O
a	JJ	O
MW	NNS	O
of	DT	O
about	VBG	O
2-40	DT	O
kDa,	NNP	O
such	IN	O
as	IN	O
about	JJ	O
2	,	O
kDa,	JJ	O
about	IN	O
5	IN	O
kDa,	CD	O
about	,	O
12	RB	O
kDa,	CD	O
about	,	O
15	RB	O
kDa,	CD	O
about	,	O
20	RB	O
kDa,	CD	O
about	,	O
30	RB	O
kDa,	CD	O
or	,	O
about	RB	O
40	CD	O
kDa.	,	O
In	CC	O
the	IN	O
conjugate	CD	O
of	.	O
the	IN	O
invention,	DT	O
some,	NN	O
most,	IN	O
or	DT	O
substantially	,	O
all	,	O
conjugatable	,	O
attachment	CC	O
groups	RB	O
are	DT	O
occupied	JJ	O
by	NN	O
the	NNS	O
relevant	VBP	O
non-polypeptide	VBN	O
moiety.	IN	O
The	DT	O
conjugate	JJ	O
of	JJ	O
the	.	O
invention	DT	O
may	NN	O
exhibit	IN	O
one	DT	O
or	NN	O
more	MD	O
of	VB	O
the	CD	O
following	CC	O
improved	JJR	O
properties.	IN	O
For	DT	O
example,	VBG	O
the	JJ	O
conjugate	.	O
may	IN	O
exhibit	,	O
a	DT	O
reduced	NN	O
immunogenicity	MD	O
as	VB	O
compared	DT	O
to	JJ	O
the	NN	O
corresponding	IN	O
non-conjugated	VBN	O
polypeptide,	TO	O
e.g.	DT	O
a	JJ	O
reduction	JJ	O
of	,	O
at	.	O
least	DT	O
10%,	NN	O
such	IN	O
as	IN	O
a	JJS	O
reduction	,	O
of	JJ	O
at	IN	O
least	DT	O
of	NN	O
25%,	IN	O
such	IN	O
as	JJS	O
a	IN	O
reduction	,	O
of	JJ	O
at	IN	O
least	DT	O
of	NN	O
50%,	IN	O
e.g.	IN	O
a	JJS	O
reduction	IN	O
of	,	O
at	.	O
least	DT	O
75%	NN	O
compared	IN	O
to	IN	O
the	JJS	O
non-conjugated	NN	O
polypeptide.	VBN	O
In	TO	O
another	DT	O
aspect	JJ	O
the	.	O
conjugate	IN	O
may	DT	O
exhibit	NN	O
a	DT	O
reduced	NN	O
reaction	MD	O
or	VB	O
no	DT	O
reaction	JJ	O
with	NN	O
neutralizing	CC	O
antibodies	DT	O
from	NN	O
patients	IN	O
treated	VBG	O
with	NNS	O
the	IN	O
parent	NNS	O
polypeptide	VBN	O
as	IN	O
compared	DT	O
to	NN	O
the	NN	O
corresponding	IN	O
non-conjugated	VBN	O
polypeptide,	TO	O
e.g.,	DT	O
a	JJ	O
reduction	JJ	O
of	,	O
neutralization	,	O
of	DT	O
at	NN	O
least	IN	O
10%,	NN	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
25%,	JJ	O
such	IN	O
as	IN	O
of	JJS	O
at	,	O
least	JJ	O
50%,	IN	O
e.g.,	IN	O
at	IN	O
least	JJS	O
75%.	,	O
In	,	O
another	IN	O
aspect	JJS	O
of	.	O
the	IN	O
invention	DT	O
the	NN	O
conjugate	IN	O
may	DT	O
exhibit	NN	O
an	DT	O
increased	NN	O
functional	MD	O
in	VB	O
vivo	DT	O
half-life	JJ	O
and/or	NN	O
increased	IN	O
serum	JJ	O
half-life	JJ	O
as	NN	O
compared	VBD	O
to	JJ	O
a	NN	O
reference	IN	O
molecule	VBN	O
or	TO	O
as	DT	O
compared	NN	O
to	NN	O
the	CC	O
corresponding	RB	O
non-conjugated	VBN	O
polypeptide.	TO	O
Particular	DT	O
preferred	JJ	O
conjugates	JJ	O
are	.	O
such	JJ	O
conjugates	VBN	O
where	NNS	O
the	VBP	O
ratio	JJ	O
between	NNS	O
the	WRB	O
functional	DT	O
in	NN	O
vivo	IN	O
half-life	DT	O
(or	NN	O
serum	IN	O
half-life)	JJ	O
of	NN	O
said	CC	O
conjugate	VB	O
and	)	O
the	IN	O
functional	VBD	O
in	NN	O
vivo	CC	O
half-life	DT	O
(or	JJ	O
serum	IN	O
half-life)	JJ	O
of	NN	O
said	CC	O
reference	VB	O
molecule	)	O
is	IN	O
at	VBD	O
least	NN	O
1.25,	NN	O
such	VBZ	O
as	IN	O
at	JJS	O
least	,	O
1.50,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
1.75,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
2,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
3,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
4,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
5,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
6,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
7,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
8,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
9,	JJ	O
e.g.	IN	O
10-100.	IN	O
As	JJS	O
mentioned	,	O
above,	.	O
the	.	O
half-life	IN	O
is	VBN	O
conveniently	,	O
determined	DT	O
in	NN	O
an	VBZ	O
experimental	RB	O
animal,	VBN	O
such	IN	O
as	DT	O
rat	JJ	O
or	,	O
monkey,	JJ	O
and	IN	O
may	NN	O
be	CC	O
based	,	O
on	CC	O
intravenous,	MD	O
subcutaneous,	VB	O
or	VBN	O
other	IN	O
route	,	O
of	,	O
administration.	CC	O
In	JJ	O
a	NN	O
further	IN	O
aspect	.	O
the	IN	O
conjugate	DT	O
may	JJ	O
exhibit	NN	O
an	DT	O
increased	NN	O
bioavailability	MD	O
as	VB	O
compared	DT	O
to	JJ	O
a	NN	O
reference	IN	O
molecule	VBN	O
or	TO	O
the	DT	O
corresponding	NN	O
non-conjugated	NN	O
polypeptide.	CC	O
For	DT	O
example,	JJ	O
the	JJ	O
conjugate	.	O
may	IN	O
exhibit	,	O
an	DT	O
increased	NN	O
AUCsc	MD	O
as	VB	O
compared	DT	O
to	JJ	O
a	NNP	O
reference	IN	O
molecule	VBN	O
or	TO	O
the	DT	O
corresponding	NN	O
non-conjugated	NN	O
polypeptide.	CC	O
Thus,	DT	O
exemplary	JJ	O
conjugates	JJ	O
are	.	O
such	,	O
conjugates	JJ	O
where	NNS	O
the	VBP	O
ratio	JJ	O
between	NNS	O
the	WRB	O
AUCsc	DT	O
of	NN	O
said	IN	O
conjugate	DT	O
and	NNP	O
the	IN	O
AUCsc	VBD	O
of	NN	O
said	CC	O
reference	DT	O
molecule	NNP	O
is	IN	O
at	VBD	O
least	NN	O
1.25,	NN	O
such	VBZ	O
as	IN	O
at	JJS	O
least	,	O
1.5,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
2,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
3,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
4,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
5	JJ	O
or	IN	O
at	IN	O
least	JJS	O
6,	CD	O
such	CC	O
as	IN	O
at	JJS	O
least	,	O
7,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
8,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
9	JJ	O
or	IN	O
at	IN	O
least	JJS	O
10,	CD	O
such	CC	O
as	IN	O
at	JJS	O
least	,	O
12,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
14,	JJ	O
e.g.	IN	O
at	IN	O
least	JJS	O
16,	,	O
at	.	O
least	IN	O
18	JJS	O
or	,	O
at	IN	O
least	JJS	O
20	CD	O
when	CC	O
administered	IN	O
subcutaneously,	JJS	O
intravenously,	CD	O
intrathecally,	WRB	O
intramuscularly,	VBN	O
or	,	O
intraperitoneally,	,	O
or	,	O
by	,	O
ingestion	CC	O
or	,	O
inhalation,	CC	O
in	IN	O
particular	NN	O
when	CC	O
administered	,	O
subcutaneously	IN	O
in	JJ	O
an	WRB	O
experimental	VBN	O
animal	RB	O
such	IN	O
as	DT	O
rat	JJ	O
or	NN	O
monkey.	JJ	O
Analogously,	IN	O
some	NN	O
conjugates	CC	O
of	.	O
the	,	O
invention	DT	O
are	NNS	O
such	IN	O
conjugates	DT	O
wherein	NN	O
the	VBP	O
ratio	JJ	O
between	NNS	O
Tmax	VBP	O
for	DT	O
said	NN	O
conjugate	IN	O
and	NNP	O
Tmax	IN	O
for	VBD	O
said	NN	O
reference	CC	O
molecule,	NNP	O
or	IN	O
the	VBD	O
corresponding	NN	O
non-conjugated	,	O
polypeptide,	CC	O
is	DT	O
at	JJ	O
least	JJ	O
1.2,	,	O
such	VBZ	O
as	IN	O
at	JJS	O
least	,	O
1.4,	JJ	O
e.g.	IN	O
at	IN	O
least	JJS	O
1.6,	,	O
such	.	O
as	IN	O
at	JJS	O
least	,	O
1.8,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
2,	JJ	O
e.g.,	IN	O
at	IN	O
least	JJS	O
2.5,	,	O
such	,	O
as	IN	O
at	JJS	O
least	,	O
3,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
4,	JJ	O
e.g.	IN	O
at	IN	O
least	JJS	O
5,	,	O
such	.	O
as	IN	O
at	JJS	O
least	,	O
6,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
7,	JJ	O
e.g.	IN	O
at	IN	O
least	JJS	O
8,	,	O
such	.	O
as	IN	O
at	JJS	O
least	,	O
9,	JJ	O
such	IN	O
as	IN	O
at	JJS	O
least	,	O
10,	JJ	O
when	IN	O
administered	IN	O
subcutaneously,	JJS	O
intravenously,	,	O
intrathecally,	WRB	O
intramuscularly,	VBN	O
or	,	O
intraperitoneally,	,	O
or	,	O
by	,	O
ingestion	CC	O
or	,	O
inhalation,	CC	O
in	IN	O
particular	NN	O
when	CC	O
administered	,	O
subcutaneously	IN	O
in	JJ	O
an	WRB	O
experimental	VBN	O
animal	RB	O
such	IN	O
as	DT	O
rat	JJ	O
or	NN	O
monkey.	JJ	O
In	IN	O
some	NN	O
instances,	CC	O
the	.	O
magnitude	IN	O
of	DT	O
the	,	O
antiviral,	DT	O
anticancer,	NN	O
anti-neoplastic,	IN	O
anti-inflammatory,	DT	O
pro-regenerative	,	O
or	,	O
other	,	O
therapeutic	,	O
activity	JJ	O
of	CC	O
a	JJ	O
conjugate	JJ	O
of	NN	O
the	IN	O
invention	DT	O
may	NN	O
be	IN	O
reduced	DT	O
(e.g.,	NN	O
by	MD	O
at	VB	O
least	VBN	O
about	,	O
75%,	IN	O
at	IN	O
least	JJS	O
about	IN	O
50%,	,	O
at	IN	O
least	JJS	O
about	IN	O
25%,	,	O
at	IN	O
least	JJS	O
about	IN	O
10%)	,	O
or	IN	O
increased	JJS	O
(e.g.	IN	O
by	)	O
at	CC	O
least	VBN	O
about	.	O
10%)	IN	O
or	IN	O
is	JJS	O
about	IN	O
equal	)	O
(e.g.	CC	O
within	VBZ	O
about	IN	O
+/−10%	JJ	O
or	.	O
about	IN	O
+/−5%)	RB	O
to	NN	O
that	CC	O
of	IN	O
the	)	O
corresponding	TO	O
non-conjugated	DT	O
polypeptide.	IN	O
In	DT	O
one	JJ	O
aspect,	JJ	O
the	.	O
invention	IN	O
relates	CD	O
to	,	O
a	DT	O
conjugate	NN	O
comprising	VBZ	O
at	TO	O
least	DT	O
one	NN	O
non-polypeptide	NN	O
moiety	IN	O
conjugated	JJS	O
to	CD	O
at	JJ	O
least	NN	O
one	VBD	O
lysine	TO	O
residue	IN	O
and/or	JJS	O
to	CD	O
the	NN	O
N-terminal	JJ	O
amino	NN	O
group	TO	O
of	DT	O
a	NNP	O
polypeptide	NN	O
of	NN	O
the	IN	O
invention	DT	O
most	NN	O
particularly	IN	O
the	DT	O
polypeptides	NN	O
described	RBS	O
in	RB	O
FIG.	DT	O
1.	NNS	O
In	VBN	O
another	IN	O
aspect,	.	O
the	.	O
invention	IN	O
relates	DT	O
to	,	O
a	DT	O
conjugate	NN	O
comprising	VBZ	O
at	TO	O
least	DT	O
one	NN	O
non-polypeptide	NN	O
moiety	IN	O
conjugated	JJS	O
to	CD	O
at	JJ	O
least	NN	O
one	VBD	O
lysine	TO	O
residue,	IN	O
or	JJS	O
to	CD	O
the	NN	O
N-terminal	,	O
amino	CC	O
group,	TO	O
of	DT	O
a	NNP	O
polypeptide	NN	O
comprising	,	O
a	IN	O
sequence	DT	O
which	NN	O
differs	VBG	O
in	DT	O
1	NN	O
to	WDT	O
34	NNS	O
amino	IN	O
acid	CD	O
positions	TO	O
from	CD	O
SEQUENCE:1	NN	O
(SEQ	JJ	O
ID	NNS	O
NO:1)	IN	O
of	NNP	O
FIG.	NNP	O
1.	NNP	O
Some	)	O
conjugates	IN	O
of	.	O
the	.	O
invention	DT	O
comprise	NNS	O
a	IN	O
polypeptide	DT	O
sequence	NN	O
comprising	NN	O
a	DT	O
substitution	NN	O
of	NN	O
an	VBG	O
amino	DT	O
acid	NN	O
residue	IN	O
for	DT	O
a	NN	O
different	NN	O
amino	NN	O
acid	IN	O
residue,	DT	O
or	JJ	O
a	NN	O
deletion	NN	O
of	,	O
an	CC	O
amino	DT	O
acid	NN	O
residue,	IN	O
which	DT	O
removes	NN	O
one	NN	O
or	,	O
more	WDT	O
lysines	VBZ	O
from	CD	O
a	CC	O
polypeptide	JJR	O
of	NNS	O
the	IN	O
invention.	DT	O
The	NN	O
one	IN	O
or	DT	O
more	.	O
lysine	DT	O
residue(s)	CD	O
to	CC	O
be	JJR	O
removed	JJ	O
may	)	O
be	TO	O
substituted	VB	O
with	VBN	O
any	MD	O
other	VB	O
amino	VBN	O
acid,	IN	O
may	DT	O
be	JJ	O
substituted	NN	O
with	,	O
an	MD	O
Arg	VB	O
(R),	VBN	O
His	IN	O
(H)	DT	O
or	NNP	O
Gln	,	O
(Q),	PRP$	O
or	)	O
may	CC	O
be	NNP	O
deleted.	,	O
In	CC	O
instances	MD	O
where	VB	O
amine-reactive	.	O
conjugation	IN	O
chemistries	NNS	O
are	WRB	O
employed,	JJ	O
it	NN	O
may	NNS	O
be	VBP	O
advantageous	,	O
to	PRP	O
avoid	MD	O
or	VB	O
to	JJ	O
minimize	TO	O
the	VB	O
potential	CC	O
for	TO	O
conjugation	VB	O
to	DT	O
histidine	NN	O
residues.	IN	O
Therefore,	NN	O
some	TO	O
conjugates	VB	O
of	.	O
the	,	O
invention	DT	O
comprise	NNS	O
a	IN	O
polypeptide	DT	O
sequence	NN	O
comprising	NN	O
a	DT	O
substitution	NN	O
or	NN	O
a	VBG	O
deletion	DT	O
which	NN	O
removes	CC	O
one	DT	O
or	NN	O
more	WDT	O
histidines	VBZ	O
from	CD	O
any	CC	O
polypeptide	JJR	O
sequence	NNS	O
of	IN	O
the	DT	O
invention.	JJ	O
The	NN	O
one	IN	O
or	DT	O
more	.	O
histidine	DT	O
residue(s)	CD	O
to	CC	O
be	JJR	O
removed	JJ	O
may	)	O
be	TO	O
substituted	VB	O
with	VBN	O
any	MD	O
other	VB	O
amino	VBN	O
acid,	IN	O
may	DT	O
be	JJ	O
substituted	NN	O
with	,	O
an	MD	O
Arg	VB	O
(R),	VBN	O
Lys	IN	O
(L)	DT	O
or	NNP	O
Gln	,	O
(Q),	NNP	O
or	)	O
may	CC	O
be	NNP	O
deleted.	,	O
Alternatively,	CC	O
or	MD	O
in	VB	O
addition,	.	O
some	,	O
conjugates	CC	O
of	IN	O
the	,	O
invention	DT	O
comprise	NNS	O
a	IN	O
polypeptide	DT	O
sequence	NN	O
comprising	NN	O
a	DT	O
modification	NN	O
which	NN	O
introduces	VBG	O
a	DT	O
lysine	NN	O
into	WDT	O
a	VBZ	O
position	DT	O
that	NN	O
is	IN	O
occupied	DT	O
in	NN	O
the	WDT	O
parent	VBZ	O
sequence	VBN	O
by	IN	O
an	DT	O
amino	NN	O
acid	NN	O
residue	IN	O
that	DT	O
is	NN	O
exposed	NN	O
to	NN	O
the	WDT	O
surface	VBZ	O
of	VBN	O
the	TO	O
molecule,	DT	O
e.g.,	NN	O
one	IN	O
that	DT	O
has	,	O
at	,	O
least	CD	O
25%,	WDT	O
such	VBZ	O
as	IN	O
at	JJS	O
least	,	O
50%	JJ	O
of	IN	O
its	IN	O
side	JJS	O
chain	NN	O
exposed	IN	O
to	PRP$	O
the	NN	O
surface.	NN	O
Non-polypeptide	VBD	O
moieties	TO	O
contemplated	DT	O
for	.	O
this	JJ	O
aspect	NNS	O
of	VBN	O
the	IN	O
invention	DT	O
include	NN	O
polymer	IN	O
molecules,	DT	O
such	NN	O
as	VBP	O
PEG	NN	O
or	,	O
mPEG	JJ	O
or	IN	O
mPEG2.	NNP	O
The	CC	O
conjugation	NN	O
between	CC	O
the	.	O
lysine-containing	DT	O
polypeptide	NN	O
and	IN	O
the	DT	O
polymer	JJ	O
molecule	NN	O
may	CC	O
be	DT	O
achieved	NN	O
in	NN	O
any	MD	O
suitable	VB	O
manner	VBN	O
as	IN	O
known	DT	O
in	JJ	O
the	NN	O
art.	IN	O
An	VBN	O
exemplary	IN	O
method	DT	O
for	.	O
PEGylating	DT	O
the	JJ	O
polypeptide	NN	O
is	IN	O
to	VBG	O
covalently	DT	O
attach	NN	O
PEG	VBZ	O
to	TO	O
lysine	RB	O
residues	VB	O
using	NNP	O
lysine-reactive	TO	O
PEGs.	VB	O
A	NNS	O
number	VBG	O
of	JJ	O
highly	.	O
specific,	DT	O
lysine-reactive	NN	O
PEGs	IN	O
(such	RB	O
as	,	O
for	JJ	O
example,	NNP	O
succinimidyl	JJ	O
propionate	IN	O
(SPA),	IN	O
succinimidyl	,	O
butanoate	JJ	O
(SBA),	NN	O
N-hydroxylsuccinimide	,	O
(NHS),	JJ	O
and	NN	O
aldehyde	,	O
(e.g.,	NNP	O
ButyrALD))	,	O
and	CC	O
different	NN	O
size	,	O
linear	)	O
or	CC	O
branched	JJ	O
PEGs	NN	O
(e.g.,	NN	O
2-40	CC	O
kDa,	VBN	O
such	NNP	O
as	,	O
2	JJ	O
kDa,	,	O
5	JJ	O
kDa,	IN	O
12	CD	O
kDa,	,	O
15	CD	O
kDa,	,	O
20	CD	O
kDa,	,	O
30	CD	O
kDa,	,	O
or	CD	O
40	,	O
kDa)	CD	O
are	,	O
commercially	CC	O
available,	CD	O
e.g.	)	O
from	VBP	O
Nektar	RB	O
Therapeutics	,	O
Inc.,	.	O
Huntsville,	IN	O
Ala.,	NNP	O
USA,	NNP	O
or	,	O
SunBio,	,	O
Anyang	,	O
City,	,	O
South	CC	O
Korea.	,	O
In	NNP	O
another	,	O
aspect,	NNP	O
the	.	O
invention	IN	O
includes	DT	O
a	,	O
composition	DT	O
comprising	NN	O
a	VBZ	O
population	DT	O
of	NN	O
conjugates	VBG	O
wherein	DT	O
the	NN	O
majority	IN	O
of	NNS	O
the	VBP	O
conjugates	DT	O
of	NN	O
said	IN	O
population	DT	O
each	NNS	O
contain	IN	O
a	VBD	O
single	NN	O
non-polypeptide	DT	O
moiety	VBP	O
(such	DT	O
as,	JJ	O
a	JJ	O
single	NN	O
polymer	JJ	O
molecule,	,	O
e.g.,	DT	O
a	JJ	O
single	NN	O
PEG,	,	O
such	,	O
as	DT	O
a	JJ	O
linear	,	O
PEG	JJ	O
or	IN	O
a	DT	O
branched	JJ	O
PEG)	NNP	O
covalently	CC	O
attached	DT	O
to	JJ	O
a	)	O
single	RB	O
lysine	VBN	O
residue	TO	O
or	DT	O
N-terminal	JJ	O
amino	NN	O
group	NN	O
of	CC	O
the	JJ	O
polypeptide.	NN	O
For	NN	O
example,	IN	O
a	DT	O
“monoconjugated”	.	O
(such	IN	O
as,	,	O
a	DT	O
“monoPEGylated”)	NN	O
composition	JJ	O
of	,	O
the	DT	O
invention	)	O
comprises	NN	O
one	IN	O
or	DT	O
more	NN	O
“positional	VBZ	O
isomers”	CD	O
of	CC	O
said	JJR	O
conjugate,	JJ	O
wherein	NN	O
each	IN	O
positional	VBD	O
isomer	,	O
contains	WP	O
a	DT	O
single	JJ	O
non-polypeptide	NN	O
moiety	VBZ	O
(e.g.,	DT	O
a	JJ	O
single	JJ	O
PEG	NN	O
molecule)	,	O
covalently	DT	O
attached	JJ	O
to	NNP	O
a	)	O
single	RB	O
lysine	VBN	O
residue	TO	O
of	DT	O
the	JJ	O
polypeptide.	NN	O
The	NN	O
invention	IN	O
includes	DT	O
a	.	O
monoPEGylated	DT	O
composition	NN	O
comprising	VBZ	O
a	DT	O
population	JJ	O
of	NN	O
conjugates,	VBG	O
wherein	DT	O
the	NN	O
majority	IN	O
of	,	O
the	VBP	O
conjugates	DT	O
of	NN	O
said	IN	O
population	DT	O
are	NNS	O
positional	IN	O
isomers	VBD	O
each	NN	O
containing	VBP	O
a	JJ	O
single	NNS	O
PEG	DT	O
molecule	VBG	O
(such	DT	O
as,	JJ	O
a	NNP	O
linear	NN	O
or	JJ	O
branched	,	O
PEG,	DT	O
such	JJ	O
as	CC	O
a	VBN	O
2	,	O
kDa,	JJ	O
5	IN	O
kDa,	DT	O
12	CD	O
kDa,	,	O
15	CD	O
kDa,	,	O
20	CD	O
kDa,	,	O
30	CD	O
kDa,	,	O
or	CD	O
40	,	O
kDa	CD	O
mPEG	,	O
or	CC	O
mPEG2	CD	O
molecule)	NNS	O
covalently	NN	O
attached	CC	O
to	VB	O
a	)	O
single	RB	O
lysine	VBN	O
residue	TO	O
of	DT	O
a	JJ	O
polypeptide	NN	O
of	NN	O
the	IN	O
invention.	DT	O
In	NN	O
one	IN	O
aspect,	DT	O
the	.	O
invention	IN	O
relates	CD	O
to	,	O
a	DT	O
conjugate	NN	O
comprising	VBZ	O
at	TO	O
least	DT	O
one	NN	O
non-polypeptide	NN	O
moiety	IN	O
conjugated	JJS	O
to	CD	O
at	JJ	O
least	NN	O
one	VBD	O
cysteine	TO	O
residue	IN	O
of	JJS	O
a	CD	O
polypeptide	NN	O
of	NN	O
the	IN	O
invention	DT	O
or	NN	O
a	IN	O
polypeptide	DT	O
comprising	NN	O
a	CC	O
sequence	DT	O
which	JJ	O
differs	VBG	O
in	DT	O
1	NN	O
to	WDT	O
34	NNS	O
amino	IN	O
acid	CD	O
positions	TO	O
from	CD	O
SEQUENCE:1	NN	O
(SEQ	JJ	O
ID	NNS	O
NO:1)	IN	O
of	NNP	O
FIG.	NNP	O
1.	NNP	O
Some	)	O
conjugates	IN	O
according	.	O
to	.	O
this	DT	O
aspect	NNS	O
comprise	VBG	O
at	TO	O
least	DT	O
one	JJ	O
introduced	NN	O
cysteine	IN	O
residue.	JJS	O
In	CD	O
another	JJ	O
aspect,	NN	O
the	.	O
invention	IN	O
relates	DT	O
to	,	O
conjugation	DT	O
of	NN	O
the	VBZ	O
non-polypeptide	TO	O
moiety	NN	O
to	IN	O
one	DT	O
or	JJ	O
more	NN	O
cysteine	TO	O
residues	CD	O
of	CC	O
the	JJR	O
polypeptides	JJ	O
of	NNS	O
the	IN	O
invention	DT	O
including	NNS	O
Cys25,	IN	O
Cys38,	DT	O
Cys45,	NN	O
Cys54,	VBG	O
Cys109,	,	O
Cys177,	,	O
Cys189,	,	O
Cys219,	,	O
Cys269,	,	O
or	,	O
Cys331.	,	O
Included	,	O
among	,	O
these	CC	O
conjugates	.	O
are	VBN	O
those	IN	O
defined	DT	O
as	NNS	O
Class	VBP	O
IV	DT	O
in	VBN	O
FIG.	IN	O
1	NNP	O
and	NNP	O
as	IN	O
implemented	.	O
in	CD	O
FIG.	CC	O
6.	RB	O
In	VBN	O
another	IN	O
aspect,	.	O
the	.	O
invention	IN	O
relates	DT	O
to	,	O
the	DT	O
addition	NN	O
of	VBZ	O
one	TO	O
or	DT	O
more	NN	O
cysteine	IN	O
residues	CD	O
to	CC	O
the	JJR	O
polypeptides	JJ	O
of	NNS	O
the	TO	O
invention	DT	O
to	NNS	O
enable	IN	O
conjugation	DT	O
of	NN	O
a	TO	O
non-polypeptide	VB	O
moiety	NN	O
at	IN	O
a	DT	O
location	JJ	O
other	NN	O
than	IN	O
Cys25,	DT	O
Cys38,	NN	O
Cys45,	JJ	O
Cys54,	IN	O
Cys109,	,	O
Cys177,	,	O
Cys189,	,	O
Cys219,	,	O
Cys269,	,	O
or	,	O
Cys331.	,	O
It	,	O
is	,	O
to	CC	O
be	.	O
understood	PRP	O
that	VBZ	O
while	TO	O
the	VB	O
examples	JJ	O
of	IN	O
modifications	IN	O
or	DT	O
conjugations	NNS	O
to	IN	O
the	NNS	O
parent	CC	O
polypeptide	NNS	O
are	TO	O
generally	DT	O
provided	NN	O
herein	NN	O
relative	VBP	O
to	RB	O
the	VBN	O
sequence	RB	O
SEQUENCE:1	JJ	O
(SEQ	TO	O
ID	DT	O
NO:1)	NN	O
of	NNP	O
FIG.	NNP	O
1	NNP	O
(or	)	O
relative	IN	O
to	.	O
some	CD	O
other	CC	O
specified	VB	O
sequence),	TO	O
the	DT	O
disclosed	JJ	O
modifications	JJ	O
may	,	O
also	DT	O
be	JJ	O
made	NNS	O
in	MD	O
equivalent	RB	O
amino	VB	O
acid	VBN	O
positions	IN	O
of	JJ	O
the	NN	O
other	JJ	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	JJ	O
described	NNS	O
herein.	IN	O
In	DT	O
some	NN	O
instances,	VBD	O
only	.	O
a	IN	O
single	DT	O
cysteine	,	O
residue	RB	O
is	DT	O
introduced	JJ	O
in	NN	O
order	NN	O
to	VBZ	O
avoid	VBN	O
formation	IN	O
of	NN	O
disulfide	TO	O
bridges	VB	O
between	NN	O
two	IN	O
or	NN	O
more	NNS	O
introduced	IN	O
cysteine	CD	O
residues.	CC	O
Non-polypeptide	JJR	O
moieties	JJ	O
contemplated	NN	O
in	.	O
this	JJ	O
aspect	NNS	O
of	VBN	O
the	IN	O
invention	DT	O
include	NN	O
polymer	IN	O
molecules,	DT	O
such	NN	O
as	VBP	O
PEG	NN	O
or	,	O
mPEG	JJ	O
and	IN	O
others	NNP	O
as	CC	O
known	NNS	O
to	CC	O
those	NNS	O
skilled	IN	O
in	VBN	O
the	TO	O
art	DT	O
and	VBN	O
as	IN	O
described	DT	O
herein.	NN	O
The	CC	O
conjugation	IN	O
between	JJ	O
the	.	O
cysteine-containing	DT	O
polypeptide	NN	O
and	IN	O
the	DT	O
polymer	JJ	O
molecule	NN	O
may	CC	O
be	DT	O
achieved	NN	O
in	NN	O
any	MD	O
suitable	VB	O
manner	VBN	O
as	IN	O
known	DT	O
to	JJ	O
those	NN	O
skilled	IN	O
in	VBN	O
the	TO	O
art.	DT	O
An	VBN	O
exemplary	IN	O
method	DT	O
for	.	O
PEGylating	DT	O
the	JJ	O
polypeptides	NN	O
of	IN	O
the	VBG	O
invention	DT	O
is	NNS	O
to	IN	O
covalently	DT	O
attach	NN	O
PEG	VBZ	O
to	TO	O
cysteine	RB	O
residues	VB	O
using	NNP	O
cysteine-reactive	TO	O
PEGs.	VB	O
A	NNS	O
number	VBG	O
of	JJ	O
highly	.	O
specific,	DT	O
cysteine-reactive	NN	O
PEGs	IN	O
with	RB	O
different	,	O
groups	JJ	O
(e.g.,	NNP	O
orthopyridyl-disulfide	IN	O
(OPSS),	JJ	O
maleimide	NNS	O
(MAL)	,	O
and	JJ	O
vinylsulfone	,	O
(VS))	RB	O
and	)	O
different	CC	O
size	NN	O
linear	)	O
or	CC	O
branched	JJ	O
PEGs	NN	O
(e.g.,	NN	O
2-40	CC	O
kDa,	VBN	O
such	NNP	O
as	,	O
2	JJ	O
kDa,	,	O
5	JJ	O
kDa,	IN	O
12	CD	O
kDa,	,	O
15	CD	O
kDa,	,	O
20	CD	O
kDa,	,	O
30	CD	O
kDa,	,	O
or	CD	O
40	,	O
kDa)	CD	O
are	,	O
commercially	CC	O
available,	CD	O
e.g.,	)	O
from	VBP	O
Nektar	RB	O
Therapeutics	,	O
Inc.,	,	O
Huntsville,	IN	O
Ala.,	NNP	O
USA,	NNP	O
or	,	O
SunBio,	,	O
Anyang	,	O
City,	,	O
South	CC	O
Korea.	,	O
As	NNP	O
indicated	,	O
above,	NNP	O
the	.	O
non-polypeptide	IN	O
moiety	VBN	O
of	,	O
the	DT	O
conjugate	JJ	O
of	NN	O
the	IN	O
invention	DT	O
is	NN	O
generally	IN	O
selected	DT	O
from	NN	O
the	VBZ	O
group	RB	O
consisting	VBN	O
of	IN	O
a	DT	O
polymer	NN	O
molecule,	VBG	O
a	IN	O
lipophilic	DT	O
compound,	NN	O
a	,	O
sugar	DT	O
moiety	JJ	O
(e.g.,	,	O
by	DT	O
way	NN	O
of	NN	O
in	,	O
vivo	IN	O
N-glycosylation)	NN	O
and	IN	O
an	IN	O
organic	JJ	O
derivatizing	)	O
agent.	CC	O
All	DT	O
of	JJ	O
these	NN	O
agents	.	O
may	DT	O
confer	IN	O
desirable	DT	O
properties	NNS	O
to	MD	O
the	VB	O
polypeptide	JJ	O
part	NNS	O
of	TO	O
the	DT	O
conjugate,	JJ	O
such	NN	O
as	IN	O
reduced	DT	O
immunogenicity,	,	O
increased	JJ	O
functional	IN	O
in	JJ	O
vivo	,	O
half-life,	VBD	O
increased	JJ	O
serum	IN	O
half-life,	JJ	O
increased	,	O
bioavailability	JJ	O
and/or	NN	O
increased	,	O
AUCsc.	VBN	O
The	NN	O
polypeptide	NN	O
part	VBD	O
of	.	O
the	DT	O
conjugate	JJ	O
is	NN	O
often	IN	O
conjugated	DT	O
to	NN	O
only	VBZ	O
one	RB	O
type	VBN	O
of	TO	O
non-polypeptide	RB	O
moiety,	CD	O
but	NN	O
may	IN	O
also	JJ	O
be	,	O
conjugated	CC	O
to	MD	O
two	RB	O
or	VB	O
more	VBN	O
different	TO	O
types	CD	O
of	CC	O
non-polypeptide	JJR	O
moieties,	JJ	O
e.g.,	NNS	O
to	IN	O
a	JJ	O
polymer	,	O
molecule	,	O
and	TO	O
a	DT	O
sugar	NN	O
moiety,	NN	O
etc.	CC	O
The	DT	O
conjugation	NN	O
to	,	O
two	.	O
or	DT	O
more	NN	O
different	TO	O
non-polypeptide	CD	O
moieties	CC	O
may	JJR	O
be	JJ	O
done	JJ	O
simultaneously	NNS	O
or	MD	O
sequentially.	VB	O
The	VBN	O
choice	RB	O
of	CC	O
non-polypeptide	.	O
moiety/moieties,	DT	O
depends	NN	O
especially	IN	O
on	JJ	O
the	,	O
effect	VBZ	O
desired	RB	O
to	IN	O
be	DT	O
achieved	NN	O
by	VBD	O
the	TO	O
conjugation.	VB	O
For	VBN	O
instance,	IN	O
sugar	DT	O
moieties	.	O
have	IN	O
been	,	O
found	NN	O
particularly	NNS	O
useful	VBP	O
for	VBN	O
reducing	VBN	O
immunogenicity,	RB	O
whereas	JJ	O
polymer	IN	O
molecules	VBG	O
such	,	O
as	JJ	O
PEG	NN	O
are	NNS	O
of	JJ	O
particular	IN	O
use	NNP	O
for	VBP	O
increasing	IN	O
functional	JJ	O
in	NN	O
vivo	IN	O
half-life	VBG	O
and/or	JJ	O
serum	IN	O
half-life.	JJ	O
Using	JJ	O
a	NN	O
combination	NN	O
of	.	O
a	VBG	O
polymer	DT	O
molecule	NN	O
and	IN	O
a	DT	O
sugar	NN	O
moiety	NN	O
may	CC	O
enhance	DT	O
the	NN	O
reduction	NN	O
in	MD	O
immunogenicity	VB	O
and	DT	O
the	NN	O
increase	IN	O
in	NN	O
functional	CC	O
in	DT	O
vivo	NN	O
or	IN	O
serum	JJ	O
half-life.	IN	O
For	NN	O
conjugation	CC	O
to	JJ	O
a	.	O
lipophilic	IN	O
compound,	NN	O
the	TO	O
following	DT	O
polypeptide	JJ	O
groups	,	O
may	DT	O
function	JJ	O
as	NN	O
attachment	NNS	O
groups:	MD	O
the	VB	O
N-terminus	IN	O
or	JJ	O
C-terminus	:	O
of	DT	O
the	NNP	O
polypeptide,	CC	O
the	NNP	O
hydroxy	IN	O
groups	DT	O
of	,	O
the	DT	O
amino	JJ	O
acid	NNS	O
residues	IN	O
Ser,	DT	O
Thr	NN	O
or	NN	O
Tyr,	NNS	O
the	,	O
epsilon-amino	NNP	O
group	CC	O
of	,	O
Lys,	DT	O
the	JJ	O
SH	NN	O
group	IN	O
of	,	O
Cys	DT	O
or	NNP	O
the	NN	O
carboxyl	IN	O
group	NNP	O
of	CC	O
Asp	DT	O
and	JJ	O
Glu.	NN	O
The	IN	O
polypeptide	NNP	O
and	CC	O
the	.	O
lipophilic	DT	O
compound	NN	O
may	CC	O
be	DT	O
conjugated	JJ	O
to	NN	O
each	MD	O
other	VB	O
either	VBN	O
directly	TO	O
or	DT	O
by	JJ	O
use	CC	O
of	RB	O
a	CC	O
linker.	IN	O
The	NN	O
lipophilic	IN	O
compound	DT	O
may	.	O
be	DT	O
a	JJ	O
natural	NN	O
compound	MD	O
such	VB	O
as	DT	O
a	JJ	O
saturated	NN	O
or	JJ	O
unsaturated	IN	O
fatty	DT	O
acid,	JJ	O
a	CC	O
fatty	JJ	O
acid	JJ	O
diketone,	,	O
a	DT	O
terpene,	JJ	O
a	NN	O
prostaglandin,	,	O
a	DT	O
vitamin,	,	O
a	DT	O
carotenoid	,	O
or	DT	O
steroid,	,	O
or	DT	O
a	NN	O
synthetic	CC	O
compound	,	O
such	CC	O
as	DT	O
a	JJ	O
carbon	NN	O
acid,	JJ	O
an	IN	O
alcohol,	DT	O
an	NN	O
amine	,	O
and	DT	O
sulphonic	,	O
acid	DT	O
with	NN	O
one	CC	O
or	JJ	O
more	NN	O
alkyl,	IN	O
aryl,	CD	O
alkenyl	CC	O
or	JJR	O
other	,	O
multiple	,	O
unsaturated	NN	O
compounds.	CC	O
The	JJ	O
conjugation	JJ	O
between	JJ	O
the	.	O
polypeptide	DT	O
and	NN	O
the	IN	O
lipophilic	DT	O
compound,	NN	O
optionally	CC	O
through	DT	O
a	JJ	O
linker	,	O
may	RB	O
be	IN	O
done	DT	O
according	NN	O
to	MD	O
methods	VB	O
known	VBN	O
in	VBG	O
the	TO	O
art,	NNS	O
e.g.	VBN	O
as	IN	O
described	DT	O
by	,	O
Bodanszky	.	O
in	IN	O
Peptide	VBN	O
Synthesis,	IN	O
John	NNP	O
Wiley,	IN	O
New	NNP	O
York,	,	O
1976	NNP	O
and	,	O
in	NNP	O
WO	,	O
96/12505.	CD	O
The	CC	O
polymer	IN	O
molecule	NNP	O
to	.	O
be	DT	O
coupled	NN	O
to	NN	O
the	TO	O
polypeptide	VB	O
may	VBN	O
be	TO	O
any	DT	O
suitable	NN	O
polymer	MD	O
molecule,	VB	O
such	DT	O
as	JJ	O
a	NN	O
natural	,	O
or	JJ	O
synthetic	IN	O
homo-polymer	DT	O
or	JJ	O
heteropolymer,	CC	O
typically	JJ	O
with	NN	O
a	CC	O
molecular	,	O
weight	RB	O
in	IN	O
the	DT	O
range	JJ	O
of	NN	O
about	IN	O
300-100,000	DT	O
Da,	NN	O
such	IN	O
as	IN	O
about	CD	O
1000-50,000	,	O
Da,	JJ	O
e.g.	IN	O
in	IN	O
the	CD	O
range	,	O
of	.	O
about	IN	O
1000-40,000	DT	O
Da.	NN	O
More	IN	O
particularly,	IN	O
the	CD	O
polymer	.	O
molecule,	RBR	O
such	,	O
as	DT	O
PEG,	NN	O
in	,	O
particular	JJ	O
mPEG,	IN	O
will	,	O
typically	IN	O
have	JJ	O
a	,	O
molecular	MD	O
weight	RB	O
of	VB	O
about	DT	O
2,	JJ	O
5,	NN	O
10,	IN	O
12,	IN	O
15,	,	O
20,	,	O
30,	,	O
40	,	O
or	,	O
50	,	O
kDa,	,	O
in	CD	O
particular	CC	O
a	CD	O
molecular	,	O
weight	IN	O
of	JJ	O
about	DT	O
5	JJ	O
kDa,	NN	O
about	IN	O
10	IN	O
kDa,	CD	O
about	,	O
12	RB	O
kDa,	CD	O
about	,	O
15	RB	O
kDa,	CD	O
about	,	O
20	RB	O
kDa,	CD	O
about	,	O
30	RB	O
kDa	CD	O
or	,	O
about	RB	O
40	CD	O
kDa.	NNS	O
The	CC	O
PEG	IN	O
molecule	CD	O
may	.	O
be	DT	O
branched	NNP	O
(e.g.,	NN	O
mPEG2),	MD	O
or	VB	O
may	VBN	O
be	,	O
unbranched	,	O
(i.e.,	CC	O
linear).	MD	O
When	VB	O
used	VBN	O
about	,	O
polymer	.	O
molecules	WRB	O
herein,	VBN	O
the	IN	O
word	NN	O
“about”	NNS	O
indicates	,	O
an	DT	O
approximate	NN	O
average	NNP	O
molecular	VBZ	O
weight	DT	O
and	JJ	O
reflects	NN	O
the	JJ	O
fact	NN	O
that	CC	O
there	VBZ	O
will	DT	O
normally	NN	O
be	IN	O
a	EX	O
certain	MD	O
molecular	RB	O
weight	VB	O
distribution	DT	O
in	JJ	O
a	JJ	O
given	NN	O
polymer	NN	O
preparation.	IN	O
Examples	DT	O
of	VBN	O
homo-polymers	NN	O
include	.	O
a	NNS	O
polyol	IN	O
(i.e.,	NNS	O
poly-OH),	VBP	O
a	DT	O
polyamine	NN	O
(i.e.	,	O
poly-NH2)	,	O
and	DT	O
a	NN	O
polycarboxylic	.	O
acid	)	O
(i.e.	CC	O
poly-COOH).	DT	O
A	JJ	O
hetero-polymer	NN	O
is	.	O
a	.	O
polymer	DT	O
which	NN	O
comprises	VBZ	O
one	DT	O
or	NN	O
more	WDT	O
different	VBZ	O
coupling	CD	O
groups,	CC	O
such	JJR	O
as	JJ	O
a	NN	O
hydroxyl	,	O
group	JJ	O
and	IN	O
an	DT	O
amine	NN	O
group.	NN	O
Examples	CC	O
of	DT	O
suitable	NN	O
polymer	.	O
molecules	NNS	O
include	IN	O
polymer	JJ	O
molecules	NN	O
selected	NNS	O
from	VBP	O
the	JJ	O
group	NNS	O
consisting	VBN	O
of	IN	O
polyalkylene	DT	O
oxide	NN	O
(PAO),	VBG	O
including	IN	O
polyalkylene	NN	O
glycol	NN	O
(PAG),	,	O
such	VBG	O
as	NN	O
polyethylene	NN	O
glycol	,	O
(PEG)	JJ	O
and	IN	O
polypropylene	NN	O
glycol	NN	O
(PPG),	)	O
branched	CC	O
PEGs	JJ	O
(PEG2),	NN	O
poly-vinyl	,	O
alcohol	VBN	O
(PVA),	NNP	O
poly-carboxylate,	,	O
poly-(vinylpyrolidone),	JJ	O
polyethylene-co-maleic	NN	O
acid	,	O
anhydride,	,	O
polystyrene-co-malic	,	O
acid	JJ	O
anhydride,	NN	O
dextran	,	O
including	JJ	O
carboxymethyl-dextran,	NN	O
or	,	O
any	JJ	O
other	VBG	O
biopolymer	,	O
suitable	CC	O
for	DT	O
reducing	JJ	O
immunogenicity	NN	O
and/or	NN	O
increasing	IN	O
functional	VBG	O
in	NN	O
vivo	NN	O
half-life	VBG	O
and/or	JJ	O
serum	IN	O
half-life.	JJ	O
Generally,	JJ	O
polyalkylene	NN	O
glycol-derived	NN	O
polymers	.	O
are	,	O
biocompatible,	JJ	O
non-toxic,	JJ	O
non-antigenic,	NNS	O
non-immunogenic,	VBP	O
have	,	O
various	,	O
water	,	O
solubility	,	O
properties,	VBP	O
and	JJ	O
are	NN	O
easily	NN	O
excreted	,	O
from	CC	O
living	VBP	O
organisms.	RB	O
PEG	VBN	O
is	IN	O
the	VBG	O
preferred	.	O
polymer	NNP	O
molecule	VBZ	O
to	DT	O
be	JJ	O
used,	NN	O
since	NN	O
it	TO	O
has	VB	O
only	,	O
few	IN	O
reactive	PRP	O
groups	VBZ	O
capable	RB	O
of	JJ	O
cross-linking	JJ	O
compared	NNS	O
to	JJ	O
e.g.,	IN	O
polysaccharides	NN	O
such	VBN	O
as	TO	O
dextran.	,	O
In	NNS	O
particular,	JJ	O
monofunctional	IN	O
PEG,	.	O
e.g.,	IN	O
monomethoxypolyethylene	,	O
glycol	JJ	O
(mPEG),	,	O
is	,	O
of	NN	O
interest	NN	O
since	,	O
its	VBZ	O
coupling	IN	O
chemistry	NN	O
is	IN	O
relatively	PRP$	O
simple	VBG	O
(only	NN	O
one	VBZ	O
reactive	RB	O
group	JJ	O
is	RB	O
available	CD	O
for	JJ	O
conjugating	NN	O
with	VBZ	O
attachment	JJ	O
groups	IN	O
on	VBG	O
the	IN	O
polypeptide).	JJ	O
Consequently,	NNS	O
the	IN	O
risk	DT	O
of	.	O
cross-linking	,	O
is	DT	O
eliminated,	NN	O
the	IN	O
resulting	NN	O
polypeptide	VBZ	O
conjugates	,	O
are	DT	O
more	VBG	O
homogeneous	NN	O
and	NNS	O
the	VBP	O
reaction	RBR	O
of	JJ	O
the	CC	O
polymer	DT	O
molecules	NN	O
with	IN	O
the	DT	O
polypeptide	NN	O
is	NNS	O
easier	IN	O
to	DT	O
control.	NN	O
To	VBZ	O
effect	JJR	O
covalent	TO	O
attachment	.	O
of	TO	O
the	NN	O
polymer	JJ	O
molecule(s)	NN	O
to	IN	O
the	DT	O
polypeptide,	NN	O
the	)	O
hydroxyl	TO	O
end	DT	O
groups	,	O
of	DT	O
the	JJ	O
polymer	NN	O
molecule	NNS	O
must	IN	O
be	DT	O
provided	NN	O
in	NN	O
activated	MD	O
form,	VB	O
i.e.	VBN	O
with	IN	O
reactive	JJ	O
functional	,	O
groups	.	O
(examples	IN	O
of	JJ	O
which	JJ	O
include	NNS	O
primary	NNS	O
amino	IN	O
groups,	WDT	O
hydrazide	VBP	O
(HZ),	JJ	O
thiol,	NN	O
succinate	,	O
(SUC),	NN	O
succinimidyl	,	O
succinate	,	O
(SS),	NN	O
succinimidyl	,	O
succinamide	JJ	O
(SSA),	NN	O
succinimidyl	,	O
propionate	JJ	O
(SPA),	NN	O
succinimidyl	,	O
butanoate	JJ	O
(SBA),	NN	O
succinimidyl	,	O
carboxymethylate	JJ	O
(SCM),	NN	O
benzotriazole	,	O
carbonate	JJ	O
(BTC),	NN	O
N-hydroxysuccinimide	,	O
(NHS),	JJ	O
aldehyde,	NN	O
nitrophenylcarbonate	,	O
(NPC),	NNP	O
and	,	O
tresylate	,	O
(TRES)).	NN	O
Suitably	,	O
activated	CC	O
polymer	NN	O
molecules	.	O
are	RB	O
commercially	VBN	O
available,	NN	O
e.g.,	NNS	O
from	VBP	O
Nektar	RB	O
Therapeutics,	,	O
Inc.,	,	O
Huntsville,	IN	O
Ala.,	NNP	O
USA;	,	O
PolyMASC	,	O
Pharmaceuticals	,	O
plc,	,	O
UK;	:	O
or	NNP	O
SunBio	NNP	O
Corporation,	,	O
Anyang	:	O
City,	CC	O
South	NNP	O
Korea.	,	O
Alternatively,	NNP	O
the	,	O
polymer	NNP	O
molecules	.	O
can	,	O
be	DT	O
activated	NN	O
by	NNS	O
conventional	MD	O
methods	VB	O
known	VBN	O
in	IN	O
the	JJ	O
art,	NNS	O
e.g.	VBN	O
as	IN	O
disclosed	DT	O
in	,	O
WO	.	O
90/13540.	IN	O
Specific	VBN	O
examples	IN	O
of	NNP	O
activated	.	O
linear	JJ	O
or	NNS	O
branched	IN	O
polymer	JJ	O
molecules	NN	O
suitable	CC	O
for	VBN	O
use	NN	O
in	NNS	O
the	JJ	O
present	IN	O
invention	NN	O
are	IN	O
described	DT	O
in	JJ	O
the	NN	O
Nektar	VBP	B
Therapeutics,	VBN	I
Inc.	IN	I
2003	DT	I
Catalog	NNP	I
(“Nektar	,	I
Molecule	NNP	I
Engineering:	CD	I
Polyethylene	NNP	I
Glycol	JJ	I
and	NNP	I
Derivatives	:	I
for	NNP	I
Advanced	NNP	I
Pegylation,	CC	I
Catalog	NNP	I
2003”),	IN	I
incorporated	NNP	O
by	,	O
reference	NNP	O
herein.	,	O
Specific	VBN	O
examples	IN	O
of	NN	O
activated	.	O
PEG	JJ	O
polymers	NNS	O
include	IN	O
the	JJ	O
following	NNP	O
linear	NNS	O
PEGs:	VBP	O
NHS-PEG,	DT	O
SPA-PEG,	JJ	O
SSPA-PEG,	JJ	O
SBA-PEG,	:	O
SS-PEG,	,	O
SSA-PEG,	,	O
SC-PEG,	,	O
SG-PEG,	,	O
SCM-PEG,	,	O
NOR-PEG,	,	O
BTC-PEG,	,	O
EPDX-PEG,	,	O
NCO-PEG,	,	O
NPC-PEG,	,	O
CDI-PEG,	,	O
ALD-PEG,	,	O
TRES-PEG,	,	O
VS-PEG,	,	O
OPSS-PEG,	,	O
IODO-PEG,	,	O
and	,	O
MAL-PEG,	,	O
and	,	O
branched	,	O
PEGs,	CC	O
such	,	O
as	CC	O
PEG2-NHS,	VBD	O
PEG2-MAL,	,	O
and	JJ	O
those	IN	O
disclosed	,	O
in	,	O
U.S.	CC	O
Pat.	DT	O
No.	VBN	O
5,932,462	IN	O
and	NNP	O
U.S.	.	O
Pat.	.	O
No.	CD	O
5,643,575,	CC	O
both	NNP	O
of	.	O
which	.	O
are	,	O
incorporated	DT	O
herein	IN	O
by	WDT	O
reference.	VBP	O
Furthermore,	VBN	O
the	NN	O
following	IN	O
publications,	.	O
incorporated	,	O
herein	DT	O
by	JJ	O
reference,	,	O
disclose	VBN	O
useful	NN	O
polymer	IN	O
molecules	,	O
and/or	VB	O
PEGylation	JJ	O
chemistries:	NN	O
U.S.	NNS	O
Pat.	VBP	O
No.	NNP	O
5,824,778,	:	O
U.S.	NNP	O
Pat.	.	O
No.	.	O
5,476,653,	,	O
WO	NNP	O
97/32607,	.	O
EP	.	O
229,108,	,	O
EP	NNP	O
402,378,	,	O
U.S.	NNP	O
Pat.	,	O
No.	NNP	O
4,902,502,	,	O
U.S.	NNP	O
Pat.	.	O
No.	.	O
5,281,698,	,	O
U.S.	NNP	O
Pat.	.	O
No.	.	O
5,122,614,	,	O
U.S.	NNP	O
Pat.	.	O
No.	.	O
5,219,564,	,	O
WO	NNP	O
92/16555,	.	O
WO	.	O
94/04193,	,	O
WO	NNP	O
94/14758,	,	O
WO	NNP	O
94/17039,	,	O
WO	NNP	O
94/18247,	,	O
WO	NNP	O
94/28024,	,	O
WO	NNP	O
95/00162,	,	O
WO	NNP	O
95/11924,	,	O
WO95/13090,	NNP	O
WO	,	O
95/33490,	NNP	O
WO	,	O
96/00080,	,	O
WO	NNP	O
97/18832,	,	O
WO	NNP	O
98/41562,	,	O
WO	NNP	O
98/48837,	,	O
WO	NNP	O
99/32134,	,	O
WO	NNP	O
99/32139,	,	O
WO	NNP	O
99/32140,	,	O
WO	NNP	O
96/40791,	,	O
WO	NNP	O
98/32466,	,	O
WO	NNP	O
95/06058,	,	O
EP	NNP	O
439	,	O
508,	NNP	O
WO	,	O
97/03106,	NNP	O
WO	CD	O
96/21469,	,	O
WO	NNP	O
95/13312,	,	O
EP	NNP	O
921	,	O
131,	NNP	O
U.S.	,	O
Pat.	NNP	O
No.	CD	O
5,736,625,	,	O
WO	NNP	O
98/05363,	.	O
EP	.	O
809	,	O
996,	NNP	O
U.S.	,	O
Pat.	NNP	O
No.	CD	O
5,629,384,	,	O
WO	NNP	O
96/41813,	.	O
WO	.	O
96/07670,	,	O
U.S.	NNP	O
Pat.	,	O
No.	NNP	O
5,473,034,	,	O
U.S.	NNP	O
Pat.	.	O
No.	.	O
5,516,673,	,	O
EP	NNP	O
605	.	O
963,	.	O
U.S.	,	O
Pat.	NNP	O
No.	CD	O
5,382,657,	,	O
EP	NNP	O
510	.	O
356,	.	O
EP	,	O
400	NNP	O
472,	CD	O
EP	,	O
183	NNP	O
503	CD	O
and	,	O
EP	NNP	O
154	CD	O
316.	CD	O
The	CC	O
conjugation	NNP	O
of	CD	O
the	.	O
polypeptide	DT	O
and	NN	O
the	IN	O
activated	DT	O
polymer	NN	O
molecules	CC	O
is	DT	O
conducted	JJ	O
by	NN	O
use	NNS	O
of	VBZ	O
any	VBN	O
conventional	IN	O
method,	NN	O
e.g.,	IN	O
as	DT	O
described	JJ	O
in	,	O
the	,	O
following	IN	O
references	VBN	O
(which	IN	O
also	DT	O
describe	JJ	O
suitable	NNS	O
methods	WDT	O
for	RB	O
activation	VBP	O
of	JJ	O
polymer	NNS	O
molecules):	IN	O
Harris	NN	B
and	IN	I
Zalipsky,	NN	I
eds.,	:	I
Poly(ethylene	NNP	I
glycol)	CC	I
Chemistry	,	I
and	,	I
Biological	JJ	I
Applications,	)	I
AZC,	NN	I
Washington;	CC	I
R.	NNP	I
F.	,	I
Taylor,	,	I
(1991),	:	I
“Protein	NNP	I
immobilisation.	NNP	I
Fundamental	,	I
and	,	I
applications”,	JJ	I
Marcel	.	I
Dekker,	JJ	I
N.Y.;	CC	I
S.	,	B
S.	NNP	I
Wong,	,	I
(1992),	:	I
“Chemistry	NNP	I
of	NNP	I
Protein	,	I
Conjugation	,	I
and	NN	I
Crosslinking”,	IN	I
CRC	NNP	I
Press,	NNP	I
Boca	CC	I
Raton;	,	I
G.	NNP	B
T.	,	I
Hermanson	NNP	I
et	:	I
al.,	NNP	I
(1993),	NNP	I
“Immobilized	NNP	I
Affinity	FW	I
Ligand	,	I
Techniques”,	,	I
Academic	VBN	I
Press,	NNP	I
New	NNP	I
York.
For	,	O
PEGylation	NNP	O
of	,	O
cysteine	NNP	O
residues,	.	O
the	IN	O
polypeptide	NNP	O
is	IN	O
usually	NN	O
treated	,	O
with	DT	O
a	NN	O
reducing	VBZ	O
agent,	RB	O
such	VBN	O
as	IN	O
dithiothreitol	DT	O
(DDT)	VBG	O
prior	,	O
to	JJ	O
PEGylation.	IN	O
The	NN	O
reducing	)	O
agent	RB	O
is	TO	O
subsequently	.	O
removed	DT	O
by	NN	O
any	NN	O
conventional	VBZ	O
method,	RB	O
such	VBN	O
as	IN	O
by	DT	O
desalting.	JJ	O
Conjugation	,	O
of	JJ	O
PEG	IN	O
to	IN	O
a	.	O
cysteine	NN	O
residue	IN	O
typically	NNP	O
takes	TO	O
place	DT	O
in	NN	O
a	NN	O
suitable	RB	O
buffer	VBZ	O
at	NN	O
pH	IN	O
6-9	DT	O
at	JJ	O
temperatures	NN	O
varying	IN	O
from	JJ	O
4°	JJ	O
C.	IN	O
to	NNS	O
25°	VBG	O
C.	IN	O
for	CD	O
periods	NNP	O
up	TO	O
to	CD	O
about	NNP	O
16	IN	O
hours.	NNS	O
Examples	RB	O
of	TO	O
activated	IN	O
PEG	CD	O
polymers	.	O
for	NNS	O
coupling	IN	O
to	JJ	O
cysteine	NNP	O
residues	NNS	O
include	IN	O
the	VBG	O
following	TO	O
linear	VB	O
and	NNS	O
branched	VBP	O
PEGs:	DT	O
vinylsulfone-PEG	JJ	O
(PEG-VS),	NN	O
such	CC	O
as	VBD	O
vinylsulfone-mPEG	:	O
(mPEG-VS);	JJ	O
orthopyridyl-disulfide-PEG	,	O
(PEG-OPSS),	JJ	O
such	IN	O
as	JJ	O
orthopyridyl-disulfide-mPE-G	:	O
(mPEG-OPSS);	JJ	O
and	,	O
maleimide-PEG	JJ	O
(PEG-MAL),	IN	O
such	JJ	O
as	:	O
maleimide-mPEG	CC	O
(mPEG-MAL)	JJ	O
and	,	O
branched	JJ	O
maleimide-mPEG2	IN	O
(mPEG2-MAL).	JJ	O
Pegylation	)	O
of	CC	O
lysines	VBN	O
often	NN	O
employs	.	O
PEG-N-hydroxylsuccinimide	NN	O
(e.g.,	IN	O
mPEG-NHS	NNS	O
or	RB	O
mPEG2-NHS),	VBZ	O
or	NNP	O
esters	,	O
such	JJ	O
as	CC	O
PEG	,	O
succinimidyl	CC	O
propionate	NNS	O
(e.g.,	JJ	O
mPEG-SPA)	IN	O
or	NNP	O
PEG	NN	O
succinimidyl	NN	O
butanoate	,	O
(e.g.,	)	O
mPEG-SBA).	CC	O
One	NNP	O
or	JJ	O
more	NN	O
PEGs	,	O
can	.	O
be	CD	O
attached	CC	O
to	JJR	O
a	NNS	O
protein	MD	O
within	VB	O
30	VBN	O
minutes	TO	O
at	DT	O
pH	NN	O
8-9.5	IN	O
at	CD	O
room	NNS	O
temperature	IN	O
if	JJ	O
about	CD	O
equimolar	IN	O
amounts	NN	O
of	NN	O
PEG	IN	O
and	IN	O
protein	JJ	O
are	NNS	O
mixed.	IN	O
A	NNP	O
molar	CC	O
ratio	NN	O
of	VBP	O
PEG	.	O
to	DT	O
protein	JJ	O
amino	NN	O
groups	IN	O
of	NNP	O
1-5	TO	O
to	VB	O
1	JJ	O
will	NNS	O
usually	IN	O
suffice.	JJ	O
Increasing	TO	O
pH	CD	O
increases	MD	O
the	RB	O
rate	.	O
of	VBG	O
reaction,	NN	O
while	VBZ	O
lowering	DT	O
pH	NN	O
reduces	IN	O
the	,	O
rate	IN	O
of	VBG	O
reaction.	NN	O
These	VBZ	O
highly	DT	O
reactive	NN	O
active	IN	O
esters	.	O
can	DT	O
couple	RB	O
at	JJ	O
physiological	JJ	O
pH,	NNS	O
but	MD	O
less	VB	O
reactive	IN	O
derivatives	JJ	O
typically	,	O
require	CC	O
higher	RBR	O
pH.	JJ	O
Low	NNS	O
temperatures	RB	O
may	VBP	O
also	JJR	O
be	.	O
employed	JJ	O
if	NNS	O
a	MD	O
labile	RB	O
protein	VB	O
is	VBN	O
being	IN	O
used.	DT	O
Under	NN	O
low	NN	O
temperature	VBZ	O
conditions,	VBG	O
a	.	O
longer	IN	O
reaction	JJ	O
time	NN	O
may	,	O
be	DT	O
used.	JJR	O
N-terminal	NN	O
PEGylation	NN	O
is	MD	O
facilitated	VB	O
by	.	O
the	JJ	O
difference	NNP	O
between	VBZ	O
the	VBN	O
pKa	IN	O
values	DT	O
of	NN	O
the	IN	O
alpha-amino	DT	O
group	NN	O
of	NNS	O
the	IN	O
N-terminal	DT	O
amino	JJ	O
acid	NN	O
(about	IN	O
6	DT	O
to	NNP	O
8.0)	NN	O
and	NN	O
the	IN	O
epsilon-amino	CD	O
group	TO	O
of	)	O
lysine	CC	O
(about	DT	O
10).	JJ	O
PEGylation	NN	O
of	IN	O
the	NN	O
N-terminal	IN	O
amino	.	O
group	NN	O
often	IN	O
employs	DT	O
PEG-aldehydes	NNP	O
(such	NN	O
as	NN	O
mPEG-propionaldehyde	RB	O
or	VBZ	O
mPEG-butylaldehyde),	NNS	O
which	JJ	O
are	IN	O
more	JJ	O
selective	CC	O
for	,	O
amines	WDT	O
and	VBP	O
thus	RBR	O
are	JJ	O
less	IN	O
likely	NNS	O
to	CC	O
react	RB	O
with	VBP	O
the	RBR	O
imidazole	JJ	O
group	TO	O
of	VB	O
histidine;	IN	O
in	DT	O
addition,	JJ	O
PEG	NN	O
reagents	IN	O
used	:	O
for	IN	O
lysine	,	O
conjugation	NNP	O
(such	NNS	O
as	VBD	O
mPEG-SPA,	IN	O
mPEG-SBA,	JJ	O
or	NN	O
mPEG-NHS)	JJ	O
may	IN	O
also	,	O
be	,	O
used	CC	O
for	)	O
conjugation	MD	O
of	RB	O
the	VB	O
N-terminal	VBN	O
amine.	IN	O
Conjugation	NN	O
of	IN	O
a	DT	O
PEG-aldehyde	JJ	O
to	.	O
the	NN	O
N-terminal	IN	O
amino	DT	O
group	NNP	O
typically	TO	O
takes	DT	O
place	NNP	O
in	NN	O
a	NN	O
suitable	RB	O
buffer	VBZ	O
(such	NN	O
as,	IN	O
100	DT	O
mM	JJ	O
sodium	NN	O
acetate	JJ	O
or	,	O
100	CD	O
mM	NN	O
sodium	NN	O
bisphosphate	NN	O
buffer	CC	O
with	CD	O
20	JJ	O
mM	NN	O
sodium	NN	O
cyanoborohydride)	NN	O
at	IN	O
pH	CD	O
about	NNS	O
5.0	JJ	O
overnight	)	O
at	IN	O
temperatures	NN	O
varying	IN	O
from	CD	O
about	NN	O
4°	IN	O
C.	NNS	O
to	VBG	O
25°	IN	O
C.	IN	O
Useful	CD	O
N-terminal	NNP	O
PEGylation	TO	O
methods	CD	O
and	NNP	O
chemistries	NNP	O
are	JJ	O
also	NNP	O
described	NNS	O
in	CC	O
U.S.	NNS	O
Pat.	VBP	O
No.	RB	O
5,985,265	VBN	O
and	IN	O
U.S.	NNP	O
Pat.	.	O
No.	.	O
6,077,939,	CD	O
both	CC	O
incorporated	NNP	O
herein	.	O
by	.	O
reference.	,	O
Typically,	DT	O
linear	VBN	O
PEG	NN	O
or	IN	O
mPEG	.	O
polymers	,	O
will	JJ	O
have	NNP	O
a	CC	O
molecular	NN	O
weight	NNS	O
of	MD	O
about	VB	O
5	DT	O
kDa,	JJ	O
about	NN	O
10	IN	O
kDa,	IN	O
about	CD	O
12	,	O
kDa,	RB	O
about	CD	O
15	,	O
kDa,	RB	O
about	CD	O
20	,	O
kDa,	RB	O
or	CD	O
about	,	O
30	RB	O
kDa.	CD	O
Branched	,	O
PEG	CC	O
(PEG2	IN	O
or	CD	O
mPEG2)	.	O
polymers	VBN	O
will	NNP	O
typically	NNP	O
have	CC	O
a	)	O
molecular	NNS	O
weight	MD	O
of	RB	O
about	VB	O
10	DT	O
kDa,	JJ	O
about	NN	O
20	IN	O
kDa,	IN	O
or	CD	O
about	,	O
40	RB	O
kDa.	CD	O
In	,	O
some	CC	O
instances,	IN	O
the	CD	O
higher-molecular	.	O
weight	IN	O
branched	DT	O
PEG2	,	O
reagents,	DT	O
such	JJ	O
as	NN	O
20	VBD	O
kDa	NNP	O
or	,	O
40	JJ	O
kDa	IN	O
PEG2,	CD	O
including	NN	O
e.g.	CC	O
mPEG2-NHS	CD	O
for	NN	O
lysine	,	O
PEGylation,	VBG	O
mPEG2-MAL	.	O
for	NN	O
cysteine	IN	O
PEGylation,	JJ	O
or	,	O
MPEG2-aldehyde	NN	O
for	IN	O
N-terminal	NN	O
PEGylation	,	O
(all	CC	O
available	NNP	O
from	IN	O
Nektar	NNP	O
Therapeutics,	NNP	O
Inc,	DT	O
Huntsville	JJ	O
Ala.),	IN	O
may	NNP	O
be	,	O
used.	,	O
The	NNP	O
branched	,	O
structure	MD	O
of	VB	O
the	.	O
PEG2	DT	O
compound	JJ	O
results	NN	O
in	IN	O
a	DT	O
relatively	NNP	O
large	NN	O
molecular	NNS	O
volume,	IN	O
so	DT	O
fewer	RB	O
attached	JJ	O
molecules	JJ	O
(or,	,	O
one	RB	O
attached	JJR	O
molecule)	JJ	O
may	NNS	O
impart	,	O
the	CD	O
desired	VBN	O
characteristics	)	O
of	MD	O
the	VB	O
PEGylated	DT	O
molecule.	JJ	O
The	NNS	O
skilled	IN	O
person	DT	O
will	NNP	O
be	.	O
aware	DT	O
that	JJ	O
the	NN	O
activation	MD	O
method	VB	O
and/or	JJ	O
conjugation	IN	O
chemistry	DT	O
to	NN	O
be	NN	O
used	JJ	O
depends	NN	O
on	NN	O
the	TO	O
attachment	VB	O
group(s)	VBN	O
of	VBZ	O
the	IN	O
oligoadenylate	DT	O
synthetase	NN	O
polypeptide	)	O
as	IN	O
well	DT	O
as	JJ	O
the	NN	O
functional	NN	O
groups	RB	O
of	RB	O
the	IN	O
polymer	DT	O
(e.g.,	JJ	O
being	NNS	O
amino,	IN	O
hydroxyl,	DT	O
carboxyl,	NN	O
aldehyde	,	O
or	VBG	O
sulfhydryl).	,	O
The	,	O
PEGylation	,	O
may	NN	O
be	CC	O
directed	.	O
towards	DT	O
conjugation	NN	O
to	MD	O
all	VB	O
available	VBN	O
attachment	NNS	O
groups	NN	O
on	TO	O
the	DT	O
polypeptide	JJ	O
(i.e.	NN	O
such	NNS	O
attachment	IN	O
groups	DT	O
that	NN	O
are	.	O
exposed	JJ	O
at	NN	O
the	NNS	O
surface	WDT	O
of	VBP	O
the	VBN	O
polypeptide)	IN	O
or	DT	O
may	NN	O
be	IN	O
directed	DT	O
towards	)	O
specific	CC	O
attachment	MD	O
groups,	VB	O
e.g.	VBN	O
cysteine	NNS	O
residues,	JJ	O
lysine	NN	O
residues,	,	O
or	.	O
the	NN	O
N-terminal	,	O
amino	NN	O
group.	,	O
Furthermore,	CC	O
the	DT	O
conjugation	JJ	O
may	NN	O
be	.	O
achieved	,	O
in	DT	O
one	NN	O
step	MD	O
or	VB	O
in	VBN	O
a	IN	O
stepwise	CD	O
manner	NN	O
(e.g.,	CC	O
as	IN	O
described	DT	O
in	NN	O
WO	NN	O
99/55377).	,	O
In	IN	O
some	VBN	O
instances,	IN	O
the	NNP	O
polymer	.	O
conjugation	IN	O
is	DT	O
performed	,	O
under	DT	O
conditions	NN	O
aiming	NN	O
at	VBZ	O
reacting	VBN	O
as	IN	O
many	NNS	O
of	VBG	O
the	IN	O
available	VBG	O
polymer	IN	O
attachment	JJ	O
groups	IN	O
as	DT	O
possible	JJ	O
with	NN	O
polymer	NN	O
molecules.	NNS	O
This	IN	O
is	JJ	O
achieved	IN	O
by	JJ	O
means	.	O
of	DT	O
a	VBZ	O
suitable	VBN	O
molar	IN	O
excess	NNS	O
of	IN	O
the	DT	O
polymer	JJ	O
in	JJ	O
relation	NN	O
to	IN	O
the	DT	O
polypeptide.	NN	O
Typical	IN	O
molar	NN	O
ratios	TO	O
of	DT	O
activated	.	O
polymer	JJ	O
molecules	JJ	O
to	NNS	O
polypeptide	IN	O
are	JJ	O
up	NN	O
to	NNS	O
about	TO	O
1000-1,	VB	O
such	VBP	O
as	RB	O
up	TO	O
to	IN	O
about	,	O
200-1	JJ	O
or	IN	O
up	IN	O
to	TO	O
about	IN	O
100-1.	CD	O
In	CC	O
some	RB	O
cases,	TO	O
the	IN	O
ratio	.	O
may	IN	O
be	DT	O
somewhat	,	O
lower,	DT	O
however,	NN	O
such	MD	O
as	VB	O
up	RB	O
to	,	O
about	,	O
50-1,	JJ	O
10-1	IN	O
or	IN	O
5-1.	TO	O
Also	IN	O
equimolar	,	O
ratios	JJ	O
may	CC	O
be	.	O
used.	RB	O
It	JJ	O
is	NNS	O
also	MD	O
contemplated	VB	O
according	.	O
to	PRP	O
the	VBZ	O
invention	RB	O
to	VBN	O
couple	VBG	O
the	TO	O
polymer	DT	O
molecules	NN	O
to	TO	O
the	VB	O
polypeptide	DT	O
through	NN	O
a	NNS	O
linker.	TO	O
Suitable	DT	O
linkers	NN	O
are	IN	O
well	DT	O
known	.	O
to	JJ	O
the	NNS	O
skilled	VBP	O
person.	RB	O
A	VBN	O
preferred	TO	O
example	DT	O
is	JJ	O
cyanuric	.	O
chloride	DT	O
Abuchowski	JJ	B
et	NN	I
al.,	VBZ	I
(1977),	JJ	I
J.	NN	I
Biol.	NNP	I
Chem.,	RB	I
252,	,	I
3578-3581;	,	I
(U.S.	NNP	O
Pat.	.	O
No.	,	O
4,179,337;	,	O
Shafer	:	B
et	NNP	I
al.,	.	I
(1986),	.	I
J.	:	I
Polym.	NNP	I
Sci.	FW	I
Polym.	,	I
Chem.	,	I
Ed.,	NNP	I
24,	.	I
375-378).Subsequent	.	O
to	.	O
the	.	O
conjugation	,	O
residual	,	O
activated	.	O
polymer	JJ	O
molecules	TO	O
are	DT	O
blocked	NN	O
according	JJ	O
to	VBD	O
methods	NN	O
known	NNS	O
in	VBP	O
the	VBN	O
art,	VBG	O
e.g.,	TO	O
by	NNS	O
addition	VBN	O
of	IN	O
primary	DT	O
amine	,	O
to	,	O
the	IN	O
reaction	NN	O
mixture,	IN	O
and	JJ	O
the	NN	O
resulting	TO	O
inactivated	DT	O
polymer	NN	O
molecules	,	O
removed	CC	O
by	DT	O
a	VBG	O
suitable	JJ	O
method.	NN	O
Covalent	NNS	O
in	VBN	O
vitro	IN	O
coupling	DT	O
of	JJ	O
a	.	O
sugar	NN	O
moiety	IN	O
to	JJ	O
amino	NN	O
acid	IN	O
residues	DT	O
of	NN	O
the	NN	O
polypeptides	TO	O
of	VB	O
the	JJ	O
invention	NNS	O
may	IN	O
be	DT	O
used	NNS	O
to	IN	O
modify	DT	O
or	NN	O
increase	MD	O
the	VB	O
number	VBN	O
or	TO	O
profile	VB	O
of	CC	O
sugar	VB	O
substituents.	DT	O
Depending	NN	O
on	CC	O
the	NN	O
coupling	IN	O
mode	NN	O
used,	.	O
the	VBG	O
carbohydrate(s)	IN	O
may	DT	O
be	NN	O
attached	NN	O
to:	,	O
a)	DT	O
arginine	)	O
and	MD	O
histidine	VB	O
(Lundblad	VBN	O
and	:	O
Noyes,	)	O
Chemical	NN	O
Reagents	CC	O
for	NN	O
Protein	NNP	O
Modification,	CC	O
CRC	,	O
Press	NNP	O
Inc.	NNP	O
Boca	IN	O
Raton,	NNP	O
Fla.),	,	O
b)	NNP	O
free	NNP	O
carboxyl	NNP	O
groups	NNP	O
(e.g.,	,	O
of	,	O
the	)	O
C-terminal	JJ	O
amino	NN	O
acid	NNS	O
residue,	,	O
asparagine	IN	O
or	DT	O
glutamine),	NNP	O
c)	NN	O
free	NN	O
sulfhydryl	,	O
groups	NN	O
such	CC	O
as	,	O
that	)	O
of	JJ	O
cysteine,	NN	O
d)	NNS	O
free	JJ	O
hydroxyl	IN	O
groups	DT	O
such	IN	O
as	,	O
those	)	O
of	JJ	O
serine,	NN	O
threonine,	NNS	O
tyrosine	JJ	O
or	IN	O
hydroxyproline,	DT	O
e)	IN	O
aromatic	,	O
residues	,	O
such	NN	O
as	CC	O
those	,	O
of	)	O
phenylalanine	JJ	O
or	NNS	O
tryptophan	JJ	O
or	IN	O
f)	DT	O
the	IN	O
amide	NN	O
group	CC	O
of	NN	O
glutamine.	CC	O
These	)	O
amino	DT	O
acid	JJ	O
residues	NN	O
constitute	IN	O
examples	.	O
of	DT	O
attachment	JJ	O
groups	NN	O
for	NNS	O
a	VBP	O
sugar	NNS	O
moiety,	IN	O
which	NN	O
may	NNS	O
be	IN	O
introduced	DT	O
and/or	NN	O
removed	,	O
in	WDT	O
the	MD	O
polypeptides	VB	O
of	VBN	O
the	RB	O
invention.	VBN	O
Suitable	IN	O
methods	DT	O
of	NNS	O
in	IN	O
vitro	DT	O
coupling	.	O
are	JJ	O
described	NNS	O
in	IN	O
WO	IN	O
87/05330	NN	O
and	NN	O
in	VBP	O
Aplin	VBN	B
et	IN	I
al.,	NNP	I
CRC	CD	I
Crit	CC	I
Rev.	IN	I
Biochem.,	NNP	I
pp.	CC	I
259-306,	,	I
1981.	NNP	I
The	NNP	O
in	.	O
vitro	,	O
coupling	.	O
of	,	O
sugar	.	O
moieties	DT	O
or	IN	O
PEG	JJ	O
to	NN	O
protein-	IN	O
and	NN	O
peptide-bound	NNS	O
Gln-residues	CC	O
can	NNP	O
also	TO	O
be	NN	O
carried	CC	O
out	JJ	O
by	NNS	O
transglutaminases	MD	O
(TGases),	RB	O
e.g.	VB	O
as	VBN	O
described	RP	O
by	IN	O
Sato	NNS	B
et	,	I
al.,	.	I
1996	IN	I
Biochemistry	VBN	I
35,	IN	I
13072-13080	NNP	I
or	FW	O
in	,	O
EP	CD	O
725145.	NNP	O
In	,	O
order	CD	O
to	CC	O
achieve	IN	O
in	NNP	O
vivo	.	O
glycosylation	IN	O
of	NN	O
an	TO	O
oligoadenylate	VB	O
synthetase	IN	O
polypeptide	JJ	O
that	NN	O
has	IN	O
been	DT	O
modified	JJ	O
by	NN	O
introduction	NN	O
of	WDT	O
one	VBZ	O
or	VBN	O
more	VBN	O
glycosylation	IN	O
sites,	NN	O
the	IN	O
nucleotide	CD	O
sequence	CC	O
encoding	JJR	O
the	NN	O
polypeptide	,	O
part	DT	O
of	JJ	O
the	NN	O
conjugate	VBG	O
is	DT	O
inserted	JJ	O
in	NN	O
a	IN	O
glycosylating,	DT	O
eukaryotic	NN	O
expression	VBZ	O
host.	VBN	O
The	IN	O
expression	DT	O
host	,	O
cell	JJ	O
may	NN	O
be	.	O
selected	DT	O
from	NN	O
fungal	NN	O
(filamentous	NN	O
fungal	MD	O
or	VB	O
yeast),	VBN	O
insect,	IN	O
mammalian	JJ	O
animal	JJ	O
cells,	NN	O
from	CC	O
transgenic	,	O
plant	,	O
cells	JJ	O
or	NN	O
from	,	O
transgenic	IN	O
animals.	JJ	O
Furthermore,	NN	O
the	NNS	O
glycosylation	CC	O
may	IN	O
be	JJ	O
achieved	.	O
in	,	O
the	DT	O
human	NN	O
body	MD	O
when	VB	O
using	VBN	O
a	IN	O
nucleotide	DT	O
sequence	JJ	O
encoding	NN	O
the	WRB	O
polypeptide	VBG	O
part	DT	O
of	JJ	O
a	NN	O
conjugate	VBG	O
of	DT	O
the	JJ	O
invention	NN	O
or	IN	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
in	CC	O
gene	DT	O
therapy.	NN	O
In	IN	O
one	DT	O
aspect	NN	O
the	IN	O
host	NN	O
cell	.	O
is	IN	O
a	CD	O
mammalian	NN	O
cell,	DT	O
such	NN	O
as	NN	O
a	VBZ	O
CHO	DT	O
cell,	JJ	O
a	,	O
COS	JJ	O
cell,	IN	O
a	DT	O
BHK	NNP	O
or	,	O
HEK	DT	O
cell,	NNP	O
e.g.,	,	O
HEK293,	DT	O
or	NNP	O
an	CC	O
insect	NNP	O
cell,	,	O
such	,	O
as	,	O
an	CC	O
SF9	DT	O
cell,	JJ	O
or	,	O
a	JJ	O
yeast	IN	O
cell,	DT	O
e.g.	NNP	O
Saccharomyces	,	O
cerevisiae,	CC	O
Pichia	DT	O
pastoris	NN	O
or	,	O
any	.	O
other	NNS	O
suitable	,	O
glycosylating	NNP	O
host,	NN	O
e.g.	CC	O
as	DT	O
described	JJ	O
further	JJ	O
below.	VBG	O
Optionally,	,	O
sugar	.	O
moieties	IN	O
attached	VBN	O
to	RB	O
the	.	O
oligoadenylate	,	O
synthetase	NN	O
polypeptide	NNS	O
by	VBN	O
in	TO	O
vivo	DT	O
glycosylation	JJ	O
are	NN	O
further	NN	O
modified	IN	O
by	IN	O
use	JJ	O
of	NN	O
glycosyltransferases,	VBP	O
e.g.,	JJ	O
using	VBN	O
the	IN	O
GlycoAdvance™	NN	O
technology	IN	O
marketed	,	O
by	,	O
Neose,	VBG	O
Horsham,	DT	O
Pa.,	NNP	O
USA.	NN	O
Thereby,	VBN	O
it	IN	O
is	,	O
possible	,	O
to,	,	O
e.g.,	.	O
increase	,	O
the	PRP	O
sialyation	VBZ	O
of	JJ	O
the	,	O
glycosylated	,	O
oligoadenylate	VB	O
synthetase	DT	O
polypeptide	NN	O
following	IN	O
expression	DT	O
and	JJ	O
in	NN	O
vivo	NN	O
glycosylation	NN	O
by	VBG	O
CHO	NN	O
cells.	CC	O
Covalent	IN	O
modification	JJ	O
of	NN	O
the	IN	O
polypeptides	NNP	O
of	.	O
the	JJ	O
invention	NN	O
may	IN	O
be	DT	O
performed	NNS	O
by	IN	O
reacting	DT	O
(an)	NN	O
attachment	MD	O
group(s)	VB	O
of	VBN	O
the	IN	O
polypeptide	VBG	O
with	)	O
an	NN	O
organic	)	O
derivatizing	IN	O
agent.	DT	O
Suitable	NN	O
derivatizing	IN	O
agents	DT	O
and	JJ	O
methods	NN	O
are	.	O
well	JJ	O
known	VBG	O
in	NNS	O
the	CC	O
art.	NNS	O
For	VBP	O
example,	RB	O
cysteinyl	VBN	O
residues	IN	O
most	DT	O
commonly	.	O
are	IN	O
reacted	,	O
with	NN	O
alpha-haloacetates	NNS	O
(and	RBS	O
corresponding	RB	O
amines),	VBP	O
such	VBN	O
as	IN	O
chloroacetic	NNS	O
acid	CC	O
or	VBG	O
chloroacetamide,	,	O
to	JJ	O
give	IN	O
carboxymethyl	JJ	O
or	NN	O
carboxyamidomethyl	CC	O
derivatives.	,	O
Cysteinyl	TO	O
residues	VB	O
also	NN	O
are	CC	O
derivatized	NN	O
by	.	O
reaction	NNP	O
with	NNS	O
bromotrifluoroacetone,	RB	O
alpha-bromo-beta-(4-imidozoyl-)propionic	VBP	O
acid,	VBN	O
chloroacetyl	IN	O
phosphate,	NN	O
N-alkylmaleimides,	IN	O
3-nitro-2-pyridyl	,	O
disulfide,	JJ	O
methyl	,	O
2-pyridyl	NN	O
disulfide,	,	O
p-chloromercuribenzoate,	,	O
2-chloromercuri-4-nitrophenol,	JJ	O
or	,	O
chloro-7-nitrobenzo-2-oxa-1,3-diazole.	JJ	O
Histidyl	JJ	O
residues	,	O
are	,	O
derivatized	,	O
by	CC	O
reaction	.	O
with	NNP	O
diethylpyrocarbonate	NNS	O
at	VBP	O
pH	VBN	O
5.5-7.0	IN	O
because	NN	O
this	IN	O
agent	NN	O
is	IN	O
relatively	JJ	O
specific	JJ	O
for	IN	O
the	DT	O
histidyl	NN	O
side	VBZ	O
chain.	RB	O
Para-bromophenacyl	JJ	O
bromide	IN	O
is	DT	O
also	JJ	O
useful;	NN	O
the	.	O
reaction	NNP	O
is	NN	O
preferably	VBZ	O
performed	RB	O
in	:	O
0.1	DT	O
M	NN	O
sodium	VBZ	O
cacodylate	RB	O
at	VBN	O
pH	IN	O
6.0.	CD	O
Lysinyl	NNP	O
and	NN	O
amino	NN	O
terminal	IN	O
residues	JJ	O
are	.	O
reacted	NNP	O
with	CC	O
succinic	JJ	O
or	NN	O
other	NNS	O
carboxylic	VBP	O
acid	VBN	O
anhydrides.	IN	O
Derivatization	JJ	O
with	CC	O
these	JJ	O
agents	JJ	O
has	NN	O
the	.	O
effect	NN	O
of	IN	O
reversing	DT	O
the	NNS	O
charge	VBZ	O
of	DT	O
the	NN	O
lysinyl	IN	O
residues.	VBG	O
Other	DT	O
suitable	NN	O
reagents	IN	O
for	DT	O
derivatizing	NN	O
alpha-amino-containing	.	O
residues	JJ	O
include	JJ	O
imidoesters	NNS	O
such	IN	O
as	VBG	O
methyl	JJ	O
picolinimidate;	NNS	O
pyridoxal	VBP	O
phosphate;	NNS	O
pyridoxal;	JJ	O
chloroborohydride;	IN	O
trinitrobenzenesulfonic	JJ	O
acid;	:	O
O-methylisourea;	JJ	O
2,4-pentanedione;	:	O
and	:	O
transaminase-catalyzed	:	O
reaction	JJ	O
with	:	O
glyoxylate.	:	O
Arginyl	:	O
residues	CC	O
are	JJ	O
modified	NN	O
by	IN	O
reaction	.	O
with	NNP	O
one	NNS	O
or	VBP	O
several	VBN	O
conventional	IN	O
reagents,	NN	O
among	IN	O
them	CD	O
phenylglyoxal,	CC	O
2,3-butanedione,	JJ	O
1,2-cyclohexanedione,	JJ	O
and	,	O
ninhydrin.	IN	O
Derivatization	PRP	O
of	,	O
arginine	,	O
residues	,	O
requires	CC	O
that	.	O
the	NN	O
reaction	IN	O
be	NN	O
performed	NNS	O
in	VBZ	O
alkaline	IN	O
conditions	DT	O
because	NN	O
of	VB	O
the	VBN	O
high	IN	O
pKa	JJ	O
of	NNS	O
the	IN	O
guanidine	IN	O
functional	DT	O
group.	JJ	O
Furthermore,	NN	O
these	IN	O
reagents	DT	O
may	JJ	O
react	JJ	O
with	.	O
the	,	O
groups	DT	O
of	NNS	O
lysine	MD	O
as	VB	O
well	IN	O
as	DT	O
the	NNS	O
arginine	IN	O
guanidino	NN	O
group.	RB	O
Carboxyl	RB	O
side	IN	O
groups	DT	O
(aspartyl	NN	O
or	NN	O
glutamyl	.	O
or	NNP	O
C-terminal	NN	O
amino	NNS	O
acid	NN	O
residue)	CC	O
are	NN	O
selectively	CC	O
modified	JJ	O
by	NN	O
reaction	IN	O
with	)	O
carbodiimides	VBP	O
(R—N-double	RB	O
bond-C-double	VBN	O
bond-N—R′),	IN	O
where	NN	O
R	IN	O
and	NNS	O
R′	JJ	O
are	JJ	O
different	,	O
alkyl	WRB	O
groups,	NNP	O
such	CC	O
as	NNP	O
1-cyclohexyl-3-(2-morpholinyl-4-ethyl)carbodiimide	VBP	O
or	JJ	O
1-ethyl-3-(4-azonia-4,4-dimethylpentyl)carbodiimide.	NN	O
Furthermore,	,	O
aspartyl	JJ	O
and	IN	O
glutamyl	NN	O
residues	CC	O
are	.	O
converted	,	O
to	NN	O
asparaginyl	CC	O
and	NN	O
glutaminyl	NNS	O
residues	VBP	O
by	VBN	O
reaction	TO	O
with	VB	O
ammonium	CC	O
ions.	VB	O
Since	NNS	O
excessive	IN	O
polymer	NN	O
conjugation	IN	O
may	NN	O
lead	.	O
to	IN	O
a	JJ	O
loss	NN	O
of	NN	O
activity	MD	O
of	VB	O
the	TO	O
oligoadenylate	DT	O
synthetase	NN	O
polypeptides	IN	O
to	NN	O
which	IN	O
the	DT	O
polymer	JJ	O
is	NN	O
conjugated,	NNS	O
it	TO	O
may	WDT	O
be	DT	O
advantageous	NN	O
to	VBZ	O
remove	,	O
attachment	PRP	O
groups	MD	O
located	VB	O
at	JJ	O
the	TO	O
functional	VB	O
site	NN	O
or	NNS	O
to	VBN	O
block	IN	O
the	DT	O
functional	JJ	O
site	NN	O
prior	CC	O
to	TO	O
conjugation.	VB	O
These	DT	O
latter	JJ	O
strategies	NN	O
constitute	RB	O
further	TO	O
aspects	.	O
of	DT	O
the	JJ	O
invention	NNS	O
(the	VBP	O
first	JJ	O
strategy	NNS	O
being	IN	O
exemplified	DT	O
further	NN	O
above,	DT	O
e.g.	JJ	O
by	NN	O
removal	VBG	O
of	VBN	O
lysine	RBR	O
residues	,	O
which	.	O
may	IN	O
be	NN	O
located	IN	O
close	NN	O
to	NNS	O
a	WDT	O
functional	MD	O
site).	VB	O
More	VBN	O
specifically,	RB	O
according	TO	O
to	DT	O
the	JJ	O
second	.	O
strategy	RBR	O
the	,	O
conjugation	VBG	O
between	TO	O
the	DT	O
oligoadenylate	JJ	O
synthetase	NN	O
polypeptide	DT	O
and	NN	O
the	IN	O
non-polypeptide	DT	O
moiety	JJ	O
is	NN	O
conducted	NN	O
under	CC	O
conditions	DT	O
where	JJ	O
the	NN	O
functional	VBZ	O
site	VBN	O
of	IN	O
the	NNS	O
polypeptide	WRB	O
is	DT	O
blocked	JJ	O
by	NN	O
a	IN	O
helper	DT	O
molecule	NN	O
capable	VBZ	O
of	VBN	O
binding	IN	O
to	DT	O
the	NN	O
functional	NN	O
site	JJ	O
of	IN	O
the	VBG	O
polypeptide.	TO	O
Preferably,	DT	O
the	JJ	O
helper	NN	O
molecule	IN	O
is	DT	O
one	.	O
which	,	O
specifically	DT	O
recognizes	NN	O
a	NN	O
functional	VBZ	O
site	CD	O
of	WDT	O
the	RB	O
polypeptide.	VBZ	O
Alternatively,	DT	O
the	JJ	O
helper	NN	O
molecule	IN	O
may	DT	O
be	.	O
an	,	O
antibody,	DT	O
in	NN	O
particular	NN	O
a	MD	O
monoclonal	VB	O
antibody	DT	O
recognizing	,	O
the	IN	O
polypeptide.	JJ	O
In	DT	O
particular,	JJ	O
the	NN	O
helper	VBG	O
molecule	DT	O
may	.	O
be	IN	O
a	,	O
neutralizing	DT	O
monoclonal	NN	O
antibody.	NN	O
The	MD	O
polypeptide	VB	O
is	DT	O
allowed	JJ	O
to	JJ	O
interact	.	O
with	DT	O
the	NN	O
helper	VBZ	O
molecule	VBN	O
before	TO	O
effecting	VB	O
conjugation.	IN	O
This	DT	O
ensures	NN	O
that	NN	O
the	IN	O
functional	VBG	O
site	.	O
of	DT	O
the	VBZ	O
polypeptide	IN	O
is	DT	O
shielded	JJ	O
or	NN	O
protected	IN	O
and	DT	O
consequently	NN	O
unavailable	VBZ	O
for	VBN	O
derivatization	CC	O
by	VBN	O
the	CC	O
non-polypeptide	RB	O
moiety	JJ	O
such	IN	O
as	NN	O
a	IN	O
polymer.	DT	O
Following	JJ	O
its	NN	O
elution	JJ	O
from	IN	O
the	DT	O
helper	.	O
molecule,	VBG	O
the	PRP$	O
conjugate	NN	O
between	IN	O
the	DT	O
non-polypeptide	NN	O
moiety	,	O
and	DT	O
the	NN	O
polypeptide	IN	O
can	DT	O
be	JJ	O
recovered	NN	O
with	CC	O
at	DT	O
least	NN	O
a	MD	O
partially	VB	O
preserved	VBN	O
functional	IN	O
site.	IN	O
The	JJS	O
subsequent	DT	O
conjugation	RB	O
of	VBN	O
the	JJ	O
polypeptide	.	O
having	DT	O
a	JJ	O
blocked	NN	O
functional	IN	O
site	DT	O
to	NN	O
a	VBG	O
polymer,	DT	O
a	JJ	O
lipophilic	JJ	O
compound,	NN	O
an	TO	O
organic	DT	O
derivatizing	,	O
agent	DT	O
or	JJ	O
any	,	O
other	DT	O
compound	JJ	O
is	NN	O
conducted	NN	O
in	CC	O
the	DT	O
normal	JJ	O
way.	NN	O
Irrespective	VBZ	O
of	VBN	O
the	IN	O
nature	DT	O
of	JJ	O
the	.	O
helper	NNP	O
molecule	IN	O
to	DT	O
be	NN	O
used	IN	O
to	DT	O
shield	NN	O
the	NN	O
functional	TO	O
site	VB	O
of	VBN	O
the	TO	O
polypeptide	VB	O
from	DT	O
conjugation,	JJ	O
it	NN	O
is	IN	O
desirable	DT	O
that	NN	O
the	IN	O
helper	,	O
molecule	PRP	O
is	VBZ	O
free	JJ	O
from	IN	O
or	DT	O
comprises	NN	O
only	NN	O
a	VBZ	O
few	JJ	O
attachment	IN	O
groups	CC	O
for	VBZ	O
the	RB	O
non-polypeptide	DT	O
moiety	JJ	O
of	NN	O
choice	NNS	O
in	IN	O
parts	DT	O
of	JJ	O
the	NN	O
molecule	IN	O
where	NN	O
the	IN	O
conjugation	NNS	O
to	IN	O
such	DT	O
groups	NN	O
would	WRB	O
hamper	DT	O
the	NN	O
desorption	TO	O
of	JJ	O
the	NNS	O
conjugated	MD	O
polypeptide	VB	O
from	DT	O
the	NN	O
helper	IN	O
molecule.	DT	O
Hereby,	JJ	O
selective	NN	O
conjugation	IN	O
to	DT	O
attachment	NN	O
groups	.	O
present	,	O
in	JJ	O
non-shielded	NN	O
parts	TO	O
of	VB	O
the	NNS	O
polypeptide	JJ	O
can	IN	O
be	JJ	O
obtained	NNS	O
and	IN	O
it	DT	O
is	NN	O
possible	MD	O
to	VB	O
reuse	VBN	O
the	CC	O
helper	PRP	O
molecule	VBZ	O
for	JJ	O
repeated	TO	O
cycles	VB	O
of	DT	O
conjugation.	NN	O
For	NN	O
instance,	IN	O
if	JJ	O
the	NNS	O
non-polypeptide	IN	O
moiety	.	O
is	IN	O
a	,	O
polymer	IN	O
molecule	DT	O
such	JJ	O
as	NN	O
PEG,	VBZ	O
which	DT	O
has	JJ	O
the	NN	O
epsilon	JJ	O
amino	IN	O
group	,	O
of	WDT	O
a	VBZ	O
lysine	DT	O
or	NN	O
N-terminal	NN	O
amino	NN	O
acid	IN	O
residue	DT	O
as	NN	O
an	CC	O
attachment	JJ	O
group,	NN	O
it	NN	O
is	NN	O
desirable	IN	O
that	DT	O
the	NN	O
helper	,	O
molecule	PRP	O
is	VBZ	O
substantially	JJ	O
free	IN	O
from	DT	O
conjugatable	NN	O
epsilon	NN	O
amino	VBZ	O
groups,	RB	O
preferably	JJ	O
free	IN	O
from	JJ	O
any	NN	O
epsilon	NN	O
amino	,	O
groups.	RB	O
Accordingly,	JJ	O
in	IN	O
some	DT	O
instances	NN	O
the	NN	O
helper	.	O
molecule	,	O
is	IN	O
a	DT	O
protein	NNS	O
or	DT	O
peptide	NN	O
capable	NN	O
of	VBZ	O
binding	DT	O
to	NN	O
the	CC	O
functional	NN	O
site	JJ	O
of	IN	O
the	VBG	O
polypeptide,	TO	O
which	DT	O
protein	JJ	O
or	NN	O
peptide	IN	O
is	DT	O
free	,	O
from	WDT	O
any	VBP	O
conjugatable	CC	O
attachment	VBP	O
groups	VBZ	O
for	JJ	O
the	IN	O
non-polypeptide	DT	O
moiety	JJ	O
of	NN	O
choice.	NNS	O
In	IN	O
a	DT	O
further	JJ	O
aspect,	NN	O
the	IN	O
helper	.	O
molecule	IN	O
is	DT	O
first	JJ	O
covalently	,	O
linked	DT	O
to	NN	O
a	NN	O
solid	VBZ	O
phase	RB	O
such	RB	O
as	VBN	O
column	TO	O
packing	DT	O
materials,	JJ	O
for	NN	O
instance	JJ	O
Sephadex	IN	O
or	NN	O
agarose	NN	O
beads,	,	O
or	IN	O
a	NN	O
surface,	NNP	O
e.g.	CC	O
reaction	JJ	O
vessel.	,	O
Subsequently,	CC	O
the	DT	O
polypeptide	,	O
is	.	O
loaded	NN	O
onto	.	O
the	,	O
column	DT	O
material	NN	O
carrying	VBZ	O
the	VBN	O
helper	IN	O
molecule	DT	O
and	NN	O
conjugation	NN	O
carried	VBG	O
out	DT	O
according	NN	O
to	NN	O
methods	CC	O
known	NN	O
in	VBD	O
the	RP	O
art.	VBG	O
This	TO	O
procedure	NNS	O
allows	VBN	O
the	IN	O
polypeptide	DT	O
conjugate	.	O
to	DT	O
be	NN	O
separated	VBZ	O
from	DT	O
the	NN	O
helper	NN	O
molecule	TO	O
by	VB	O
elution.	VBN	O
The	IN	O
polypeptide	DT	O
conjugate	NN	O
is	NN	O
eluted	IN	O
by	.	O
conventional	DT	O
techniques	NN	O
under	NN	O
physico-chemical	VBZ	O
conditions	VBN	O
that	IN	O
do	JJ	O
not	NNS	O
lead	IN	O
to	JJ	O
a	NNS	O
substantive	WDT	O
degradation	VBP	O
of	RB	O
the	VB	O
polypeptide	TO	O
conjugate.	DT	O
The	JJ	O
fluid	NN	O
phase	IN	O
containing	DT	O
the	NN	O
polypeptide	.	O
conjugate	DT	O
is	NN	O
separated	NN	O
from	VBG	O
the	DT	O
solid	NN	O
phase	NN	O
to	VBZ	O
which	VBN	O
the	IN	O
helper	DT	O
molecule	JJ	O
remains	NN	O
covalently	TO	O
linked.	WDT	O
The	DT	O
separation	NN	O
can	NN	O
be	VBZ	O
achieved	RB	O
in	.	O
other	DT	O
ways.	NN	O
For	MD	O
instance,	VB	O
the	VBN	O
helper	IN	O
molecule	JJ	O
may	.	O
be	IN	O
derivatized	,	O
with	DT	O
a	NN	O
second	NN	O
molecule	MD	O
(e.g.,	VB	O
biotin)	VBN	O
that	IN	O
can	DT	O
be	JJ	O
recognized	NN	O
by	,	O
a	)	O
specific	WDT	O
binder	MD	O
(e.g.,	VB	O
streptavidin).	VBN	O
The	IN	O
specific	DT	O
binder	JJ	O
may	NN	O
be	,	O
linked	.	O
to	DT	O
a	JJ	O
solid	NN	O
phase	MD	O
thereby	VB	O
allowing	VBN	O
the	TO	O
separation	DT	O
of	JJ	O
the	NN	O
polypeptide	RB	O
conjugate	VBG	O
from	DT	O
the	NN	O
helper	IN	O
molecule-second	DT	O
molecule	JJ	O
complex	NN	O
through	IN	O
passage	DT	O
over	JJR	O
a	NN	O
second	NN	O
helper-solid	NN	O
phase	IN	O
column	NN	O
which	IN	O
will	DT	O
retain,	JJ	O
upon	JJ	O
subsequent	NN	O
elution,	NN	O
the	WDT	O
helper	MD	O
molecule-second	,	O
molecule	IN	O
complex,	JJ	O
but	,	O
not	DT	O
the	JJR	O
polypeptide	NN	O
conjugate.	NN	O
The	,	O
polypeptide	CC	O
conjugate	RB	O
may	DT	O
be	NN	O
released	.	O
from	DT	O
the	JJ	O
helper	NN	O
molecule	MD	O
in	VB	O
any	VBN	O
appropriate	IN	O
fashion.	DT	O
De-protection	NN	O
may	NN	O
be	IN	O
achieved	DT	O
by	JJ	O
providing	.	O
conditions	NN	O
in	MD	O
which	VB	O
the	VBN	O
helper	IN	O
molecule	VBG	O
dissociates	NNS	O
from	IN	O
the	WDT	O
functional	DT	O
site	NN	O
of	NN	O
the	VBZ	O
polypeptide	IN	O
to	DT	O
which	JJ	O
it	NN	O
is	IN	O
bound;	DT	O
for	NN	O
instance,	TO	O
a	WDT	O
complex	PRP	O
between	VBZ	O
an	:	O
antibody	IN	O
to	,	O
which	DT	O
a	NN	O
polymer	IN	O
is	DT	O
conjugated	NN	O
and	TO	O
an	WDT	O
anti-idiotypic	DT	O
antibody	NN	O
can	VBZ	O
be	VBN	O
dissociated	CC	O
by	DT	O
adjusting	JJ	O
the	NN	O
pH	MD	O
to	VB	O
an	VBN	O
acid	IN	O
or	VBG	O
alkaline	DT	O
pH.	NN	O
In	TO	O
another	DT	O
aspect	NN	O
the	CC	O
oligoadenylate	NN	O
synthetase	.	O
polypeptide	IN	O
is	DT	O
expressed	NN	O
as	DT	O
a	NN	O
fusion	NN	O
protein	NN	O
with	VBZ	O
a	VBN	O
tag,	IN	O
i.e.	DT	O
an	NN	O
amino	NN	O
acid	IN	O
sequence	DT	O
or	,	O
peptide	.	O
made	DT	O
up	NN	O
of	NN	O
typically	NN	O
1-30,	CC	O
such	NN	O
as	VBD	O
1-20	IN	O
or	IN	O
1-15	RB	O
or	,	O
1-10	JJ	O
or	IN	O
1-5	JJ	O
amino	CC	O
acid	JJ	O
residues,	CC	O
e.g.,	JJ	O
added	CC	O
to	JJ	O
the	NN	O
N-terminus	NN	O
or	,	O
to	,	O
the	VBD	O
C-terminus	TO	O
of	DT	O
the	NNP	O
polypeptide.	CC	O
Besides	TO	O
allowing	DT	O
for	NNP	O
fast	IN	O
and	DT	O
easy	.	O
purification,	IN	O
the	VBG	O
tag	IN	O
is	NN	O
a	CC	O
convenient	JJ	O
tool	,	O
for	DT	O
achieving	NN	O
conjugation	VBZ	O
between	DT	O
the	JJ	O
tagged	NN	O
polypeptide	IN	O
and	VBG	O
the	NN	O
non-polypeptide	IN	O
moiety.	DT	O
In	VBN	O
particular,	NN	O
the	CC	O
tag	DT	O
may	JJ	O
be	.	O
used	IN	O
for	,	O
achieving	DT	O
conjugation	NN	O
in	MD	O
microtiter	VB	O
plates	VBN	O
or	IN	O
other	VBG	O
carriers,	NN	O
such	IN	O
as	NN	O
paramagnetic	NNS	O
beads,	CC	O
to	JJ	O
which	,	O
the	JJ	O
tagged	IN	O
polypeptide	JJ	O
can	,	O
be	TO	O
immobilised	WDT	O
via	DT	O
the	VBN	O
tag.	NN	O
The	MD	O
conjugation	VB	O
to	VBN	O
the	IN	O
tagged	DT	O
polypeptide	.	O
in,	DT	O
e.g.,	NN	O
microtiter	TO	O
plates	DT	O
has	VBN	O
the	NN	O
advantage	,	O
that	,	O
the	NN	O
tagged	NNS	O
polypeptide	VBZ	O
can	DT	O
be	NN	O
immobilised	IN	O
in	DT	O
the	JJ	O
microtiter	NN	O
plates	MD	O
directly	VB	O
from	VBN	O
the	IN	O
culture	DT	O
broth	NN	O
(in	VBZ	O
principle	RB	O
without	IN	O
any	DT	O
purification)	NN	O
and	NN	O
subjected	IN	O
to	NN	O
conjugation.	IN	O
Thereby,	DT	O
the	)	O
total	CC	O
number	VBN	O
of	TO	O
process	.	O
steps	,	O
(from	DT	O
expression	JJ	O
to	NN	O
conjugation)	IN	O
can	JJ	O
be	NNS	O
reduced.	IN	O
Furthermore,	NN	O
the	TO	O
tag	)	O
may	MD	O
function	VB	O
as	.	O
a	,	O
spacer	DT	O
molecule	NN	O
ensuring	MD	O
an	VB	O
improved	IN	O
accessibility	DT	O
to	NN	O
the	NN	O
immobilised	VBG	O
polypeptide	DT	O
to	JJ	O
be	NN	O
conjugated.	TO	O
The	DT	O
conjugation	JJ	O
using	NN	O
a	TO	O
tagged	VB	O
polypeptide	.	O
may	DT	O
be	NN	O
to	VBG	O
any	DT	O
of	JJ	O
the	NN	O
non-polypeptide	MD	O
moieties	VB	O
disclosed	TO	O
herein,	DT	O
e.g.	IN	O
to	DT	O
a	JJ	O
polymer	NNS	O
molecule	VBN	O
such	,	O
as	.	O
PEG.	TO	O
The	DT	O
identity	NN	O
of	NN	O
the	JJ	O
specific	IN	O
tag	.	O
to	DT	O
be	NN	O
used	IN	O
is	DT	O
not	JJ	O
critical	NN	O
as	TO	O
long	VB	O
as	VBN	O
the	VBZ	O
tag	RB	O
is	JJ	O
capable	RB	O
of	RB	O
being	IN	O
expressed	DT	O
with	NN	O
the	VBZ	O
polypeptide	JJ	O
and	IN	O
is	VBG	O
capable	VBN	O
of	IN	O
being	DT	O
immunobilised	NN	O
on	CC	O
a	VBZ	O
suitable	JJ	O
surface	IN	O
or	VBG	O
carrier	VBN	O
material.	IN	O
A	DT	O
number	JJ	O
of	NN	O
suitable	CC	O
tags	NN	O
are	.	O
commercially	DT	O
available,	NN	O
e.g.	IN	O
from	JJ	O
Unizyme	NNS	O
Laboratories,	VBP	O
Denmark.	RB	O
Antibodies	,	O
against	.	O
such	IN	O
tags	NNP	O
are	,	O
commercially	.	O
available,	NNS	O
e.g.	IN	O
from	JJ	O
ADI,	NNS	O
Ayes	VBP	O
Lab	RB	O
and	,	O
Research	.	O
Diagnostics.	IN	O
The	,	O
polypeptides	NNP	O
of	NNP	O
the	CC	O
invention	NNP	O
include	.	O
modified	DT	O
or	NNS	O
mutant	IN	O
oligoadenylate	DT	O
synthetases	NN	O
with	VBP	O
increased	VBN	O
cell	CC	O
permeability,	JJ	O
such	NN	O
increased	NNS	O
cell	IN	O
permeability	VBN	O
being	NN	O
affected	,	O
by	JJ	O
the	VBN	O
addition	NN	O
of	NN	O
one	VBG	O
or	VBN	O
more	IN	O
basic	DT	O
amino	NN	O
acids	IN	O
residues	CD	O
(e.g.,	CC	O
arginine,	JJR	O
lysine,	JJ	O
histidine),	NN	O
such	NNS	O
as	NNS	O
the	,	O
addition	,	O
of	,	O
one	,	O
basic	JJ	O
residue,	IN	O
such	DT	O
as	NN	O
two	IN	O
basic	CD	O
residues,	JJ	O
e.g.,	,	O
three	JJ	O
basic	IN	O
residues,	CD	O
such	JJ	O
as	,	O
about	,	O
four	CD	O
basic	JJ	O
residues,	,	O
e.g.,	JJ	O
five	IN	O
basic	IN	O
residues,	CD	O
such	JJ	O
as	,	O
about	,	O
six	CD	O
basic	JJ	O
residues,	,	O
e.g.,	JJ	O
about	IN	O
10	IN	O
basic	CD	O
residues,	JJ	O
e.g.	,	O
1-10	,	O
basic	IN	O
residues,	CD	O
such	JJ	O
as	,	O
about	.	O
5-10	JJ	O
basic	JJ	O
residues,	,	O
such	JJ	O
as	IN	O
about	IN	O
10-15	JJ	O
basic	JJ	O
residues,	,	O
e.g.,	JJ	O
5-20	IN	O
basic	IN	O
residues,	JJ	O
said	JJ	O
residues	,	O
being	,	O
added	JJ	O
anywhere	JJ	O
within	,	O
the	VBD	O
polypeptides	NNS	O
of	VBG	O
the	VBN	O
invention,	RB	O
including	IN	O
but	DT	O
not	NNS	O
limited	IN	O
to	DT	O
at	,	O
the	VBG	O
N-terminus	CC	O
or	RB	O
C-terminus.	JJ	O
Polynucleotides	TO	O
and	IN	O
Methods	DT	O
of	NNP	O
Mutagenesis	CC	O
The	.	O
invention	NNS	O
includes	CC	O
nucleic	NNS	O
acids	IN	O
and	NNP	O
polynucleotides	DT	O
that	NN	O
encode	VBZ	O
the	JJ	O
polypeptides	NNS	O
of	CC	O
the	NNS	O
invention.	WDT	O
The	VBP	O
invention	DT	O
includes	NNS	O
compositions	IN	O
produced	DT	O
by	.	O
digesting	DT	O
one	NN	O
or	VBZ	O
more	NNS	O
of	VBN	O
any	IN	O
of	VBG	O
the	CD	O
polynucleotides	CC	O
of	JJR	O
the	IN	O
invention	DT	O
with	IN	O
a	DT	O
restriction	NNS	O
endonuclease,	IN	O
an	DT	O
RNAse,	NN	O
or	IN	O
a	DT	O
DNAse	NN	O
(e.g.,	,	O
as	DT	O
is	,	O
performed	CC	O
in	DT	O
certain	NNP	O
of	,	O
the	IN	O
recombination	VBZ	O
formats	VBN	O
elsewhere	IN	O
in	JJ	O
the	IN	O
specification);	DT	O
and	NN	O
compositions	NNS	O
produced	RB	O
by	IN	O
fragmenting	DT	O
or	:	O
shearing	CC	O
one	NNS	O
or	VBN	O
more	IN	O
polynucleotides	VBG	O
of	CC	O
the	VBG	O
invention	CD	O
by	CC	O
mechanical	JJR	O
means	NNS	O
(e.g.,	IN	O
sonication,	DT	O
vortexing,	NN	O
and	IN	O
the	JJ	O
like),	NNS	O
which	,	O
can	,	O
also	,	O
be	CC	O
used	DT	O
to	,	O
provide	WDT	O
substrates	MD	O
for	RB	O
recombination	VB	O
in	VBN	O
the	TO	O
methods	VB	O
described	NNS	O
herein.	IN	O
The	NN	O
invention	IN	O
also	DT	O
provides	NNS	O
compositions	VBD	O
produced	.	O
by	DT	O
cleaving	NN	O
at	RB	O
least	VBZ	O
one	NNS	O
of	VBN	O
any	IN	O
of	VBG	O
the	IN	O
polynucleotides	JJS	O
of	CD	O
the	IN	O
invention.	DT	O
The	IN	O
cleaving	DT	O
may	NNS	O
comprise	IN	O
mechanical,	DT	O
chemical,	.	O
or	DT	O
enzymatic	NN	O
cleavage,	MD	O
and	VB	O
the	,	O
enzymatic	,	O
cleavage	CC	O
may	JJ	O
comprise	,	O
cleavage	CC	O
with	DT	O
a	JJ	O
restriction	NN	O
endonuclease,	MD	O
an	VB	O
RNAse,	NN	O
or	IN	O
a	DT	O
DNAse.	NN	O
Also	,	O
included	DT	O
in	,	O
the	CC	O
invention	DT	O
are	.	O
compositions	RB	O
produced	VBN	O
by	IN	O
a	DT	O
process	NN	O
comprising	VBP	O
incubating	NNS	O
one	VBN	O
or	IN	O
more	DT	O
of	NN	O
the	VBG	O
fragmented	VBG	O
polynucleotides	CD	O
of	CC	O
the	JJR	O
invention	IN	O
in	DT	O
the	JJ	O
presence	NNS	O
of	IN	O
ribonucleotide	DT	O
or	NN	O
deoxyribonucleotide	IN	O
triphosphates	DT	O
and	NN	O
a	IN	O
nucleic	NN	O
acid	CC	O
polymerase.	VB	O
This	NNS	O
resulting	CC	O
composition	DT	O
forms	JJ	O
a	NN	O
recombination	.	O
mixture	DT	O
for	VBG	O
many	NN	O
of	NNS	O
the	DT	O
recombination	NN	O
formats	NN	O
noted	IN	O
above.	JJ	O
The	IN	O
nucleic	DT	O
acid	NN	O
polymerase	NNS	O
may	VBD	O
be	.	O
an	DT	O
RNA	JJ	O
polymerase,	JJ	O
a	NN	O
DNA	MD	O
polymerase,	VB	O
or	DT	O
an	NNP	O
RNA-directed	,	O
DNA	DT	O
polymerase	NN	O
(e.g.,	,	O
a	CC	O
“reverse	DT	O
transcriptase”);	JJ	O
the	NN	O
polymerase	NN	O
can	,	O
be,	DT	O
e.g.,	JJ	O
a	:	O
thermostable	DT	O
DNA	NN	O
polymerase	MD	O
(e.g.,	,	O
VENT,	,	O
TAQ,	DT	O
or	JJ	O
the	NN	O
like).	NN	O
Similarly,	,	O
compositions	,	O
comprising	,	O
sets	CC	O
of	DT	O
oligonucleotides	.	O
corresponding	,	O
to	NNS	O
more	VBG	O
than	NNS	O
one	IN	O
nucleic	NNS	O
acids	VBG	O
of	TO	O
the	JJR	O
invention	IN	O
are	CD	O
useful	JJ	O
as	NNS	O
recombination	IN	O
substrates	DT	O
and	NN	O
are	VBP	O
a	JJ	O
feature	IN	O
of	NN	O
the	NNS	O
invention.	CC	O
For	VBP	O
convenience,	DT	O
these	NN	O
fragmented,	IN	O
sheared,	DT	O
or	.	O
oligonucleotide	IN	O
synthesized	,	O
mixtures	DT	O
are	,	O
referred	,	O
to	CC	O
as	RB	O
fragmented	JJ	O
nucleic	NNS	O
acid	VBP	O
sets.	VBN	O
The	TO	O
invention	IN	O
also	JJ	O
provides	JJ	O
an	NN	O
isolated	.	O
or	DT	O
recombinant	NN	O
nucleic	RB	O
acid	VBZ	O
encoding	DT	O
a	JJ	O
polypeptide	CC	O
produced	JJ	O
by	JJ	O
mutating	NN	O
or	VBG	O
recombining	DT	O
at	NN	O
least	VBN	O
one	IN	O
polynucleotide	VBG	O
of	CC	O
the	VBG	O
invention.	IN	O
Polynucleotides,	JJS	O
oligonucleotides,	CD	O
and	NN	O
nucleic	IN	O
acid	DT	O
fragments	.	O
of	,	O
the	,	O
invention	CC	O
can	JJ	O
be	NN	O
prepared	NNS	O
by	IN	O
standard	DT	O
solid-phase	NN	O
methods,	MD	O
according	VB	O
to	VBN	O
known	IN	O
synthetic	JJ	O
methods.	NN	O
Typically,	,	O
fragments	VBG	O
of	TO	O
up	VBN	O
to	JJ	O
about	.	O
100	,	O
bases	NNS	O
are	IN	O
individually	IN	O
synthesized,	TO	O
then	IN	O
joined	CD	O
(e.g.,	NNS	O
by	VBP	O
enzymatic	RB	O
or	,	O
chemical	RB	O
ligation	VBD	O
methods,	,	O
or	IN	O
polymerase	JJ	O
mediated	CC	O
recombination	JJ	O
methods)	NN	O
to	,	O
form	CC	O
essentially	NN	O
any	VBN	O
desired	NN	O
continuous	)	O
sequence.	TO	O
For	VB	O
example,	RB	O
the	DT	O
polynucleotides	JJ	O
and	JJ	O
oligonucleotides	.	O
of	IN	O
the	,	O
invention	DT	O
can	NNS	O
be	CC	O
prepared	NNS	O
by	IN	O
chemical	DT	O
synthesis	NN	O
using,	MD	O
e.g.,	VB	O
classical	VBN	O
phosphoramidite	IN	O
method	NN	O
described	NN	O
by,	,	O
e.g.,	,	O
Beaucage	JJ	B
et	NN	I
al.	NN	I
(1981)	VBN	I
Tetrahedron	,	I
Letters	,	I
22:1859-69,	NNP	I
or	FW	O
the	.	O
method	)	O
described	NNP	O
by	NNP	O
Matthes	,	B
et	CC	I
al.	DT	I
(1984)	NN	I
EMBO	VBN	I
J	IN	I
3:801-05,	NNP	I
e.g.,	CC	O
as	.	O
is	)	O
typically	NNP	O
practiced	NNP	O
in	,	O
automated	,	O
synthetic	IN	O
methods.	VBZ	O
According	RB	O
to	VBN	O
the	IN	O
phosphoramidite	JJ	O
method,	JJ	O
oligonucleotides	.	O
are	VBG	O
synthesized,	TO	O
e.g.,	DT	O
in	NN	O
an	,	O
automatic	NNS	O
DNA	VBP	O
synthesizer,	,	O
purified,	,	O
annealed,	IN	O
ligated	DT	O
and	JJ	O
cloned	NNP	O
into	,	O
appropriate	,	O
vectors.	,	O
In	VBN	O
addition,	CC	O
essentially	VBN	O
any	IN	O
polynucleotide	JJ	O
can	.	O
be	IN	O
custom	,	O
ordered	RB	O
from	DT	O
any	NN	O
of	MD	O
a	VB	O
variety	VBN	O
of	VBN	O
commercial	IN	O
sources,	DT	O
such	IN	O
as	DT	O
Operon	NN	O
Technologies	IN	O
Inc.	JJ	O
(Alameda,	,	O
Calif.)	JJ	O
and	IN	O
many	NNP	O
others.	NNPS	O
Similarly,	NNP	O
peptides	,	O
and	)	O
antibodies	CC	O
can	JJ	O
be	.	O
custom	,	O
ordered	NNS	O
from	CC	O
any	NNS	O
of	MD	O
a	VB	O
variety	VBN	O
of	VBN	O
sources,	IN	O
e.g.,	DT	O
Celtek	IN	O
Peptides	DT	O
(Nashville,	NN	O
Term.);	IN	O
Washington	,	O
Biotechnology,	,	O
Inc.	NNP	O
(Baltimore	NNP	O
Md.);	,	O
Global	:	O
Peptide	NNP	O
Services	,	O
(Ft.	NNP	O
Collin	NNP	O
Colo.),	:	O
and	NNP	O
many	NNP	O
others.	NNP	O
Certain	NNP	O
polynucleotides	NNP	O
of	,	O
the	CC	O
invention	JJ	O
may	.	O
also	NNP	O
be	NNS	O
obtained	IN	O
by	DT	O
screening	NN	O
cDNA	MD	O
libraries	RB	O
(e.g.,	VB	O
libraries	VBN	O
generated	IN	O
by	VBG	O
recombining	NN	O
homologous	NNS	O
nucleic	,	O
acids	NNS	O
as	VBN	O
in	IN	O
typical	VBG	O
recursive	JJ	O
sequence	JJ	O
recombination	NNS	O
methods)	IN	O
using	IN	O
oligonucleotide	JJ	O
probes	JJ	O
that	NN	O
can	NN	O
hybridize	)	O
to	VBG	O
or	JJ	O
PCR-amplify	NNS	O
polynucleotides	WDT	O
which	MD	O
encode	VB	O
OAS	TO	O
polypeptides	CC	O
and	NNP	O
fragments	NNS	O
of	WDT	O
those	VBP	O
polypeptides.	NNP	O
Procedures	NNS	O
for	CC	O
screening	NNS	O
and	IN	O
isolating	DT	O
cDNA	.	O
clones	NNS	O
are	IN	O
well-known	VBG	O
to	CC	O
those	VBG	O
of	NN	O
skill	NNS	O
in	VBP	O
the	JJ	O
art.	TO	O
Such	DT	O
techniques	IN	O
are	NN	O
described	IN	O
in,	DT	O
e.g.,	.	O
Berger	JJ	B
and	NNS	I
Kimmel,	VBP	I
Guide	VBN	I
to	,	I
Molecular	,	I
Cloning	NNP	I
Techniques,	CC	I
Methods	,	I
in	NNP	I
Enzymol.	TO	I
Vol.	NNP	I
152,	NNP	I
Acad.	,	I
Press,	NNP	I
Inc.,	IN	I
San	.	I
Diego,	.	I
Calif.	,	I
(“Berger”);	.	I
J.	,	B
Sambrook	,	I
and	NNP	I
D.	,	I
W.	NNP	I
Russell,	:	I
Molecular	NNP	I
Cloning:	NNP	I
A	CC	I
Laboratory	NNP	I
Manual,	NNP	I
Third	,	I
Edition.	NNP	I
Cold	:	I
Spring	DT	I
Harbor	NNP	I
Press,	,	I
Cold	NNP	I
Spring	.	I
Harbor,	JJ	I
N.Y.,	NN	I
(“Sambrook”);	NNP	I
and	,	O
F.	NNP	O
M.	NNP	B
Ausubel	,	I
et	,	I
al.	:	I
(1987-2005)	CC	I
Current	NNP	I
Protocols	NNP	I
in	NNP	I
Molecular	FW	I
Biology.	.	I
Wiley	)	I
Interscience,	NN	I
New	NNP	I
York,	IN	I
N.Y.	NNP	I
(“Ausubel”).	.	I
Some	NNP	O
polynucleotides	,	O
of	NNP	O
the	,	O
invention	NNP	O
can	.	O
be	DT	O
obtained	NNS	O
by	IN	O
altering	DT	O
a	NN	O
naturally	MD	O
occurring	VB	O
sequence,	VBN	O
e.g.,	IN	O
by	VBG	O
mutagenesis,	DT	O
recursive	RB	O
sequence	VBG	O
recombination	,	O
(e.g.,	,	O
shuffling),	IN	O
or	,	O
oligonucleotide	JJ	O
recombination.	NN	O
In	NN	O
other	,	O
cases,	,	O
such	CC	O
polynucleotides	JJ	O
can	.	O
be	IN	O
made	JJ	O
in	,	O
silico	JJ	O
or	NNS	O
through	MD	O
oligonucleotide	VB	O
recombination	VBN	O
methods	IN	O
as	NN	O
described	CC	O
in	IN	O
the	JJ	O
references	NN	O
cited	NNS	O
herein.	IN	O
As	VBN	O
described	IN	O
in	DT	O
more	NNS	O
detail	VBD	O
herein,	.	O
the	IN	O
polynucleotides	VBN	O
of	IN	O
the	JJR	O
invention	NN	O
include	,	O
polynucleotides	DT	O
that	NNS	O
encode	IN	O
polypeptides	DT	O
of	NN	O
the	VBP	O
invention,	NNS	O
polynucleotide	WDT	O
sequences	VBP	O
complementary	NNS	O
to	IN	O
these	DT	O
polynucleotide	,	O
sequences,	JJ	O
and	NNS	O
polynucleotides	VBP	O
that	TO	O
hybridize	DT	O
under	JJ	O
at	,	O
least	CC	O
stringent	NNS	O
conditions	IN	O
to	NN	O
the	IN	O
sequences	IN	O
defined	JJS	O
herein.	JJ	O
A	NNS	O
coding	TO	O
sequence	DT	O
refers	NNS	O
to	VBD	O
a	.	O
polynucleotide	DT	O
sequence	NN	O
encoding	NN	O
a	NNS	O
particular	TO	O
polypeptide	DT	O
or	JJ	O
domain,	NN	O
region,	VBG	O
or	DT	O
fragment	JJ	O
of	NN	O
said	CC	O
polypeptide.	,	O
The	,	O
polynucleotides	CC	O
of	NN	O
the	IN	O
invention	VBD	O
may	.	O
be	DT	O
in	NNS	O
the	IN	O
form	DT	O
of	NN	O
RNA	MD	O
or	VB	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
DNA,	NNP	O
and	CC	O
include	IN	O
mRNA,	DT	O
cRNA,	NN	O
synthetic	IN	O
RNA	,	O
and	CC	O
DNA,	VBP	O
and	,	O
cDNA.	,	O
The	JJ	O
polynucleotides	NNP	O
may	CC	O
be	,	O
double-stranded	CC	O
or	.	O
single-stranded,	DT	O
and	NNS	O
if	MD	O
single-stranded,	VB	O
can	JJ	O
be	CC	O
the	,	O
coding	CC	O
strand	IN	O
or	,	O
the	MD	O
non-coding	VB	O
(anti-sense,	DT	O
complementary)	VBG	O
strand.	NN	O
The	CC	O
polynucleotides	DT	O
of	JJ	O
the	,	O
invention	)	O
include	.	O
the	DT	O
coding	NNS	O
sequence	IN	O
of	DT	O
a	NN	O
polypeptide	VBP	O
of	DT	O
the	VBG	O
invention	NN	O
(i)	IN	O
in	DT	O
isolation,	NN	O
(ii)	IN	O
in	DT	O
combination	NN	O
with	)	O
one	IN	O
or	,	O
more	)	O
additional	IN	O
coding	NN	O
sequences,	IN	O
so	CD	O
as	CC	O
to	JJR	O
encode,	JJ	O
e.g.,	NN	O
a	,	O
fusion	RB	O
protein,	IN	O
a	TO	O
pre-protein,	,	O
a	,	O
prepro-protein,	DT	O
or	NN	O
the	,	O
like,	DT	O
(iii)	,	O
in	DT	O
combination	,	O
with	CC	O
non-coding	DT	O
sequences,	,	O
such	)	O
as	IN	O
introns,	NN	O
control	IN	O
elements,	JJ	O
such	,	O
as	JJ	O
a	IN	O
promoter	,	O
(e.g.,	NN	O
naturally	,	O
occurring	JJ	O
or	IN	O
recombinant	DT	O
or	NN	O
shuffled	,	O
promoter),	RB	O
a	VBG	O
terminator	CC	O
element,	JJ	O
or	CC	O
5′	JJ	O
and/or	,	O
3′	DT	O
untranslated	NN	O
regions	,	O
effective	CC	O
for	CD	O
expression	JJ	O
of	CD	O
the	JJ	O
coding	NNS	O
sequence	JJ	O
in	IN	O
a	NN	O
suitable	IN	O
host,	DT	O
and/or	VBG	O
(iv)	NN	O
in	IN	O
a	DT	O
vector,	JJ	O
cell,	,	O
or	NN	O
host	)	O
environment	IN	O
in	DT	O
which	,	O
the	,	O
coding	CC	O
sequence	NN	O
is	NN	O
a	IN	O
heterologous	WDT	O
gene.	DT	O
Polynucleotides	NN	O
of	NN	O
the	VBZ	O
invention	DT	O
can	JJ	O
also	.	O
be	NNS	O
found	IN	O
in	DT	O
combination	NN	O
with	MD	O
typical	RB	O
compositional	VB	O
formulations	VBN	O
of	IN	O
nucleic	NN	O
acids,	IN	O
including	JJ	O
in	JJ	O
the	NNS	O
presence	IN	O
of	JJ	O
carriers,	,	O
buffers,	VBG	O
adjuvants,	IN	O
excipients,	DT	O
and	NN	O
the	IN	O
like,	,	O
as	,	O
are	,	O
known	,	O
to	CC	O
those	DT	O
of	,	O
ordinary	IN	O
skill	VBP	O
in	VBN	O
the	TO	O
art.	DT	O
Polynucleotide	IN	O
fragments	JJ	O
typically	NN	O
comprise	IN	O
at	DT	O
least	.	O
about	NN	O
200	NNS	O
nucleotide	RB	O
bases,	VBP	O
such	IN	O
as	JJS	O
at	IN	O
least	CD	O
about	JJ	O
250,	,	O
300,	JJ	O
350,	IN	O
400,	IN	O
450,	JJS	O
460,	IN	O
470,	,	O
or	,	O
more	,	O
bases.	,	O
The	,	O
nucleotide	,	O
fragments	,	O
of	CC	O
polynucleotides	JJR	O
of	.	O
the	DT	O
invention	JJ	O
may	NNS	O
hybridize	IN	O
under	NNS	O
highly	IN	O
stringent	DT	O
conditions	NN	O
to	MD	O
a	VB	O
polynucleotide	IN	O
sequence	RB	O
described	JJ	O
herein	NNS	O
and/or	TO	O
encode	DT	O
amino	JJ	O
acid	NN	O
sequences	VBD	O
having	JJ	O
at	JJ	O
least	NN	O
one	NN	O
of	NN	O
the	NNS	O
properties	VBG	O
of	IN	O
polypeptides	JJS	O
of	CD	O
the	IN	O
invention	DT	O
described	NNS	O
herein.	IN	O
As	NNS	O
will	IN	O
be	DT	O
understood	NN	O
by	VBD	O
those	.	O
of	IN	O
ordinary	MD	O
skill	VB	O
in	VBN	O
the	IN	O
art,	DT	O
it	IN	O
can	JJ	O
be	NN	O
advantageous	IN	O
to	DT	O
modify	,	O
a	PRP	O
coding	MD	O
sequence	VB	O
to	JJ	O
enhance	TO	O
its	VB	O
expression	DT	O
in	NN	O
a	NN	O
particular	TO	O
host.	VB	O
The	PRP$	O
genetic	NN	O
code	IN	O
is	DT	O
redundant	JJ	O
with	.	O
64	DT	O
possible	JJ	O
codons,	NN	O
but	VBZ	O
most	JJ	O
organisms	IN	O
preferentially	CD	O
use	JJ	O
a	,	O
subset	CC	O
of	JJS	O
these	NNS	O
codons.	RB	O
The	VBP	O
codons	DT	O
that	NN	O
are	IN	O
utilized	DT	O
most	.	O
often	DT	O
in	NNS	O
a	WDT	O
species	VBP	O
are	JJ	O
considered	RBS	O
optimal	RB	O
codons,	IN	O
and	DT	O
those	NNS	O
not	VBP	O
utilized	VBN	O
very	JJ	O
often	,	O
are	CC	O
classified	DT	O
as	RB	O
rare	JJ	O
or	RB	O
low-usage	RB	O
codons	VBP	O
(see,	VBN	O
e.g.,	IN	O
Zhang,	JJ	B
S.	CC	I
P.	JJ	I
et	NNS	I
al.	,	I
(1991)	,	I
Gene	,	I
105:61-72).Codons	NNP	O
can	NNP	O
be	FW	O
substituted	.	O
to	)	O
reflect	NNP	O
the	.	O
preferred	NNS	O
codon	MD	O
usage	VB	O
of	VBN	O
the	TO	O
host,	VB	O
a	DT	O
process	JJ	O
sometimes	NN	O
termed	NN	O
“codon	IN	O
optimization”	DT	O
or	,	O
“controlling	DT	O
for	NN	O
species	RB	O
codon	VBD	O
bias.”	JJ	O
Modified	NN	O
coding	CC	O
sequence	VBG	O
containing	IN	O
codons	NNS	O
preferred	VBP	O
by	JJ	O
a	NNP	O
particular	VBG	O
prokaryotic	NN	O
or	VBG	O
eukaryotic	NNS	O
host	VBN	O
(see,	IN	O
e.g.,	DT	O
Murray,	JJ	B
E.	NN	I
et	CC	I
al.	JJ	I
(1989)	NN	I
Nuc	,	I
Acids	,	I
Res	,	I
17:477-508;	NNP	I
Griswold	CC	B
et	.	I
al.,	)	I
(2003)	NNP	I
Protein	NNP	I
Expr.	NNP	I
Purif.	:	I
27(1):	NNP	I
134-42)	FW	I
can	,	O
be	)	O
prepared,	NNP	O
for	.	O
example,	.	O
to	:	O
increase	)	O
the	MD	O
rate	VB	O
of	,	O
translation	IN	O
or	,	O
to	TO	O
produce	VB	O
recombinant	DT	O
RNA	NN	O
transcripts	IN	O
having	NN	O
desirable	CC	O
properties,	TO	O
such	VB	O
as	JJ	O
a	NNP	O
longer	NNS	O
half-life,	VBG	O
as	JJ	O
compared	,	O
with	JJ	O
transcripts	IN	O
produced	DT	O
from	RBR	O
a	,	O
non-optimized	IN	O
sequence.	VBN	O
Translation	IN	O
stop	NNS	O
codons	VBN	O
can	IN	O
also	DT	O
be	JJ	O
modified	.	O
to	NNP	O
reflect	JJ	O
host	NNS	O
preference.	MD	O
For	RB	O
example,	VB	O
preferred	VBN	O
stop	TO	O
codons	VB	O
for	NN	O
S.	.	O
cerevisiae	IN	O
and	,	O
mammals	VBD	O
are	JJ	O
UAA	NNS	O
and	IN	O
UGA	NNP	O
respectively.	NN	O
The	CC	O
preferred	NNS	O
stop	VBP	O
codon	NNP	O
for	CC	O
monocotyledonous	NNP	O
plants	.	O
is	DT	O
UGA,	JJ	O
whereas	NN	O
insects	NN	O
and	IN	O
E.	JJ	O
coli	NNS	O
prefer	VBZ	O
to	,	O
use	JJ	O
UAA	NNS	O
as	CC	O
the	NNP	O
stop	NNS	O
codon	VBP	O
Dalphin,	TO	B
M.	VB	I
E.	NNP	I
et	IN	I
al.	DT	I
(1996)	NN	I
Nucl.	NN	I
Acids	,	I
Res.	NNP	I
24:216-218).(	NNP	O
The	FW	O
polynucleotide	.	O
sequences	)	O
of	.	O
the	NNP	O
present	.	O
invention	.	O
can	DT	O
be	JJ	O
engineered	NNS	O
in	IN	O
order	DT	O
to	JJ	O
alter	NN	O
a	MD	O
coding	VB	O
sequence	VBN	O
of	IN	O
the	NN	O
invention	TO	O
for	VB	O
a	DT	O
variety	NN	O
of	NN	O
reasons,	IN	O
including	DT	O
but	NN	O
not	IN	O
limited	DT	O
to,	NN	O
alterations	IN	O
which	,	O
modify	VBG	O
the	CC	O
cloning,	RB	O
processing	JJ	O
and/or	,	O
expression	NNS	O
of	WDT	O
the	VBP	O
gene	DT	O
product.	,	O
For	VBG	O
example,	JJ	O
alterations	NN	O
may	IN	O
be	DT	O
introduced	NN	O
using	.	O
techniques	IN	O
which	,	O
are	NNS	O
well	MD	O
known	VB	O
in	VBN	O
the	VBG	O
art,	NNS	O
e.g.,	WDT	O
site-directed	VBP	O
mutagenesis,	RB	O
to	VBN	O
insert	IN	O
new	DT	O
restriction	,	O
sites,	,	O
to	JJ	O
alter	,	O
glycosylation	TO	O
patterns,	VB	O
to	JJ	O
introduce	NN	O
or	,	O
remove	TO	O
attachment	VB	O
groups	NN	O
(e.g.,	,	O
for	TO	O
pegylation	VB	O
or	CC	O
other	VB	O
conjugation),	NN	O
to	NNS	O
change	,	O
codon	IN	O
preference,	NN	O
to	CC	O
introduce	JJ	O
splice	,	O
sites,	TO	O
etc.	VB	O
Because	JJ	O
of	,	O
the	TO	O
degeneracy	VB	O
of	NN	O
the	,	O
genetic	.	O
code,	IN	O
a	IN	O
large	DT	O
number	NN	O
of	IN	O
functionally	DT	O
identical	JJ	O
nucleic	,	O
acids	DT	O
encode	JJ	O
any	NN	O
given	IN	O
polypeptide.	RB	O
For	JJ	O
instance	JJ	O
codons	NNS	O
AGA,	VBP	O
AGG,	DT	O
CGA,	VBN	O
CGC,	.	O
CGG,	IN	O
and	NN	O
CGU	NNS	O
all	,	O
encode	,	O
the	,	O
amino	,	O
acid	,	O
arginine.	CC	O
Thus,	NNP	O
at	DT	O
every	VBP	O
position	DT	O
in	NN	O
a	JJ	O
nucleic	.	O
acid	,	O
sequence	IN	O
where	DT	O
an	NN	O
arginine	IN	O
is	DT	O
specified	JJ	O
by	NN	O
a	NN	O
codon,	WRB	O
the	DT	O
codon	NN	O
can	VBZ	O
be	VBN	O
altered	IN	O
to	DT	O
any	,	O
of	DT	O
the	NN	O
corresponding	MD	O
codons	VB	O
described	VBN	O
above	TO	O
without	DT	O
altering	IN	O
the	DT	O
encoded	JJ	O
polypeptide.	NNS	O
Such	VBN	O
nucleic	IN	O
acid	IN	O
variations	VBG	O
are	DT	O
“silent	JJ	O
variations”.	.	O
It	JJ	O
is	JJ	O
to	NN	O
be	NNS	O
understood	VBP	O
that	JJ	O
U	.	O
in	PRP	O
an	VBZ	O
RNA	TO	O
sequence	VB	O
corresponds	JJ	O
to	IN	O
T	NNP	O
in	IN	O
a	DT	O
DNA	NNP	O
sequence.	NN	O
It	NNS	O
will	TO	O
thus	NNP	O
be	IN	O
appreciated	DT	O
by	NN	O
those	.	O
skilled	PRP	O
in	MD	O
the	RB	O
art	VB	O
that	VBN	O
due	IN	O
to	DT	O
the	VBN	O
degeneracy	IN	O
of	DT	O
the	NN	O
genetic	WDT	O
code,	JJ	O
a	TO	O
multitude	DT	O
of	NN	O
nucleic	IN	O
acids	DT	O
sequences	JJ	O
encoding	,	O
polypeptides	DT	O
of	NN	O
the	IN	O
invention	JJ	O
may	NNS	O
be	NNS	O
produced,	VBG	O
some	NNS	O
of	IN	O
which	DT	O
may	NN	O
bear	MD	O
minimal	VB	O
sequence	,	O
identity	DT	O
to	IN	O
the	WDT	O
nucleic	MD	O
acid	VB	O
sequences	JJ	O
explicitly	NN	O
disclosed	NN	O
herein.	TO	O
One	DT	O
of	JJ	O
ordinary	NN	O
skill	NNS	O
in	RB	O
the	VBN	O
art	.	O
will	CD	O
recognize	IN	O
that	JJ	O
each	NN	O
codon	IN	O
in	DT	O
a	NN	O
nucleic	MD	O
acid	VB	O
(except	IN	O
AUG	DT	O
and	NN	O
UGC,	IN	O
which	DT	O
are	JJ	O
ordinarily	NN	O
the	IN	O
only	NNP	O
codon	CC	O
for	,	O
methionine	WDT	O
and	VBP	O
tryptophan,	RB	O
respectively)	DT	O
can	JJ	O
be	NN	O
modified	IN	O
by	NN	O
standard	CC	O
techniques	,	O
to	)	O
encode	MD	O
a	VB	O
functionally	VBN	O
identical	IN	O
polypeptide.	JJ	O
Accordingly,	NNS	O
each	TO	O
silent	VB	O
variation	DT	O
of	RB	O
a	JJ	O
nucleic	.	O
acid	,	O
which	DT	O
encodes	JJ	O
a	NN	O
polypeptide	IN	O
is	DT	O
implicit	NN	O
in	NN	O
any	WDT	O
described	VBZ	O
sequence.	DT	O
The	NN	O
invention	VBZ	O
also	JJ	O
provides	IN	O
each	DT	O
and	JJ	O
every	.	O
possible	DT	O
variation	NN	O
of	RB	O
a	VBZ	O
nucleic	DT	O
acid	CC	O
sequence	DT	O
encoding	JJ	O
a	NN	O
polypeptide	IN	O
of	DT	O
the	JJ	O
invention	NN	O
that	NN	O
can	VBG	O
be	DT	O
made	NN	O
by	IN	O
selecting	DT	O
combinations	NN	O
based	WDT	O
on	MD	O
possible	VB	O
codon	VBN	O
choices.	IN	O
These	VBG	O
combinations	NNS	O
are	VBN	O
made	IN	O
in	JJ	O
accordance	NN	O
with	.	O
the	DT	O
standard	NNS	O
triplet	VBP	O
(codon)	VBN	O
genetic	IN	O
code,	NN	O
as	IN	O
applied	DT	O
to	JJ	O
the	NN	O
nucleic	)	O
acid	JJ	O
sequence	,	O
encoding	IN	O
a	VBN	O
polypeptide	TO	O
of	DT	O
the	JJ	O
invention.	NN	O
All	NN	O
such	VBG	O
variations	DT	O
of	NN	O
every	IN	O
nucleic	DT	O
acid	.	O
herein	DT	O
are	JJ	O
specifically	NNS	O
provided	IN	O
and	DT	O
described	JJ	O
by	NN	O
consideration	NN	O
of	VBP	O
the	RB	O
sequence	VBN	O
in	CC	O
combination	VBN	O
with	IN	O
the	NN	O
genetic	IN	O
code.	DT	O
One	NN	O
of	IN	O
skill	NN	O
is	IN	O
fully	DT	O
able	JJ	O
to	.	O
generate	CD	O
any	IN	O
silent	NN	O
substitution	VBZ	O
of	RB	O
the	JJ	O
sequences	TO	O
listed	VB	O
herein.	DT	O
The	JJ	O
polynucleotides	NN	O
of	IN	O
the	DT	O
invention	NNS	O
have	VBN	O
a	.	O
variety	DT	O
of	NNS	O
uses	IN	O
in,	DT	O
for	NN	O
example,	VBP	O
recombinant	DT	O
production	NN	O
(i.e.,	IN	O
expression)	NNS	O
of	,	O
the	IN	O
polypeptides	,	O
of	JJ	O
the	NN	O
invention	,	O
typically	)	O
through	IN	O
expression	DT	O
of	NNS	O
a	IN	O
plasmid	DT	O
expression	NN	O
vector	RB	O
comprising	IN	O
a	NN	O
sequence	IN	O
encoding	DT	O
the	JJ	O
polypeptide	NN	O
or	NN	O
fragment	VBG	O
thereof;	DT	O
as	NN	O
therapeutics;	VBG	O
as	DT	O
prophylactics;	NN	O
as	CC	O
diagnostic	JJ	O
tools;	:	O
as	IN	O
immunogens;	:	O
as	IN	O
adjuvants;	:	O
as	IN	O
diagnostic	JJ	O
probes	:	O
for	IN	O
the	:	O
presence	IN	O
of	:	O
complementary	IN	O
or	JJ	O
partially	NNS	O
complementary	IN	O
nucleic	DT	O
acids	NN	O
(including	IN	O
for	JJ	O
detection	CC	O
of	RB	O
a	JJ	O
wild-type	JJ	O
oligoadenylate	NNS	O
synthetase	VBG	O
nucleic	IN	O
acid),	NN	O
as	IN	O
substrates	DT	O
for	JJ	O
further	NN	O
reactions,	NN	O
e.g.,	JJ	O
recursive	,	O
sequence	IN	O
recombination	NNS	O
reactions	IN	O
or	JJ	O
mutation	,	O
reactions	,	O
to	JJ	O
produce	NN	O
new	NN	O
and/or	NNS	O
improved	CC	O
variants,	NN	O
and	NNS	O
the	TO	O
like.	VB	O
Expression	JJ	O
Vectors,	NNS	O
Methods	VBN	O
of	,	O
Manufacturing,	CC	O
Gene	DT	O
Therapy	.	O
Recombinant	NN	O
methods	,	O
for	NNS	O
producing	IN	O
and	,	O
isolating	NNP	O
polypeptides	NNP	O
of	NNP	O
the	NNS	O
invention	IN	O
are	VBG	O
described	CC	O
herein.	VBG	O
In	NNS	O
addition	IN	O
to	DT	O
recombinant	NN	O
production,	VBP	O
the	VBN	O
polypeptides	.	O
may	IN	O
be	NN	O
produced	TO	O
by	VB	O
direct	,	O
peptide	DT	O
synthesis	NNS	O
using	MD	O
solid-phase	VB	O
techniques	VBN	O
(see,	IN	O
e.g.,	JJ	O
Stewart	NN	B
et	NN	I
al.	VBG	I
(1969)	JJ	I
Solid-Phase	NNS	I
Peptide	,	I
Synthesis,	,	I
WH	NNP	I
Freeman	VBZ	I
Co,	.	I
San	)	I
Francisco;	NNP	I
Merrifield	NNP	B
J.	,	I
(1963)	NNP	I
J	NNP	I
Am	,	I
Chem	NNP	I
Soc	:	I
85:2149-2154).Peptide	NNP	O
synthesis	.	O
may	)	O
be	NNP	O
performed	NNP	O
using	NNP	O
manual	NNP	O
techniques	.	O
or	NNP	O
by	NN	O
automation.	MD	O
Automated	VB	O
synthesis	VBN	O
may	VBG	O
be	JJ	O
achieved,	NNS	O
for	CC	O
example,	IN	O
using	.	O
Applied	VBN	O
Biosystems	NN	O
431A	MD	O
Peptide	VB	O
Synthesizer	,	O
(Perkin	IN	O
Elmer,	,	O
Foster	VBG	O
City,	NNP	O
Calif.)	NNP	O
in	CD	O
accordance	NNP	O
with	NNP	O
the	NNP	O
instructions	,	O
provided	NNP	O
by	,	O
the	)	O
manufacturer.	IN	O
For	NN	O
example,	IN	O
subsequences	DT	O
may	NNS	O
be	VBN	O
chemically	IN	O
synthesized	DT	O
separately	.	O
and	IN	O
combined	,	O
using	NNS	O
chemical	MD	O
methods	VB	O
to	RB	O
provide	VBN	O
full-length	RB	O
polypeptides	CC	O
or	VBN	O
fragments	VBG	O
thereof.	NN	O
Alternatively,	NNS	O
such	TO	O
sequences	VB	O
may	JJ	O
be	NNS	O
ordered	CC	O
from	NNS	O
any	.	O
number	,	O
of	JJ	O
companies	NNS	O
which	MD	O
specialize	VB	O
in	VBN	O
production	IN	O
of	DT	O
polypeptides.	NN	O
Most	IN	O
commonly,	NNS	O
polypeptides	WDT	O
of	VBP	O
the	IN	O
invention	NN	O
may	IN	O
be	.	O
produced	JJS	O
by	,	O
expressing	NNS	O
coding	IN	O
nucleic	DT	O
acids	NN	O
and	MD	O
recovering	VB	O
polypeptides,	VBN	O
e.g.,	IN	O
as	VBG	O
described	VBG	O
below.	JJ	O
Methods	NNS	O
for	CC	O
producing	VBG	O
the	,	O
polypeptides	,	O
of	IN	O
the	VBN	O
invention	.	O
are	NNS	O
also	IN	O
included.	VBG	O
One	DT	O
such	NNS	O
method	IN	O
comprises	DT	O
introducing	NN	O
into	VBP	O
a	RB	O
population	.	O
of	CD	O
cells	JJ	O
any	NN	O
nucleic	NNS	O
acid	VBG	O
of	IN	O
the	DT	O
invention,	NN	O
which	IN	O
is	NNS	O
operatively	DT	O
linked	JJ	O
to	NN	O
a	IN	O
regulatory	DT	O
sequence	,	O
effective	WDT	O
to	VBZ	O
produce	RB	O
the	VBN	O
encoded	TO	O
polypeptide,	DT	O
culturing	JJ	O
the	NN	O
cells	JJ	O
in	TO	O
a	VB	O
culture	DT	O
medium	JJ	O
to	,	O
express	VBG	O
the	DT	O
polypeptide,	NNS	O
and	IN	O
isolating	DT	O
the	NN	O
polypeptide	NN	O
from	TO	O
the	VB	O
cells	DT	O
or	,	O
from	CC	O
the	VBG	O
culture	DT	O
medium.	NN	O
An	IN	O
amount	DT	O
of	NNS	O
nucleic	CC	O
acid	IN	O
sufficient	DT	O
to	NN	O
facilitate	.	O
uptake	DT	O
by	NN	O
the	IN	O
cells	JJ	O
(transfection)	JJ	O
and/or	NN	O
expression	TO	O
of	VB	O
the	NN	O
polypeptide	IN	O
is	DT	O
utilized.	NNS	O
The	)	O
nucleic	VBZ	O
acid	NN	O
is	IN	O
introduced	DT	O
into	NN	O
such	VBZ	O
cells	.	O
by	DT	O
any	JJ	O
delivery	NN	O
method	VBZ	O
as	VBN	O
is	IN	O
known	JJ	O
in	NNS	O
the	IN	O
art,	DT	O
including,	NN	O
e.g.,	NN	O
injection,	IN	O
gene	VBZ	O
gun,	VBN	O
passive	IN	O
uptake,	DT	O
etc.	,	O
As	,	O
one	,	O
skilled	,	O
in	NN	O
the	,	O
art	JJ	O
will	,	O
recognize,	.	O
the	IN	O
nucleic	CD	O
acid	VBD	O
may	IN	O
be	DT	O
part	NN	O
of	MD	O
a	,	O
vector,	DT	O
such	JJ	O
as	NN	O
a	MD	O
recombinant	VB	O
expression	NN	O
vector,	IN	O
including	DT	O
a	,	O
DNA	JJ	O
plasmid	IN	O
vector,	DT	O
or	JJ	O
any	NN	O
vector	,	O
as	VBG	O
known	DT	O
in	NN	O
the	NN	O
art.	,	O
The	CC	O
nucleic	DT	O
acid	NN	O
or	IN	O
vector	VBN	O
comprising	IN	O
a	DT	O
nucleic	.	O
acid	DT	O
of	JJ	O
the	NN	O
invention	CC	O
may	NN	O
be	VBG	O
prepared	DT	O
and	JJ	O
formulated	NN	O
by	IN	O
standard	DT	O
recombinant	NN	O
DNA	MD	O
technologies	VB	O
and	VBN	O
isolation	CC	O
methods	VBN	O
as	IN	O
known	JJ	O
in	NN	O
the	NNP	O
art.	NNS	O
Such	CC	O
a	NN	O
nucleic	NNS	O
acid	IN	O
or	VBN	O
expression	IN	O
vector	DT	O
may	.	O
be	JJ	O
introduced	DT	O
into	JJ	O
a	NN	O
population	CC	O
of	NN	O
cells	NN	O
of	MD	O
a	VB	O
mammal	VBN	O
in	IN	O
vivo,	DT	O
or	NN	O
selected	IN	O
cells	NNS	O
of	IN	O
the	DT	O
mammal	NN	O
(e.g.,	IN	O
tumor	,	O
cells)	CC	O
may	VBN	O
be	NNS	O
removed	IN	O
from	DT	O
the	NN	O
mammal	,	O
and	JJ	O
the	)	O
nucleic	MD	O
acid	VB	O
expression	VBN	O
vector	IN	O
introduced	DT	O
ex	NN	O
vivo	CC	O
into	DT	O
the	JJ	O
population	JJ	O
of	NN	O
such	NN	O
cells	VBD	O
in	JJ	O
an	NN	O
amount	IN	O
sufficient	DT	O
such	NN	O
that	IN	O
uptake	JJ	O
and	NNS	O
expression	IN	O
of	DT	O
the	NN	O
encoded	NN	O
polypeptide	JJ	O
results.	IN	O
Or,	JJ	O
a	CC	O
nucleic	NN	O
acid	IN	O
or	DT	O
vector	JJ	O
comprising	NN	O
a	.	O
nucleic	,	O
acid	DT	O
of	JJ	O
the	NN	O
invention	CC	O
is	NN	O
produced	VBG	O
using	DT	O
cultured	JJ	O
cells	NN	O
in	IN	O
vitro.	DT	O
In	NN	O
one	VBZ	O
aspect,	VBN	O
the	VBG	O
method	JJ	O
of	NNS	O
producing	IN	O
a	.	O
polypeptide	IN	O
of	CD	O
the	,	O
invention	DT	O
comprises	NN	O
introducing	IN	O
into	VBG	O
a	DT	O
population	NN	O
of	IN	O
cells	DT	O
a	NN	O
recombinant	VBZ	O
expression	VBG	O
vector	IN	O
comprising	DT	O
any	NN	O
nucleic	IN	O
acid	NNS	O
of	DT	O
the	JJ	O
invention	NN	O
described	NN	O
herein	VBG	O
in	DT	O
an	JJ	O
amount	NN	O
and	IN	O
formula	DT	O
such	NN	O
that	VBD	O
uptake	NN	O
of	IN	O
the	DT	O
vector	NN	O
and	CC	O
expression	NN	O
of	JJ	O
the	IN	O
encoded	NN	O
polypeptide	IN	O
will	DT	O
result;	NN	O
administering	CC	O
the	NN	O
expression	IN	O
vector	DT	O
into	JJ	O
a	NN	O
mammal	MD	O
by	:	O
any	VBG	O
introduction/delivery	DT	O
format	NN	O
described	NN	O
herein;	IN	O
and	DT	O
isolating	JJ	O
the	IN	O
polypeptide	DT	O
from	JJ	O
the	NN	O
mammal	VBD	O
or	:	O
from	CC	O
a	VBG	O
byproduct	DT	O
of	NN	O
the	IN	O
mammal.	DT	O
The	NN	O
invention	CC	O
provides	IN	O
isolated	DT	O
or	NN	O
recombinant	IN	O
nucleic	DT	O
acids	.	O
(also	DT	O
referred	NN	O
to	VBZ	O
herein	JJ	O
as	CC	O
polynucleotides),	JJ	O
collectively	JJ	O
referred	NNS	O
to	RB	O
as	VBN	O
“nucleic	TO	O
acids	VB	O
(or	IN	O
polynucleotides)	,	O
of	RB	O
the	VBD	O
invention”,	TO	O
which	IN	O
encode	JJ	O
polypeptides	NNS	O
of	CC	O
the	)	O
invention.	IN	O
The	DT	O
polynucleotides	,	O
of	WDT	O
the	VBP	O
invention	NNS	O
are	IN	O
useful	DT	O
in	.	O
a	DT	O
variety	NNS	O
of	IN	O
applications.	DT	O
As	NN	O
discussed	VBP	O
above,	JJ	O
the	IN	O
polynucleotides	DT	O
are	NN	O
useful	IN	O
in	.	O
producing	IN	O
polypeptides	VBN	O
of	,	O
the	DT	O
invention.	NNS	O
In	VBP	O
addition,	JJ	O
polynucleotides	IN	O
of	VBG	O
the	NNS	O
invention	IN	O
can	DT	O
be	.	O
incorporated	IN	O
into	,	O
expression	NNS	O
vectors	IN	O
useful	DT	O
for	NN	O
gene	MD	O
therapy,	VB	O
DNA	VBN	O
vaccination,	IN	O
and	NN	O
immunotherapy,	NNS	O
as	JJ	O
described	IN	O
elsewhere	NN	O
in	,	O
this	NNP	O
application.	,	O
Any	CC	O
of	,	O
the	IN	O
polynucleotides	VBN	O
of	RB	O
the	IN	O
invention	DT	O
(which	.	O
includes	DT	O
those	IN	O
described	DT	O
above)	NNS	O
may	IN	O
encode	DT	O
a	NN	O
fusion	WDT	O
protein	VBZ	O
comprising	DT	O
at	VBN	O
least	)	O
one	MD	O
additional	VB	O
amino	DT	O
acid	NN	O
sequence,	NN	O
such	VBG	O
as,	IN	O
for	JJS	O
example,	CD	O
a	JJ	O
secretion/localization	NN	O
sequence,	NN	O
a	,	O
sequence	JJ	O
useful	,	O
for	IN	O
solubilization	,	O
or	DT	O
immobilization	NN	O
(e.g.,	,	O
for	DT	O
cell	NN	O
surface	JJ	O
display)	IN	O
of	NN	O
the	CC	O
polypeptide,	NN	O
a	,	O
sequence	IN	O
useful	NN	O
for	NN	O
detection	)	O
and/or	IN	O
purification	DT	O
of	,	O
the	DT	O
polypeptide	NN	O
(e.g.,	JJ	O
a	IN	O
polypeptide	NN	O
purification	JJ	O
subsequence,	NN	O
such	IN	O
as	DT	O
an	NN	O
epitope	,	O
tag,	DT	O
a	JJ	O
polyhistidine	NN	O
sequence,	,	O
and	JJ	O
the	IN	O
like).	DT	O
In	NN	O
another	,	O
aspect,	DT	O
the	NN	O
invention	,	O
provides	CC	O
cells	DT	O
comprising	.	O
one	IN	O
or	DT	O
more	,	O
of	DT	O
the	NN	O
polynucleotides	VBZ	O
of	NNS	O
the	VBG	O
invention.	CD	O
Such	CC	O
cells	JJR	O
may	IN	O
express	DT	O
one	NNS	O
or	IN	O
more	DT	O
polypeptides	.	O
encoded	JJ	O
by	NNS	O
the	MD	O
polynucleotides	VB	O
of	CD	O
the	CC	O
invention.	JJR	O
The	NNS	O
invention	VBN	O
also	IN	O
provides	DT	O
vectors	NNS	O
comprising	IN	O
any	DT	O
of	.	O
the	DT	O
polynucleotides	NN	O
of	RB	O
the	VBZ	O
invention.	NNS	O
Such	VBG	O
vectors	DT	O
may	IN	O
comprise	DT	O
a	NNS	O
plasmid,	IN	O
a	DT	O
cosmid,	.	O
a	JJ	O
phage,	NNS	O
a	MD	O
virus,	VB	O
or	DT	O
a	,	O
fragment	DT	O
of	,	O
a	DT	O
virus.	,	O
Such	DT	O
vectors	,	O
may	CC	O
comprise	DT	O
an	NN	O
expression	IN	O
vector,	DT	O
and,	.	O
if	JJ	O
desired,	NNS	O
the	MD	O
nucleic	VB	O
acid	DT	O
is	NN	O
operably	,	O
linked	,	O
to	IN	O
a	,	O
promoter,	DT	O
including	JJ	O
those	NN	O
discussed	VBZ	O
herein	RB	O
and	VBN	O
below.	TO	O
Furthermore,	DT	O
in	,	O
another	VBG	O
aspect,	DT	O
the	VBN	O
invention	NN	O
provides	CC	O
compositions	.	O
comprising	,	O
an	IN	O
excipient	DT	O
or	,	O
carrier	DT	O
and	NN	O
at	VBZ	O
least	NNS	O
one	VBG	O
of	DT	O
any	NN	O
of	CC	O
the	NN	O
polynucleotides	CC	O
of	IN	O
the	JJS	O
invention,	CD	O
or	IN	O
vectors,	DT	O
cells,	IN	O
or	DT	O
host	NNS	O
comprising	IN	O
such	DT	O
nucleic	,	O
acids.	CC	O
Such	,	O
composition	,	O
may	CC	O
be	NN	O
pharmaceutical	NN	O
compositions,	JJ	O
and	JJ	O
the	.	O
excipient	JJ	O
or	NN	O
carrier	MD	O
may	VB	O
be	JJ	O
a	,	O
pharmaceutically	CC	O
acceptable	DT	O
excipient	NN	O
or	CC	O
carrier.	NN	O
The	MD	O
invention	VB	O
also	DT	O
includes	RB	O
compositions	JJ	O
comprising	NN	O
two	CC	O
or	.	O
more	DT	O
nucleic	NN	O
acids	RB	O
of	VBZ	O
the	NNS	O
invention,	VBG	O
or	CD	O
fragments	CC	O
thereof	JJR	O
(e.g.,	JJ	O
as	NNS	O
substrates	IN	O
for	DT	O
recombination).	,	O
The	CC	O
composition	NNS	O
can	VBP	O
comprise	,	O
a	IN	O
library	NNS	O
of	IN	O
recombinant	.	O
nucleic	DT	O
acids,	NN	O
where	MD	O
the	VB	O
library	DT	O
contains	NN	O
at	IN	O
least	JJ	O
2,	JJ	O
at	,	O
least	WRB	O
3,	DT	O
at	NN	O
least	NNS	O
5,	IN	O
at	JJS	O
least	,	O
10,	IN	O
at	JJS	O
least	,	O
20,	IN	O
at	JJS	O
least	,	O
50,	IN	O
or	JJS	O
at	,	O
least	IN	O
100	JJS	O
or	,	O
more	IN	O
nucleic	JJS	O
acids	,	O
described	CC	O
above.	IN	O
The	JJS	O
nucleic	CD	O
acids	CC	O
are	JJR	O
optionally	JJ	O
cloned	NNS	O
into	VBN	O
expression	.	O
vectors,	DT	O
providing	JJ	O
expression	NNS	O
libraries.	VBP	O
The	RB	O
polynucleotides	VBN	O
of	IN	O
the	NN	O
invention	,	O
and	VBG	O
fragments	NN	O
thereof,	.	O
as	DT	O
well	NNS	O
as	IN	O
vectors	DT	O
comprising	NN	O
such	CC	O
polynucleotides,	NNS	O
may	,	O
be	RB	O
employed	RB	O
for	IN	O
therapeutic	NNS	O
or	VBG	O
prophylactic	JJ	O
uses	,	O
in	MD	O
combination	VB	O
with	VBN	O
a	IN	O
suitable	JJ	O
carrier,	CC	O
such	JJ	O
as	NNS	O
a	IN	O
pharmaceutical	NN	O
carrier.	IN	O
Such	DT	O
compositions	JJ	O
comprise	,	O
a	JJ	O
therapeutically	IN	O
and/or	DT	O
prophylactically	JJ	O
effective	.	O
amount	JJ	O
of	NNS	O
the	VBP	O
compound,	DT	O
and	RB	O
a	JJ	O
pharmaceutically	RB	O
acceptable	JJ	O
carrier	NN	O
or	IN	O
excipient.	DT	O
Such	,	O
a	CC	O
carrier	DT	O
or	RB	O
excipient	JJ	O
includes,	NN	O
but	CC	O
is	.	O
not	JJ	O
limited	DT	O
to,	NN	O
saline,	CC	O
buffered	NN	O
saline,	,	O
dextrose,	CC	O
water,	VBZ	O
glycerol,	RB	O
ethanol,	VBN	O
and	,	O
combinations	,	O
thereof.	VBN	O
The	,	O
formulation	,	O
should	,	O
suit	,	O
the	,	O
mode	CC	O
of	NNS	O
administration.	.	O
Methods	DT	O
of	NN	O
administering	MD	O
nucleic	VB	O
acids,	DT	O
polypeptides,	NN	O
and	IN	O
proteins	.	O
are	NNS	O
well	IN	O
known	VBG	O
in	JJ	O
the	,	O
art.	,	O
The	CC	O
present	NNS	O
invention	VBP	O
also	RB	O
includes	VBN	O
recombinant	IN	O
constructs	DT	O
comprising	.	O
one	DT	O
or	JJ	O
more	NN	O
of	RB	O
the	VBZ	O
nucleic	JJ	O
acid	NNS	O
sequences	VBG	O
as	CD	O
broadly	CC	O
described	JJR	O
above.	IN	O
The	DT	O
constructs	JJ	O
comprise	NN	O
a	NNS	O
vector,	IN	O
such	RB	O
as,	VBN	O
a	.	O
plasmid,	DT	O
a	NNS	O
cosmid,	VBP	O
a	DT	O
phage,	,	O
a	JJ	O
virus,	,	O
a	DT	O
bacterial	,	O
artificial	DT	O
chromosome	,	O
(BAC),	DT	O
a	,	O
yeast	DT	O
artificial	,	O
chromosome	DT	O
(YAC),	JJ	O
and	JJ	O
the	NN	O
like,	,	O
into	DT	O
which	JJ	O
a	JJ	O
nucleic	NN	O
acid	,	O
sequence	CC	O
of	DT	O
the	,	O
invention	IN	O
has	WDT	O
been	DT	O
inserted,	NN	O
in	JJ	O
a	NN	O
forward	IN	O
or	DT	O
reverse	NN	O
orientation.	VBZ	O
In	VBN	O
some	,	O
instances,	IN	O
the	DT	O
construct	NN	O
further	CC	O
comprises	NN	O
regulatory	.	O
sequences,	IN	O
including,	DT	O
for	,	O
example,	DT	O
a	NN	O
promoter,	JJ	O
operably	NNS	O
linked	JJ	O
to	,	O
the	,	O
nucleic	IN	O
acid	,	O
sequence.	DT	O
Large	,	O
numbers	RB	O
of	VBN	O
suitable	TO	O
vectors	DT	O
and	JJ	O
promoters	NN	O
are	.	O
known	JJ	O
to	NNS	O
those	IN	O
of	JJ	O
skill	NNS	O
in	CC	O
the	NNS	O
art,	VBP	O
and	VBN	O
are	TO	O
commercially	DT	O
available.	IN	O
General	NN	O
texts	IN	O
that	DT	O
describe	,	O
molecular	CC	O
biological	VBP	O
techniques	RB	O
useful	.	O
herein,	NNP	O
including	NN	O
the	WDT	O
use	VBZ	O
of	JJ	O
vectors,	JJ	O
promoters	NNS	O
and	JJ	O
many	,	O
other	VBG	O
relevant	DT	O
topics,	NN	O
include	IN	O
Berger,	,	O
supra;	NNS	O
Sambrook	CC	O
(1989),	JJ	O
supra,	JJ	O
and	JJ	O
Ausubel,	,	O
supra.	VBP	O
Examples	,	O
of	:	O
techniques	NNP	O
sufficient	,	O
to	,	O
direct	CC	O
persons	,	O
of	.	O
skill	NNS	O
through	IN	O
in	NNS	O
vitro	JJ	O
amplification	TO	O
methods,	JJ	O
including	NNS	O
the	IN	O
polymerase	NN	O
chain	IN	O
reaction	IN	O
(PCR)	JJ	O
the	NN	O
ligase	,	O
chain	VBG	O
reaction	DT	O
(LCR),	NN	O
Q	NN	O
beta-replicase	NN	O
amplification	)	O
and	DT	O
other	NN	O
RNA	NN	O
polymerase	NN	O
mediated	,	O
techniques	NNP	O
(e.g.,	NN	O
NASBA),	NN	O
e.g.,	CC	O
for	JJ	O
the	NNP	O
production	NN	O
of	VBD	O
the	NNS	O
homologous	,	O
nucleic	,	O
acids	,	O
of	IN	O
the	DT	O
invention	NN	O
are	IN	O
found	DT	O
in	JJ	O
Berger,	JJ	O
Sambrook,	NNS	O
and	IN	O
Ausubel,	DT	O
all	NN	O
supra,	VBP	O
as	VBN	O
well	IN	O
as	,	O
Mullis	,	O
et	CC	O
al.	,	O
(1987)	DT	O
U.S.	,	O
Pat.	RB	O
No.	RB	O
4,683,202;	IN	O
PCR	NNP	B
Protocols:	CC	I
A	.	I
Guide	)	I
to	NNP	I
Methods	.	I
and	.	I
Applications	:	I
(Innis	NNP	I
et	:	I
al.,	DT	I
eds.)	NNP	I
Academic	TO	I
Press	NNP	I
Inc.	CC	I
San	NNP	I
Diego,	NNP	I
Calif.	RB	I
(1990)	,	I
(“Innis”);	)	I
Arnheim	NNP	B
&	NNP	I
Levinson	NNP	I
(Oct.	NNP	I
1,	,	I
1990)	NNP	I
C&EN	)	I
36-47;	:	I
The	NNP	B
Journal	CC	I
Of	NNP	I
NIH	NNP	I
Research	,	I
(1991)	)	I
3:81-94;	NNP	I
Kwoh	:	B
et	DT	I
al.	NNP	I
(1989)	IN	I
Proc	NNP	I
Natl	NNP	I
Acad	)	I
Sci	:	I
USA	NNP	I
86:1173-1177;	RB	I
Guatelli	.	B
et	)	I
al.	NNP	I
(1990)	NNP	I
Proc	NNP	I
Natl	NNP	I
Acad	NNP	I
Sci	:	I
USA	NNP	I
87:1874-1878;	FW	I
Lomeli	.	B
et	)	I
al.	NNP	I
(1989)	NNP	I
J	NNP	I
Clin	NNP	I
Chem	NNP	I
35:1826-1831;	:	I
Landegren	NNP	B
et	FW	I
al.	.	I
(1988)	)	I
Science	NNP	I
241:1077-1080;	NNP	I
Van	NNP	B
Brunt	:	I
(1990)	NNP	I
Biotechnology	VBZ	I
8:291-294;	.	I
Wu	)	B
and	NNP	I
Wallace	:	I
(1989)	NNP	I
Gene	NNP	I
4:560-569;	)	I
Barringer	NNP	B
et	:	I
al.	NNP	I
(1990)	CC	I
Gene	NNP	I
89:117-122,	)	I
(and	NNP	O
Sooknanan	:	B
and	NNP	I
Malek	FW	I
(1995)	.	I
Biotechnology	)	I
13:563-564.	NNP	I
Improved	,	O
methods	CC	O
of	NNP	O
cloning	CC	O
in	NNP	O
vitro	)	O
amplified	NNP	O
nucleic	.	O
acids	VBN	O
are	NNS	O
described	IN	O
in	VBG	O
Wallace	IN	O
et	NN	O
al.,	VBN	O
U.S.	JJ	O
Pat.	NNS	O
No.	VBP	O
5,426,039.	VBN	O
Improved	IN	O
methods	NNP	O
of	CC	O
amplifying	,	O
large	NNP	O
nucleic	.	O
acids	.	O
by	.	O
PCR	VBN	O
are	NNS	O
summarized	IN	O
in	VBG	O
Cheng	JJ	B
et	JJ	I
al.	NNS	I
(1994)	IN	I
Nature	NNP	I
369:684-685	VBP	I
and	VBN	O
the	IN	O
references	NNP	O
therein,	CC	O
in	.	O
which	)	O
PCR	NN	O
amplicons	JJ	O
of	CC	O
up	DT	O
to	NNS	O
40	,	O
kilobases	IN	O
(kb)	WDT	O
are	NNP	O
generated.	NNS	O
One	IN	O
of	IN	O
skill	TO	O
will	CD	O
appreciate	NNS	O
that	)	O
essentially	VBP	O
any	.	O
RNA	CD	O
can	IN	O
be	NN	O
converted	MD	O
into	VB	O
a	DT	O
double	RB	O
stranded	DT	O
DNA	NNP	O
suitable	MD	O
for	VB	O
restriction	VBN	O
digestion,	IN	O
PCR	DT	O
expansion	JJ	O
and	JJ	O
sequencing	NNP	O
using	NN	O
reverse	IN	O
transcriptase	NN	O
and	,	O
a	NNP	O
polymerase.	NN	O
See	CC	O
Ausubel,	VBG	O
Sambrook	VBG	O
and	JJ	O
Berger,	NN	O
all	CC	O
supra.	DT	O
The	.	O
present	VB	O
invention	,	O
also	NNP	O
provides	CC	O
host	,	O
cells	DT	O
that	.	O
are	DT	O
transduced	JJ	O
with	NN	O
vectors	RB	O
of	VBZ	O
the	NN	O
invention,	NNS	O
and	WDT	O
the	VBP	O
production	VBN	O
of	IN	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	,	O
by	CC	O
recombinant	DT	O
techniques.	NN	O
Host	IN	O
cells	NNS	O
are	IN	O
genetically	DT	O
engineered	NN	O
(e.g.,	IN	O
transduced,	JJ	O
transformed	.	O
or	NNP	O
transfected)	NNS	O
with	VBP	O
the	RB	O
vectors	VBN	O
of	,	O
this	,	O
invention,	VBD	O
which	CC	O
may	)	O
be,	IN	O
for	DT	O
example,	NNS	O
a	IN	O
cloning	DT	O
vector	,	O
or	WDT	O
an	MD	O
expression	,	O
vector.	IN	O
The	,	O
vector	DT	O
may	VBG	O
be,	NN	O
for	CC	O
example,	DT	O
in	NN	O
the	.	O
form	DT	O
of	NN	O
a	MD	O
plasmid,	,	O
a	IN	O
viral	,	O
particle,	IN	O
a	DT	O
phage,	NN	O
etc.	IN	O
The	DT	O
engineered	,	O
host	DT	O
cells	JJ	O
can	,	O
be	DT	O
cultured	,	O
in	.	O
conventional	DT	O
nutrient	JJ	O
media	NN	O
modified	NNS	O
as	MD	O
appropriate	VB	O
for	VBN	O
activating	IN	O
promoters,	JJ	O
selecting	JJ	O
transformants,	NNS	O
or	VBD	O
amplifying	IN	O
genes.	NN	O
The	IN	O
culture	VBG	O
conditions,	,	O
such	VBG	O
as	,	O
temperature,	CC	O
pH,	VBG	O
and	.	O
the	DT	O
like,	NN	O
are	,	O
those	JJ	O
previously	IN	O
used	,	O
with	,	O
the	CC	O
host	DT	O
cell	,	O
selected	VBP	O
for	DT	O
expression,	RB	O
and	VBN	O
will	IN	O
be	DT	O
apparent	NN	O
to	NN	O
those	VBN	O
skilled	IN	O
in	,	O
the	CC	O
art	MD	O
and	VB	O
in	JJ	O
the	TO	O
references	DT	O
cited	VBN	O
herein,	IN	O
including,	DT	O
e.g.,	NN	O
Freshney	CC	B
(1994)	IN	I
Culture	DT	I
of	NNS	I
Animal	VBD	I
Cells,	,	I
a	,	I
Manual	,	I
of	NNP	I
Basic	)	I
Technique,	NN	I
third	IN	I
edition,	NNP	I
Wiley-Liss,	,	I
New	DT	I
York	NNP	I
and	IN	O
the	NNP	O
references	,	O
cited	JJ	O
therein.	,	O
The	,	O
polypeptides	NNP	O
of	NNP	O
the	CC	O
invention	DT	O
can	NNS	O
also	VBD	O
be	.	O
produced	DT	O
in	NNS	O
non-animal	IN	O
cells	DT	O
such	NN	O
as	MD	O
plants,	RB	O
yeast,	VB	O
fungi,	VBN	O
bacteria	IN	O
and	JJ	O
the	NNS	O
like.	JJ	O
In	IN	O
addition	,	O
to	,	O
Sambrook,	,	O
Berger	NNS	O
and	CC	O
Ausubel,	DT	O
details	.	O
regarding	IN	O
cell	NN	O
culture	TO	O
are	,	O
found	NNP	O
in,	CC	O
e.g.,	,	O
Payne	NNS	B
et	VBG	I
al.	NN	I
(1992)	NN	I
Plant	VBP	I
Cell	VBN	I
and	,	I
Tissue	,	I
Culture	NNP	I
in	CC	I
Liquid	.	I
Systems	)	I
John	NNP	I
Wiley	NNP	I
&	CC	I
Sons,	NNP	I
Inc.	NNP	I
New	IN	I
York,	NNP	I
N.Y.;	NNP	I
Gamborg	NNP	B
and	NNP	I
Phillips	CC	I
(eds.)	,	I
(1995)	NNP	I
Plant	NNP	I
Cell,	,	I
Tissue	:	I
and	NNP	I
Organ	CC	I
Culture;	NNP	I
Fundamental	)	B
Methods	)	I
Springer	NNP	I
Lab	,	I
Manual,	NNP	I
Springer-Verlag	CC	I
(Berlin	NNP	I
Heidelberg	:	I
New	NNP	I
York);	NNP	I
Atlas	NNP	B
&	NNP	I
Parks	,	I
(eds.)	NNP	I
The	NNP	I
Handbook	NNP	I
of	NNP	I
Microbiological	:	I
Media	NNP	I
(1993)	CC	I
CRC	NNP	I
Press,	)	I
Boca	DT	I
Raton,	NNP	I
Fla.
The	IN	O
polynucleotides	NNP	O
of	NNP	O
the	)	O
present	NNP	O
invention	,	O
and	NNP	O
fragments	,	O
thereof	.	O
may	DT	O
be	NNS	O
included	IN	O
in	DT	O
any	JJ	O
one	NN	O
of	CC	O
a	NNS	O
variety	NN	O
of	MD	O
expression	VB	O
vectors	VBN	O
for	IN	O
expressing	DT	O
a	CD	O
polypeptide.	IN	O
Such	DT	O
vectors	NN	O
include	IN	O
chromosomal,	NN	O
nonchromosomal	NNS	O
and	IN	O
synthetic	VBG	O
DNA	DT	O
sequences,	.	O
e.g.,	JJ	O
derivatives	NNS	O
of	VBP	O
SV40,	,	O
bacterial	JJ	O
plasmids,	CC	O
phage	JJ	O
DNA,	NNP	O
baculovirus,	,	O
yeast	,	O
plasmids,	NNS	O
vectors	IN	O
derived	,	O
from	JJ	O
combinations	,	O
of	NN	O
plasmids	,	O
and	,	O
phage	NN	O
DNA,	,	O
viral	NNS	O
DNA	VBD	O
such	IN	O
as	NNS	O
vaccinia,	IN	O
adenovirus,	NNS	O
fowl	CC	O
pox	NN	O
virus,	,	O
pseudorabies,	JJ	O
adeno-associated	NNP	O
virus,	JJ	O
retroviruses	IN	O
and	,	O
many	,	O
others.	NN	O
Any	NN	O
vector	,	O
that	,	O
transduces	JJ	O
genetic	,	O
material	NNS	O
into	CC	O
a	JJ	O
cell,	.	O
and,	DT	O
if	NN	O
replication	WDT	O
is	VBZ	O
desired,	JJ	O
which	NN	O
is	IN	O
replicable	DT	O
and	,	O
viable	,	O
in	IN	O
the	NN	O
relevant	VBZ	O
host	,	O
can	WDT	O
be	VBZ	O
used.	JJ	O
The	CC	O
nucleic	JJ	O
acid	IN	O
sequence	DT	O
in	JJ	O
the	NN	O
expression	MD	O
vector	VB	O
is	.	O
operatively	DT	O
linked	JJ	O
to	NN	O
an	NN	O
appropriate	IN	O
transcription	DT	O
control	NN	O
sequence	NN	O
(promoter)	VBZ	O
to	RB	O
direct	VBN	O
mRNA	TO	O
synthesis.	DT	O
Examples	JJ	O
of	NN	O
such	NN	O
promoters	NN	O
include:	)	O
LTR	TO	O
or	VB	O
SV40	JJ	O
promoter,	.	O
E.	NNS	O
coli	IN	O
lac	JJ	O
or	NNS	O
trp	:	O
promoter,	NNP	O
phage	CC	O
lambda	NNP	O
PL	,	O
promoter,	NNP	O
CMV	VBP	O
promoter,	NN	O
and	CC	O
other	NN	O
promoters	,	O
known	NN	O
to	NN	O
control	NNP	O
expression	,	O
of	NNP	O
genes	,	O
in	CC	O
prokaryotic	JJ	O
or	NNS	O
eukaryotic	VBN	O
cells	TO	O
or	VB	O
their	NN	O
viruses.	IN	O
The	NNS	O
expression	IN	O
vector	JJ	O
also	CC	O
contains	JJ	O
a	NNS	O
ribosome	CC	O
binding	PRP$	O
site	.	O
for	DT	O
translation	NN	O
initiation,	NN	O
and	RB	O
a	VBZ	O
transcription	DT	O
terminator.	NN	O
The	NN	O
vector	NN	O
optionally	IN	O
includes	NN	O
appropriate	,	O
sequences	CC	O
for	DT	O
amplifying	NN	O
expression,	.	O
e.g.,	DT	O
an	NN	O
enhancer.	RB	O
In	VBZ	O
addition,	JJ	O
the	NNS	O
expression	IN	O
vectors	VBG	O
optionally	,	O
comprise	,	O
one	DT	O
or	.	O
more	IN	O
selectable	,	O
marker	DT	O
genes	NN	O
to	NNS	O
provide	RB	O
a	VBP	O
phenotypic	CD	O
trait	CC	O
for	JJR	O
selection	JJ	O
of	NN	O
transformed	NNS	O
host	TO	O
cells,	VB	O
such	DT	O
as	NN	O
dihydrofolate	NN	O
reductase	IN	O
or	NN	O
neomycin	IN	O
resistance	JJ	O
for	NN	O
eukaryotic	,	O
cell	JJ	O
culture,	IN	O
or	JJ	O
such	NN	O
as	CC	O
tetracycline,	JJ	O
kanamycin	NN	O
or	IN	O
ampicillin	JJ	O
resistance	NN	O
in	,	O
E.	CC	O
coli.	JJ	O
The	IN	O
vector	,	O
containing	NN	O
the	CC	O
appropriate	NN	O
DNA	NN	O
sequence	IN	O
encoding	NNP	O
a	.	O
polypeptide	DT	O
of	NN	O
the	VBG	O
invention,	DT	O
as	JJ	O
well	NNP	O
as	NN	O
an	VBG	O
appropriate	DT	O
promoter	NN	O
or	IN	O
control	DT	O
sequence,	,	O
may	RB	O
be	RB	O
employed	IN	O
to	DT	O
transform	JJ	O
an	NN	O
appropriate	CC	O
host	NN	O
to	,	O
permit	MD	O
the	VB	O
host	VBN	O
to	TO	O
express	VB	O
the	DT	O
polypeptide.	JJ	O
Examples	NN	O
of	TO	O
appropriate	VB	O
expression	DT	O
hosts	NN	O
include:	TO	O
bacterial	VB	O
cells,	DT	O
such	.	O
as	NNS	O
E.	IN	O
coli,	JJ	O
Streptomyces,	NN	O
and	NNS	O
Salmonella	:	O
typhimurium;	JJ	O
fungal	,	O
cells,	JJ	O
such	IN	O
as	NNP	O
Saccharomyces	,	O
cerevisiae,	,	O
Pichia	CC	O
pastoris,	NNP	O
and	:	O
Neurospora	JJ	O
crassa;	,	O
insect	JJ	O
cells	IN	O
such	NNS	O
as	,	O
Drosophila	NNP	O
and	,	O
Spodoptera	CC	O
frugiperda;	NNP	O
mammalian	:	O
cells	JJ	O
such	NNS	O
as	JJ	O
CHO,	IN	O
COS,	NNP	O
BHK,	CC	O
HEK	NNP	O
293	:	O
or	JJ	O
Bowes	NNS	O
melanoma;	JJ	O
plant	IN	O
cells,	,	O
etc.	,	O
It	,	O
is	NNP	O
understood	CD	O
that	CC	O
not	NNP	O
all	:	O
cells	NN	O
or	,	O
cell	.	O
lines	PRP	O
need	VBZ	O
to	JJ	O
be	IN	O
capable	RB	O
of	DT	O
producing	NNS	O
fully	CC	O
functional	NN	O
polypeptides	NNS	O
of	VBP	O
the	TO	O
invention	VB	O
or	JJ	O
fragments	IN	O
thereof;	VBG	O
for	RB	O
example,	JJ	O
antigenic	NNS	O
fragments	IN	O
of	DT	O
the	NN	O
polypeptide	CC	O
may	NNS	O
be	:	O
produced	IN	O
in	,	O
a	JJ	O
bacterial	NNS	O
or	IN	O
other	DT	O
expression	NN	O
system.	MD	O
The	VB	O
invention	VBN	O
is	IN	O
not	DT	O
limited	JJ	O
by	CC	O
the	JJ	O
host	NN	O
cells	.	O
employed.	DT	O
In	NN	O
bacterial	VBZ	O
systems,	RB	O
a	VBN	O
number	IN	O
of	DT	O
expression	NN	O
vectors	NNS	O
may	.	O
be	IN	O
selected	JJ	O
depending	,	O
upon	DT	O
the	NN	O
use	IN	O
intended	NN	O
for	NNS	O
the	MD	O
polypeptide	VB	O
or	VBN	O
fragment	VBG	O
thereof.	IN	O
For	DT	O
example,	NN	O
when	VBN	O
large	IN	O
quantities	DT	O
of	NN	O
a	CC	O
polypeptide	JJ	O
or	.	O
fragments	IN	O
thereof	,	O
are	WRB	O
needed	JJ	O
for	NNS	O
the	IN	O
induction	DT	O
of	NN	O
antibodies,	CC	O
vectors	NNS	O
which	NNS	O
direct	VBP	O
high	VBN	O
level	IN	O
expression	DT	O
of	NN	O
fusion	IN	O
proteins	,	O
that	NNS	O
are	WDT	O
readily	VBP	O
purified	JJ	O
may	NN	O
be	NN	O
desirable.	IN	O
Such	NN	O
vectors	NNS	O
include,	WDT	O
but	VBP	O
are	RB	O
not	VBN	O
limited	MD	O
to,	VB	O
multifunctional	.	O
E.	JJ	O
coli	NNS	O
cloning	,	O
and	CC	O
expression	VBP	O
vectors	RB	O
such	VBN	O
as	,	O
BLUESCRIPT	JJ	O
(Stratagene),	NNP	O
in	NNS	O
which	VBG	O
the	CC	O
nucleotide	NN	O
coding	NNS	O
sequence	JJ	O
may	IN	O
be	NNP	O
ligated	,	O
into	IN	O
the	WDT	O
vector	DT	O
in-frame	NN	O
with	VBG	O
sequences	NN	O
for	MD	O
the	VB	O
amino-terminal	VBN	O
Met	IN	O
and	DT	O
the	NN	O
subsequent	NN	O
7	IN	O
residues	NNS	O
of	IN	O
beta-galactosidase	DT	O
so	JJ	O
that	NNP	O
a	CC	O
hybrid	DT	O
protein	JJ	O
is	CD	O
produced;	NNS	O
pIN	IN	O
vectors	NN	O
Van	IN	B
Heeke	IN	I
&	DT	I
Schuster	JJ	I
(1989)	NN	I
J	VBZ	I
Biol	:	I
Chem	JJ	I
264:5503-5509);(	NNS	O
pET	NNP	O
vectors	NNP	O
(Novagen,	CC	O
Madison	NNP	O
Wis.);	)	O
and	NNP	O
the	NNP	O
like.	NNP	O
Similarly,	:	O
in	JJ	O
the	NNS	O
yeast	,	O
Saccharomyces	NNP	O
cerevisiae	:	O
a	CC	O
number	DT	O
of	.	O
vectors	,	O
containing	IN	O
constitutive	DT	O
or	NN	O
inducible	NNP	O
promoters	VBZ	O
such	DT	O
as	NN	O
alpha	IN	O
factor,	NNS	O
alcohol	VBG	O
oxidase	NN	O
and	CC	O
PGH	JJ	O
may	NNS	O
be	JJ	O
used	IN	O
for	JJ	O
production	,	O
of	NN	O
the	NN	O
polypeptides	CC	O
of	NNP	O
the	MD	O
invention.	VB	O
For	VBN	O
reviews,	IN	O
see	NN	O
Ausubel,	IN	B
supra,	DT	I
Berger,	NNS	I
supra,	IN	I
and	DT	I
Grant	.	I
et	IN	I
al.	,	I
(1987)	VBP	I
Methods	,	I
in	,	I
Enzymology	,	I
153:516-544.
In	,	O
mammalian	CC	O
host	NNP	O
cells,	VBD	O
a	.	O
number	)	O
of	NNS	O
expression	IN	O
systems,	NNP	O
such	.	O
as	IN	O
viral-based	JJ	O
systems,	NN	O
may	,	O
be	DT	O
utilized.	NN	O
In	IN	O
cases	NN	O
where	,	O
an	JJ	O
adenovirus	IN	O
is	JJ	O
used	,	O
as	MD	O
an	VB	O
expression	.	O
vector,	IN	O
a	NNS	O
coding	WRB	O
sequence	DT	O
is	NN	O
optionally	VBZ	O
ligated	VBN	O
into	IN	O
an	DT	O
adenovirus	NN	O
transcription/translation	,	O
complex	DT	O
consisting	NN	O
of	NN	O
the	VBZ	O
late	RB	O
promoter	VBN	O
and	IN	O
tripartite	DT	O
leader	JJ	O
sequence.	NN	O
Insertion	JJ	O
in	NN	O
a	IN	O
nonessential	DT	O
E1	JJ	O
or	NN	O
E3	CC	O
region	JJ	O
of	NN	O
the	.	O
viral	NN	O
genome	IN	O
results	DT	O
in	JJ	O
a	NNP	O
viable	CC	O
virus	NNP	O
capable	NN	O
of	IN	O
expressing	DT	O
a	JJ	O
polypeptide	NN	O
of	NNS	O
the	IN	O
invention	DT	O
in	JJ	O
infected	NN	O
host	JJ	O
cells	IN	O
Logan	VBG	B
and	DT	I
Shenk	NN	I
(1984)	IN	I
Proc	DT	I
Natl	NN	I
Acad	IN	I
Sci	JJ	I
USA	NN	I
81:3655-3659).(	NNS	O
In	NNP	O
addition,	CC	O
transcription	NNP	O
enhancers,	)	O
such	NNP	O
as	NNP	O
the	NNP	O
rous	NNP	O
sarcoma	NNP	O
virus	.	O
(RSV)	IN	O
enhancer,	,	O
are	NN	O
used	,	O
to	JJ	O
increase	IN	O
expression	DT	O
in	JJ	O
mammalian	NN	O
host	NN	O
cells.	)	O
Host	,	O
cells,	VBP	O
media,	VBN	O
expression	TO	O
systems,	VB	O
and	NN	O
methods	IN	O
of	JJ	O
production	NN	O
include	.	O
those	NNP	O
known	,	O
for	,	O
cloning	NN	O
and	,	O
expression	CC	O
of	NNS	O
various	IN	O
mammalian	NN	O
proteins.	VBP	O
Specific	DT	O
initiation	VBN	O
signals	IN	O
can	VBG	O
aid	CC	O
in	NN	O
efficient	IN	O
translation	JJ	O
of	JJ	O
a	.	O
polynucleotide	JJ	O
coding	NN	O
sequence	NNS	O
of	MD	O
the	VB	O
invention	IN	O
and/or	JJ	O
fragments	NN	O
thereof.	IN	O
These	DT	O
signals	NN	O
can	VBG	O
include,	NN	O
e.g.,	IN	O
the	DT	O
ATG	NN	O
initiation	NN	O
codon	NNS	O
and	.	O
adjacent	DT	O
sequences.	NNS	O
In	MD	O
cases	,	O
where	,	O
a	DT	O
coding	NNP	O
sequence,	NN	O
its	NN	O
initiation	CC	O
codon	JJ	O
and	.	O
upstream	IN	O
sequences	NNS	O
are	WRB	O
inserted	DT	O
into	NN	O
the	,	O
appropriate	PRP$	O
expression	NN	O
vector,	NN	O
no	CC	O
additional	JJ	O
translational	NNS	O
control	VBP	O
signals	VBN	O
may	IN	O
be	DT	O
needed.	JJ	O
However,	NN	O
in	,	O
cases	DT	O
where	JJ	O
only	NN	O
coding	NN	O
sequence	NNS	O
(e.g.,	MD	O
a	VB	O
mature	.	O
protein	,	O
coding	IN	O
sequence),	NNS	O
or	WRB	O
a	RB	O
portion	VBG	O
thereof,	NN	O
is	,	O
inserted,	DT	O
exogenous	NN	O
nucleic	NN	O
acid	VBG	O
transcriptional	,	O
control	CC	O
signals	DT	O
including	NN	O
the	,	O
ATG	VBZ	O
initiation	,	O
codon	JJ	O
must	JJ	O
be	JJ	O
provided.	JJ	O
Furthermore,	NN	O
the	NNS	O
initiation	VBG	O
codon	DT	O
must	NNP	O
be	NN	O
in	NN	O
the	MD	O
correct	VB	O
reading	.	O
frame	,	O
to	DT	O
ensure	NN	O
transcription	NN	O
of	MD	O
the	VB	O
entire	IN	O
insert.	DT	O
Exogenous	JJ	O
transcriptional	NN	O
elements	NN	O
and	TO	O
initiation	VB	O
codons	NN	O
can	IN	O
be	DT	O
of	JJ	O
various	.	O
origins,	JJ	O
both	JJ	O
natural	NNS	O
and	CC	O
synthetic.	NN	O
The	NNS	O
efficiency	MD	O
of	VB	O
expression	IN	O
can	JJ	O
be	,	O
enhanced	DT	O
by	JJ	O
the	CC	O
inclusion	.	O
of	DT	O
enhancers	NN	O
appropriate	IN	O
to	NN	O
the	MD	O
cell	VB	O
system	VBN	O
in	IN	O
use	DT	O
(see,	NN	O
e.g.,	IN	O
Scharf	NNS	B
D.	VBP	I
et	TO	I
al.	DT	I
(1994)	NN	I
Results	NN	I
Probl	IN	I
Cell	NN	I
Differ	,	I
20:125-62;	,	I
and	NNP	O
Bittner	NNP	B
et	FW	I
al.	.	I
(1987)	)	I
Methods	NNP	I
in	NNP	I
Enzymol	NNP	I
153:516-544).Polynucleotides	NNP	O
encoding	:	O
polypeptides	CC	O
of	NNP	O
the	VBP	O
invention	.	O
can	)	O
also	NNS	O
be	IN	O
fused,	NNP	O
for	.	O
example,	NNS	O
in-frame	VBG	O
to	NNS	O
nucleic	IN	O
acids	DT	O
encoding	NN	O
a	MD	O
secretion/localization	RB	O
sequence,	VB	O
to	,	O
target	IN	O
polypeptide	,	O
expression	JJ	O
to	TO	O
a	JJ	O
desired	NNS	O
cellular	VBG	O
compartment,	DT	O
membrane,	NN	O
or	,	O
organelle,	TO	O
or	VB	O
to	JJ	O
direct	NN	O
polypeptide	TO	O
secretion	DT	O
to	VBN	O
the	JJ	O
periplasmic	,	O
space	,	O
or	CC	O
into	,	O
the	CC	O
cell	TO	O
culture	VB	O
media.	JJ	O
Such	NN	O
sequences	TO	O
are	DT	O
known	JJ	O
to	NN	O
those	CC	O
of	IN	O
skill,	DT	O
and	NN	O
include	NN	O
secretion	.	O
leader	JJ	O
or	NNS	O
signal	VBP	O
peptides,	VBN	O
organelle	TO	O
targeting	DT	O
sequences	IN	O
(e.g.,	,	O
nuclear	CC	O
localization	VBP	O
sequences,	JJ	O
ER	NN	O
retention	CC	O
signals,	JJ	O
mitochondrial	,	O
transit	IN	O
sequences,	VBG	O
chloroplast	NNS	O
transit	,	O
sequences),	JJ	O
membrane	NN	O
localization/anchor	,	O
sequences	NNP	O
(e.g.,	NN	O
stop	,	O
transfer	JJ	O
sequences,	NN	O
GPI	,	O
anchor	JJ	O
sequences),	NN	O
and	,	O
the	FW	O
like.	NN	O
In	NNS	O
a	,	O
further	VB	O
aspect,	NN	O
the	,	O
present	NNP	O
invention	NN	O
relates	,	O
to	CC	O
host	DT	O
cells	.	O
containing	IN	O
any	DT	O
of	JJ	O
the	,	O
above-described	DT	O
nucleic	JJ	O
acids,	NN	O
vectors,	VBZ	O
or	TO	O
other	VB	O
constructs	NNS	O
of	VBG	O
the	DT	O
invention.	IN	O
The	DT	O
host	JJ	O
cell	JJ	O
can	,	O
be	,	O
a	CC	O
eukaryotic	JJ	O
cell,	NNS	O
such	IN	O
as	DT	O
a	.	O
mammalian	DT	O
cell,	NN	O
a	NN	O
yeast	MD	O
cell,	VB	O
or	DT	O
a	JJ	O
plant	,	O
cell,	JJ	O
or	IN	O
the	DT	O
host	JJ	O
cell	,	O
can	DT	O
be	NN	O
a	,	O
prokaryotic	CC	O
cell,	DT	O
such	NN	O
as	,	O
a	CC	O
bacterial	DT	O
cell.	NN	O
Introduction	NN	O
of	MD	O
the	VB	O
construct	DT	O
into	JJ	O
the	,	O
host	JJ	O
cell	IN	O
can	DT	O
be	JJ	O
effected	.	O
by	NN	O
calcium	IN	O
phosphate	DT	O
transfection,	NN	O
DEAE-Dextran	IN	O
mediated	DT	O
transfection,	NN	O
electroporation,	NN	O
gene	MD	O
or	VB	O
vaccine	VBN	O
gun,	IN	O
injection,	NN	O
or	NN	O
other	,	O
common	NNP	O
techniques	VBD	O
(see,	,	O
e.g.,	,	O
Davis,	NN	B
L.,	CC	I
Dibner,	NN	I
M.,	,	I
and	,	I
Battey,	CC	I
I.	JJ	I
(1986)	JJ	I
Basic	NNS	I
Methods	,	I
in	,	I
Molecular	,	I
Biology)	,	I
for	,	O
in	,	O
vivo,	CC	O
ex	,	O
vivo	.	O
or	)	O
in	NNP	O
vitro	NNP	O
methods.	IN	O
A	NNP	O
host	)	O
cell	IN	O
strain	IN	O
is	,	O
optionally	FW	O
chosen	FW	O
for	CC	O
its	IN	O
ability	JJ	O
to	.	O
modulate	DT	O
the	NN	O
expression	NN	O
of	NN	O
the	VBZ	O
inserted	RB	O
sequences	VBN	O
or	IN	O
to	PRP$	O
process	NN	O
the	TO	O
expressed	VB	O
protein	DT	O
in	NN	O
the	IN	O
desired	DT	O
fashion.	JJ	O
Such	NNS	O
modifications	CC	O
of	TO	O
the	VB	O
protein	DT	O
include,	VBN	O
but	NN	O
are	IN	O
not	DT	O
limited	JJ	O
to,	.	O
acetylation,	JJ	O
carboxylation,	NNS	O
glycosylation,	IN	O
phosphorylation,	DT	O
lipidation	NN	O
and	,	O
acylation.	CC	O
Post-translational	VBP	O
processing	RB	O
which	VBN	O
cleaves	,	O
a	,	O
“pre”	,	O
or	,	O
a	,	O
“prepro”	NN	O
form	CC	O
of	.	O
the	JJ	O
protein	NN	O
may	WDT	O
also	VBZ	O
be	DT	O
important	NN	O
for	CC	O
correct	DT	O
insertion,	JJ	O
folding	NN	O
and/or	IN	O
function.	DT	O
Different	NN	O
host	MD	O
cells	RB	O
such	VB	O
as	JJ	O
E.	IN	O
coli,	JJ	O
Bacillus	,	O
sp.,	VBG	O
yeast	JJ	O
or	.	O
mammalian	NN	O
cells	NN	O
such	NNS	O
as	JJ	O
CHO,	IN	O
HeLa,	NNP	O
BHK,	,	O
MDCK,	NNP	O
HEK	,	O
293,	NN	O
W138,	CC	O
etc.	JJ	O
have	NNS	O
specific	JJ	O
cellular	IN	O
machinery	,	O
and	,	O
characteristic	,	O
mechanisms	,	O
for	NNP	O
such	,	O
post-translational	,	O
activities	.	O
and	VB	O
may	JJ	O
be	JJ	O
chosen	NN	O
to	CC	O
ensure	JJ	O
the	NNS	O
correct	IN	O
modification	JJ	O
and	JJ	O
processing	NNS	O
of	CC	O
the	MD	O
introduced	VB	O
foreign	VBN	O
protein.	TO	O
Stable	VB	O
expression	DT	O
can	JJ	O
be	NN	O
used	CC	O
for	NN	O
long-term,	IN	O
high-yield	DT	O
production	JJ	O
of	JJ	O
recombinant	.	O
proteins.	JJ	O
For	NN	O
example,	MD	O
cell	VB	O
lines	VBN	O
which	IN	O
stably	,	O
express	JJ	O
a	NN	O
polypeptide	IN	O
of	JJ	O
the	.	O
invention	IN	O
are	,	O
transduced	NN	O
using	NNS	O
expression	WDT	O
vectors	RB	O
which	VBP	O
contain	DT	O
viral	NN	O
origins	IN	O
of	DT	O
replication	NN	O
or	VBP	O
endogenous	VBN	O
expression	VBG	O
elements	NN	O
and	NNS	O
a	WDT	O
selectable	VBP	O
marker	JJ	O
gene.	NNS	O
Following	IN	O
the	NN	O
introduction	CC	O
of	JJ	O
the	NN	O
vector,	NNS	O
cells	CC	O
may	DT	O
be	JJ	O
allowed	NN	O
to	.	O
grow	VBG	O
for	DT	O
1-2	NN	O
days	IN	O
in	DT	O
an	,	O
enriched	NNS	O
media	MD	O
before	VB	O
they	VBN	O
are	TO	O
switched	VB	O
to	IN	O
selective	JJ	O
media.	NNS	O
The	IN	O
purpose	DT	O
of	JJ	O
the	NNS	O
selectable	IN	O
marker	PRP	O
is	VBP	O
to	VBN	O
confer	TO	O
resistance	JJ	O
to	.	O
selection,	DT	O
and	NN	O
its	IN	O
presence	DT	O
allows	JJ	O
growth	NN	O
and	VBZ	O
recovery	TO	O
of	VB	O
cells	NN	O
which	TO	O
successfully	,	O
express	CC	O
the	PRP$	O
introduced	NN	O
sequences.	VBZ	O
For	NN	O
example,	CC	O
resistant	NN	O
clumps	IN	O
of	NNS	O
stably	WDT	O
transformed	RB	O
cells	VBP	O
can	DT	O
be	JJ	O
proliferated	.	O
using	IN	O
tissue	,	O
culture	JJ	O
techniques	NNS	O
appropriate	IN	O
to	RB	O
the	VBN	O
cell	NNS	O
type.	MD	O
Host	VB	O
cells	VBN	O
transformed	VBG	O
with	JJ	O
a	NN	O
nucleotide	NNS	O
sequence	VBP	O
encoding	TO	O
a	DT	O
polypeptide	NN	O
of	.	O
the	NNP	O
invention	NNS	O
are	VBD	O
optionally	IN	O
cultured	DT	O
under	JJ	O
conditions	NN	O
suitable	VBG	O
for	DT	O
the	NN	O
expression	IN	O
and	DT	O
recovery	NN	O
of	VBP	O
the	RB	O
encoded	VBN	O
protein	IN	O
from	NNS	O
cell	JJ	O
culture.	IN	O
The	DT	O
polypeptide	NN	O
produced	CC	O
by	NN	O
a	IN	O
recombinant	DT	O
cell	JJ	O
may	NN	O
be	IN	O
secreted,	JJ	O
membrane-bound,	.	O
or	DT	O
contained	NN	O
intracellularly,	VBN	O
depending	IN	O
on	DT	O
the	JJ	O
sequence	NN	O
and/or	MD	O
the	VB	O
vector	,	O
used.	,	O
As	CC	O
will	VBD	O
be	,	O
understood	VBG	O
by	IN	O
those	DT	O
of	NN	O
skill	VBD	O
in	DT	O
the	NN	O
art,	.	O
expression	IN	O
vectors	MD	O
containing	VB	O
polynucleotides	VBN	O
encoding	IN	O
polypeptides	DT	O
of	IN	O
the	NN	O
invention	IN	O
can	DT	O
be	,	O
designed	NN	O
with	NNS	O
signal	VBG	O
sequences	NNS	O
which	VBG	O
direct	NNS	O
secretion	IN	O
of	DT	O
the	NN	O
mature	MD	O
polypeptides	VB	O
through	VBN	O
a	IN	O
prokaryotic	NN	O
or	NNS	O
eukaryotic	WDT	O
cell	VBP	O
membrane.	NN	O
The	IN	O
polynucleotides	DT	O
of	NN	O
the	VBZ	O
present	IN	O
invention	DT	O
optionally	JJ	O
comprise	CC	O
a	JJ	O
coding	NN	O
sequence	.	O
fused	DT	O
in-frame	NNS	O
to	IN	O
a	DT	O
marker	JJ	O
sequence	NN	O
which,	RB	O
e.g.,	VB	O
facilitates	DT	O
purification	NN	O
and/or	NN	O
detection	VBD	O
of	NN	O
the	TO	O
encoded	DT	O
polypeptide.	NN	O
Such	NN	O
purification	,	O
subsequences	,	O
include,	VBZ	O
but	NN	O
are	JJ	O
not	NN	O
limited	IN	O
to,	DT	O
metal	JJ	O
chelating	.	O
peptides	JJ	O
such	NN	O
as	NNS	O
histidine-tryptophan	,	O
modules	CC	O
that	VBP	O
allow	RB	O
purification	VBN	O
on	,	O
immobilized	NN	O
metals,	VBG	O
a	NNS	O
sequence	JJ	O
which	IN	O
binds	JJ	O
glutathione	NNS	O
(e.g.,	WDT	O
GST),	VBP	O
a	NN	O
hemagglutinin	IN	O
(HA)	JJ	O
tag	,	O
(corresponding	DT	O
to	NN	O
an	WDT	O
epitope	VBZ	O
derived	NN	O
from	,	O
the	,	O
influenza	DT	O
hemagglutinin	NN	O
protein;	)	O
Wilson,	NN	B
I.	VBG	I
et	TO	I
al.	DT	I
(1984)	NN	I
Cell	VBN	I
37:767),maltose	IN	O
binding	DT	O
protein	NN	O
sequences,	NN	O
the	:	O
FLAG	,	O
epitope	NNP	O
utilized	CC	O
in	.	O
the	)	O
FLAGS	NNP	O
extension/affinity	,	O
purification	JJ	O
system,	VBG	O
and	NN	O
the	,	O
like.	DT	O
The	NNP	O
inclusion	NN	O
of	VBN	O
a	IN	O
protease-cleavable	DT	O
polypeptide	NNP	O
linker	NN	O
sequence	NN	O
between	,	O
the	CC	O
purification	DT	O
domain	.	O
and	DT	O
the	NN	O
polypeptide	IN	O
sequence	DT	O
is	JJ	O
useful	NN	O
to	NN	O
facilitate	NN	O
purification.	IN	O
For	DT	O
example,	NN	O
one	NN	O
expression	CC	O
vector	DT	O
possible	NN	O
to	NN	O
use	VBZ	O
in	JJ	O
the	TO	O
compositions	VB	O
and	.	O
methods	IN	O
described	,	O
herein	CD	O
provides	NN	O
for	NN	O
expression	JJ	O
of	TO	O
a	VB	O
fusion	IN	O
protein	DT	O
comprising	NNS	O
a	CC	O
polypeptide	NNS	O
of	VBD	O
the	JJ	O
invention	VBZ	O
fused	IN	O
to	NN	O
a	IN	O
polyhistidine	DT	O
region	NN	O
separated	NN	O
by	VBG	O
an	DT	O
enterokinase	NN	O
cleavage	IN	O
site.	DT	O
The	NN	O
histidine	VBD	O
residues	TO	O
facilitate	DT	O
purification	JJ	O
on	NN	O
IMIAC	VBN	O
(immobilized	IN	O
metal	DT	O
ion	NN	O
affinity	NN	O
chromatography,	.	O
as	DT	O
described	NN	O
in	VBZ	O
Porath	JJ	B
et	NN	I
al.	IN	I
(1992)	NNP	I
Protein	VBN	I
Expression	NN	I
and	NN	I
Purification	NN	I
3:263-281)	,	I
while	IN	O
the	VBN	O
enterokinase	IN	O
cleavage	NNP	O
site	CC	O
provides	.	O
a	)	O
method	NNP	O
for	NNP	O
separating	CC	O
the	NNP	O
desired	)	O
polypeptide	IN	O
from	DT	O
the	NN	O
polyhistidine	NN	O
region.	NN	O
pGEX	VBZ	O
vectors	DT	O
(Promega;	NN	O
Madison,	IN	O
Wis.)	VBG	O
are	DT	O
optionally	VBN	O
used	NN	O
to	IN	O
express	DT	O
foreign	JJ	O
polypeptides	.	O
as	NN	O
fusion	NNS	O
proteins	:	O
with	,	O
glutathione	)	O
S-transferase	VBP	O
(GST).	RB	O
In	VBN	O
general,	TO	O
such	VB	O
fusion	JJ	O
proteins	NNS	O
are	IN	O
soluble	NN	O
and	NNS	O
can	IN	O
easily	JJ	O
be	NNP	O
purified	.	O
from	IN	O
lysed	,	O
cells	JJ	O
by	NN	O
adsorption	NNS	O
to	VBP	O
ligand-agarose	JJ	O
beads	CC	O
(e.g.,	MD	O
glutathione-agarose	RB	O
in	VB	O
the	VBN	O
case	IN	O
of	VBN	O
GST-fusions)	NNS	O
followed	IN	O
by	NN	O
elution	TO	O
in	JJ	O
the	NNS	O
presence	,	O
of	JJ	O
free	IN	O
ligand.	DT	O
An	NN	O
additional	IN	O
construction	)	O
in	VBN	O
the	IN	O
compositions	NN	O
and	IN	O
methods	DT	O
described	NN	O
herein	IN	O
provides	JJ	O
for	.	O
proteins,	DT	O
and	JJ	O
their	NN	O
encoding	IN	O
nucleic	DT	O
acids,	NNS	O
comprising	CC	O
polypeptides	NNS	O
of	VBD	O
the	JJ	O
invention	VBZ	O
(or	IN	O
one	,	O
or	CC	O
more	PRP$	O
fragments	NN	O
thereof),	JJ	O
e.g.,	,	O
as	VBG	O
described	NNS	O
herein,	IN	O
fused	DT	O
to	NN	O
an	CC	O
Ig	CD	O
molecule,	CC	O
e.g.,	JJR	O
human	NNS	O
IgG	,	O
Fc	,	O
(“fragment	IN	O
crystallizable,”	VBN	O
or	,	O
fragment	VBD	O
complement	TO	O
binding)	DT	O
hinge,	NNP	O
CH2	,	O
domain	,	O
and	JJ	O
CH3	NNP	O
domain	NNP	O
(and	JJ	O
nucleotide	''	O
sequences	CC	O
encoding	JJ	O
them).	NN	O
Fc	)	O
is	,	O
the	NNP	O
portion	NN	O
of	CC	O
the	NNP	O
antibody	NN	O
responsible	CC	O
for	RB	O
binding	NNS	O
to	VBG	O
antibody	.	O
receptors	NNP	O
on	VBZ	O
cells	DT	O
and	NN	O
the	IN	O
C1q	DT	O
component	NN	O
of	JJ	O
complement.	IN	O
These	VBG	O
fusion	TO	O
proteins	NN	O
or	NNS	O
fragments	IN	O
thereof	NNS	O
and	CC	O
their	DT	O
encoding	NNP	O
nucleic	NN	O
acids	IN	O
are	.	O
optionally	DT	O
useful	NN	O
as	VBZ	O
prophylactic	CC	O
and/or	NNS	O
therapeutic	NNS	O
drugs	CC	O
or	PRP$	O
as	NN	O
diagnostic	JJ	O
tools	NNS	O
(see	VBP	O
also,	RB	O
e.g.,	JJ	O
Challita-Eid,	IN	B
P.	JJ	I
et	NN	I
al.	JJ	I
(1998)	NNS	I
J	CC	I
Immunol	IN	I
160:3419-3426;	JJ	I
Sturmhoefel,	NNS	B
K.	VB	I
et	,	I
al.	,	I
(1999)	,	I
Cancer	NNP	I
Res	CC	I
59:4964-4972).Following	.	O
transduction	)	O
of	NNP	O
a	NNP	O
suitable	:	O
host	,	O
strain	NNP	O
and	CC	O
growth	.	O
of	)	O
the	NNP	O
host	NNP	O
strain	.	O
to	VBG	O
an	NN	O
appropriate	IN	O
cell	DT	O
density,	JJ	O
the	NN	O
selected	NN	O
promoter	CC	O
is	NN	O
induced	IN	O
by	DT	O
appropriate	NN	O
means	NN	O
(e.g.,	TO	O
temperature	DT	O
shift	JJ	O
or	NN	O
chemical	,	O
induction)	DT	O
and	VBN	O
cells	NN	O
are	VBZ	O
cultured	VBN	O
for	IN	O
an	JJ	O
additional	NNS	O
period.	,	O
Cells	NN	O
are	NN	O
typically	CC	O
harvested	JJ	O
by	)	O
centrifugation,	CC	O
disrupted	NNS	O
by	VBP	O
physical	VBN	O
or	IN	O
chemical	DT	O
means,	JJ	O
and	.	O
the	NNS	O
resulting	VBP	O
crude	RB	O
extract	VBN	O
retained	IN	O
for	,	O
further	VBN	O
purification.	IN	O
Eukaryotic	JJ	O
or	CC	O
microbial	NN	O
cells	,	O
employed	CC	O
in	DT	O
expression	VBG	O
of	JJ	O
the	NN	O
proteins	VBN	O
can	IN	O
be	JJ	O
disrupted	.	O
by	JJ	O
any	CC	O
convenient	JJ	O
method,	NNS	O
including	VBN	O
freeze-thaw	IN	O
cycling,	NN	O
sonication,	IN	O
mechanical	DT	O
disruption,	NNS	O
or	MD	O
use	VB	O
of	VBN	O
cell	IN	O
lysing	DT	O
agents,	JJ	O
or	,	O
other	VBG	O
methods,	JJ	O
which	,	O
are	,	O
well	JJ	O
know	,	O
to	CC	O
those	NN	O
skilled	IN	O
in	NN	O
the	VBG	O
art.	,	O
As	CC	O
noted,	JJ	O
many	,	O
references	WDT	O
are	VBP	O
available	RB	O
for	JJ	O
the	TO	O
culture	DT	O
and	VBN	O
production	IN	O
of	DT	O
many	.	O
cells,	IN	O
including	,	O
cells	JJ	O
of	NNS	O
bacterial,	VBP	O
plant,	JJ	O
animal	IN	O
(especially	DT	O
mammalian)	NN	O
and	CC	O
archebacterial	NN	O
origin.	IN	O
See,	JJ	O
e.g.,	,	O
Sambrook,	VBG	O
Ausubel,	NNS	O
and	IN	O
Berger	,	O
(all	,	O
supra),	NN	O
as	RB	O
well	)	O
as	CC	O
Freshney	JJ	O
(1994)	.	O
Culture	,	O
of	,	O
Animal	,	O
Cells,	,	O
a	CC	O
Manual	NNP	O
of	DT	O
Basic	,	O
Technique,	RB	O
third	RB	O
edition,	IN	O
Wiley-Liss,	NNP	O
New	)	O
York	NN	O
and	IN	O
the	NNP	O
references	,	O
cited	DT	O
therein;	NNP	O
Doyle	IN	B
and	NNP	I
Griffiths	,	I
(1997)	JJ	I
Mammalian	,	I
Cell	,	I
Culture:	NNP	I
Essential	NNP	I
Techniques	CC	I
John	DT	I
Wiley	NNS	I
and	VBD	I
Sons,	:	I
New	NNP	I
York;	CC	I
Humason	NNP	B
(1979)	)	I
Animal	NNP	I
Tissue	NNP	I
Techniques,	:	I
fourth	JJ	I
edition	NNP	I
W.H.	NNP	I
Freeman	NNP	I
and	CC	I
Company;	,	I
and	NNP	O
Ricciardelli	:	B
et	NNP	I
al.	)	I
(1989)	NNP	I
In	NNP	I
vitro	,	I
Cell	JJ	I
Dev	NN	I
Biol	.	I
25:1016-1024.	NNP	I
For	CC	O
plant	:	O
cell	CC	O
culture	NNP	O
and	VBP	O
regeneration	.	O
see,	)	O
e.g.,	IN	O
Payne	NN	B
et	NNP	I
al.	NNP	I
(1992)	NNP	I
Plant	.	I
Cell	IN	I
and	NN	I
Tissue	NN	I
Culture	NN	I
in	CC	I
Liquid	NN	I
Systems	,	I
John	,	I
Wiley	NNP	I
&	CC	I
Sons,	.	I
Inc.	)	I
New	NNP	I
York,	NNP	I
N.Y.;	CC	I
Gamborg	NNP	B
and	NNP	I
Phillips	IN	I
(eds.)	NNP	I
(1995)	NNP	I
Plant	NNP	I
Cell,	NNP	I
Tissue	CC	I
and	,	I
Organ	NNP	I
Culture;	NNP	I
Fundamental	,	B
Methods	:	I
Springer	NNP	I
Lab	CC	I
Manual,	NNP	I
Springer-Verlag	)	I
(Berlin	)	I
Heidelberg	NNP	I
New	,	I
York)	NNP	I
and	CC	O
Plant	NNP	B
Molecular	:	I
Biology	NNP	I
(1993)	NNP	I
R.	NNP	I
R.	NNP	I
D.	,	I
Croy	NNP	I
(ed.)	NNP	I
Bios	NNP	I
Scientific	NNP	I
Publishers,	)	I
Oxford,	CC	I
U.K.	NNP	I
ISBN	NNP	I
0	NNP	I
12	)	I
198370	NNP	I
6.	NNP	I
Cell	NNP	O
culture	NNP	O
media	)	O
in	NNP	O
general	NNP	O
are	,	O
set	,	O
forth	NNP	O
in	NNP	O
Atlas	CD	B
and	CD	I
Parks	CD	I
(eds.)	.	I
The	NNP	I
Handbook	NN	I
of	NNS	I
Microbiological	IN	I
Media	JJ	I
(1993)	VBP	I
CRC	VBN	I
Press,	NN	I
Boca	IN	I
Raton,	NNP	I
Fla.	CC	I
Additional	NNP	O
information	)	O
for	DT	O
cell	NNP	O
culture	IN	O
is	NNP	O
found	NNP	O
in	)	O
available	NNP	O
commercial	,	O
literature	NNP	O
such	,	O
as	NNP	O
the	NNP	O
Life	NN	O
Science	IN	O
Research	NN	O
Cell	NN	O
Culture	VBZ	O
Catalogue	VBN	O
from	IN	O
Sigma-Aldrich,	JJ	O
Inc	JJ	O
(St	NN	O
Louis,	JJ	O
Mo.)	IN	O
(“Sigma-LSRCCC”)	DT	O
and,	NNP	O
e.g.,	NNP	O
the	NNP	O
Plant	NNP	O
Culture	NNP	O
Catalogue	NNP	O
and	IN	O
supplement	,	O
also	NNP	O
from	NNP	O
Sigma-Aldrich,	,	O
Inc	)	O
(St	)	O
Louis,	,	O
Mo.)	,	O
(“Sigma-PCCS”).	DT	O
Polypeptides	NNP	O
of	NNP	O
the	NNP	O
invention	CC	O
can	NN	O
be	RB	O
recovered	IN	O
and	,	O
purified	NNP	O
from	NNP	O
recombinant	,	O
cell	)	O
cultures	.	O
by	NNS	O
any	IN	O
of	DT	O
a	NN	O
number	MD	O
of	VB	O
methods	VBN	O
well	CC	O
known	VBN	O
in	IN	O
the	NN	O
art,	NN	O
including	NNS	O
ammonium	IN	O
sulfate	DT	O
or	IN	O
ethanol	DT	O
precipitation,	NN	O
acid	IN	O
extraction,	NNS	O
anion	RB	O
or	VBN	O
cation	IN	O
exchange	DT	O
chromatography,	,	O
phosphocellulose	VBG	O
chromatography,	NN	O
hydrophobic	NN	O
interaction	CC	O
chromatography,	JJ	O
affinity	,	O
chromatography	JJ	O
(e.g.,	,	O
using	NN	O
any	CC	O
of	NN	O
the	NN	O
tagging	,	O
systems	JJ	O
noted	,	O
herein),	JJ	O
hydroxylapatite	NN	O
chromatography,	,	O
and	NN	O
lectin	NN	O
chromatography.	,	O
Protein	VBG	O
refolding	DT	O
steps	IN	O
can	DT	O
be	VBG	O
used,	NNS	O
as	VBD	O
desired,	,	O
in	JJ	O
completing	,	O
configuration	CC	O
of	JJ	O
the	.	O
mature	NNP	O
protein	VBG	O
or	NNS	O
fragments	MD	O
thereof.	VB	O
Finally,	,	O
high	IN	O
performance	,	O
liquid	IN	O
chromatography	VBG	O
(HPLC)	NN	O
can	IN	O
be	DT	O
employed	NN	O
in	NN	O
the	CC	O
final	NNS	O
purification	.	O
steps.	,	O
In	JJ	O
addition	NN	O
to	NN	O
the	NN	O
references	)	O
noted,	MD	O
supra,	VB	O
a	VBN	O
variety	IN	O
of	DT	O
purification	JJ	O
methods	NN	O
are	.	O
well	IN	O
known	NN	O
in	TO	O
the	DT	O
art,	NNS	O
including,	,	O
e.g.,	,	O
those	DT	O
set	NN	O
forth	IN	O
in	NN	O
Sandana	NNS	B
(1997)	VBP	I
Bioseparation	RB	I
of	VBN	I
Proteins,	IN	I
Academic	DT	I
Press,	,	I
Inc.;	,	I
Bollag	,	B
et	DT	I
al.	VBN	I
(1996)	NN	I
Protein	IN	I
Methods,	NNP	I
2.sup.nd	)	I
Edition	NN	I
Wiley-Liss,	IN	I
New	,	I
York;	NNP	I
Walker	,	B
(1996)	:	I
The	NNP	I
Protein	FW	I
Protocols	.	I
Handbook	)	I
Humana	NNP	I
Press,	,	I
New	CD	I
Jersey;	NNP	I
Harris	,	B
and	NNP	I
Angal	:	I
(1990)	NNP	I
Protein	)	I
Purification	DT	I
Applications:	NNP	I
A	NNP	I
Practical	NNP	I
Approach	NNP	I
IRL	,	I
Press	NNP	I
at	:	I
Oxford,	NNP	I
Oxford,	CC	I
England;	NNP	I
Harris	)	B
and	NNP	I
Angal	NNP	I
Protein	:	I
Purification	DT	I
Methods:	NNP	I
A	NNP	I
Practical	NNP	I
Approach	NNP	I
IRL	IN	I
Press	,	I
at	,	I
Oxford,	:	I
Oxford,	NNP	I
England;	CC	I
Scopes	NNP	B
(1993)	NNP	I
Protein	NNP	I
Purification	:	I
Principles	DT	I
and	NNP	I
Practice	NNP	I
3.sup.rd	NNP	I
Edition	NNP	I
Springer	IN	I
Verlag,	,	I
New	,	I
York;	:	I
Janson	NNP	B
and	)	I
Ryden	NNP	I
(1998)	NNP	I
Protein	NNP	I
Purification:	CC	I
Principles,	NNP	I
High	CD	I
Resolution	NNP	I
Methods	NNP	I
and	,	I
Applications,	NNP	I
Second	:	I
Edition	NNP	I
Wiley-VCH,	CC	I
New	NNP	I
York;	)	I
and	NNP	O
Walker	:	B
(1998)	,	I
Protein	NNP	I
Protocols	NNP	I
on	NNP	I
CD-ROM	CC	I
Humana	,	I
Press,	NNP	I
New	NNP	I
Jersey.
Cell-free	,	O
transcription/translation	NNP	O
systems	:	O
can	CC	O
also	NNP	O
be	)	O
employed	NNP	O
to	NNP	O
produce	IN	O
polypeptides	NNP	O
of	NNP	O
the	,	O
invention	NNP	O
using	.	O
polynucleotides	JJ	O
of	NN	O
the	NNS	O
present	MD	O
invention.	RB	O
Several	VB	O
such	VBN	O
systems	TO	O
are	VB	O
commercially	NNS	O
available.	IN	O
A	DT	O
general	NN	O
guide	VBG	O
to	NNS	O
in	IN	O
vitro	DT	O
transcription	JJ	O
and	.	O
translation	JJ	O
protocols	JJ	O
is	NNS	O
found	VBP	O
in	RB	O
Tymms	.	B
(1995)	DT	I
In	JJ	I
vitro	NN	I
Transcription	TO	I
and	IN	I
Translation	JJ	I
Protocols:	NN	I
Methods	CC	I
in	NN	I
Molecular	NNS	I
Biology	VBZ	I
Volume	VBN	I
37,	IN	I
Garland	NNP	I
Publishing,	)	I
New	IN	I
York.
Polynucleotides	JJ	O
that	NNP	O
encode	CC	O
a	NNP	O
polypeptide	:	O
of	NNS	O
the	IN	O
invention,	NNP	O
or	NNP	O
complements	NN	O
of	,	O
the	NNP	O
polynucleotides	,	O
(including	NNP	O
e.g.,	.	O
antisense	NNS	O
or	WDT	O
ribozyme	VBP	O
molecules),	DT	O
are	NN	O
optionally	IN	O
administered	DT	O
to	,	O
a	CC	O
cell	NNS	O
to	IN	O
accomplish	DT	O
a	NNS	O
therapeutically	VBG	O
useful	,	O
process	NN	O
or	CC	O
to	VB	O
express	,	O
a	VBP	O
therapeutically	RB	O
useful	VBN	O
product.	TO	O
These	DT	O
in	NN	O
vivo	TO	O
applications,	VB	O
including	DT	O
gene	RB	O
therapy,	JJ	O
include	NN	O
a	CC	O
multitude	TO	O
of	VB	O
techniques	DT	O
by	RB	O
which	JJ	O
gene	.	O
expression	DT	O
may	IN	O
be	NN	O
altered	,	O
in	VBG	O
cells.	NN	O
Such	,	O
methods	VBP	O
include,	DT	O
for	NN	O
instance,	IN	O
the	NNS	O
introduction	IN	O
of	WDT	O
genes	NN	O
for	NN	O
expression	MD	O
of,	VB	O
e.g.,	VBN	O
therapeutically	IN	O
and/or	.	O
prophylactically	JJ	O
useful	NNS	O
polypeptides,	,	O
such	IN	O
as	,	O
the	DT	O
polypeptides	NN	O
of	IN	O
the	NNS	O
present	IN	O
invention.	NN	O
Polynucleotides	,	O
encoding	,	O
polypeptides	RB	O
of	VBZ	O
the	RB	O
invention	JJ	O
are	,	O
particularly	JJ	O
useful	IN	O
for	DT	O
in	NNS	O
vivo	IN	O
therapeutic	DT	O
applications,	JJ	O
using	.	O
techniques	NNS	O
well	VBG	O
known	NNS	O
to	IN	O
those	DT	O
skilled	NN	O
in	VBP	O
the	RB	O
art.	JJ	O
For	IN	O
example,	IN	O
cultured	JJ	O
cells	JJ	O
are	,	O
engineered	VBG	O
ex	NNS	O
vivo	RB	O
with	VBN	O
at	TO	O
least	DT	O
one	VBN	O
polynucleotide	IN	O
(DNA	DT	O
or	.	O
RNA)	IN	O
of	,	O
the	VBN	O
invention	NNS	O
and/or	VBP	O
other	VBN	O
polynucleotide	JJ	O
sequences	NN	O
encoding,	IN	O
e.g.,	IN	O
at	JJS	O
least	CD	O
one	NN	O
of	NNP	O
an	CC	O
antigen,	)	O
cytokine,	IN	O
other	DT	O
co-stimulatory	NN	O
molecule,	VBZ	O
adjuvant,	JJ	O
etc.,	JJ	O
and	NNS	O
the	,	O
like,	,	O
with	IN	O
the	JJS	O
engineered	CD	O
cells	IN	O
then	DT	O
being	,	O
returned	,	O
to	JJ	O
the	JJ	O
patient.	,	O
Cells	,	O
may	,	O
also	CC	O
be	DT	O
engineered	,	O
in	IN	O
vivo	DT	O
for	JJ	O
expression	NNS	O
of	RB	O
one	VBG	O
or	VBN	O
more	TO	O
polypeptides	DT	O
in	.	O
vivo,	NNS	O
including	MD	O
polypeptides	RB	O
and/or	VB	O
antigenic	VBN	O
peptides	IN	O
of	NN	O
the	IN	O
invention.	NN	O
A	IN	O
number	CD	O
of	CC	O
viral	JJR	O
vectors	NNS	O
suitable	IN	O
for	,	O
organismal	VBG	O
in	NNS	O
vivo	RB	O
transduction	JJ	O
and	NNS	O
expression	IN	O
are	DT	O
known.	.	O
Such	DT	O
vectors	NN	O
include	IN	O
retroviral	JJ	O
vectors	NNS	O
(see,	JJ	O
e.g.,	IN	O
Miller,	JJ	B
Curr	IN	I
Top	JJ	I
Microbiol	NN	I
Immunol	CC	I
(1992)	NN	I
158:1-24;	VBP	I
Salmons	.	B
and	JJ	I
Gunzburg	NNS	I
(1993)	VBP	I
Human	JJ	I
Gene	NNS	I
Therapy	,	I
4:129-141;	,	I
Miller	,	B
et	NNP	I
al.	NNP	I
(1994)	NNP	I
Methods	NNP	I
in	)	I
Enzymology	:	I
217:581-599)	NNS	I
and	CC	O
adeno-associated	NNP	O
vectors	)	O
(reviewed	NNP	O
in	NNP	O
Carter	NNP	B
(1992)	:	I
Curr	NNP	I
Opinion	FW	I
Biotech	.	I
3:533-539;	)	I
Muzcyzka	NNS	B
(1992)	IN	I
Curr	NNP	I
Top	)	I
Microbiol	CC	I
Immunol.	JJ	I
158:97-129).Other	NNS	O
viral	VBN	O
vectors	IN	O
that	NNP	O
are	)	O
used	NNP	O
include	NNP	O
adenoviral	NNP	O
vectors,	:	O
herpes	NNP	O
viral	)	O
vectors	NNP	O
and	NNP	O
Sindbis	NNP	O
viral	.	O
vectors,	.	O
as	JJ	O
generally	JJ	O
described	NNS	O
in,	WDT	O
e.g.,	VBP	O
Jolly	VBN	B
(1994)	JJ	I
Cancer	JJ	I
Gene	,	I
Therapy	VBZ	I
1:51-64;	JJ	I
Latchman	NNS	B
(1994)	CC	I
Molec	NNP	I
Biotechnol	JJ	I
2:179-195;	,	I
and	IN	O
Johanning	RB	B
et	VBN	I
al.	,	I
(1995)	,	I
Nucl	NNP	I
Acids	)	I
Res	NNP	I
23:1495-1501.
In	NNP	O
one	NNP	O
aspect,	:	O
a	NNP	O
pox	)	O
virus	NNP	O
vector	NNP	O
can	:	O
be	CC	O
used.	NNP	O
The	CC	O
pox	.	O
viral	)	O
vector	NNP	O
is	NNP	O
transfected	NNP	O
with	.	O
a	IN	O
polynucleotide	CD	O
sequence	,	O
encoding	DT	O
a	NN	O
polypeptide	NN	O
of	NN	O
the	MD	O
invention	VB	O
and	.	O
is	DT	O
useful	JJ	O
in	JJ	O
prophylactic,	NN	O
therapeutic	VBZ	O
and	VBN	O
diagnostic	IN	O
applications	DT	O
where	JJ	O
enhancement	NN	O
of	VBG	O
an	DT	O
immune	NN	O
response,	IN	O
such	DT	O
as	NN	O
e.g.,	CC	O
increased	VBZ	O
or	JJ	O
improved	IN	O
T	,	O
cell	JJ	O
proliferation	CC	O
is	JJ	O
desired.	NNS	O
See	WRB	O
viral	NN	O
vectors	IN	O
discussed	DT	O
in,	JJ	O
e.g.,	,	O
Berencsi	JJ	B
et	IN	I
al.,	,	I
J	VBD	I
Infect	CC	I
Dis	VBN	I
(2001)183(8):1171-9;	NNP	I
Rosenwirth	NN	B
et	NN	I
al.,	VBZ	I
Vaccine	.	I
2001	VB	I
Feb.	JJ	I
8;	NNS	I
19(13-14):1661-70;	VBN	I
Kittlesen	,	B
et	,	I
al.,	NNP	I
J	FW	I
Immunol	,	I
(2000)	NNP	I
164(8):4204-11;	NNP	I
Brown	NNP	B
et	:	I
al.	NNP	I
Gene	FW	I
Ther	,	I
2000	NNP	I
7(19):1680-9;	CD	I
Kanesa-thasan	NNP	B
et	:	I
al.,	:	I
Vaccine	NNP	I
(2000)	FW	I
19(4-5):483-91;	,	I
Sten	NNP	B
(2000)	NNP	I
Drug	)	I
60(2):249-71.	:	I
Compositions	NNP	O
comprising	FW	O
such	.	O
vectors	NNP	O
and	NNP	O
an	CD	O
acceptable	:	O
excipient	NNP	O
are	FW	O
also	,	O
a	NNP	O
feature	)	O
of	:	O
the	NNP	O
invention.	)	O
Gene	VBZ	O
therapy	.	O
and	NNS	O
genetic	VBG	O
vaccines	JJ	O
provide	NNS	O
methods	CC	O
for	DT	O
combating	JJ	O
chronic	NN	O
infectious	VBP	O
diseases	RB	O
(e.g.,	DT	O
HIV	NN	O
infection,	IN	O
viral	DT	O
hepatitis),	.	O
as	NNP	O
well	NN	O
as	CC	O
non-infectious	JJ	O
diseases	NNS	O
including	VBP	O
cancer	NNS	O
and	IN	O
some	VBG	O
forms	JJ	O
of	JJ	O
congenital	NNS	O
defects	,	O
such	NNP	O
as	,	O
enzyme	JJ	O
deficiencies,	,	O
and	RB	O
such	RB	O
methods	IN	O
can	JJ	O
be	NNS	O
employed	VBG	O
with	NN	O
polynucleotides	CC	O
of	DT	O
the	NNS	O
invention,	IN	O
including,	JJ	O
e.g.,	NNS	O
vectors	JJ	O
and	IN	O
cells	JJ	O
comprising	,	O
such	CC	O
polynucleotides.	JJ	O
Several	NNS	O
approaches	MD	O
for	VB	O
introducing	VBN	O
nucleic	IN	O
acids	NNS	O
and	IN	O
vectors	DT	O
into	,	O
cells	,	O
in	,	O
vivo,	NNS	O
ex	CC	O
vivo	NNS	O
and	VBG	O
in	JJ	O
vitro	.	O
have	JJ	O
been	NNS	O
used	IN	O
and	VBG	O
can	JJ	O
be	NNS	O
employed	CC	O
with	NNS	O
polynucleotides	IN	O
of	NNS	O
the	IN	O
invention,	,	O
and	FW	O
vectors	NN	O
comprising	CC	O
such	IN	O
polynucleotides.	NNS	O
These	VBP	O
approaches	VBN	O
include	VBN	O
liposome	CC	O
based	MD	O
gene	VB	O
delivery	VBN	O
(Debs	IN	O
and	NNS	O
Zhu	IN	O
(1993)	DT	O
WO	,	O
93/24640	CC	O
and	NNS	O
U.S.	VBG	O
Pat.	JJ	O
No.	.	O
5,641,662;	DT	O
Mannino	NNS	B
and	VBP	I
Gould-Fogerite	JJ	I
(1988)	VBN	I
BioTechniques	NN	I
6(7):682-691;	NN	I
Rose,	NNP	O
U.S.	CC	O
Pat.	NNP	O
No.	)	O
5,279,833;	VBD	O
Brigham	CD	O
(1991)	CC	O
WO	NNP	O
91/06309;	.	O
and	.	O
Feigner	:	B
et	NNP	I
al.	CC	I
(1987)	NNP	I
Proc	)	I
Natl	VBZ	I
Acad	:	I
Sci	,	I
USA	NNP	I
84:7413-7414;	.	I
Brigham	.	B
et	:	I
al.	NNP	I
(1989)	)	I
Am	VBD	I
J	:	I
Med	CC	I
Sci	NNP	I
298:278-281;	VBP	I
Nabel	.	B
et	)	I
al.	NNP	I
(1990)	NNP	I
Science	NNP	I
249:1285-1288;	NNP	I
Hazinski	NNP	B
et	:	I
al.	NNP	I
(1991)	FW	I
Am	.	I
J	)	I
Resp	VBP	I
Cell	NNP	I
Molec	NNP	I
Biol	NNP	I
4:206-209;	:	I
and	NNP	O
Wang	FW	B
and	.	I
Huang	)	I
(1987)	NNP	I
Proc	:	I
Natl	NNP	I
Acad	FW	I
Sci	.	I
USA	)	I
84:7851-7855);adenoviral	VBP	O
vector	NNP	O
mediated	NNP	O
gene	NNP	O
delivery,	NNP	O
e.g.,	NNP	O
to	:	O
treat	CC	O
cancer	NNP	O
(see,	CC	O
e.g.,	NNP	O
Chen	)	B
et	NNP	I
al.	NNP	I
(1994)	NNP	I
Proc	NNP	I
Natl	NNP	I
Acad	:	I
Sci	JJ	I
USA	NN	I
91:3054-3057;	VBD	I
Tong	NN	B
et	,	I
al.	,	I
(1996)	TO	I
Gynecol	VB	I
Oncol	NN	I
61:175-179;	,	I
Clayman	,	B
et	NNP	I
al.	VBZ	I
(1995)	.	I
Cancer	)	I
Res.	NNP	I
5:1-6;	NNP	I
O'Malley	NNP	B
et	NNP	I
al.	NNP	I
(1995)	:	I
Cancer	NNP	I
Res	CC	I
55:1080-1085;	.	I
Hwang	)	B
et	NNP	I
al.	NNP	I
(1995)	:	I
Am	NNP	I
J	VBZ	I
Respir	.	I
Cell	)	I
Mol	NNP	I
Biol	.	I
13:7-16;	:	I
Haddada	NNP	B
et	FW	I
al.	.	I
(1995)	)	I
Curr	NNP	I
Top	NNP	I
Microbiol	:	I
Immunol.	NNP	I
1995	FW	I
(Pt.	.	I
3):297-306;	)	I
Addison	VBP	B
et	NNP	I
al.	NNP	I
(1995)	NNP	I
Proc	NNP	I
Natl	NNP	I
Acad	:	I
Sci	NNP	I
USA	FW	I
92:8522-8526;	.	I
Colak	)	B
et	NNP	I
al.	NNP	I
(1995)	NNP	I
Brain	.	I
Res	CD	I
691:76-82;	.	I
Crystal	:	B
(1995)	NNP	I
Science	FW	I
270:404-410;	.	I
Elshami	)	B
et	NNP	I
al.	NNP	I
(1996)	NNP	I
Human	NNP	I
Gene	NNP	I
Ther	:	I
7:141-148;	NNP	I
Vincent	FW	B
et	.	I
al.	)	I
(1996)	NNP	I
J	NNP	I
Neurosurg	:	I
85:648-654),	NNP	I
and	)	O
many	NNP	O
others.	:	O
Replication-defective	NNP	O
retroviral	FW	O
vectors	.	O
harboring	)	O
therapeutic	NNP	O
polynucleotide	NNP	O
sequence	NNP	O
as	:	O
part	NNP	O
of	FW	O
the	.	O
retroviral	)	O
genome	NNP	O
have	NNP	O
also	,	O
been	CC	O
used,	JJ	O
particularly	.	O
with	JJ	O
regard	JJ	O
to	NNS	O
simple	VBG	O
MuLV	JJ	O
vectors.	NN	O
See,	NN	O
e.g.,	IN	O
Miller	NN	B
et	IN	I
al.	DT	I
(1990)	JJ	I
Mol	NN	I
Cell	VBP	I
Biol	RB	I
10:4239	VBN	I
(1990);	,	I
Kolberg	RB	B
(1992)	IN	I
J	NN	I
NIH	TO	I
Res	VB	I
4:43,	NNP	I
and	.	O
Cornetta	,	B
et	,	I
al.	NNP	I
(1991)	CC	I
Hum	.	I
Gene	)	I
Ther	NNP	I
2:215).Nucleic	NNP	O
acid	NNP	O
transport	CD	O
coupled	:	O
to	NNP	O
ligand-specific,	)	O
cation-based	NNP	O
transport	NNP	O
systems	NNP	O
Wu	,	B
and	CC	I
Wu	NNP	I
(1988)	VBP	I
J	.	I
Biol	)	I
Chem,	NNP	I
263:14621-14624)	NNP	I
(has	NNP	O
also	.	O
been	NNP	O
used.	NN	O
Naked	NN	O
DNA	VBD	O
expression	TO	O
vectors	,	O
have	JJ	O
also	NN	O
been	NNS	O
described	NNP	O
Nabel	CC	B
et	NNP	I
al.	)	I
(1990),	NNP	I
supra);(	NNP	O
Wolff	,	B
et	)	I
al.	VBZ	I
(1990)	RB	I
Science,	VBN	I
247:1465-1468).In	.	O
general,	VBN	O
these	NNP	O
approaches	NN	O
can	NNS	O
be	VBP	O
adapted	RB	O
to	VBN	O
the	VBN	O
invention	NNP	O
by	RB	O
incorporating	.	O
nucleic	,	O
acids	:	O
encoding	NNP	O
the	FW	O
polypeptides	.	O
of	)	O
the	,	O
invention	.	O
into	IN	O
the	,	O
appropriate	DT	O
vectors.	NNS	O
General	MD	O
texts	VB	O
which	VBN	O
describe	TO	O
gene	DT	O
therapy	NN	O
protocols,	IN	O
which	VBG	O
can	JJ	O
be	NNS	O
adapted	VBG	O
to	DT	O
the	NNS	O
present	IN	O
invention	DT	O
by	NN	O
introducing	IN	O
the	DT	O
nucleic	JJ	O
acids	.	O
of	NNP	O
the	NN	O
invention	WDT	O
into	VBZ	O
patients,	NN	O
include,	NN	O
e.g.,	,	O
Robbins	WDT	B
(1996)	MD	I
Gene	VB	I
Therapy	VBN	I
Protocols,	TO	I
Humana	DT	I
Press,	JJ	I
New	NN	I
Jersey,	IN	I
and	VBG	O
Joyner	DT	B
(1993)	JJ	I
Gene	NNS	I
Targeting:	IN	I
A	DT	I
Practical	NN	I
Approach,	IN	I
IRL	,	I
Press,	,	I
Oxford,	,	I
England.
Antiviral	NNP	O
Treatments	)	O
The	NNP	O
polynucleotides	NNP	O
and	,	O
polypeptides	NNP	O
of	,	O
the	NNP	O
invention	,	O
may	CC	O
be	NNP	O
used	)	O
therapeutically	NNP	O
or	:	O
prophylactically	DT	O
to	NNP	O
treat	,	O
or	NNP	O
prevent	,	O
virus	,	O
infection.	.	O
Exemplary	JJ	O
viruses	NNPS	O
include,	DT	O
but	NNS	O
are	CC	O
not	NNS	O
limited	IN	O
to,	DT	O
viruses	NN	O
of	MD	O
the	VB	O
Flaviviridae	VBN	O
family,	RB	O
such	CC	O
as,	RB	O
for	TO	O
example,	VB	O
Hepatitis	CC	O
C	VB	O
Virus,	JJ	O
Yellow	.	O
Fever	JJ	O
Virus,	NNS	O
West	,	O
Nile	CC	O
Virus,	VBP	O
Japanese	RB	O
Encephalitis	VBN	O
Virus,	,	O
Dengue	NNS	O
Virus,	IN	O
and	DT	O
Bovine	NNP	O
Viral	,	O
Diarrhea	JJ	O
Virus;	,	O
viruses	IN	O
of	,	O
the	NNP	O
Hepadnaviridae	NNP	O
family,	,	O
such	NNP	O
as,	NNP	O
for	,	O
example,	NNP	O
Hepatitis	NNP	O
B	,	O
Virus;	JJ	O
viruses	NNP	O
of	,	O
the	NNP	O
Picornaviridae	,	O
family,	CC	O
such	NNP	O
as,	NNP	O
for	NNP	O
example,	:	O
Encephalomyocarditis	NNS	O
Virus,	IN	O
Human	DT	O
Rhinovirus,	NNP	O
and	,	O
Hepatitis	JJ	O
A	,	O
Virus;	IN	O
viruses	,	O
of	NNP	O
the	NNP	O
Retroviridae	:	O
family,	NNS	O
such	IN	O
as,	DT	O
for	NNP	O
example,	,	O
Human	JJ	O
Immunodeficiency	,	O
Virus,	IN	O
Simian	,	O
Immunodeficiency	NNP	O
Virus,	,	O
Human	NNP	O
T-Lymphotrophic	,	O
Virus,	CC	O
and	NNP	O
Rous	NNP	O
Sarcoma	:	O
Virus;	NNS	O
viruses	IN	O
of	DT	O
the	NNP	O
Coronaviridae	,	O
family,	JJ	O
such	,	O
as,	IN	O
for	,	O
example,	NNP	O
SARS	NNP	O
coronavirus;	,	O
viruses	JJ	O
of	NNP	O
the	,	O
Rhabdoviridae	NNP	O
family,	NNP	O
such	,	O
as,	CC	O
for	NNP	O
example,	NNP	O
Rabies	:	O
Virus	NNS	O
and	IN	O
Vesicular	DT	O
Stomatitis	NNP	O
Virus,	,	O
viruses	JJ	O
of	,	O
the	IN	O
Paramyxoviridae	,	O
family,	NNP	O
such	:	O
as,	NNS	O
for	IN	O
example,	DT	O
Respiratory	NNP	O
Syncytial	,	O
Virus	JJ	O
and	,	O
Parainfluenza	IN	O
Virus,	,	O
viruses	NNP	O
of	NNP	O
the	CC	O
Papillomaviridae	NNP	O
family,	NNP	O
such	,	O
as,	NNS	O
for	IN	O
example,	DT	O
Human	NNP	O
Papillomavirus,	,	O
and	JJ	O
viruses	,	O
of	IN	O
the	,	O
Herpesviridae	NNP	O
family,	NNP	O
such	NNP	O
as,	CC	O
for	NNP	O
example,	,	O
Herpes	NNS	O
Simplex	IN	O
Virus.	DT	O
It	NNP	O
is	,	O
another	JJ	O
object	,	O
of	IN	O
the	,	O
invention	NNP	O
to	,	O
provide	CC	O
conjugates,	NNS	O
such	IN	O
conjugates	DT	O
comprising	NNP	O
one	,	O
or	JJ	O
more	,	O
non-polypeptide	IN	O
moiety	,	O
linked	NNP	O
to	NNP	O
a	.	O
polypeptide	PRP	O
of	VBZ	O
the	DT	O
invention,	NN	O
which	IN	O
conjugate	DT	O
exhibits	NN	O
an	TO	O
antiviral	VB	O
property,	,	O
and	JJ	O
which	NNS	O
optionally	VBG	O
exhibits	CD	O
other	CC	O
desirable	JJR	O
properties,	JJ	O
such	NN	O
as	VBN	O
increased	TO	O
serum	DT	O
half-life	NN	O
and/or	IN	O
functional	DT	O
in	,	O
vivo	WDT	O
half-life,	VBP	O
and/or	NNS	O
decreased	DT	O
antigenicity,	JJ	O
compared	,	O
to	CC	O
the	WDT	O
non-conjugated	RB	O
polypeptide.	VBZ	O
Some	JJ	O
such	JJ	O
conjugates	,	O
may	JJ	O
exhibit	IN	O
enhanced	JJ	O
efficacy	NN	O
in	NN	O
clearing	JJ	O
a	NN	O
virus	IN	O
from	JJ	O
cells	,	O
infected	NN	O
with	VBD	O
the	,	O
virus,	VBN	O
compared	TO	O
to	DT	O
a	JJ	O
reference	.	O
oligoadenylate	DT	O
synthetase.	JJ	O
Some	NNS	O
such	MD	O
conjugates	VB	O
may	JJ	O
further	NN	O
have	IN	O
reduced	VBG	O
toxicity	DT	O
compared	NN	O
to	IN	O
a	NNS	O
reference	VBN	O
oligoadenylate	IN	O
synthetase.	DT	O
It	,	O
is	VBN	O
another	TO	O
object	DT	O
of	NN	O
the	NN	O
invention	.	O
to	DT	O
provide	JJ	O
a	NNS	O
method	MD	O
of	RB	O
inhibiting	VB	O
viral	VBN	O
replication	NN	O
in	VBN	O
virus-infected	TO	O
cells,	DT	O
the	NN	O
method	NN	O
comprising	.	O
administering	PRP	O
to	VBZ	O
the	DT	O
virus-infected	NN	O
cells	IN	O
a	DT	O
polypeptide	NN	O
or	TO	O
conjugate	VB	O
of	DT	O
the	NN	O
invention	IN	O
in	VBG	O
an	JJ	O
amount	NN	O
effective	IN	O
to	JJ	O
inhibit	,	O
viral	DT	O
replication	NN	O
in	VBG	O
said	VBG	O
cells.	TO	O
The	DT	O
invention	JJ	O
also	NNS	O
provides	DT	O
a	NN	O
method	CC	O
of	NN	O
reducing	IN	O
the	DT	O
number	NN	O
of	IN	O
copies	DT	O
of	NN	O
a	JJ	O
virus	TO	O
in	VB	O
virus-infected	JJ	O
cells,	NN	O
comprising	IN	O
administering	VBD	O
to	.	O
the	DT	O
virus-infected	NN	O
cells	RB	O
a	VBZ	O
polypeptide	DT	O
or	NN	O
conjugate	IN	O
of	VBG	O
the	DT	O
invention	NN	O
in	IN	O
an	NNS	O
amount	IN	O
effective	DT	O
to	NN	O
reduce	IN	O
the	JJ	O
number	,	O
of	VBG	O
copies	VBG	O
of	TO	O
the	DT	O
virus	JJ	O
in	NNS	O
said	DT	O
cells.	NN	O
The	CC	O
cells	NN	O
may	IN	O
be	DT	O
in	NN	O
culture	IN	O
or	DT	O
otherwise	NN	O
isolated	JJ	O
from	TO	O
a	VB	O
mammal	DT	O
(i.e.,	NN	O
in	IN	O
vitro	NNS	O
or	IN	O
ex	DT	O
vivo),	NN	O
or	IN	O
may	VBD	O
be	.	O
in	DT	O
vivo,	NNS	O
e.g.,	MD	O
in	VB	O
a	IN	O
subject,	NN	O
in	CC	O
a	RB	O
mammal,	VBN	O
in	IN	O
a	DT	O
primate,	NN	O
or	,	O
in	IN	O
man.	NN	O
Anticancer	CC	O
and	VB	O
Inflammation	,	O
Treatments	CC	O
It	MD	O
has	VB	O
been	IN	O
demonstrated	,	O
that	,	O
the	IN	O
polypeptides	DT	O
of	,	O
the	IN	O
invention	DT	O
can	,	O
cause	IN	O
certain	DT	O
cell	,	O
types	CC	O
and	IN	O
cell	.	O
lines	NNP	O
to	CC	O
undergo	NNP	O
apoptosis	NNP	O
or	PRP	O
to	VBZ	O
affect	VBN	O
growth	VBN	O
retardation	IN	O
of	DT	O
said	NNS	O
cell	IN	O
lines	DT	O
or	NN	O
cell	MD	O
types.	VB	O
Such	JJ	O
cell	NN	O
lines	NNS	O
or	CC	O
cell	NN	O
types	NNS	O
include	TO	O
in	VB	O
an	NN	O
exemplary	CC	O
embodiment	TO	O
those	VB	O
derived	NN	O
from	NN	O
the	IN	O
prostate	VBD	O
and	NN	O
breast.	NNS	O
The	CC	O
invention	NN	O
provides	.	O
a	JJ	O
method	NN	O
of	NNS	O
inhibiting	CC	O
proliferation	NN	O
of	NNS	O
a	VBP	O
cell	IN	O
population,	DT	O
comprising	JJ	O
contacting	NN	O
the	DT	O
cell	VBN	O
population	IN	O
with	DT	O
a	NN	O
polypeptide	CC	O
of	.	O
the	DT	O
invention	NN	O
in	VBZ	O
an	DT	O
amount	NN	O
effective	IN	O
to	VBG	O
decrease	NN	O
proliferation	IN	O
of	DT	O
the	NN	O
cell	,	O
population.	VBG	O
The	VBG	O
cell	DT	O
population	NN	O
may	NN	O
be	IN	O
in	DT	O
culture	NN	O
or	IN	O
otherwise	DT	O
isolated	NN	O
from	IN	O
a	DT	O
mammal	NN	O
(i.e.,	JJ	O
in	TO	O
vitro	VB	O
or	NN	O
ex	IN	O
vivo),	DT	O
or	NN	O
may	.	O
be	DT	O
in	NN	O
vivo,	NN	O
e.g.,	MD	O
in	VB	O
a	IN	O
subject,	NN	O
in	CC	O
a	RB	O
mammal,	VBN	O
a	IN	O
primate,	DT	O
or	NN	O
man.	,	O
The	IN	O
invention	NN	O
provides	CC	O
for	VB	O
treating	,	O
cancers	CC	O
and	MD	O
neoplastic	VB	O
diseases	IN	O
using	,	O
the	,	O
polypeptides	IN	O
and	DT	O
polynucleotides	,	O
of	IN	O
the	DT	O
invention.	,	O
Exemplary	DT	O
cancers	,	O
and	CC	O
neoplastic	.	O
diseases	DT	O
include	NN	O
but	VBZ	O
are	IN	O
not	VBG	O
limited	NNS	O
to:	CC	O
adrenocortical	JJ	O
carcinoma,	NNS	O
AIDS	VBG	O
related	DT	O
cancers,	NNS	O
such	CC	O
as	NNS	O
for	IN	O
example,	DT	O
Kaposi's	.	O
sarcoma,	JJ	O
AIDS-related	NNS	O
lymphoma,	CC	O
anal	JJ	O
cancer,	NNS	O
astrocytoma,	VBP	O
basal	CC	O
cell	VBP	O
carcinoma,	RB	O
bile	VBN	O
duct	:	O
cancers,	JJ	O
such	,	O
as	NNP	O
for	VBD	O
example	,	O
those	JJ	O
of	IN	O
an	IN	O
extrahepatic	,	O
nature,	POS	O
bladder	,	O
cancer,	JJ	O
bone	,	O
cancers,	JJ	O
such	,	O
as	,	O
for	NN	O
example	NN	O
osteosarcomas	,	O
and	JJ	O
malignant	NN	O
fibrous	,	O
histiocytomas,	JJ	O
brain	IN	O
stem	IN	O
glioma,	NN	O
brain	DT	O
tumors,	IN	O
such	DT	O
as	JJ	O
for	,	O
example	NN	O
gliomas,	,	O
astrocytomas,	NN	O
malignant	,	O
gliomas,	JJ	O
ependymomas,	IN	O
medulloblastomas,	IN	O
and	NN	O
neuroblastomas,	NN	O
supratentorial	CC	O
primitive	JJ	O
neuroectodermal	JJ	O
tumor,	,	O
visual	NN	O
pathway	NN	O
and	,	O
hypothalamic	NN	O
glioma,	,	O
breast	JJ	O
cancer,	IN	O
bronchial	IN	O
adenoma,	NN	O
Burkitt's	,	O
lymphoma,	,	O
carcinoid	JJ	O
tumors,	,	O
central	,	O
nervous	,	O
system	CC	O
lymphoma,	,	O
cervical	JJ	O
cancer,	JJ	O
leukemias,	JJ	O
such	,	O
as	JJ	O
for	NN	O
example,	CC	O
hairy	JJ	O
cell	,	O
leukemia,	NN	O
acute	,	O
lymphoblastic	JJ	O
leukemia,	,	O
acute	POS	O
myeloid	,	O
leukemia,	JJ	O
chronic	,	O
lymphocytic	JJ	O
leukemia	JJ	O
and	NN	O
chronic	,	O
myelogenous	JJ	O
leukemia,	,	O
chronic	,	O
myeloproliferative	JJ	O
disorders,	IN	O
colorectal	IN	O
cancer,	,	O
cutaneous	NN	O
T-cell	NN	O
lymphoma,	,	O
endometrial	JJ	O
cancer,	JJ	O
esophageal	,	O
cancer,	JJ	O
Ewing's	NN	O
family	,	O
of	JJ	O
tumors,	JJ	O
extracranial	NN	O
germ	CC	O
cell	JJ	O
tumor,	JJ	O
extragonadal	,	O
germ	JJ	O
cell	NN	O
tumor,	,	O
eye	JJ	O
cancers,	,	O
such	JJ	O
as	NNP	O
for	,	O
example,	JJ	O
intraocular	,	O
melanoma	JJ	O
and	,	O
retinoblastoma,	POS	O
gallbladder	NN	O
cancer,	IN	O
stomach	,	O
cancer,	JJ	O
gestational	NN	O
trophoblastic	NN	O
tumor,	,	O
head	JJ	O
and	NN	O
neck	NN	O
cancer,	,	O
hepatocellular	NN	O
carcinoma,	,	O
Hodgkin's	JJ	O
lymphoma,	IN	O
Non-Hodgkin's	IN	O
lymphoma,	,	O
primary	JJ	O
CNS	NN	O
lymphoma,	CC	O
nasopharyngeal	,	O
cancer,	NN	O
islet	,	O
cell	NN	O
carcinoma,	,	O
kidney	JJ	O
(renal	JJ	O
cell)	,	O
cancer,	NN	O
laryngeal	CC	O
cancer,	NN	O
lip	,	O
and	JJ	O
oral	,	O
cancer,	POS	O
liver	,	O
cancer,	POS	O
lung	,	O
cancer,	JJ	O
such	NNP	O
as	,	O
for	JJ	O
example	,	O
non-small	NN	O
cell	NN	O
and	,	O
small	NN	O
cell	JJ	O
lung	)	O
cancers,	,	O
Waldenstrom's	JJ	O
macroglobulinemia,	,	O
Merkel	NN	O
cell	CC	O
carcinoma,	JJ	O
mesothelioma,	,	O
metastatic	RB	O
squamous	,	O
neck	NN	O
cancer,	,	O
multiple	JJ	O
endocrine	IN	O
neoplasia,	IN	O
multiple	NN	O
myeloma,	JJ	O
plasma	NN	O
cell	CC	O
neoplasm,	JJ	O
mycosis	NN	O
fungoides,	NN	O
myelodysplastic	,	O
syndromes,	POS	O
myeloproliferative	,	O
diseases,	NNP	O
nasal	NN	O
cavity	,	O
and	,	O
paranasal	JJ	O
sinus	JJ	O
cancer,	NN	O
ovarian	,	O
cancer,	JJ	O
such	NN	O
as	,	O
germ	JJ	O
cell	,	O
and	NN	O
epithelial,	NN	O
low-malignant	,	O
potential	NN	O
ovarian	,	O
tumor,	JJ	O
pancreatic	,	O
cancer,	JJ	O
parathyroid	,	O
cancer,	JJ	O
penile	NN	O
cancer,	CC	O
pheochromocytoma,	NN	O
pituitary	NN	O
tumor,	,	O
pleuropulmonary	JJ	O
blastoma,	,	O
prostate	JJ	O
cancer,	IN	O
rhabdomyosarcoma,	NN	O
salivary	NN	O
gland	CC	O
cancer,	,	O
sarcomas,	JJ	O
Sezary	JJ	O
syndrome,	JJ	O
skin	,	O
cancer,	JJ	O
such	,	O
as	JJ	O
for	,	O
example	JJ	O
melanoma	,	O
and	,	O
squamous	JJ	O
cell	,	O
carcinoma,	JJ	O
testicular	,	O
cancer,	NN	O
thymoma,	,	O
thymic	,	O
carcinoma,	JJ	O
thyroid	NN	O
cancer,	,	O
transitional	,	O
cell	NNP	O
cancer,	,	O
trophoblastic	JJ	O
tumor,	,	O
urethral	JJ	O
cancer,	IN	O
uterine	IN	O
cancer,	NN	O
vaginal	NN	O
cancer,	CC	O
vulvar	JJ	O
cancer,	NN	O
and	,	O
Wilms'	JJ	O
tumor.	,	O
The	,	O
invention	JJ	O
further	,	O
provides	JJ	O
for	,	O
treating	JJ	O
autoimmune	NN	O
diseases	,	O
and	JJ	O
inflammation	,	O
using	JJ	O
the	,	O
polypeptides	JJ	O
and	,	O
polynucleotides	JJ	O
of	,	O
the	NN	O
invention,	,	O
said	CC	O
autoimmune	POS	O
and	.	O
inflammatory	DT	O
diseases	NN	O
include	RBR	O
but	VBZ	O
are	IN	O
not	VBG	O
limited	NN	O
to:	NNS	O
asthma,	CC	O
Crohn's	NN	O
disease,	VBG	O
Guillain-Barre	DT	O
syndrome,	NNS	O
multiple	CC	O
sclerosis,	NNS	O
myasthenia	IN	O
gravis,	DT	O
optic	,	O
neuritis,	VBD	O
psoriasis,	NN	O
rheumatoid	CC	O
arthritis,	JJ	O
Grave's	NNS	O
disease,	VBP	O
Hashimoto's	CC	O
(thyroiditis)	VBP	O
disease,	RB	O
Ord's	VBN	O
thyroiditis,	:	O
diabetes,	,	O
diabetes	POS	O
mellitus,	,	O
Reiter's	NNP	O
syndrome,	,	O
autoimmune	JJ	O
hepatitis,	,	O
primary	NN	O
biliary	,	O
cirrhosis,	JJ	O
liver	,	O
cirrhosis,	,	O
liver	JJ	O
fibrosis,	,	O
antiphospholipid	POS	O
antibody	,	O
syndrome,	POS	O
opsoclonus	)	O
myoclonus	,	O
syndrome,	POS	O
temporal	,	O
arteritis,	,	O
acute	VBZ	O
disseminated	,	O
encephalomyelitis,	POS	O
Goodpasture's	,	O
syndrome,	JJ	O
Wegener's	,	O
granulomatosis,	JJ	O
coeliac	JJ	O
disease,	,	O
pemphigus,	JJ	O
polyarthritis,	,	O
warm	JJ	O
autoimmune	,	O
hemolytic	JJ	O
anemia,	NN	O
Takayasu's	,	O
arteritis,	JJ	O
coronary	NN	O
artery	,	O
disease,	JJ	O
endometriosis,	,	O
interstitial	NN	O
cystitis,	VBD	O
neuromyotonia,	,	O
scleroderma,	POS	O
vitiligo,	,	O
vulvodynia,	POS	O
Chagas'	,	O
disease,	JJ	O
sarcoidosis,	,	O
chronic	,	O
fatigue	,	O
syndrome,	JJ	O
acute	NN	O
respiratory	JJ	O
distress	,	O
syndrome,	POS	O
tendonitis,	,	O
bursitis,	JJ	O
polymyalgia	NN	O
rheumatica,	,	O
inflammatory	,	O
bowel	JJ	O
disease,	,	O
chronic	,	O
obstructive	,	O
pulmonary	,	O
disease,	,	O
allergic	POS	O
rhinitis,	,	O
cardiovascular	,	O
disease,	JJ	O
chronic	NN	O
cholecystitis,	,	O
bronchiectasis,	JJ	O
pneumoconiosis,	NN	O
such	NN	O
as	,	O
for	,	O
example,	,	O
silicosis,	NN	O
osteoarthritis,	,	O
atherosclerosis,	JJ	O
dysautonomia,	NN	O
ankylosing	,	O
spondylitis,	JJ	O
acute	JJ	O
anterior	JJ	O
uvelitis,	,	O
systemic	JJ	O
lupus	,	O
erythematosus,	JJ	O
insulin-dependent	,	O
diabetes	JJ	O
mellitus,	,	O
pemphigus	,	O
vulgaris,	,	O
experimental	JJ	O
allergic	IN	O
encephalomyelitis,	IN	O
experimental	,	O
autoimmune	,	O
uveorenitis,	,	O
mixed	,	O
connective	,	O
tissue	VBG	O
disease,	,	O
Sjorgen's	JJ	O
syndrome,	JJ	O
autoimmune	,	O
hemolytic	JJ	O
anemia,	NN	O
autoimmune	,	O
thrombocytopenic	JJ	O
purpura,	NNS	O
acute	,	O
rheumatic	JJ	O
fever,	,	O
mixed	JJ	O
essential	NN	O
cryoglobulinemia,	,	O
juvenile	JJ	O
rheumatoid	NN	O
arthritis,	,	O
degenerative	JJ	O
joint	JJ	O
disease,	NN	O
ankylosing	,	O
spondylitis,	POS	O
psoriatic	,	O
arthritis,	JJ	O
neuralgia,	JJ	O
synoviitis,	,	O
glomerulonephritis,	JJ	O
vasculitis,	JJ	O
inflammations	,	O
that	JJ	O
occur	JJ	O
as	,	O
sequellae	JJ	O
to	JJ	O
influenza,	,	O
the	NN	O
common	NN	O
cold	,	O
and	JJ	O
other	NN	O
viral	,	O
infections,	VBG	O
gout,	,	O
contact	JJ	O
dermatitis,	,	O
low	,	O
back	,	O
and	,	O
neck	,	O
pain,	NNS	O
dysmenorrhea,	WDT	O
headache,	VBP	O
toothache,	IN	O
sprains,	NN	O
strains,	TO	O
myositis,	,	O
burns,	DT	O
injuries,	JJ	O
and	NN	O
pain	CC	O
and	JJ	O
inflammation	JJ	O
that	,	O
follow	,	O
surgical	NN	O
and	,	O
dental	JJ	O
procedures	RB	O
in	CC	O
a	NN	O
subject.	,	O
Cell	,	O
Growth	,	O
and	,	O
Tissue	,	O
Regeneration	,	O
Treatments	,	O
The	,	O
polypeptides	,	O
of	CC	O
the	NN	O
invention	CC	O
have	NN	O
been	IN	O
shown	JJ	O
to	JJ	O
stimulate	CC	O
a	JJ	O
mitogenic,	NNS	O
cell	IN	O
growth-promoting	DT	O
program	.	O
in	NNP	O
specific	NNP	O
cell	CC	O
types	NNP	O
and	NNP	O
cell	VBZ	O
lines,	DT	O
such	NNS	O
as	IN	O
for	DT	O
example,	NN	O
Huh7	VBP	O
hepatoma	VBN	O
cells	VBN	O
and	TO	O
MRC5	VB	O
fetal	DT	O
lung	,	O
fibroblast	VBP	O
cells.	JJ	O
This	NN	O
mitogenic	IN	O
program	JJ	O
is	NN	O
identified	NNS	O
using	CC	O
expression	NN	O
microarray	,	O
analysis	JJ	O
and	IN	O
cell	IN	O
viability	,	O
assays	NNP	O
of	NN	O
cells	NNS	O
and	CC	O
cell	NNP	O
lines	JJ	O
treated	NN	O
with	NN	O
the	.	O
polypeptides	DT	O
of	JJ	O
the	NN	O
invention.	VBZ	O
The	VBN	O
invention	VBG	O
provides	NN	O
for	NN	O
uses	NN	O
of	CC	O
the	NN	O
polypeptides	NN	O
of	NNS	O
the	IN	O
invention	NNS	O
to	CC	O
stimulate	NN	O
cell	NNS	O
growth	VBN	O
and	IN	O
tissue	DT	O
regeneration	NNS	O
in	IN	O
vitro,	DT	O
in	.	O
vivo,	DT	O
and	NN	O
ex	VBZ	O
vivo	IN	O
using	NNS	O
tissues	IN	O
and	DT	O
cells	NNS	O
derived	IN	O
from	DT	O
subjects	NN	O
or	TO	O
mammals.	VB	O
Derivatives	NN	O
of	NN	O
the	CC	O
Polypeptides	NN	O
of	NN	O
the	IN	O
Invention	,	O
The	IN	O
invention	,	O
provides	CC	O
for	FW	O
polypeptides	FW	O
that	VBG	O
differ	NNS	O
from	CC	O
the	NNS	O
polypeptides	VBN	O
of	IN	O
FIG.	NNS	O
1	CC	O
by	.	O
1	NNS	O
to	IN	O
34	DT	O
amino	NNP	O
acids,	IN	O
such	DT	O
differences	NNP	O
may	DT	O
include	NN	O
substitutions,	VBZ	O
insertions,	IN	O
deletions,	NNS	O
the	WDT	O
incorporation	VBP	O
of	IN	O
modified	DT	O
amino	NNS	O
acids	IN	O
or	.	O
amino	CD	O
acid	IN	O
derivatives,	CD	O
and	TO	O
the	CD	O
addition	NN	O
or	,	O
deletion	JJ	O
of	NNS	O
amino	MD	O
acids	VB	O
from	,	O
the	,	O
C-terminus	,	O
or	DT	O
N-terminus	NN	O
of	IN	O
the	VBN	O
polypeptides.	NN	O
One	NNS	O
or	CC	O
more	NN	O
amino	JJ	O
acid	,	O
substitutions	CC	O
may	DT	O
be	NN	O
made	CC	O
to	NN	O
the	IN	O
polypeptides	JJ	O
of	NNS	O
the	IN	O
invention	DT	O
according	NNP	O
to,	CC	O
for	NNP	O
example,	IN	O
a	DT	O
substitution	.	O
group	CD	O
(such	CC	O
as,	JJR	O
a	JJ	O
conservative	JJ	O
substitution	NNS	O
group),	MD	O
such	VB	O
as	VBN	O
one	TO	O
set	DT	O
forth	NNS	O
below.	IN	O
Alternatively,	DT	O
or	NN	O
in	VBG	O
addition,	,	O
one	IN	O
or	,	O
more	DT	O
amino	NN	O
acid	NN	O
substitutions	JJ	O
may	,	O
made	DT	O
in	JJ	O
the	NN	O
polypeptides	,	O
which	JJ	O
introduces	IN	O
or	CD	O
removes	NN	O
an	NN	O
amino	.	O
acid	,	O
residue	CC	O
comprising	IN	O
an	,	O
attachment	CD	O
group	CC	O
for	JJR	O
a	JJ	O
non-polypeptide	JJ	O
moiety.	NNS	O
Examples	MD	O
include	VB	O
introduction	IN	O
of	DT	O
one	NNS	O
or	WDT	O
more	NNS	O
N-glycosylation	CC	O
site(s),	VBZ	O
introduction	DT	O
of	NN	O
one	NN	O
or	JJ	O
more	VBG	O
cysteine	DT	O
residue(s)	NN	O
or	NN	O
lysine	IN	O
residue(s),	DT	O
removal	JJ	O
of	.	O
one	NNS	O
or	VBP	O
more	NN	O
N-glycosylation	IN	O
site(s),	CD	O
and/or	CC	O
or	JJR	O
removal	JJ	O
of	,	O
one	NN	O
or	IN	O
more	CD	O
lysine(s)	CC	O
or	JJR	O
histidine(s).	JJ	O
Some	)	O
such	CC	O
polypeptides	JJ	O
exhibit	,	O
an	NN	O
oligoadenylate	IN	O
synthetase	CD	O
activity.	CC	O
Conservative	JJR	O
substitutions	JJ	O
groups	,	O
include:	''	O
Group	CC	O
1,	NN	O
Alanine	IN	O
(A)	CD	O
Glycine	CC	O
(G)	JJR	O
Serine	)	O
(S)	CC	O
Threonine	.	O
(T),	DT	O
Group	JJ	O
2,	NNS	O
Aspartic	VBP	O
acid	DT	O
(D)	JJ	O
Glutamic	NN	O
acid	.	O
(E),	JJ	O
Group	NNS	O
3,	NNS	O
Asparagine	:	O
(N)	NNP	O
Glutamine	,	O
(Q),	NNP	O
Group	)	O
4,	NNP	O
Arginine	)	O
(R)	NNP	O
Lysine	)	O
(K)	NNP	O
Histidine	,	O
(H),	NNP	O
Group	,	O
5,	NNP	O
Isoleucine	NN	O
(I)	)	O
Leucine	NNP	O
(L)	NN	O
Methionine	,	O
(M)	NNP	O
Valine	,	O
(V),	NNP	O
and	)	O
Group	NNP	O
6,	,	O
Phenylalanine	NNP	O
(F)	,	O
Tyrosine	NNP	O
(Y)	)	O
Tryptophan	NNP	O
(W).	)	O
Other	NNP	O
substitution	,	O
groups	NNP	O
of	,	O
amino	NNP	O
acids	)	O
can	NNP	O
be	)	O
envisioned.	NNP	O
For	)	O
example,	NNP	O
amino	,	O
acids	CC	O
can	NNP	O
be	,	O
grouped	NNP	O
by	)	O
similar	NNP	O
function	)	O
or	NNP	O
chemical	.	O
structure	JJ	O
or	NN	O
composition	NNS	O
(e.g.,	IN	O
acidic,	JJ	O
basic,	NNS	O
aliphatic,	MD	O
aromatic,	VB	O
sulfur-containing).	.	O
For	IN	O
example,	,	O
an	JJ	O
Aliphatic	NNS	O
grouping	MD	O
may	VB	O
comprise:	VBN	O
Glycine	IN	O
(G),	JJ	O
Alanine	NN	O
(A),	CC	O
Valine	NN	O
(V),	NN	O
Leucine	CC	O
(L),	NN	O
Isoleucine	,	O
(I).	,	O
Other	,	O
groups	,	O
containing	,	O
amino	.	O
acids	IN	O
that	,	O
are	DT	O
considered	JJ	O
conservative	NN	O
substitutions	MD	O
for	:	O
one	NNP	O
another	,	O
include:	NNP	O
Aromatic:	,	O
Phenylalanine	NNP	O
(F),	,	O
Tyrosine	NNP	O
(Y),	,	O
Tryptophan	NNP	O
(W);	.	O
Sulfur-containing:	JJ	O
Methionine	NNS	O
(M),	VBG	O
Cysteine	NN	O
(C);	NNS	O
Basic:	WDT	O
Arginine	VBP	O
(R),	VBN	O
Lysine	JJ	O
(K),	NNS	O
Histidine	IN	O
(H);	CD	O
Acidic:	DT	O
Aspartic	:	O
acid	:	O
(D),	NN	O
Glutamic	,	O
acid	NNP	O
(E),	,	O
Asparagine	NNP	O
(N),	:	O
Glutamine	:	O
(Q).	NNP	O
See	,	O
also	NNP	O
Creighton	:	B
(1984)	:	I
Proteins,	NN	I
W.H.	,	I
Freeman	NNP	I
and	,	I
Company,	NNP	I
for	:	O
additional	:	O
groupings	JJ	O
of	NN	O
amino	,	O
acids.	NNP	O
Listing	NN	O
of	,	O
a	NNP	O
polypeptide	,	O
sequence	NNP	O
herein,	.	O
in	NNP	O
conjunction	RB	O
with	NNP	O
the	)	O
above	,	O
substitution	.	O
groups,	NNP	O
provides	CC	O
an	,	O
express	IN	O
listing	JJ	O
of	NNS	O
all	IN	O
conservatively	JJ	O
substituted	.	O
polypeptide	NN	O
sequences.	IN	O
In	DT	O
one	JJ	O
aspect,	NN	O
the	,	O
invention	IN	O
provides	NN	O
isolated	IN	O
or	DT	O
recombinant	JJ	O
polypeptides	NN	O
each	,	O
comprising	VBZ	O
a	DT	O
sequence	JJ	O
having	NN	O
at	IN	O
least	DT	O
90%	RB	O
sequence	VBN	O
identity	NN	O
(e.g.,	.	O
at	IN	O
least	CD	O
about	,	O
91%,	DT	O
at	NN	O
least	VBZ	O
about	JJ	O
92%,	CC	O
at	JJ	O
least	NNS	O
about	DT	O
93%,	VBG	O
at	DT	O
least	NN	O
about	VBG	O
94%,	IN	O
at	JJS	O
least	NN	O
about	NN	O
95%,	NN	O
at	,	O
least	IN	O
about	JJS	O
96%,	IN	O
at	,	O
least	IN	O
about	JJS	O
97%,	IN	O
at	,	O
least	IN	O
about	JJS	O
98%,	IN	O
or	,	O
at	IN	O
least	JJS	O
about	IN	O
99%	,	O
amino	IN	O
acid	JJS	O
sequence	IN	O
identity)	,	O
to	IN	O
any	JJS	O
one	IN	O
of	,	O
the	IN	O
polypeptides	JJS	O
of	IN	O
FIG.	,	O
1.	IN	O
In	JJS	O
some	IN	O
instances	,	O
the	CC	O
polypeptide	IN	O
exhibits	JJS	O
oligoadenylate	IN	O
synthetase	NN	O
activity.	NN	O
The	JJ	O
degree	NN	O
to	)	O
which	TO	O
a	DT	O
sequence	CD	O
(polypeptide	IN	O
or	DT	O
nucleic	NNS	O
acid)	IN	O
is	.	O
similar	.	O
to	IN	O
another	DT	O
provides	NNS	O
an	DT	O
indication	NN	O
of	VBZ	O
similar	JJ	O
structural	NN	O
and	.	O
functional	DT	O
properties	NN	O
for	TO	O
the	WDT	O
two	DT	O
sequences.	NN	O
Accordingly,	JJ	O
in	CC	O
the	JJ	O
context	)	O
of	VBZ	O
the	JJ	O
present	TO	O
invention,	DT	O
sequences	VBZ	O
which	DT	O
have	NN	O
a	IN	O
similar	JJ	O
sequence	JJ	O
to	CC	O
any	JJ	O
given	NNS	O
exemplar	IN	O
sequence	DT	O
are	CD	O
a	.	O
feature	,	O
of	IN	O
the	DT	O
present	NN	O
invention.	IN	O
In	DT	O
particular,	JJ	O
sequences	,	O
that	NNS	O
have	WDT	O
percent	VBP	O
sequence	DT	O
identities	JJ	O
as	NN	O
defined	TO	O
below	DT	O
are	VBN	O
a	JJ	O
feature	NN	O
of	VBP	O
the	DT	O
invention.	NN	O
A	IN	O
variety	DT	O
of	JJ	O
methods	.	O
of	IN	O
determining	,	O
sequence	NNS	O
relationships	WDT	O
can	VBP	O
be	VBN	O
used,	NN	O
including	NNS	O
manual	IN	O
alignment	VBN	O
and	IN	O
computer	VBP	O
assisted	DT	O
sequence	NN	O
alignment	IN	O
and	DT	O
analysis.	.	O
A	DT	O
variety	NN	O
of	IN	O
computer	NNS	O
programs	IN	O
for	VBG	O
performing	NN	O
sequence	NNS	O
alignments	MD	O
are	VB	O
available,	,	O
or	VBG	O
an	JJ	O
alignment	NN	O
can	CC	O
be	NN	O
prepared	VBD	O
manually	NN	O
by	NN	O
one	CC	O
of	.	O
skill.	DT	O
As	NN	O
noted	IN	O
above,	NN	O
the	NNS	O
sequences	IN	O
of	VBG	O
the	NN	O
polypeptides	NNS	O
and	VBP	O
nucleic	,	O
acids	CC	O
employed	DT	O
in	NN	O
the	MD	O
subject	VB	O
invention	VBN	O
need	RB	O
not	IN	O
be	CD	O
identical,	IN	O
but	.	O
can	IN	O
be	VBN	O
substantially	,	O
identical	DT	O
to	NNS	O
the	IN	O
corresponding	DT	O
sequence	NNS	O
of	CC	O
a	JJ	O
polypeptide	NNS	O
of	VBN	O
the	IN	O
invention	DT	O
or	JJ	O
nucleic	NN	O
acid	MD	O
of	RB	O
the	VB	O
invention.	,	O
For	CC	O
example,	MD	O
polypeptides	VB	O
of	RB	O
the	JJ	O
invention	TO	O
can	DT	O
be	JJ	O
subject	NN	O
to	IN	O
various	DT	O
changes,	NN	O
such	IN	O
as	DT	O
one	NN	O
or	CC	O
more	JJ	O
amino	NN	O
acid	IN	O
insertions,	DT	O
deletions,	.	O
and/or	IN	O
substitutions,	,	O
either	NNS	O
conservative	IN	O
or	DT	O
non-conservative,	NN	O
including	MD	O
where,	VB	O
e.g.,	JJ	O
such	TO	O
changes	JJ	O
might	,	O
provide	JJ	O
for	IN	O
certain	CD	O
advantages	CC	O
in	JJR	O
their	JJ	O
use,	NN	O
such	,	O
as,	,	O
in	JJ	O
their	,	O
therapeutic	RB	O
or	JJ	O
prophylactic	CC	O
use	,	O
or	VBG	O
administration	,	O
or	,	O
diagnostic	JJ	O
application.	NNS	O
The	MD	O
nucleic	VB	O
acids	IN	O
of	JJ	O
the	NNS	O
invention	IN	O
can	PRP$	O
also	,	O
be	JJ	O
subject	,	O
to	IN	O
various	PRP$	O
changes,	JJ	O
such	CC	O
as	JJ	O
one	NN	O
or	CC	O
more	NN	O
substitutions	CC	O
of	JJ	O
one	.	O
or	DT	O
more	JJ	O
nucleic	NNS	O
acids	IN	O
in	DT	O
one	NN	O
or	MD	O
more	RB	O
codons	VB	O
such	JJ	O
that	TO	O
a	JJ	O
particular	,	O
codon	JJ	O
encodes	IN	O
the	CD	O
same	CC	O
or	JJR	O
a	NNS	O
different	IN	O
amino	CD	O
acid,	CC	O
resulting	JJR	O
in	JJ	O
either	NNS	O
a	IN	O
silent	CD	O
variation	CC	O
(as	JJR	O
defined	NNS	O
herein)	JJ	O
or	IN	O
non-silent	DT	O
variation,	JJ	O
or	NN	O
one	VBZ	O
or	DT	O
more	JJ	O
deletions	CC	O
of	DT	O
one	JJ	O
or	NN	O
more	,	O
nucleic	VBG	O
acids	IN	O
(or	CC	O
codons)	DT	O
in	JJ	O
the	NN	O
sequence.	IN	O
The	VBN	O
nucleic	)	O
acids	CC	O
can	JJ	O
also	,	O
be	CC	O
modified	CD	O
to	CC	O
include	JJR	O
one	NNS	O
or	IN	O
more	CD	O
codons	CC	O
that	JJR	O
provide	JJ	O
for	NNS	O
optimum	CC	O
expression	)	O
in	IN	O
an	DT	O
expression	.	O
system	DT	O
(e.g.,	JJ	O
bacterial	NNS	O
or	MD	O
mammalian),	RB	O
while,	VB	O
if	VBN	O
desired,	TO	O
said	VB	O
one	CD	O
or	CC	O
more	JJR	O
codons	NNS	O
still	WDT	O
encode	VBP	O
the	IN	O
same	JJ	O
amino	NN	O
acid(s).	IN	O
Such	DT	O
nucleic	NN	O
acid	NN	O
changes	,	O
might	JJ	O
provide	CC	O
for	,	O
certain	,	O
advantages	IN	O
in	,	O
their	VBD	O
therapeutic	CD	O
or	CC	O
prophylactic	JJR	O
use	NNS	O
or	RB	O
administration,	VBP	O
or	DT	O
diagnostic	JJ	O
application.	NN	O
The	.	O
nucleic	JJ	O
acids	JJ	O
and	NNS	O
polypeptides	NNS	O
can	MD	O
be	VB	O
modified	IN	O
in	JJ	O
a	NNS	O
number	IN	O
of	PRP$	O
ways	JJ	O
so	CC	O
long	JJ	O
as	NN	O
they	CC	O
comprise	,	O
a	CC	O
sequence	JJ	O
substantially	.	O
identical	DT	O
(as	JJ	O
defined	NNS	O
below)	CC	O
to	NNS	O
a	MD	O
sequence	VB	O
in	VBN	O
a	IN	O
respective	DT	O
nucleic	NN	O
acid	IN	O
or	NNS	O
polypeptide	RB	O
of	RB	O
the	IN	O
invention.	PRP	O
The	VBP	O
term	DT	O
“identical”	NN	O
or	RB	O
“identity,”	JJ	O
in	IN	O
the	VBN	O
context	)	O
of	TO	O
two	DT	O
or	NN	O
more	IN	O
nucleic	DT	O
acid	JJ	O
or	JJ	O
polypeptide	NN	O
sequences,	CC	O
refers	NN	O
to	IN	O
two	DT	O
or	.	O
more	DT	O
sequences	NN	O
that	NN	O
are	CC	O
the	NN	O
same	IN	O
or	DT	O
have	NN	O
a	IN	O
specified	CD	O
percentage	CC	O
of	JJR	O
amino	JJ	O
acid	NN	O
residues	CC	O
or	NN	O
nucleotides	,	O
that	NNS	O
are	TO	O
the	CD	O
same,	CC	O
when	JJR	O
compared	NNS	O
and	WDT	O
aligned	VBP	O
for	DT	O
maximum	JJ	O
similarity,	CC	O
as	VBP	O
determined	DT	O
using	VBN	O
a	NN	O
sequence	IN	O
comparison	NN	O
algorithm	NN	O
or	NNS	O
by	CC	O
visual	NNS	O
inspection.	WDT	O
The	VBP	O
“percent	DT	O
sequence	,	O
identity”	WRB	O
(“%	VBN	O
identity”)	CC	O
of	VBN	O
a	IN	O
subject	JJ	O
sequence	,	O
to	IN	O
a	VBN	O
reference	VBG	O
(i.e.	DT	O
query)	NN	O
sequence	NN	O
means	NN	O
that	CC	O
the	IN	O
subject	JJ	O
sequence	.	O
is	DT	O
identical	JJ	O
(i.e.,	NN	O
on	NN	O
an	NN	O
amino	)	O
acid-by-amino	IN	O
acid	DT	O
basis	JJ	O
for	NN	O
a	TO	O
polypeptide	DT	O
sequence,	NN	O
or	.	O
a	)	O
nucleotide-by-nucleotide	NN	O
basis	VBZ	O
for	IN	O
a	DT	O
polynucleotide	JJ	O
sequence)	NN	O
by	VBZ	O
a	JJ	O
specified	,	O
percentage	IN	O
to	DT	O
the	JJ	O
query	JJ	O
sequence	JJ	O
over	NN	O
a	IN	O
comparison	DT	O
length.	JJ	O
Site	,	O
Directed	CC	O
Mutagenesis	DT	O
to	JJ	O
Create	NN	O
the	IN	O
Polypeptides	DT	O
of	JJ	O
the	)	O
Invention	IN	O
The	DT	O
polypeptides	JJ	O
of	NN	O
the	TO	O
present	DT	O
invention	NN	O
can	NN	O
be	IN	O
engineered	DT	O
using	NN	O
any	.	O
standard	NNP	O
method	VBD	O
of	NNP	O
site-directed	TO	O
mutagenesis.	VB	O
The	DT	O
nucleic	NNP	O
acid	IN	O
sequences	DT	O
corresponding	NNP	O
to	DT	O
the	NNS	O
polypeptides	IN	O
of	DT	O
the	JJ	O
invention	NN	O
are	MD	O
synthetized	VB	O
using	VBN	O
specific	VBG	O
oligonucleotide	DT	O
primers	JJ	O
and	NN	O
a	IN	O
high	JJ	O
fidelity	.	O
DNA	DT	O
polymerase.	JJ	O
The	NN	O
target	NNS	O
sequence	VBG	O
is	TO	O
contained	DT	O
on	NNS	O
a	IN	O
double	DT	O
stranded	NN	O
plasmid	VBP	O
isolated	VBN	O
from	VBG	O
a	JJ	O
methylation-competent	JJ	O
E.	NNS	O
coli	CC	O
strain.	DT	O
Complimentary	JJ	O
oligonucleotides	NN	O
containing	NNP	O
the	.	O
desired	DT	O
mutation	NN	O
are	NN	O
synthesized	VBZ	O
and	VBN	O
purified	IN	O
using	DT	O
polyacrylamide	JJ	O
gel	VBN	O
electrophoresis.	NN	O
A	VBN	O
thermal	IN	O
cycler	DT	O
is	JJ	O
used	NNP	O
to	NNS	O
control	.	O
the	NNP	O
temperature	NNS	O
for	VBG	O
alternating	DT	O
cycles	VBN	O
of	NN	O
denaturation	VBP	O
of	VBN	O
the	CC	O
double	VBN	O
stranded	VBG	O
plasmid	JJ	O
template	JJ	O
(94°	.	O
C.	DT	O
for	JJ	O
30	NN	O
seconds),	VBZ	O
annealing	VBN	O
of	TO	O
the	VB	O
oligonucleotide	DT	O
primers	NN	O
(55°	IN	O
C.	VBG	O
for	NNS	O
1	IN	O
minute),	NN	O
and	IN	O
extension	DT	O
of	NN	O
the	VBD	O
primers	JJ	O
with	NN	O
a	CD	O
high	NNP	O
fidelity	IN	O
polymerase	CD	O
(68°	,	O
C.	VBG	O
for	IN	O
1	DT	O
minute/kb	JJ	O
of	NNS	O
plasmid	CD	O
length).	NNP	O
After	IN	O
approximately	CD	O
15	,	O
cycles,	CC	O
the	NN	O
mixture	IN	O
of	DT	O
newly	NNS	O
synthetized	IN	O
and	DT	O
input	JJ	O
DNA	NN	O
are	NN	O
treated	CD	O
with	NNP	O
a	IN	O
restriction	CD	O
enzyme	NN	O
specific	IN	O
for	JJ	O
methylated	.	O
residues	IN	O
(Dpn	RB	O
I)	CD	O
to	,	O
digest	DT	O
the	NN	O
parental	IN	O
plasmid.	RB	O
The	VBN	O
resulting	CC	O
DNA	VBN	O
is	NNP	O
introduced	VBP	O
into	VBN	O
chemically	IN	O
or	DT	O
electrically	NN	O
competent	NN	O
bacterial	NN	O
strains	IN	O
for	JJ	O
screening	NNS	O
and	NNP	O
isolation	)	O
of	TO	O
plasmids	VB	O
containing	DT	O
the	JJ	O
desired	.	O
mutation.	DT	O
Plasmid	VBG	O
DNA	NN	O
is	VBZ	O
isolated	VBN	O
from	IN	O
the	RB	O
transformants	CC	O
and	RB	O
screened	JJ	O
via	JJ	O
fluorescent	NNS	O
dye-terminator	IN	O
sequencing	VBG	O
to	CC	O
confirm	NN	O
the	IN	O
mutant	NNS	O
sequence.	VBG	O
Bulk	DT	O
Drug	JJ	O
Product	.	O
Expression,	NNP	O
Fermentation,	NNP	O
and	VBZ	O
Purification	VBN	O
An	IN	O
E.	DT	O
coli	NNS	O
strain	CC	O
containing	VBD	O
a	IN	O
lysogen	JJ	O
of	NN	O
ADE3,	VBG	O
and	TO	O
therefore	VB	O
carrying	DT	O
a	JJ	O
chromosomal	.	O
copy	JJ	O
of	NNP	O
the	NNP	O
T7	,	O
RNA	,	O
polymerase	CC	O
gene	NNP	O
under	DT	O
the	NNP	O
control	NNS	O
of	VBP	O
the	VBG	O
lacUV5	DT	O
promoter,	NN	O
is	IN	O
transformed	,	O
with	CC	O
a	RB	O
bacterial	VBG	O
expression	DT	O
vector	JJ	O
containing	NN	O
an	IN	O
IPTG-inducible	DT	O
promoter	NNP	O
encoding	NNP	O
a	NN	O
nucleic	NN	O
acid	IN	O
sequence	DT	O
corresponding	NN	O
to	IN	O
one	DT	O
or	NN	O
more	,	O
of	VBZ	O
the	VBN	O
polypeptides	IN	O
of	DT	O
the	JJ	O
present	NN	O
invention.	NN	O
Cultures	VBG	O
are	DT	O
grown	JJ	O
in	NN	O
luria	VBG	O
broth	DT	O
medium	JJ	O
supplemented	NN	O
with	NN	O
34	VBG	O
μg/mL	TO	O
chloroamphenicol	CD	O
and	CC	O
15	JJR	O
μg/mL	IN	O
kanamycin	DT	O
at	NNS	O
37°	IN	O
C.	DT	O
When	JJ	O
the	.	O
OD600	NNS	O
reaches	VBP	O
>0.4,	VBN	O
the	IN	O
temperature	JJ	O
is	DT	O
reduced	NN	O
to	VBD	O
18°	IN	O
C.	CD	O
and	NNS	O
the	NN	O
cells	CC	O
are	CD	O
induced	JJ	O
with	NN	O
0.5	IN	O
mM	CD	O
IPTG	NNP	O
for	WRB	O
17	DT	O
hours.	NNP	O
The	VBZ	O
bacterial	,	O
cells	DT	O
are	NN	O
then	VBZ	O
resuspended	VBN	O
in	TO	O
buffer	CD	O
containing	NNP	O
50	CC	O
mM	DT	O
NaH2PO4,	NNS	O
pH	VBP	O
8,	VBN	O
300	IN	O
mM	CD	O
NaCl,	NNS	O
20	NNP	O
mM	IN	O
imidazole,	CD	O
10%	.	O
glycerol,	DT	O
0.1%	JJ	O
NP40,	NNS	O
2	VBP	O
mM	RB	O
DTT	VBN	O
and	IN	O
protease	NN	O
inhibitors	VBG	O
(VWR),	CD	O
lysed	JJ	O
in	,	O
a	NN	O
Gaulin	,	O
homogenizer,	CD	O
and	NN	O
centrifuged	,	O
to	CD	O
remove	NN	O
cell	,	O
debris	NN	O
before	,	O
protein	NN	O
purification.	,	O
In	CD	O
one	NN	O
embodiment,	NNP	O
purification	CC	O
of	NN	O
the	NNS	O
polypeptides	,	O
of	VBN	O
the	IN	O
present	DT	O
invention	NNP	O
can	,	O
be	CC	O
achieved	VBD	O
using	TO	O
a	VB	O
polyhistidine	NN	O
tag	NN	O
at	IN	O
the	JJ	O
amino-terminus.	.	O
A	IN	O
nickel	CD	O
column	,	O
is	NN	O
used	IN	O
in	DT	O
affinity	NNS	O
purifications	IN	O
of	DT	O
polyhistidine	JJ	O
tags,	NN	O
with,	MD	O
for	VB	O
example,	VBN	O
a	VBG	O
5	DT	O
mL	NN	O
column	NN	O
being	IN	O
utilized	DT	O
for	.	O
lysate	DT	O
generated	JJ	O
by	NN	O
4	VBZ	O
L	VBN	O
of	IN	O
E.	NN	O
coli.	NNS	O
The	IN	O
lysate	NN	O
is	,	O
loaded	,	O
onto	IN	O
the	,	O
column	DT	O
and	CD	O
then	NN	O
washed	NN	O
with	VBG	O
Buffer	VBN	O
A	IN	O
(50	NN	O
mM	VBN	O
NaH2PO4,	IN	O
300	CD	O
mM	NNP	O
NaCl,	IN	O
30%	NNP	O
glycerol,	.	O
20	DT	O
mM	NN	O
imidazole,	VBZ	O
2	VBN	O
mM	IN	O
DTT	DT	O
at	NN	O
pH	CC	O
7.5).	RB	O
A	VBD	O
step	IN	O
elution	NNP	O
to	NNP	O
7%	CD	O
Buffer	NN	O
B	,	O
(50	CD	O
mM	NN	O
NaH2PO4,	,	O
300	NN	O
mM	,	O
NaCl,	CD	O
30%	NN	O
glycerol,	,	O
2	CD	O
M	NN	O
imidazole,	NNP	O
2	IN	O
mM	RB	O
DTT	.	O
at	DT	O
pH	NN	O
6.8),	NN	O
for	TO	O
3.2	NN	O
column	NNP	O
volumes	NNP	O
is	CD	O
then	NN	O
carried	,	O
out.	CD	O
A	NN	O
gradient	,	O
to	NN	O
100%	,	O
Buffer	CD	O
B	NNP	O
over	,	O
3	CD	O
column	NN	O
volumes	NNP	O
is	IN	O
then	RB	O
carried	,	O
out.	IN	O
The	CD	O
polypeptide	NN	O
of	NNS	O
the	VBZ	O
present	RB	O
invention	VBN	O
can	.	O
then	DT	O
be	NN	O
gel-filtered	TO	O
into	NN	O
Buffer	NNP	O
C	NNP	O
(50	IN	O
mM	CD	O
NaH2PO4,	NN	O
150	NNS	O
mM	VBZ	O
NaCl,	RB	O
40%	VBN	O
glycerol,	.	O
1	DT	O
mM	NN	O
EDTA,	IN	O
2	DT	O
mM	JJ	O
DTT	NN	O
at	MD	O
pH	RB	O
6.8)	VB	O
and	JJ	O
loaded	IN	O
onto	NNP	O
a	NNP	O
cation	CD	O
exchange	NN	O
column	,	O
for	CD	O
further	NN	O
purification.	,	O
After	NN	O
the	,	O
protein	CD	O
is	NN	O
loaded,	,	O
the	CD	O
column	NN	O
is	NNP	O
washed	IN	O
with	RB	O
Buffer	)	O
C	CC	O
followed	VBN	O
by	IN	O
a	DT	O
step	NN	O
elution	NN	O
to	NN	O
75%	IN	O
of	JJ	O
Buffer	.	O
D	IN	O
(50	DT	O
mM	NN	O
NaH2PO4,	VBZ	O
1	,	O
M	DT	O
NaCl,	NN	O
40%	VBZ	O
glycerol,	VBN	O
1	IN	O
mM	NNP	O
EDTA,	NNP	O
2	VBN	O
mM	IN	O
DTT	DT	O
at	NN	O
pH	NN	O
6.8),	TO	O
then	NN	O
a	IN	O
5	NNP	O
column	NNP	O
volume	CD	O
gradient	NN	O
to	,	O
100%	CD	O
Buffer	NNP	O
D.	,	O
The	NN	O
protein	,	O
is	CD	O
then	NN	O
gel	,	O
filtered	CD	O
into	NN	O
Buffer	NNP	O
E	IN	O
(50	RB	O
mM	,	O
NaH2PO4,	RB	O
300	DT	O
mM	CD	O
NaCl,	NN	O
40%	NN	O
glycerol,	NN	O
1	TO	O
mM	NN	O
EDTA,	NNP	O
2	NNP	O
mM	DT	O
DTT	NN	O
at	VBZ	O
pH	RB	O
6.8)	JJ	O
and	VBN	O
stored	IN	O
at	NNP	O
−20°	NNP	O
C.	CD	O
Different	NN	O
embodiments	,	O
of	CD	O
the	NN	O
polypeptides	,	O
of	NN	O
the	,	O
invention,	CD	O
including	NN	O
but	,	O
not	CD	O
limited	NN	O
to:	NNP	O
those	IN	O
lacking	RB	O
a	)	O
polyhistidine	CC	O
tag,	VBN	O
those	IN	O
possessing	NNP	O
a	NNP	O
polyarginine	NNP	O
tag,	NNS	O
those	IN	O
with	DT	O
reduced	NNS	O
cysteine	IN	O
content,	DT	O
those	,	O
with	VBG	O
amino	CC	O
acid	RB	O
sequence	JJ	O
variations	:	O
designed	DT	O
to	VBG	O
make	DT	O
the	NN	O
drug	,	O
candidate	DT	O
more	VBG	O
thermally	DT	O
stable,	NN	O
those	,	O
with	DT	O
modifications	IN	O
to	JJ	O
enhance	NN	O
or	,	O
reduce	DT	O
a	IN	O
particular	JJ	O
activity	JJ	O
of	NN	O
the	NNS	O
drug	VBN	O
candidate,	TO	O
may	VB	O
require	DT	O
alternative	NN	O
purification	NN	O
strategies.	RBR	O
Embodiments	RB	O
of	,	O
the	DT	O
polypeptide	IN	O
drug	NNS	O
candidate	TO	O
lacking	VB	O
a	CC	O
polyhistidine	VB	O
tag,	DT	O
for	JJ	O
example,	NN	O
may	IN	O
be	DT	O
directly	NN	O
applied	,	O
to	MD	O
a	VB	O
cation	JJ	O
exchange	NN	O
column.	.	O
Additional	NNS	O
steps,	IN	O
for	DT	O
example	JJ	O
the	NN	O
use	NN	O
of	VBG	O
hydrophobic	DT	O
interaction	NN	O
chromatography,	,	O
may	IN	O
be	,	O
utilized	MD	O
by	VB	O
taking	RB	O
the	VBN	O
protein	TO	O
in	DT	O
Buffer	NN	O
F	NN	O
(50	.	O
mM	JJ	O
NaH2PO4,	,	O
300	IN	O
mM	NN	O
NaCl,	DT	O
1	NN	O
M	IN	O
(NH4)2SO4,	JJ	O
30%	NN	O
glycerol,	,	O
1	MD	O
mM	VB	O
EDTA,	VBN	O
2	IN	O
mM	VBG	O
DTT	DT	O
at	NN	O
pH	IN	O
6.8)	NNP	O
and	NNP	O
running	CD	O
a	NN	O
10	,	O
column	CD	O
volume	NN	O
gradient	,	O
to	CD	O
100%	NNP	O
Buffer	,	O
E.	NN	O
Other	,	O
affinity	CD	O
columns	NN	O
or	,	O
sizing	CD	O
columns	NN	O
may	NNP	O
be	IN	O
used	RB	O
to	)	O
purify	CC	O
different	VBG	O
embodiments	DT	O
of	CD	O
the	NN	O
polypeptide	NN	O
drug	NN	O
candidates.	TO	O
Alternative	NN	O
techniques	NNP	O
may	NNP	O
also	JJ	O
be	NN	O
used	NNS	O
for	CC	O
exchange	VBG	O
of	NNS	O
buffers,	MD	O
concentration	VB	O
of	VBN	O
the	TO	O
drug	VB	O
candidates	JJ	O
and	NNS	O
purification	IN	O
of	DT	O
the	JJ	O
drug	NN	O
candidates.	.	O
These	NNP	O
could	NNS	O
include,	MD	O
but	RB	O
are	VB	O
not	VBN	O
limited	IN	O
to,	NN	O
ultrafiltration,	IN	O
tangential	,	O
flow	NN	O
filtration	IN	O
and	DT	O
diafiltration	NN	O
for	NNS	O
the	CC	O
concentration	NN	O
of	IN	O
the	DT	O
drug	NN	O
candidate	.	O
and	DT	O
for	MD	O
exchange	,	O
of	CC	O
buffers.	VBP	O
Techniques	RB	O
such	VBN	O
a	,	O
precipitation	,	O
of	JJ	O
the	NN	O
drug	NN	O
candidates	CC	O
by	NN	O
(NH4)2SO4	IN	O
or	DT	O
some	NN	O
other	IN	O
chemical	DT	O
agent	NN	O
may	NN	O
also	CC	O
be	IN	O
used.	NN	O
Denaturing	IN	O
the	.	O
drug	NNS	O
candidate	PDT	O
in	DT	O
urea	NN	O
or	IN	O
some	DT	O
other	NN	O
denaturant	NNS	O
and	IN	O
refolding	CD	O
it	CC	O
may	DT	O
also	JJ	O
be	JJ	O
used.	NN	O
The	MD	O
polypeptides	RB	O
of	VB	O
the	.	O
present	VBG	O
invention	DT	O
are	NN	O
stabilized	NN	O
by	IN	O
excipients	NN	O
containing	CC	O
salts;	DT	O
solutions	JJ	O
stable	NN	O
at	CC	O
300	VBG	O
mM	PRP	O
NaCl	MD	O
can	RB	O
begin	VB	O
to	.	O
precipitate	DT	O
at	NNS	O
150	IN	O
mM	DT	O
NaCl.	JJ	O
For	NN	O
this	VBP	O
reason	VBN	O
excipient	IN	O
mixtures	NNS	O
will	VBG	O
favor	:	O
these	NNS	O
stabilizing	VBP	O
salt	IN	O
concentrations,	CD	O
which	NNS	O
could	NNP	O
include	MD	O
but	VB	O
are	TO	O
not	VB	O
limited	IN	O
to	CD	O
sodium	NN	O
phosphate,	.	O
sodium	IN	O
chloride,	DT	O
calcium	NN	O
chloride,	NN	O
and	NNS	O
magnesium	MD	O
chloride.	VB	O
The	DT	O
addition	VBG	O
of	NN	O
amino	,	O
acid-based	WDT	O
excipients	MD	O
such	VB	O
as	CC	O
arginine	VBP	O
have	RB	O
proven	VBN	O
to	TO	O
be	VB	O
stabilizing	,	O
to	NN	O
the	,	O
polypeptides	NN	O
of	,	O
the	CC	O
present	NN	O
invention.	.	O
A	DT	O
10%	NN	O
solution	IN	O
of	JJ	O
sucrose	JJ	O
allows	NNS	O
the	JJ	O
polypeptides	IN	O
of	NN	O
the	VBP	O
invention	VBN	O
to	TO	O
be	VB	O
stable	VBG	O
at	TO	O
1	DT	O
mg/mL,	NNS	O
the	IN	O
addition	DT	O
of	JJ	O
2%	.	O
w/v	DT	O
arginine	NN	O
allows	NN	O
some	IN	O
embodiments	JJ	O
of	VBZ	O
the	DT	O
polypeptides	NNS	O
to	IN	O
be	DT	O
stable	NN	O
at	TO	O
3	VB	O
mg/mL.	JJ	O
For	IN	O
this	CD	O
reason,	,	O
other	DT	O
amino	NN	O
acid	IN	O
based	NN	O
compounds,	JJ	O
including	NN	O
but	VBZ	O
not	DT	O
limited	NNS	O
to	IN	O
histidine,	DT	O
glutamine,	NNS	O
glycine	TO	O
and	VB	O
human	JJ	O
albumin,	IN	O
may	CD	O
be	.	O
used	IN	O
as	DT	O
excipients.	,	O
The	JJ	O
addition	NN	O
of	NNS	O
excipients	VBN	O
such	,	O
as	VBG	O
glycerol	CC	O
is	RB	O
stabilizing	JJ	O
to	TO	O
polypeptides	,	O
of	,	O
the	NN	O
present	CC	O
invention.	JJ	O
For	,	O
example,	MD	O
in	VB	O
one	VBN	O
embodiment,	IN	O
a	.	O
polypeptide	DT	O
has	NN	O
a	IN	O
maximum	NNS	O
concentration	JJ	O
with	IN	O
10%	NN	O
glycerol	VBZ	O
(v/v)	VBG	O
of	TO	O
1	NNS	O
mg/mL;	IN	O
while	DT	O
at	JJ	O
40%	.	O
glycerol,	IN	O
the	,	O
drug	IN	O
candidates	CD	O
are	,	O
stable	DT	O
up	NN	O
to	VBZ	O
12	DT	O
mg/mL.	JJ	O
Excipient	NN	O
mixtures	IN	O
containing	NN	O
compounds	NN	O
with	)	O
similar	IN	O
chemical	CD	O
properties	:	O
are	IN	O
envisioned	IN	O
that	NN	O
include	,	O
but	DT	O
are	NN	O
not	NNS	O
limited	VBP	O
to	JJ	O
polyols	IN	O
such	TO	O
as	CD	O
mannitol,	.	O
xylitol	JJ	O
and	NNS	O
sorbitol.	VBG	O
Disaccharides	NNS	O
such	IN	O
as	JJ	O
sucrose	NN	O
have	NNS	O
been	VBP	O
found	VBN	O
to	IN	O
be	VBP	O
stabilizing	CC	O
at	VBP	O
10%	RB	O
w/v;	VBN	O
other	TO	O
disaccharides	NNS	O
including	JJ	O
but	IN	O
not	,	O
limited	NNP	O
to	CC	O
maltose	.	O
and	NNS	O
trehalose	JJ	O
can	IN	O
also	NNS	O
be	VBP	O
used.	VBN	O
Monosaccharides	VBN	O
can	TO	O
also	VB	O
be	VBG	O
used	IN	O
in	NN	O
the	:	O
present	JJ	O
invention.	NNS	O
Polysorbates,	VBG	O
polyethyleneglycols	CC	O
and	RB	O
similar	JJ	O
compounds	TO	O
can	VB	O
also	CC	O
be	VB	O
used	MD	O
to	RB	O
practice	VB	O
the	.	O
present	NNS	O
invention.	MD	O
As	RB	O
one	VB	O
skilled	VBN	O
in	IN	O
the	DT	O
art	JJ	O
will	.	O
recognize,	,	O
the	NNS	O
use	CC	O
of	JJ	O
antioxidants	NNS	O
and	MD	O
preservatives	RB	O
may	VB	O
also	VBN	O
be	TO	O
used	NN	O
to	DT	O
ensure	JJ	O
stability	.	O
of	IN	O
the	CD	O
polypeptides	VBD	O
during	IN	O
storage.	DT	O
Antioxidants,	NN	O
including	MD	O
but	,	O
not	DT	O
limited	NN	O
to	IN	O
sodium	NNS	O
citrate,	CC	O
may	NNS	O
be	MD	O
stabilizing	RB	O
for	VB	O
long	VBN	O
term	TO	O
storage	VB	O
of	NN	O
the	IN	O
polypeptides	DT	O
of	NNS	O
the	IN	O
invention.	.	O
Preservatives,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to,	TO	O
benzyl	VB	O
alcohol	,	O
may	MD	O
also	VB	O
be	VBG	O
stabilizing	IN	O
to	JJ	O
the	NN	O
polypeptides	NN	O
during	IN	O
storage	DT	O
and	NNS	O
may	IN	O
be	DT	O
used	.	O
in	,	O
final	VBG	O
excipient	CC	O
mixtures.	RB	O
Measurement	JJ	O
of	,	O
Oligoadenylate	VB	O
Synthetase	NN	O
Activity	MD	O
of	RB	O
Polypeptides	VB	O
The	VBG	O
oligoadenylate	TO	O
synthetase	DT	O
activities	NNS	O
of	IN	O
the	NN	O
polypeptides	CC	O
of	MD	O
the	VB	O
invention	VBN	O
are	IN	O
measured	JJ	O
according	NN	O
to	.	O
previously	NN	O
published	IN	O
methods	NNP	O
(Justesen,	NNP	O
J.,	NNP	O
et	IN	O
al.	NNP	O
Nuc	DT	O
Acids	JJ	O
Res.	NN	O
8:3073-3085,	NNS	O
1980).	IN	O
Briefly,	DT	O
protein	NNS	O
is	IN	O
activated	DT	O
with	NN	O
200	VBP	O
μg/ml	VBN	O
polyinosinic:polycytidylic	VBG	O
acid	TO	O
in	RB	O
buffer	VBN	O
containing	NNS	O
20	,	O
mM	,	O
Tris-HCl,	RB	O
pH	.	O
7.8,	NNP	O
50	NNP	O
mM	.	O
Mg(OAc)2,	,	O
1	.	O
mM	,	O
DTT,	NN	O
0.2	VBZ	O
mM	VBN	O
EDTA,	IN	O
2.5	CD	O
mM	JJ	O
ATP,	JJ	O
α[32P]ATP,	NN	O
0.5	IN	O
mg/ml	NN	O
BSA,	VBG	O
and	CD	O
10%	JJ	O
glycerol.	,	O
The	NN	O
reaction	,	O
proceeds	CD	O
at	NN	O
37°	,	O
C.	CD	O
for	NN	O
30	,	O
minutes	CD	O
to	NN	O
24	,	O
hours	CD	O
and	NN	O
is	,	O
terminated	,	O
by	CD	O
heating	NN	O
to	,	O
90°	CC	O
C.	NN	O
for	.	O
3	DT	O
minutes.	NN	O
2-4	NNS	O
μl	IN	O
of	CD	O
the	NNP	O
reaction	IN	O
mixture	CD	O
is	NNS	O
spotted	TO	O
onto	CD	O
a	NNS	O
PEI-cellulose	CC	O
thin	VBZ	O
layer	VBN	O
plate.	IN	O
After	VBG	O
drying,	TO	O
the	CD	O
plate	NNP	O
is	IN	O
developed	CD	O
with	.	O
0.4	JJ	O
M	NN	O
Tris-HCl,	IN	O
30	DT	O
mM	NN	O
MgCl2,	NN	O
pH	VBZ	O
8.7.	VBN	O
The	IN	O
plate	DT	O
is	JJ	O
dried	JJ	O
and	NN	O
visualized	.	O
by	IN	O
phosphorimager	,	O
analysis.	DT	O
Alternatively,	NN	O
the	VBZ	O
reaction	VBN	O
mixture	IN	O
can	CD	O
be	NNP	O
further	,	O
incubated	CD	O
with	NN	O
0.05	,	O
U/μl	VBD	O
calf	.	O
intestinal	DT	O
phosphatase	NN	O
to	VBZ	O
remove	VBN	O
the	CC	O
terminal	VBN	O
phosphate.	IN	O
Thin	NN	O
layer	.	O
chromatographic	,	O
separation	DT	O
is	NN	O
achieved	NN	O
using	MD	O
a	VB	O
0.76	RB	O
M	VBN	O
KH2PO4,	IN	O
pH	CD	O
3.6	NNP	O
developing	NN	O
buffer	JJ	O
system.	NN	O
The	TO	O
plate	VB	O
is	DT	O
then	JJ	O
dried	.	O
and	NNP	O
visualized	NN	O
by	JJ	O
phosphorimager	NN	O
analysis.	VBZ	O
Measurement	VBN	O
of	VBG	O
Antiviral	DT	O
Activity	CD	O
of	NNP	O
Polypeptides	,	O
The	VBZ	O
ability	CD	O
of	VBG	O
the	NN	O
polypeptides	.	O
of	DT	O
the	NN	O
present	VBZ	O
invention	RB	O
to	VBN	O
protect	CC	O
cultured	VBN	O
cells	IN	O
from	NN	O
cytotoxic	.	O
viruses	NN	O
is	IN	O
demonstrated	NNP	O
using	NNP	O
a	IN	O
murine	NNP	O
encephalomyocarditis	DT	O
virus	NN	O
(EMCV,	IN	O
ATCC	DT	O
strain	NNS	O
VR-129B)	IN	O
infection	DT	O
model.	JJ	O
Other	NN	O
in	TO	O
vitro	VB	O
virus	JJ	O
infection	NNS	O
models	IN	O
include	NN	O
but	NNS	O
are	VBZ	O
not	VBN	O
limited	VBG	O
to	DT	O
flaviviruses	NN	O
such	NN	O
as	NN	O
bovine	,	O
diarrheal	NNP	O
virus,	VBP	O
West	)	O
Nile	NN	O
Virus,	.	O
and	JJ	O
GBV-C	IN	O
virus,	JJ	O
other	NN	O
RNA	NN	O
viruses	NNS	O
such	VBP	O
as	CC	O
respiratory	VBP	O
syncytial	RB	O
virus,	VBN	O
and	TO	O
the	NNS	O
HCV	JJ	O
replicon	IN	O
systems	JJ	O
(e.g.	NN	O
Blight,	,	B
K.	NNP	I
J.,	NNP	I
et	,	I
al.	CC	I
2002.	NNP	I
J.	,	I
Virology,	JJ	I
76:13001-13014).Any	NNP	O
appropriate	NNS	O
cultured	JJ	O
cell	IN	O
competent	JJ	O
for	JJ	O
viral	,	O
replication	CC	O
can	DT	O
be	NNP	O
utilized	NN	O
in	NNS	O
the	.	O
antiviral	,	O
assays.	NNP	O
Human	,	O
Huh7	RB	O
hepatoma	.	O
cells	.	O
are	NNP	O
seeded	,	O
at	.	O
a	DT	O
density	JJ	O
of	VBN	O
1×104	NN	O
cells/well	NN	O
in	IN	O
96	JJ	O
well	NN	O
culture	MD	O
plates	VB	O
and	VBN	O
incubated	IN	O
overnight	DT	O
in	JJ	O
complete	.	O
medium	NNP	O
(DMEM	NNP	O
containing	NN	O
10%	NNS	O
fetal	VBP	O
bovine	VBN	O
serum).	IN	O
The	DT	O
following	NN	O
morning,	IN	O
the	CD	O
media	NN	O
is	IN	O
replaced	CD	O
with	RB	O
complete	NN	O
medium	NNS	O
containing	CC	O
0-10	JJ	O
μM	NN	O
protein	IN	O
or	JJ	O
equivalent	NN	O
amounts	NNP	O
of	VBG	O
protein	NN	O
dilution	JJ	O
buffer.	NN	O
When	.	O
desired,	DT	O
alpha-interferon	JJ	O
is	,	O
added	DT	O
at	NNS	O
a	VBZ	O
concentration	VBN	O
of	IN	O
100	JJ	O
IU/ml.	NN	O
Cells	VBG	O
are	JJ	O
pretreated	JJ	O
for	NN	O
2-8	CC	O
hours	JJ	O
preceding	NNS	O
viral	IN	O
infection.	NN	O
After	NN	O
pretreatment,	.	O
an	WRB	O
equal	,	O
volume	NN	O
of	VBZ	O
medium	VBN	O
containing	IN	O
dilutions	DT	O
of	NN	O
EMC	IN	O
virus	CD	O
in	.	O
complete	NNS	O
medium	VBP	O
is	VBN	O
added	IN	O
to	JJ	O
the	NNS	O
wells.	VBG	O
In	JJ	O
the	.	O
experiments	IN	O
described	,	O
herein,	DT	O
a	JJ	O
range	NN	O
of	IN	O
50-500	NN	O
plaque	VBG	O
forming	NNS	O
units	IN	O
(pfu)	NNP	O
is	NN	O
added	IN	O
per	JJ	O
well.	NN	O
Viral	VBZ	O
infection	VBN	O
is	TO	O
allowed	DT	O
to	.	O
proceed	IN	O
overnight	DT	O
(approximately	NNS	O
18	VBD	O
hours),	,	O
and	DT	O
the	NN	O
proportion	IN	O
of	JJ	O
viable	NN	O
cells	VBG	O
is	NNS	O
calculated	)	O
using	VBZ	O
any	VBN	O
available	IN	O
cell	.	O
viability	JJ	O
or	NN	O
cytotoxicity	VBZ	O
reagents.	VBN	O
The	TO	O
results	VB	O
described	JJ	O
herein	RB	O
are	CD	O
obtained	,	O
using	CC	O
a	DT	O
cell	NN	O
viability	IN	O
assay	JJ	O
that	NNS	O
measures	VBZ	O
conversion	VBN	O
of	VBG	O
a	DT	O
tetrazolium	JJ	O
compound	NN	O
[3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,	NN	O
inner	CC	O
salt;	NN	O
MTS]	.	O
to	DT	O
a	NNS	O
colored	VBD	O
formazan	NNS	O
compound	VBP	O
in	VBN	O
viable	VBG	O
cells.	DT	O
The	NN	O
conversion	NN	O
of	VBP	O
MTS	IN	O
to	VBZ	O
formazan	NN	O
is	IN	O
detected	DT	O
in	NN	O
a	NN	O
96-well	,	O
plate	JJ	O
reader	:	O
at	NNP	O
an	TO	O
absorbance	DT	O
of	VBN	O
492	NN	O
nm.	NN	O
The	IN	O
resulting	JJ	O
optical	.	O
densities	DT	O
either	NN	O
are	IN	O
plotted	NNP	O
directly	TO	O
to	VB	O
estimate	VBZ	O
cell	VBN	O
viability	IN	O
or	DT	O
are	JJ	O
normalized	NN	O
by	NN	O
control-treated	IN	O
samples	DT	O
to	NN	O
calculate	IN	O
a	CD	O
percentage	.	O
of	DT	O
viable	VBG	O
cells	JJ	O
after	NNS	O
treatment.	CC	O
FIG.	VBP	O
3	VBN	O
shows	RB	O
representative	TO	O
data	VB	O
from	NN	O
experiments	NN	O
comparing	CC	O
the	VBP	O
antiviral	VBN	O
activity	IN	O
of	JJ	O
a	NNS	O
Class	TO	O
I	VB	O
enzymatically	DT	O
inactive	NN	O
mutant	IN	O
to	JJ	O
a	NNS	O
reference	IN	O
polypeptide	.	O
which	.	O
is	CD	O
identical	NNS	O
except	JJ	O
for	NNS	O
the	IN	O
Class	NNS	O
I	VBG	O
modification.	DT	O
In	JJ	O
this	NN	O
particular	IN	O
case,	DT	O
the	NN	O
reference	PRP	O
is	RB	O
itself	JJ	O
a	NN	O
Class	TO	O
III	DT	O
mutant	NN	O
polypeptide	NN	O
of	WDT	O
the	VBZ	O
invention.	JJ	O
Treatment	IN	O
of	IN	O
cells	DT	O
with	NN	O
protein	PRP	O
or	.	O
vehicle	IN	O
containing	DT	O
medium	JJ	O
alone	,	O
did	DT	O
not	NN	O
result	VBZ	O
in	PRP	O
significant	DT	O
decreases	NN	O
in	NNP	O
cell	JJ	O
viability.	NN	O
Conversely,	IN	O
pretreatment	DT	O
of	.	O
cells	NN	O
with	IN	O
increasing	NNS	O
concentrations	IN	O
of	NN	O
vehicle	CC	O
containing	NN	O
medium	VBG	O
did	NN	O
not	RB	O
protect	VBD	O
against	RB	O
EMCV-induced	VB	O
cell	IN	O
death	JJ	O
when	NNS	O
infected	IN	O
with	NN	O
either	.	O
50	,	O
or	NN	O
250	IN	O
pfu	NNS	O
EMCV.	IN	O
Pretreatment	VBG	O
with	NNS	O
either	IN	O
the	NN	O
reference	VBG	O
polypeptide	NN	O
or	VBD	O
a	RB	O
Class	VB	O
I	IN	O
mutant	NNP	O
polypeptide	NN	O
resulted	NN	O
in	WRB	O
very	VBN	O
similar	IN	O
dose-dependent	DT	O
increases	CD	O
in	CC	O
cell	CD	O
viability	JJ	O
of	.	O
Huh7	NN	O
cells,	IN	O
with	CC	O
half-maximal	DT	O
inhibitory	NN	O
doses	NN	O
of	CC	O
approximately	DT	O
1	NN	O
μM	PRP	O
and	VBP	O
2.5-3	RB	O
μM	VBN	O
at	IN	O
viral	RB	O
doses	JJ	O
of	NN	O
50	NNS	O
and	IN	O
250	NN	O
pfu,	NN	O
respectively.	IN	O
Polypeptide	NNP	O
Pegylation;	,	O
Sulfhydryl	IN	O
Conjugation	JJ	O
of	NN	O
polyethylene	NNS	O
glycol	IN	O
(PEG)	RB	O
to	CD	O
the	NNS	O
polypeptides	CC	O
of	JJ	O
the	NN	O
invention	IN	O
was	JJ	O
achieved	NNS	O
by	IN	O
mixing	CD	O
diothiothreitol	CC	O
(DTT)-free	CD	O
purified	,	O
polypeptide	.	O
with	NNP	O
activated	:	O
mPEG-MAL	NNP	O
(Nektar	NNP	O
Therapeutics)	IN	O
at	NN	O
a	NN	O
0.5-10:1	)	O
molar	TO	O
ratio.	DT	O
The	NNS	O
reaction	IN	O
proceeded	DT	O
at	NN	O
room	VBD	O
temperature	VBN	O
for	IN	O
5	VBG	O
min-2	NN	O
hours	VBP	O
and	VBN	O
was	IN	O
quenched	IN	O
by	JJ	O
the	NN	O
addition	NNP	O
of	)	O
2	IN	O
mM	DT	O
DTT.	JJ	O
Conjugation	NN	O
occurred	.	O
at	DT	O
multiple	NN	O
cysteine	VBD	O
sites	IN	O
using	NN	O
linear	NN	O
20	IN	O
kDa	CD	O
and	JJ	O
branched	NNS	O
40	CC	O
kDa	VBD	O
PEGs	VBN	O
(FIGS.	IN	O
6A	DT	O
and	NN	O
6B).	IN	O
Non-pegylated	CD	O
forms	NN	O
and	.	O
forms	NN	O
containing	VBD	O
one	IN	O
or	JJ	O
more	NN	O
PEG	NNS	O
can	VBG	O
be	JJ	O
separated	CD	O
from	NN	O
each	CC	O
other	VBD	O
using	CD	O
a	NN	O
variety	NNP	O
of	.	O
chromatographic	CD	O
methodologies	CC	O
as	.	O
known	JJ	O
to	NNS	O
those	CC	O
skilled	NNS	O
in	VBG	O
the	CD	O
art.	CC	O
In	JJR	O
exemplary	NNS	O
embodiments	MD	O
of	VB	O
the	VBN	O
present	IN	O
invention,	DT	O
ion	JJ	O
exchange	VBG	O
columns,	DT	O
hydrophobic	NN	O
interactions	IN	O
columns,	JJ	O
gel	NNS	O
filtration	IN	O
and	VBN	O
size	TO	O
exclusion	DT	O
chromatography,	VBN	O
each	IN	O
alone	DT	O
or	.	O
in	IN	O
combination	JJ	O
with	NNS	O
one	IN	O
another,	DT	O
can	JJ	O
be	,	O
utilized	NN	O
for	NN	O
isolation	,	O
of	JJ	O
the	NNS	O
different	,	O
PEG	JJ	O
forms.	NN	O
Polypeptide	CC	O
Pegylation;	NN	O
N-Terminal	NN	O
Polypeptides	,	O
of	DT	O
the	CD	O
invention	CC	O
can	IN	O
be	NN	O
pegylated	IN	O
at	CD	O
the	,	O
N-terminal	MD	O
amine.	VB	O
To	VBN	O
polypeptides	IN	O
in	NN	O
50	IN	O
mM	DT	O
NaH2PO4,	JJ	O
300	NNP	O
mM	.	O
NaCl,	NNP	O
30%	:	O
glycerol,	JJ	O
1	NNP	O
mM	IN	O
EDTA,	DT	O
2	NN	O
mM	MD	O
DTT	VB	O
at	VBN	O
pH	IN	O
5	DT	O
containing	JJ	O
20	.	O
mM	TO	O
sodium	NNS	O
cyanobororohydride	IN	O
and	CD	O
stirring	NN	O
in	,	O
an	CD	O
ice	NN	O
bath	,	O
are	NN	O
added	,	O
a	CD	O
5-fold	NN	O
excess	,	O
of	CD	O
mPEG	NN	O
butyrALD-40K.	NNP	O
The	IN	O
reaction	NN	O
is	CD	O
allowed	VBG	O
to	CD	O
proceed	JJ	O
for	NN	O
up	NN	O
to	CC	O
ten	NN	O
hours	IN	O
and	DT	O
then	NN	O
quenched	NN	O
by	VBP	O
the	VBN	O
addition	DT	O
of	JJ	O
a	NN	O
50-fold	IN	O
excess	JJ	O
of	.	O
glycine.	DT	O
Reaction	NN	O
products	VBZ	O
are	VBN	O
analyzed	TO	O
by	VB	O
SDS-PAGE.	IN	O
The	RB	O
following	TO	O
examples	VB	O
are	NNS	O
offered	CC	O
by	RB	O
way	VBN	O
of	IN	O
illustration	DT	O
and	NN	O
not	IN	O
by	DT	O
way	JJ	O
of	NN	O
limitation.	IN	O
EXAMPLES	.	O
Example	NN	O
1	NNS	O
Site	VBP	O
Directed	VBN	O
Mutagenesis	IN	O
The	.	O
polypeptides	DT	O
of	JJ	O
the	NNS	O
present	VBP	O
invention	VBN	O
can	IN	O
be	NN	O
engineered	IN	O
using	NN	O
any	CC	O
standard	RB	O
method	IN	O
of	NN	O
site-directed	IN	O
mutagenesis.	.	O
The	NNP	O
nucleic	NNP	O
acid	CD	O
sequences	NNP	O
corresponding	NNP	O
to	NNP	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	JJ	O
were	NN	O
synthesized	MD	O
using	VB	O
specific	VBN	O
oligonucleotide	VBG	O
primers	DT	O
and	JJ	O
a	NN	O
high	IN	O
fidelity	JJ	O
DNA	.	O
polymerase.	DT	O
The	JJ	O
target	NN	O
sequence	NNS	O
was	VBG	O
contained	TO	O
on	DT	O
a	NNS	O
double	IN	O
stranded	DT	O
plasmid	NN	O
isolated	VBD	O
from	VBN	O
a	VBG	O
methylation-competent	JJ	O
E.	JJ	O
coli	NNS	O
strain.	CC	O
Complimentary	DT	O
oligonucleotides	JJ	O
containing	NN	O
the	NNP	O
desired	.	O
mutation	DT	O
were	NN	O
synthesized	NN	O
and	VBD	O
purified	VBN	O
using	IN	O
polyacrylamide	DT	O
gel	JJ	O
electrophoresis.	VBN	O
A	NN	O
thermal	VBN	O
cycler	IN	O
was	DT	O
used	JJ	O
to	NNP	O
control	NNS	O
the	.	O
temperature	NNP	O
for	NNS	O
alternating	VBG	O
cycles	DT	O
of	VBN	O
denaturation	NN	O
of	VBD	O
the	VBN	O
double	CC	O
stranded	VBN	O
plasmid	VBG	O
template	JJ	O
(94°	JJ	O
C.	.	O
for	DT	O
30	JJ	O
seconds),	NN	O
annealing	VBD	O
of	VBN	O
the	TO	O
oligonucleotide	VB	O
primers	DT	O
(55°	NN	O
C.	IN	O
for	VBG	O
1	NNS	O
minute),	IN	O
and	NN	O
extension	IN	O
of	DT	O
the	NN	O
primers	VBD	O
with	JJ	O
a	NN	O
high	CD	O
fidelity	NNP	O
polymerase	IN	O
(68°	CD	O
C.	,	O
for	VBG	O
1	IN	O
minute/kb	DT	O
of	JJ	O
plasmid	NNS	O
length).	CD	O
After	NNP	O
approximately	IN	O
15	CD	O
cycles,	,	O
the	CC	O
mixture	NN	O
of	IN	O
newly	DT	O
synthetized	NNS	O
and	IN	O
input	DT	O
DNA	JJ	O
were	NN	O
treated	NN	O
with	CD	O
a	NNP	O
restriction	IN	O
enzyme	CD	O
specific	NN	O
for	IN	O
methylated	JJ	O
residues	.	O
(Dpn	IN	O
I)	RB	O
to	CD	O
digest	,	O
the	DT	O
parental	NN	O
plasmid.	IN	O
The	RB	O
resulting	VBN	O
DNA	CC	O
was	VBN	O
introduced	NNP	O
into	VBD	O
chemically	VBN	O
or	IN	O
electrically	DT	O
competent	NN	O
bacterial	NN	O
strains	NN	O
for	IN	O
screening	JJ	O
and	NNS	O
isolation	NNP	O
of	)	O
plasmids	TO	O
containing	VB	O
the	DT	O
desired	JJ	O
mutation.	.	O
Plasmid	DT	O
DNA	VBG	O
was	NN	O
isolated	VBD	O
from	VBN	O
the	IN	O
transformants	RB	O
and	CC	O
screened	RB	O
via	JJ	O
fluorescent	JJ	O
dye-terminator	NNS	O
sequencing	IN	O
to	VBG	O
confirm	CC	O
the	NN	O
mutant	IN	O
sequence.	NNS	O
Example	VBG	O
2	DT	O
Bulk	JJ	O
Drug	.	O
Product	NNP	O
Expression,	NNP	O
Fermentation,	VBD	O
and	VBN	O
Purification	IN	O
An	DT	O
E.	NNS	O
coli	CC	O
strain	VBD	O
containing	IN	O
a	JJ	O
lysogen	NN	O
of	VBG	O
λDE3,	TO	O
and	VB	O
therefore	DT	O
carrying	JJ	O
a	.	O
chromosomal	RB	O
copy	CD	O
of	NNP	O
the	NNP	O
T7	NNP	O
RNA	,	O
polymerase	,	O
gene	CC	O
under	NNP	O
the	DT	O
control	NNP	O
of	NNS	O
the	VBP	O
lacUV5	VBG	O
promoter,	DT	O
was	NN	O
transformed	IN	O
with	,	O
a	CC	O
bacterial	RB	O
expression	VBG	O
vector	DT	O
containing	JJ	O
an	NN	O
IPTG-inducible	IN	O
promoter	DT	O
encoding	NNP	O
a	NNP	O
nucleic	NN	O
acid	NN	O
sequence	IN	O
corresponding	DT	O
to	NN	O
one	IN	O
or	DT	O
more	NN	O
of	,	O
the	VBD	O
polypeptides	VBN	O
of	IN	O
the	DT	O
present	JJ	O
invention.	NN	O
Cultures	NN	O
were	VBG	O
grown	DT	O
in	JJ	O
luria	NN	O
broth	VBG	O
medium	DT	O
supplemented	JJ	O
with	NN	O
34	NN	O
μg/mL	VBG	O
chloroamphenicol	TO	O
and	CD	O
15	CC	O
μg/mL	JJR	O
kanamycin	IN	O
at	DT	O
37°	NNS	O
C.	IN	O
When	DT	O
the	JJ	O
OD600	.	O
reaches	NNS	O
>0.4,	VBD	O
the	VBN	O
temperature	IN	O
was	JJ	O
reduced	DT	O
to	NN	O
18°	VBD	O
C.	IN	O
and	CD	O
the	NNS	O
cells	NN	O
were	CC	O
induced	CD	O
with	JJ	O
0.5	NN	O
mM	IN	O
IPTG	CD	O
for	NNP	O
17	WRB	O
hours.	DT	O
The	NNP	O
bacterial	VBZ	O
cells	,	O
were	DT	O
then	NN	O
resuspended	VBD	O
in	VBN	O
buffer	TO	O
containing	CD	O
50	NNP	O
mM	CC	O
NaH2PO4,	DT	O
pH	NNS	O
8,	VBD	O
300	VBN	O
mM	IN	O
NaCl,	CD	O
20	NNS	O
mM	NNP	O
imidazole,	IN	O
10%	CD	O
glycerol,	.	O
0.1%	DT	O
NP40,	JJ	O
2	NNS	O
mM	VBD	O
DTT	RB	O
and	VBN	O
protease	IN	O
inhibitors	NN	O
(VWR),	VBG	O
lysed	CD	O
in	JJ	O
a	,	O
Gaulin	NN	O
homogenizer,	,	O
and	CD	O
centrifuged	NN	O
to	,	O
remove	CD	O
cell	NN	O
debris	,	O
before	NN	O
protein	,	O
purification.	NN	O
Purification	,	O
of	CD	O
histidine	NN	O
tagged	NNP	O
polypeptides:	CC	O
Purification	NN	O
of	NNS	O
the	,	O
polypeptides	VBN	O
of	IN	O
the	DT	O
present	NNP	O
invention	,	O
was	CC	O
achieved	VBD	O
using	TO	O
a	VB	O
polyhistidine	NN	O
tag	NN	O
at	IN	O
the	JJ	O
amino-terminus.	.	O
A	NN	O
nickel	IN	O
column,	NN	O
specifically	VBN	O
a	:	O
GE	NN	O
Healthcare	IN	O
5	DT	O
mL	NNS	O
HisTrap	IN	O
FF	DT	O
column	JJ	O
(17-5255-01),	NN	O
was	VBD	O
used	VBN	O
with	VBG	O
two	DT	O
stacked	NN	O
5	NN	O
mL	IN	O
columns.	DT	O
The	.	O
lysate	DT	O
was	JJ	O
loaded	,	O
onto	RB	O
the	DT	O
column	NNP	O
with	NNP	O
a	CD	O
1.5	NN	O
mL/min	NNP	O
flowrate.	NNP	O
The	NN	O
column	,	O
was	VBD	O
then	VBN	O
washed	IN	O
with	CD	O
15	VBD	O
column	CD	O
volumes	NN	O
(CV)	.	O
of	DT	O
Buffer	NN	O
A	VBD	O
(50	VBN	O
mM	IN	O
NaH2PO4,	DT	O
300	NN	O
mM	IN	O
NaCl,	DT	O
30%	CD	O
glycerol,	NN	O
20	.	O
mM	DT	O
imidazole,	NN	O
2	VBD	O
mM	RB	O
DTT	VBN	O
at	IN	O
pH	CD	O
7.5).	NN	O
A	NNS	O
step	)	O
elution	IN	O
to	NNP	O
7%	NNP	O
Buffer	CD	O
B	NN	O
(50	,	O
mM	CD	O
NaH2PO4,	NN	O
300	,	O
mM	NN	O
NaCl,	,	O
30%	CD	O
glycerol,	NN	O
2	,	O
M	CD	O
imidazole,	NN	O
2	NNP	O
mM	IN	O
DTT	RB	O
at	.	O
pH	DT	O
7.5)	NN	O
was	NN	O
run	TO	O
for	NN	O
2.5	NNP	O
CV.	NNP	O
A	CD	O
gradient	NN	O
to	,	O
100%	CD	O
B	NN	O
over	,	O
2.5	NN	O
CV	,	O
was	CD	O
then	NNP	O
carried	,	O
out.	CD	O
All	NN	O
purification	NNP	O
steps	IN	O
were	RB	O
carried	)	O
out	VBD	O
at	VBN	O
room	IN	O
temperature.	CD	O
The	.	O
peak	DT	O
fractions	NN	O
from	TO	O
the	NN	O
nickel	NNP	O
column	IN	O
containing	CD	O
the	NNP	O
polypeptide	VBD	O
were	RB	O
mixed	VBN	O
and	.	O
diluted	DT	O
1:1	NN	O
with	NNS	O
Buffer	VBD	O
A.	VBN	O
CaCl2	RP	O
(from	IN	O
sterile	NN	O
filtered	.	O
1	DT	O
M	JJ	O
stock	NNS	O
solution)	IN	O
was	DT	O
added	JJ	O
to	NN	O
a	VBG	O
2	DT	O
mM	NN	O
final	VBD	O
concentration.	JJ	O
Filtration	CC	O
was	VBD	O
done	CD	O
to	IN	O
clarify.	NNP	O
The	NN	O
filtrate	NNP	O
was	IN	O
loaded	NN	O
onto	VBD	O
an	CD	O
octyl	NNP	O
FF	NN	O
column	)	O
(GE	VBD	O
Healthcare	VBN	O
17-1359-01)	TO	O
equilibrated	DT	O
in	CD	O
buffer	NN	O
A	JJ	O
at	.	O
a	NN	O
0.5	VBD	O
mL/min	VBN	O
flowrate,	TO	O
the	.	O
polypeptide	DT	O
was	NN	O
in	VBD	O
the	VBN	O
flowthrough	IN	O
fractions.	DT	O
The	JJ	O
octyl	NNP	O
column	NN	O
flowthrough	NNP	O
was	NNP	O
added	)	O
to	VBN	O
5	IN	O
volumes	NN	O
of	NN	O
Buffer	IN	O
C	DT	O
(10	CD	O
mM	NN	O
NaH2PO4,	,	O
30%	DT	O
glycerol,	NN	O
2	VBD	O
mM	IN	O
DTT,	DT	O
pH	JJ	O
8.8).	.	O
The	DT	O
polypeptide	JJ	O
was	NN	O
loaded	NN	O
onto	VBD	O
a	VBN	O
DEAE	TO	O
FF	CD	O
(GE	NNS	O
Healthcare	IN	O
17-5154-01)	NNP	O
5	NNP	O
mL	CD	O
column	NN	O
for	,	O
endotoxin	NN	O
removal,	,	O
at	CD	O
a	NN	O
1.5	,	O
mL/min	RB	O
flowrate.	.	O
This	DT	O
was	NN	O
followed	VBD	O
by	VBN	O
a	IN	O
5	DT	O
CV	NNP	O
Buffer	NNP	O
C	NNP	O
wash,	NNP	O
1.5	)	O
mL/min	CD	O
flowrate,	JJ	O
then	NN	O
a	IN	O
10	NN	O
CV	,	O
gradient	IN	O
from	DT	O
10	CD	O
mM	NN	O
NaH2PO4,	.	O
30%	DT	O
glycerol,	VBD	O
2	VBN	O
mM	IN	O
DTT,	DT	O
pH	CD	O
8.8	NNP	O
to	NNP	O
50	NNP	O
mM	,	O
NaH2PO4,	CD	O
1	NN	O
M	,	O
NaCl,	RB	O
30%	DT	O
glycerol,	CD	O
2	NNP	O
mM	NN	O
DTT,	IN	O
pH	CD	O
8.0	NN	O
was	,	O
run.	NN	O
The	,	O
flowthrough	CD	O
fractions	NN	O
were	,	O
pooled	VBZ	O
and	CD	O
diluted	TO	O
1:1	CD	O
with	NN	O
Buffer	,	O
C	CD	O
while	NNP	O
gently	,	O
mixing,	NN	O
and	,	O
the	CD	O
pH	NN	O
was	,	O
adjusted	VBD	O
to	CD	O
6.8	VBD	O
with	.	O
2	DT	O
N	JJ	O
HCl.	NNS	O
Then	VBD	O
the	VBN	O
polypeptide	CC	O
was	VBN	O
loaded	CD	O
onto	IN	O
a	NNP	O
5	NNP	O
mL	IN	O
HiTrap	RB	O
SP	,	O
FF	CC	O
(GE	DT	O
Healthcare	NN	O
17-5157-01)	VBD	O
column	VBN	O
at	TO	O
a	CD	O
1.5	IN	O
mL/min	CD	O
flowrate.	NNP	O
After	.	O
the	RB	O
polypeptide	DT	O
was	NN	O
loaded,	VBD	O
the	VBN	O
column	IN	O
was	DT	O
washed	CD	O
with	NN	O
5	NNP	O
CV	NNP	O
of	NNP	O
Buffer	NNP	O
C	NNP	O
(adjusted	)	O
to	NN	O
pH	IN	O
6.8)	DT	O
followed	CD	O
by	NN	O
a	.	O
step	IN	O
elution	DT	O
to	NN	O
75%	VBD	O
of	,	O
Buffer	DT	O
D	NN	O
(50	VBD	O
mM	VBN	O
NaH2PO4,	IN	O
1	CD	O
M	NNP	O
NaCl,	IN	O
40%	NNP	O
glycerol,	NNP	O
1	VBN	O
mM	TO	O
EDTA,	VB	O
2	)	O
mM	VBN	O
DTT	IN	O
at	DT	O
pH	NN	O
6.8),	NN	O
then	TO	O
a	NN	O
5	IN	O
CV	NNP	O
gradient	NNP	O
to	CD	O
100%	NN	O
Buffer	,	O
D.	CD	O
The	NNP	O
polypeptide	,	O
was	NN	O
then	,	O
gel	CD	O
filtered	NN	O
into	,	O
Buffer	CD	O
E	NN	O
(50	NNP	O
mM	IN	O
NaH2PO4,	RB	O
300	,	O
mM	RB	O
NaCl,	DT	O
40%	CD	O
glycerol,	NNP	O
1	NN	O
mM	TO	O
EDTA,	NN	O
2	NNP	O
mM	NNP	O
DTT	DT	O
at	NN	O
pH	VBD	O
6.8)	RB	O
and	JJ	O
stored	VBN	O
at	IN	O
−20°	NNP	O
C.	NNP	O
Purification	CD	O
of	NN	O
non-tagged	,	O
or	CD	O
native	NN	O
polypeptides:	,	O
Purification	NN	O
of	,	O
polypeptides	CD	O
lacking	NN	O
an	,	O
affinity	CD	O
tag	NN	O
was	NNP	O
also	IN	O
achieved.	RB	O
Growth	)	O
and	CC	O
preparation	VBN	O
of	IN	O
clarified	NNP	O
lysate	NNP	O
was	NNP	O
performed	IN	O
as	JJ	O
previously	CC	O
described.	JJ	O
Alternatively,	:	O
to	NN	O
clarify	IN	O
extracts	NNS	O
and	VBG	O
remove	DT	O
endotoxin,	NN	O
tangential	NN	O
flow	VBD	O
filtration	RB	O
through	.	O
a	NNP	O
hollow	CC	O
fiber	NN	O
filtration	IN	O
device	JJ	O
was	NN	O
carried	VBD	O
out.	VBN	O
Lysate	IN	O
was	RB	O
mixed	.	O
with	,	O
CaCl2	TO	O
to	VB	O
a	NNS	O
final	CC	O
CaCl2	VB	O
concentration	,	O
of	JJ	O
2	NN	O
mM.	NN	O
Tangential	IN	O
flow	DT	O
filtration	JJ	O
was	NN	O
performed	NN	O
with	NN	O
a	VBD	O
GE	VBN	O
Healthcare	.	O
Midgee—UFP-500-E-MM01A	NNP	O
(56-4100-56)	VBD	O
which	JJ	O
has	IN	O
a	NNP	O
500	TO	O
kDa	DT	O
cutoff.	JJ	O
The	NNP	O
flowrate	NN	O
was	IN	O
190	CD	O
mL/min	.	O
and	JJ	O
the	NN	O
filtrate	NN	O
was	VBD	O
collected	VBN	O
and	IN	O
taken	DT	O
to	NNP	O
the	NNP	O
next	NNP	O
step.	)	O
The	WDT	O
protocol	VBZ	O
utilized	DT	O
GE	CD	O
Healthcare	NN	O
HITRAP	.	O
SP	DT	O
FF	NN	O
5	VBD	O
ml	CD	O
columns	NN	O
(17-5157-01),	CC	O
for	DT	O
the	NN	O
initial	VBD	O
capture	VBN	O
step,	CC	O
with	VBN	O
a	TO	O
5	DT	O
mL	JJ	O
column	.	O
volume	DT	O
utilized	NN	O
for	JJ	O
the	NNP	O
amount	NNP	O
of	NNP	O
lysate	NNP	O
generated	NNP	O
by	CD	O
a	NN	O
4	NN	O
L	,	O
growth/induction.	IN	O
The	DT	O
lysate	JJ	O
was	NN	O
loaded	,	O
onto	IN	O
the	DT	O
column	CD	O
with	JJ	O
a	NN	O
1.5	NN	O
mL/min	VBN	O
flowrate.	IN	O
The	DT	O
column	NN	O
was	IN	O
then	NN	O
washed	VBN	O
with	IN	O
5	DT	O
column	CD	O
volumes	NNP	O
of	.	O
Buffer	DT	O
A	NN	O
(50	VBD	O
mM	VBN	O
NaH2PO4,	IN	O
25	DT	O
mM	NN	O
NaCl,	IN	O
30%	DT	O
glycerol,	CD	O
2	NN	O
mM	.	O
DTT	DT	O
at	NN	O
pH	VBD	O
6.4).	RB	O
The	VBN	O
polypeptide	IN	O
was	CD	O
eluted	NN	O
via	NNS	O
a	IN	O
step	NNP	O
gradient	NNP	O
to	CD	O
33%	NN	O
Buffer	,	O
B	CD	O
(50	NN	O
mM	,	O
NaH2PO4,	NN	O
1	,	O
M	CD	O
NaCl,	NN	O
30%	NNP	O
glycerol,	IN	O
2	RB	O
mM	.	O
DTT	DT	O
at	NN	O
pH	VBD	O
6.8)	VBN	O
which	IN	O
was	DT	O
run	NN	O
for	NN	O
3	TO	O
CV.	NN	O
All	NNP	O
subsequent	NNP	O
steps	CD	O
subsequent	NN	O
were	,	O
carried	CD	O
out	NNP	O
under	,	O
endotoxin	NN	O
free	,	O
conditions.	CD	O
Peak	NN	O
fractions	NNP	O
from	IN	O
the	RB	O
cation	)	O
exchange	WDT	O
step	VBD	O
were	VBN	O
pooled	IN	O
and	CD	O
diluted	.	O
1:1	DT	O
v/v	JJ	O
with	NNS	O
Buffer	JJ	O
C	VBD	O
(50	VBN	O
mM	RP	O
NaH2PO4,	IN	O
300	JJ	O
mM	JJ	O
NaCl,	.	O
30%	JJ	O
glycerol,	NNS	O
2	IN	O
mM	DT	O
DTT,	NN	O
1	NN	O
M	NN	O
(NH4)2SO4,	VBD	O
pH	VBN	O
6.8)	CC	O
and	VBN	O
adjusted	CD	O
to	NN	O
1	IN	O
M	NNP	O
(NH4)2SO4	NNP	O
by	CD	O
adding	NN	O
the	,	O
appropriate	CD	O
volume	NN	O
of	,	O
4	NN	O
M	,	O
(NH4)2SO4	CD	O
at	NN	O
pH	,	O
6.8.	CD	O
CaCl2	NNP	O
was	,	O
added	RB	O
to	)	O
a	CC	O
2	VBN	O
mM	TO	O
final	CD	O
concentration	NNP	O
in	CD	O
the	IN	O
gently	VBG	O
stirring	DT	O
solution	JJ	O
then	NN	O
filtered	IN	O
to	CD	O
clarify.	NNP	O
The	CD	O
polypeptide	IN	O
was	NN	O
then	.	O
loaded	NNP	O
onto	VBD	O
a	VBN	O
5	TO	O
mL	DT	O
HiTrap	CD	O
Phenyl	NN	O
HP	JJ	O
(GE	NN	O
Healthcare	IN	O
17-5195-01)	DT	O
column	RB	O
at	VBG	O
a	NN	O
0.5	RB	O
mL/min	VBD	O
flowrate,	TO	O
and	.	O
the	DT	O
column	NN	O
was	VBD	O
washed	RB	O
with	VBN	O
5	IN	O
CV	DT	O
of	CD	O
Buffer	NN	O
C,	NNP	O
then	NNP	O
a	NNP	O
0.25	NNP	O
CV	NNP	O
gradient	)	O
to	NN	O
33%	IN	O
Buffer	DT	O
D	CD	O
(50	NN	O
mM	,	O
NaH2PO4,	CC	O
300	DT	O
mM	NN	O
NaCl,	VBD	O
30%	VBN	O
glycerol,	IN	O
2	CD	O
mM	NNP	O
DTT,	IN	O
at	NNP	O
pH	,	O
6.8)	RB	O
was	DT	O
performed.	CD	O
33%	NNP	O
Buffer	NN	O
D	TO	O
was	NN	O
run	NNP	O
for	NNP	O
2	CD	O
CV,	NN	O
followed	,	O
by	CD	O
a	NN	O
1	,	O
CV	NN	O
gradient	,	O
to	CD	O
55%	NN	O
D.	,	O
The	IN	O
polypeptide	JJ	O
was	)	O
then	VBD	O
eluted	.	O
with	NN	O
a	NNP	O
5	NNP	O
CV	VBD	O
elution	VBN	O
at	IN	O
55%	CD	O
Buffer	,	O
D.	VBN	O
The	IN	O
polypeptide	DT	O
then	CD	O
went	NNP	O
through	NN	O
a	TO	O
flowthrough	NN	O
anion	NNP	O
exchange	DT	O
step	NN	O
to	VBD	O
remove	RB	O
impurities	VBN	O
and	IN	O
any	DT	O
remaining	CD	O
endotoxin.	NNP	O
It	NN	O
was	IN	O
diluted	NN	O
5:1	NNP	O
with	NNP	O
Buffer	DT	O
E	NN	O
(10	RB	O
mM	VBD	O
NaH2PO4,	IN	O
20%	DT	O
glycerol,	JJ	O
2	NN	O
mM	NN	O
DTT,	NN	O
at	TO	O
pH	VB	O
8)	NNS	O
and	CC	O
adjusted	DT	O
to	VBG	O
a	.	O
final	PRP	O
pH	VBD	O
of	VBN	O
7.2	CD	O
by	IN	O
slow	NNP	O
addition	NNP	O
of	CD	O
2	NN	O
N	,	O
HCl	NN	O
to	,	O
a	CD	O
gently	NN	O
stirred	,	O
solution.	IN	O
The	JJ	O
polypeptide	)	O
was	CC	O
loaded	VBN	O
on	TO	O
a	DT	O
5	JJ	O
mL	NN	O
HiTrap	IN	O
DEAE	CD	O
FF	IN	O
(GE	JJ	O
Healthcare	NN	O
17-5154-01)	IN	O
column	CD	O
at	NNP	O
1.5	NNP	O
mL/min	TO	O
and	DT	O
washed	RB	O
with	VBN	O
5	.	O
CV	DT	O
of	NN	O
Buffer	VBD	O
E.	VBN	O
The	IN	O
polypeptide	DT	O
was	CD	O
in	NN	O
the	NNP	O
flowthrough	NNP	O
fractions.	NNP	O
The	NNP	O
flowthrough	NNP	O
fractions	)	O
were	NN	O
pooled	IN	O
and	CD	O
diluted	NN	O
1:1	CC	O
with	VBD	O
Buffer	IN	O
E	CD	O
and	NNP	O
adjusted	IN	O
to	NNP	O
pH	NNP	O
6.4.	DT	O
The	NN	O
protein	VBD	O
was	IN	O
loaded	DT	O
onto	JJ	O
a	.	O
HITRAP	DT	O
SP	JJ	O
FF	NNS	O
5	VBD	O
ml	VBN	O
column	CC	O
(GE	VBN	O
Healthcare	CD	O
17-5157-01)	IN	O
at	NNP	O
a	NNP	O
1.0	CC	O
mL/min	VBN	O
flowrate	TO	O
and	VB	O
washed	.	O
with	DT	O
2	NN	O
CV	VBD	O
of	VBN	O
Buffer	IN	O
E.	DT	O
The	NNP	O
polypeptide	NNP	O
was	NNP	O
eluted	CD	O
with	NN	O
a	NN	O
10	NNP	O
CV	NNP	O
gradient	)	O
to	IN	O
100%	DT	O
Buffer	CD	O
F	NN	O
(50	NN	O
mM	CC	O
NaH2PO4,	VBD	O
500	IN	O
mM	CD	O
NaCl,	NNP	O
30%	IN	O
glycerol,	NNP	O
2	NNP	O
mM	DT	O
DTT,	NN	O
1	VBD	O
mM	VBN	O
EDTA	IN	O
at	DT	O
pH	CD	O
6.4)	NNP	O
at	NN	O
a	TO	O
0.5	NN	O
mL/min	NNP	O
flowrate.	NNP	O
The	CD	O
peak	NN	O
fractions	,	O
were	CD	O
pooled	NN	O
and	,	O
gel-filtered	NN	O
at	,	O
a	CD	O
2	NN	O
mL/min	,	O
flowrate,	CD	O
using	NN	O
a	NNP	O
GE	IN	O
Healthcare	RB	O
HiTrap	)	O
Desalting	IN	O
column	DT	O
(17-1408-01)	CD	O
into	NN	O
Buffer	.	O
G	DT	O
(50	JJ	O
mM	NNS	O
NaH2PO4,	VBD	O
300	VBN	O
mM	CC	O
NaCl,	VBN	O
25%	IN	O
glycerol,	DT	O
1	CD	O
mM	NN	O
EDTA,	,	O
2	VBG	O
mM	DT	O
DTT	NNP	O
at	NNP	O
pH	NNP	O
6.4)	NNP	O
and	NN	O
stored	)	O
at	IN	O
−80°	NNP	O
C.	NNP	O
Alternatively,	CD	O
the	NN	O
cation	,	O
exchange	CD	O
fractions	NN	O
were	,	O
pooled	NN	O
and	,	O
uniformly	CD	O
concentrated	NN	O
via	,	O
ultrafiltration	CD	O
using	NN	O
an	NNP	O
Amicon	IN	O
polyethersulfone	RB	O
10,000	)	O
NMWL	CC	O
membrane	VBN	O
(PBGC02510).	IN	O
Buffer	NNP	O
exchange	NNP	O
into	,	O
Buffer	DT	O
G	NN	O
was	NN	O
carried	NNS	O
out	VBD	O
via	VBN	O
diafiltration	CC	O
or	RB	O
gel-filtration.	JJ	O
The	IN	O
addition	NN	O
of	VBG	O
excipients	DT	O
such	NNP	O
as	NN	O
glycerol	CD	O
was	NNP	O
stabilizing	NN	O
to	.	O
polypeptides	NNP	O
of	NN	O
the	IN	O
present	NNP	O
invention.	NNP	O
For	VBD	O
example,	VBN	O
in	RP	O
one	IN	O
embodiment,	NN	O
a	CC	O
polypeptide	.	O
with	DT	O
a	NN	O
polyhistidine	IN	O
affinity	NNS	O
tag	JJ	O
had	IN	O
a	NN	O
maximum	VBD	O
concentration	VBG	O
with	TO	O
10%	NNS	O
glycerol	IN	O
(v/v)	DT	O
of	JJ	O
1	.	O
mg/mL;	IN	O
while	,	O
at	IN	O
40%	CD	O
glycerol,	,	O
the	DT	O
polypeptide	NN	O
was	IN	O
stable	DT	O
up	JJ	O
to	NN	O
12	NN	O
mg/mL.	VBD	O
Amino	DT	O
acid-based	JJ	O
excipients	NN	O
such	IN	O
as	NN	O
arginine	NN	O
have	)	O
proven	IN	O
to	CD	O
be	:	O
stabilizing	IN	O
to	IN	O
this	NN	O
polypeptide.	,	O
A	DT	O
10%	NN	O
solution	VBD	O
of	JJ	O
sucrose	RB	O
allows	TO	O
the	CD	O
polypeptides	.	O
of	NNP	O
the	JJ	O
invention	NNS	O
to	JJ	O
be	IN	O
stable	NN	O
at	VBP	O
1	VBN	O
mg/mL,	TO	O
the	VB	O
addition	VBG	O
of	TO	O
2%	DT	O
w/v	.	O
arginine	DT	O
allowed	NN	O
an	NN	O
embodiment	IN	O
of	JJ	O
the	VBZ	O
polypeptides	DT	O
to	NNS	O
be	IN	O
stable	DT	O
at	NN	O
3	TO	O
mg/mL.	VB	O
An	JJ	O
embodiment	IN	O
of	CD	O
the	,	O
polypeptides	DT	O
lacking	NN	O
an	IN	O
affinity	NN	O
tag	JJ	O
for	NN	O
purification	VBD	O
was	DT	O
also	NN	O
stabilized	IN	O
by	DT	O
particular	NNS	O
excipients.	TO	O
The	VB	O
use	JJ	O
of	IN	O
50	CD	O
mM	.	O
NaH2PO4,	DT	O
300	NN	O
mM	IN	O
NaCl,	DT	O
25%	NNS	O
glycerol,	VBG	O
1	DT	O
mM	NN	O
EDTA,	NN	O
2	IN	O
mM	NN	O
DTT	VBD	O
at	RB	O
pH	VBN	O
6.4	IN	O
was	JJ	O
found	.	O
to	DT	O
stabilize	NN	O
the	IN	O
polypeptide	CD	O
at	NN	O
6	,	O
mg/mL.	CD	O
The	NN	O
use	,	O
of	NN	O
50	,	O
mM	CD	O
NaH2PO4,	NN	O
300	,	O
mM	CD	O
NaCl,	NN	O
10%	NNP	O
mannitol,	IN	O
1	NN	O
mM	CD	O
EDTA,	VBD	O
0.5	VBN	O
mM	TO	O
DTT,	VB	O
2%	DT	O
(w/v)	NN	O
arginine	IN	O
at	CD	O
pH	.	O
6.4	DT	O
was	NN	O
found	IN	O
to	CD	O
stabilize	NN	O
the	,	O
polypeptide	CD	O
at	NN	O
4	,	O
mg/mL.	NN	O
Example	,	O
3	CD	O
Measurement	NN	O
of	,	O
Oligoadenylate	CD	O
Synthetase	NN	O
Activity	,	O
of	NN	O
Polypeptides	)	O
The	NN	O
oligoadenylate	IN	O
synthetase	NN	O
activities	CD	O
of	VBD	O
the	VBN	O
polypeptides	TO	O
of	VB	O
the	DT	O
invention	NN	O
were	IN	O
measured	CD	O
according	.	O
to	RB	O
previously	CD	O
published	NNP	O
methods	IN	O
Justesen,	NNP	B
J.,	NNP	I
et	NNP	I
al.	IN	I
Nuc	NNP	I
Acids	DT	I
Res.	JJ	I
8:3073-3085,	NN	I
1980).